

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number
WO 2004/094671 A2

(51) International Patent Classification⁷: **C12Q 1/68**

(21) International Application Number:
PCT/US2004/012788

(22) International Filing Date: 22 April 2004 (22.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/464,586 22 April 2003 (22.04.2003) US
60/464,588 22 April 2003 (22.04.2003) US

(71) Applicants (*for all designated States except US*): **COLEY PHARMACEUTICAL GmbH [DE/DE]**; Elisabeth-Selbert-Strasse 9, D-40764 Langenfeld (DE). **COLEY PHARMACEUTICAL GROUP, INC. [US/US]**; 93 Worcester Street, Suite 101, Wellesley, MA 02481 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **VOLLMER, Jörg [DE/DE]**; Kohlrauschweg 24, D-40591 Duesseldorf (DE).

JURK, Marion [DE/DE]; Klosterstr. 4, D-41540 Dornagel (DE). LIPFORD, Grayson, B. [GB/US]; 38 Bates Road, Watertown, MA 02472 (US). SCHETTER, Christian [DE/DE]; Oerknauhof 35, D-40723 Hilden (DE). FORSBACH, Alexandra [DE/DE]; Raiffeisenstrasse N°1, D-40764 Rantingen (DE). KRIEG, Arthur, M. [US/US]; 173 Winding River Road, Wellesley, MA 02482 (US).


(74) Agent: **TREVISAN, Maria, A.; Wolf, Greenfield & Sacks, P.C.**, 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH,

[Continued on next page]

(54) Title: METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT OF TLR LIGANDS



(57) Abstract: The invention provides in part novel screening methods and compositions for identifying and distinguishing between candidate immunomodulatory compounds. The invention further provides methods for assessing biological activity of composition containing a known TLR ligand. These latter methods can be used for quality assessment and selection of various lots of test compositions, including pharmaceutical products for clinical use.

WO 2004/094671 A2



GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT
OF TLR LIGANDS**

Background of the Invention

5 Nucleic acids with immunostimulatory activity have been identified. The first recognized immunostimulatory motif was the CpG motif in which at least the C of the dinucleotide was unmethylated. It has been postulated that mammalian subjects recognize the unmethylated dinucleotide as being of bacterial origin, and thus mount a heightened immune response following exposure. The ensuing immune response includes both cell mediated and
10 humoral aspects. Since the discovery of the CpG immunostimulatory motif, other immunostimulatory motifs have also been identified including the poly-T and T-rich motifs, the TG motif and the poly-G motif. In some instances, immunostimulation has also been observed in response to exposure to methylated CpG motifs and motif-less nucleic acids having phosphorothioate backbone linkages.

15 The responses induced by immunostimulatory nucleic acids are varied and can include production and secretion of cytokines, chemokines, and other growth factors. The nucleic acids can induce a heightened immune stimulation regardless of whether an antigen is also introduced to the subject. Identification of new motifs as well as of subtle differences between response profiles of different nucleic acids oftentimes can be laborious, and a high
20 throughput system for screening nucleic acids for their ability to be immunostimulatory as well as to determine the profile of responses they induce would be useful.

Summary of the Invention

The invention provides in its broadest sense screening methods and tools for
25 identification and discrimination of immunomodulatory molecules and assessment and standardization of samples containing known immunomodulatory molecules. The immunomodulatory molecules can be immunostimulatory or immunoinhibitory, and most preferably are Toll-like receptor (TLR) ligands.

In one aspect, the invention provides a screening method for identifying TLR agonists.
30 The method comprises contacting a cell line endogenously expressing at least one TLR with a test compound and measuring a test level of TLR signaling activity, wherein a positive test level is indicative of a TLR agonist (i.e., an immunostimulatory compound). The positive test

level may be apparent without referring to a control. Preferably, however, it is determined relative to a control (i.e., the TLR signaling activity from a reference compound).

In some embodiments, the reference compound is a compound that induces no response (i.e., a zero response) or a minimal response. In this case, a test level that is greater than the reference level is indicative of a compound with TLR signaling activity. More preferably, the reference compound is a compound that induces a positive response (i.e., a non-zero response) and that is immunostimulatory. These reference compounds are referred to herein as negative and positive reference compounds, respectively. If the reference compound is immunostimulatory (i.e., a positive reference compound), a non-zero test level that is lower than the reference level is still indicative of an immunostimulatory test compound. In this latter embodiment, the test compound is less immunostimulatory than the reference compound (for that particular readout), but it is nonetheless immunostimulatory given the non-zero response induced. There may be one or more concurrent or consecutive assays with a negative reference compound, a positive reference compound, or both. The reference may also be a standard curve or data generated previously.

In a related aspect, the screening method involves exposing the same cell to a positive reference compound and a test compound in order to identify a test compound that inhibits the immunostimulatory response of the positive reference compound (i.e., a TLR antagonist or an immunoinhibitory compound).

In still a related aspect, the screening method involves exposing the same cells to a positive reference compound and a test compound in order to identify a test compound that enhances the immunostimulatory response of the positive reference compound (i.e., an enhancer).

In both of these latter aspects, the assay requires a co-incubation of the positive reference compound, the test compound and the cells. Separate assays with positive reference compound alone and optionally negative reference compound alone are usually also performed.

The positive reference compound is a known TLR ligand. Non-limiting examples include but are not limited to TLR3 ligands, TLR7 ligands, TLR8 ligands and TLR9 ligands.

In some embodiments, the positive reference compound is an immunostimulatory nucleic acid. In some embodiments, the positive reference compound is a CpG nucleic acid, a poly-T nucleic acid, a T-rich nucleic acid or a poly-G nucleic acid. Another example of a positive

- 3 -

reference compound is a nucleic acid comprising a backbone that contains at least one phosphorothioate linkage.

It has been further discovered according to the invention that the RPMI 8226 cell line expresses TLR7 and responds to the imidazoquinoline compound R-848 (Resiquimod) which is known to signal through TLR7 and TLR8. Accordingly, the screening method can be 5 performed using RPMI 8226, Raji or RAMOS cells and an imidazoquinoline compound such as R-848 or R-847 (Imiquimod) as the positive reference compound.

In one embodiment, the test compound is a nucleic acid such as but not limited to a DNA, an RNA and a DNA/RNA hybrid. The test compound may be a nucleic acid that does 10 not comprise motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif. The test compound may be a nucleic acid that comprises a phosphorothioate backbone linkage. In another embodiment, the test compound is a non-nucleic acid small molecule. The non-nucleic acid small molecule may be derived from a molecular library. In other embodiments, the test compound comprises amino acids, 15 carbohydrates such as polysaccharides. It may be a hormone or a lipid or contain moieties derived therefrom. In other embodiments, the test compounds are putative ligands for TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10 or TLR11.

In one embodiment, the cell is a RPMI 8226 cell, a Raji cell, a RAMOS cell, a THP-1 cells, a Nalm cell or a KG-1 cell and the TLR is TLR9. In another embodiment, the cell is a 20 RPMI 8226 cell, a Raji cell or a RAMOS cell and the TLR is TLR7. In yet another embodiment, the cell is a KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell and the TLR is TLR3.

In another embodiment, the cell is an RPMI 8226 cell and the TLR is TLR7 or TLR9. 25 In still another embodiment, the cell is a Raji cell and the TLR is TLR9, TLR7 or TLR3.

Depending upon the embodiment, the TLR signaling activity may be measured or detected in a number of ways. In one embodiment, the TLR signaling activity is measured by cytokine, chemokine, or growth factor secretion. The cytokine secretion may be selected 30 from the group consisting of IL-6 secretion, IL-10 secretion, IL-12 secretion, IFN- α secretion and TNF- α secretion, but is not so limited. The chemokine secretion may be IP-10 secretion or IL-8 secretion, but is not so limited.

In another embodiment, the TLR signaling activity is measured by antibody secretion. The antibody secretion may be IgM secretion, but is not limited to this antibody subtype.

In another embodiment, the TLR signaling activity is measured by phosphorylation. The total level of phosphorylation in the cell or the level of phosphorylation of particular factors in the cell may be measured. These factors are preferably signaling factors and can be selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, Jun, c-fos, and 5 subunits of NF- κ B, but are not so limited.

In still a further embodiment, the TLR signaling activity is measured by cell surface marker expression. In one embodiment, the TLR signaling activity is measured by an increase in cell surface marker expression. Examples of cell surface markers to be analyzed include CD71, CD86, HLA-DR, CD80, HLA Class I, CD54 and CD69. In other 10 embodiments, the TLR signaling activity is measured by a decrease in cell surface marker expression. Cell surface marker expression can be determined using flow cytometry. TLR signaling activity can also be measured by protein production (e.g., by Western blot).

In another embodiment, the TLR signaling activity is measured by gene expression. Gene expression profiles may be determined using Northern blot analysis or RT-PCR that 15 uses mRNA or total RNA as a starting material. The gene expression of interest may be that of the chemokines and cytokines and cell surface molecules recited above. Gene expression analysis can be performed using microarray techniques.

In yet another embodiment, the TLR signaling activity is measured by cell proliferation. Cell proliferation assays can be measured in a number of ways including but 20 not limited to 3 H-thymidine incorporation.

In one embodiment, the cell is an RPMI 8226 cell and TLR signaling is indicated by expression of a marker such as CD71, CD86 and/or HLA-DR or by expression, production or secretion of a factor such as IL-8, IL-10, IP-10 and/or TNF- α . Preferably, in this latter embodiment, the RPMI 8226 cell is unmodified. In another embodiment, the cell is a Raji 25 cell and the TLR signaling is indicated by IL-6 or IFN- α 2 expression, production or secretion. In yet another embodiment, the cell is a RAMOS cell and the TLR signaling is indicated by CD80 cell surface expression.

TLR signaling activity can be measured via a native readout or an artificial readout or both. A native readout is one that does not rely on introduction of a reporter construct into the 30 cell of interest.

The cell line may be used in a modified or unmodified form. In one embodiment, the cell line is transfected with a reporter construct. The transfection may be transient or stable. The reporter construct generally comprises a promoter, a coding sequence and a

polyadenylation signal. The coding sequence may comprise a reporter sequence selected from the group consisting of an enzyme (e.g., luciferase, alkaline phosphatase, β -galactosidase, chloramphenicol acetyltransferase (CAT), secreted alkaline phosphatase, etc.), a bioluminescence marker (e.g., green fluorescent protein (GFP, U.S. Patent No. 5,491,084), etc.), a surface-expressed molecule (e.g., CD25), a secreted molecule (e.g., IL-8, IL-12 p40, TNF- α , etc.), and other detectable protein sequences known to those of skill in the art. Preferably, the coding sequence encodes a protein, the level or activity of which can be quantified, with preferably a wide linear range.

In some embodiments, the promoter is a promoter that is responsive to TLR signaling pathways (i.e., a "TLR responsive promoter"). In some embodiments, the promoter contains a binding site for a transcription factor activated upon CpG nucleic acid exposure, such as for example NF- κ B. In other embodiments, the promoter contains a binding site for a transcription factor that is activated by a positive reference compound other than CpG nucleic acids. The transcription factor binding site may be selected from the group consisting of a NF- κ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE, as well as others known to those of skill in the art.

In another embodiment, the promoter contains a functional promoter element from an IL-1 gene, an IL-6 gene, an IL-8 gene, an IL-10 gene, an IL-12 p40 gene, an IFN- α 1 gene, an IFN- α 4 gene, an IFN- β gene, an IFN- γ gene, a TNF- α gene, a TNF- β gene, an IP-9 gene, an IP-10 gene, a RANTES gene, an ITAC gene, a MCP-1 gene, an IGFBP4 gene, a CD54 gene, a CD69 gene, a CD71 gene, a CD80 gene, a CD86 gene, a HLA-DR gene, and a HLA class I gene.

The TLR responsive promoter may be a TLR1 responsive promoter, a TLR2 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter, a TLR10 responsive promoter or a TLR11 responsive promoter.

In these latter embodiments, the cell line may be transfected with a reporter construct having a promoter derived from a particular cytokine, chemokine, or cell surface marker, and a unique reporter coding sequence conjugated thereto. In this way, the readout from a particular reporter construct is a surrogate readout for cytokine, chemokine, or cell surface marker readout. Measuring readout from the reporter coding sequences described herein is in

some instances easier than measuring cytokine or chemokine secretion, or upregulation of a cell surface marker.

In these latter embodiments, the cell line may be transfected with a number of reporter constructs each having a promoter derived from a particular cytokine, chemokine, or cell surface marker, and a unique distinguishable coding sequence conjugated thereto. In these 5 embodiments, multiple readouts are possible from one screen. In other embodiments, multiple native readouts are also possible from one screen.

In a related embodiment, the cell may be further transfected with a nucleic acid that codes for a TLR polypeptide or a fragment thereof. Preferably, the TLR is one that is not 10 endogenously expressed by the cell. As an example, if the cell is an RPMI 8226 cell which has been shown to express TLR7 and TLR9 according to the invention, then it may be modified to express TLRs other than these (e.g., TLR8) in some embodiments. In this aspect, the RPMI 8226 cell is responsive to TLR8 ligands. In preferred embodiments, the TLR is a human TLR (i.e., hTLR).

15 In another aspect, the invention provides an RPMI 8226 cell transfected with a TLR nucleic acid. In still another embodiment, the TLR nucleic acid is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR8, TLR10 and TLR11. The encoded TLRs nucleic acids can derive from human or non-human sources. Examples of 20 non-human sources include, but are not limited to, murine, bovine, canine, feline, ovine, porcine, and equine species. Other species include chicken and fish, e.g., aquaculture species. The TLR nucleic acids can also include chimeric sequences consisting of domains originating from different species. In preferred embodiments, the TLR is a human TLR.

25 In still another aspect, the invention provides kits including the cells lines (e.g., the RPMI 8226 cell line), the reporter constructs and/or expression constructs described above, and instructions for use.

Other aspects of the invention provide methods for analyzing the biological activity of individual lots of material containing previously identified specific TLR ligands (i.e., specific compounds which are ligands for a particular TLR) intended for use as, or for use in the preparation of, pharmaceutical compositions. The methods permit a qualitative and, 30 importantly, a quantitative assessment of biological activity of individual lots of TLR ligands, pre-formulation as well as post-formulation. Such methods are useful in the manufacture and validation of pharmaceutical compositions containing, as an active agent, at least one specific ligand of at least one specific TLR. The specific TLR can be any known TLR, including

without limitation TLR3, TLR7, TLR8 and TLR9. The specific TLR ligand is an isolated TLR ligand, either found in nature or synthetic (not found in nature), including in particular certain nucleic acid molecules and small molecules. Nucleic acid molecules that are specific TLR ligands include synthetic and naturally-occurring oligonucleotides having specific base sequence motifs. Furthermore, specific TLR ligands include both agonists and antagonists of specific TLR.

These methods are to be distinguished from test procedures and acceptance criteria for new drug substances and new drug products which are classified as chemical substances. Unlike the afore-mentioned test procedures and acceptance criteria, the methods of the instant invention deal specifically with characterizing drug substances and drug products which are classified as oligonucleotides. Oligonucleotides are explicitly excluded in ICH Topic Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, Step 4 – Consensus Guideline: 6 October 1999, § 1.3.

Further still, the methods of the instant invention are to be distinguished from test procedures and acceptance criteria for biotechnological/biological products. Unlike the afore-mentioned test procedures and acceptance criteria, the methods of the invention deal specifically with characterizing biotechnological/biological products which are classified as DNA products. DNA products are explicitly excluded in ICH Harmonised Tripartite Guideline Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, Step 4 – 10 March 1999, § 1.3.

In one aspect, the invention provides a method for quality assessment of a test composition containing a known TLR ligand. The method according to this aspect of the invention involves measuring a reference activity of a reference composition comprising a known TLR ligand, wherein the known TLR ligand is a nucleic acid molecule; measuring a test activity of a test composition comprising the known TLR ligand; and comparing the test activity to the reference activity. In one embodiment the method further involves the step of selecting the test composition if the test activity falls within a predetermined range of variance about the reference activity.

In one embodiment, the reference composition is a first production lot of a pharmaceutical composition comprising the known TLR ligand, and the test composition is a second production lot of a pharmaceutical composition comprising the known TLR ligand. This embodiment is particularly useful as a method for developing and applying acceptance criteria for finished pharmaceutical products containing a known TLR ligand.

In another embodiment, the reference composition is a first in-process lot of a composition comprising the known TLR ligand, and the test composition is a second in-process lot of a composition comprising the known TLR ligand. This embodiment is particularly useful as a method for developing and applying acceptance criteria for raw materials and/or other in-process materials containing a known TLR ligand bound for use in a pharmaceutical product.

In one embodiment according to this aspect of the invention, measuring the reference activity involves contacting the reference composition with an isolated cell expressing a TLR responsive to the known TLR ligand, and measuring the test activity involves contacting the test composition with the isolated cell expressing the TLR responsive to the known TLR ligand. Further, in one embodiment the isolated cell expressing the TLR responsive to the known TLR ligand includes an expression vector for the TLR responsive to the known TLR ligand. Such expression vector, and likewise for any expression vector according to the instant invention, can be introduced into the cell using any suitable method.

In one embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand naturally expresses the TLR responsive to the known TLR ligand. Such a cell can be naturally occurring or it can be a cell line, provided the cell does not include an expression vector introduced into the cell for the purpose of artificially inducing the cell to express or overexpress the TLR.

In one particular embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226. In another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is Raji, RAMOS, Nalm, THP-1 or KG-1 and the TLR is TLR9. In another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226, Raji or RAMOS and the TLR is TLR7. In yet another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is a KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell and the TLR is TLR3.

Further according to this aspect of the invention, in one embodiment measuring the reference activity and measuring the test activity each comprises measuring signaling activity mediated by a TLR responsive to the known TLR ligand. As described in greater detail elsewhere herein, TLR signaling involves a series of intracellular signaling events. These signaling events give rise to various downstream products, including certain transcription

factors (e.g., NF- κ B and AP-1), cytokines, chemokines, etc., which can affect the activity of certain gene promoters. For example, in one embodiment the signaling activity is activity of a reporter gene or reporter construct under the control of a NF- κ B response element.

In other embodiments, the signaling activity is activity of a reporter gene or reporter construct under the control of an interferon-stimulated response element (ISRE); an IFN- α promoter; an IFN- β promoter; an IL-6 promoter; an IL-8 promoter; an IL-12 p40 promoter; a RANTES promoter; an IL-10 promoter or an IP-10 promoter.

In one embodiment, the known TLR ligand is an immunostimulatory nucleic acid. An immunostimulatory nucleic acid can include, without limitation, a CpG nucleic acid. In another embodiment, the known TLR ligand is an immunoinhibitory nucleic acid. When the known TLR ligand is a TLR antagonist (e.g., an immunoinhibitory oligonucleotide), the method according to this aspect of the invention can further involve measuring the reference activity of the reference composition and measuring the test activity of the test composition, each performed in the presence of a known immunostimulatory TLR ligand.

In various embodiments, the known TLR ligand is a ligand for a particular TLR. Thus in one embodiment the known TLR ligand is a TLR9 ligand. More specifically, in one embodiment the known TLR ligand is a CpG nucleic acid.

In one embodiment, the known TLR ligand is a TLR3 ligand. Such a ligand can include, for example, a double-stranded RNA or a homolog thereof.

In one embodiment, the known TLR ligand is a TLR7 ligand. In one embodiment the known TLR ligand is a TLR8 ligand.

The invention provides in another aspect a method for quality assessment of a test lot of a pharmaceutical product containing a known TLR9 ligand. The method according to this aspect of the invention involves measuring a reference activity of a reference lot of a pharmaceutical product comprising a known TLR9 ligand, wherein the known TLR9 ligand is a nucleic acid molecule; measuring a test activity of a test lot of a pharmaceutical product comprising the known TLR9 ligand; comparing the test activity to the reference activity; and rejecting the test lot if the test activity falls outside of a predetermined range of variance about the reference activity.

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGT CGT TTT GTC GTT-3' (SEQ ID NO:1).

- 10 -

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGA CGT TTT GTC GTT-3' (SEQ ID NO:139).

5 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGT CGT TTT TTT CGA-3' (SEQ ID NO:140).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT CGT CGT TTC GTC GTT-3' (SEQ ID NO:141).

10 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3' (SEQ ID NO:142).

15 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TTC GGT CGT TTT-3' (SEQ ID NO:143).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TTC GTG CGT TTT T-3' (SEQ ID NO:144).

20 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TCG GCG GCC GCC G-3' (SEQ ID NO:145).

25 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TC_G TTT TAC_GGC GCC_GTG CCG-3' (SEQ ID NO:146), wherein every internucleoside linkage is phosphorothioate except for those indicated by “_”, which are phosphodiester.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention.

- 11 -

Fig. 1 is a bar graph showing cell surface expression of various markers by RPMI 8226 24 hours and 48 hours following stimulation with CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), LPS and IL-1.

5 Fig. 2 is a bar graph showing IL-8 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 3 is a bar graph showing IL-6 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

10 Fig. 4 is a bar graph showing IP-10 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

15 Fig. 5 is a bar graph showing IL-10 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 6 is a dose response curve showing fold induction of IL-8 production 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1) and non-CpG nucleic acid (SEQ ID NO: 2). The EC₅₀ for CpG nucleic acid is 19 nM and the EC₅₀ for non-CpG nucleic acid is 263 nM.

20 Fig. 7 is a bar graph showing NF-κB activation in RPMI 8226 transfected transiently with a NF-κB-luciferase reporter gene construct as a function of cell density and nucleic acid amount transfected, following exposure to CpG nucleic acid (SEQ ID NO: 1), LPS and TNF-α. NF-κB activation is measured by luciferase activity.

25 Fig. 8 is a bar graph showing RT-PCR results from RNA isolated from RPMI 8226 using gene specific primers for TLR7, TLR8 and TLR9 genes.

Fig. 9 is a dose response curve showing IP-10 production induced by SEQ ID NO: 1, and inhibition thereof in the presence of SEQ ID NO: 151, a immunoinhibitory nucleic acid.

Fig. 10 is a bar graph showing the results of a TLR9 RT-PCR analysis of a number of cell lines.

30 Fig. 11 is a bar graph showing the results of a TLR7 RT-PCR analysis of a number of cell lines.

Fig. 12 is a bar graph showing the results of a TLR3 RT-PCR analysis of a number of cell lines.

- 12 -

Fig. 13 is a bar graph showing the results of a TLR3, TLR7, TLR8 and TLR9 RT-PCR analysis of the Raji cell line.

Fig. 14 is a graph showing IL-6 production by the Raji cell line upon stimulation with various ODN (SEQ ID NO:1; SEQ ID NO:154; SEQ ID NO:158; SEQ ID NO:160; SEQ ID NO:159; SEQ ID NO:161).

Fig. 15 is a bar graph showing IL-6 production of the Raji cell line upon stimulation with poly I:C and R-848.

Fig. 16 is a bar graph showing IFN- α 2 production by the Raji cell line upon stimulation with CpG ODN (SEQ ID NO: 1), R-848 and poly I:C.

Fig. 17 is a bar graph showing CD80 expression (by flow cytometry) by the RAMOS cell line upon stimulation with CpG ODN (SEQ ID NO: 1) and non-CpG ODN (SEQ ID NO: 2).

Fig. 18A is a bar graph showing the induction of NF- κ B by 293 fibroblast cells transfected with human TLR9 in response to exposure to various stimuli, including CpG-ODN, GpC-ODN, LPS, and medium.

Fig. 18B is a bar graph showing the amount of IL-8 produced by 293 fibroblast cells transfected with human TLR9 in response to exposure to various stimuli, including CpG-ODN, GpC-ODN, LPS, and medium.

Fig. 19 is a bar graph showing the induction of NF- κ B-luc produced by stably transfected 293-mTLR9 cells in response to exposure to various stimuli, including CpG-ODN, methylated CpG-ODN (Me-CpG-ODN), GpC-ODN, LPS and medium.

Fig. 20 is a bar graph showing the induction of NF- κ B-luc produced by stably transfected 293-hTLR9 cells in response to exposure to various stimuli, including CpG-ODN, methylated CpG-ODN (Me-CpG-ODN), GpC-ODN, LPS and medium.

Fig. 21 is a series of gel images depicting the results of reverse transcriptase-polymerase chain reaction (RT-PCR) assays for murine TLR9 (mTLR9), human TLR9 (hTLR9), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in untransfected control 293 cells, 293 cells transfected with mTLR9 (293-mTLR9), and 293 cells transfected with hTLR9 (293-hTLR9).

30

It is to be understood that the Figures are not required for enablement of the invention.

Brief Description of Sequences

SEQ ID NO:1 is the nucleotide sequence of an immunostimulatory nucleic acid (TLR9 ligand).

SEQ ID NO:2 is the nucleotide sequence of a non-CpG nucleic acid.

SEQ ID NO:3 is the nucleotide sequence of human TLR2 cDNA (U88878).

5 SEQ ID NO:4 is the amino acid sequence of human TLR2 protein (AAC34133).

SEQ ID NO:5 is the nucleotide sequence of murine TLR2 cDNA (AF165189).

SEQ ID NO:6 is the amino acid sequence of murine TLR2 protein (NP_036035).

SEQ ID NO:7 is the nucleotide sequence of human TLR3 cDNA (NM_003265).

SEQ ID NO:8 is the amino acid sequence of human TLR3 protein (NP_003256).

10 SEQ ID NO:9 is the nucleotide sequence of murine TLR3 cDNA (AF355152).

SEQ ID NO:10 is the amino acid sequence of murine TLR3 protein (AAK26117).

SEQ ID NO:11 is the nucleotide sequence of human TLR4 cDNA (U88880).

SEQ ID NO:12 is the nucleotide sequence of human TLR4 cDNA transcript variant 4 (NM_138557).

15 SEQ ID NO:13 is the nucleotide sequence of human TLR4 cDNA transcript variant 2 (NM_138556).

SEQ ID NO:14 is the nucleotide sequence of human TLR4 cDNA transcript variant 1 (NM_138554).

20 SEQ ID NO:15 is the nucleotide sequence of human TLR4 cDNA transcript variant 3 (NM_003266).

SEQ ID NO:16 is the amino acid sequence of human TLR4 protein isoform A (NP_612564).

SEQ ID NO:17 is the amino acid sequence of human TLR4 protein isoform B (NP_612566).

25 SEQ ID NO:18 is the amino acid sequence of human TLR4 protein isoform C (NP_003257).

SEQ ID NO:19 is the amino acid sequence of human TLR4 protein isoform D (NP_612567).

SEQ ID NO:20 is the nucleotide sequence of murine TLR4 cDNA (NM_021297).

30 SEQ ID NO:21 is the nucleotide sequence of murine TLR4 mRNA (AF185285).

SEQ ID NO:22 is the nucleotide sequence of murine TLR4 mRNA (AF110133).

SEQ ID NO:23 is the amino acid sequence of murine TLR4 protein (AAD29272).

SEQ ID NO:24 is the amino acid sequence of murine TLR4 protein (AAF04278).

- 14 -

- SEQ ID NO:25 is the nucleotide sequence of human TLR5 cDNA (AB060695).
SEQ ID NO:26 is the amino acid sequence of human TLR5 protein (BAB43558).
SEQ ID NO:27 is the amino acid sequence of human TLR5 protein (O60602).
SEQ ID NO:28 is the amino acid sequence of human TLR5 protein (AAC34136).
- 5 SEQ ID NO:29 is the nucleotide sequence of murine TLR5 cDNA (AF186107).
SEQ ID NO:30 is the amino acid sequence of murine TLR5 protein (AAF65625).
SEQ ID NO:31 is the nucleotide sequence of human TLR7 cDNA (AF240467).
SEQ ID NO:32 is the nucleotide sequence of human TLR7 cDNA (AF245702).
SEQ ID NO:33 is the nucleotide sequence of human TLR7 cDNA (NM_016562).
- 10 SEQ ID NO:34 is the amino acid sequence of human TLR7 protein (AAF60188).
SEQ ID NO:35 is the amino acid sequence of human TLR7 protein (AAF78035).
SEQ ID NO:36 is the amino acid sequence of human TLR7 protein (NP_057646).
SEQ ID NO:37 is the amino acid sequence of human TLR7 protein (Q9NYK1).
SEQ ID NO:38 is the nucleotide sequence of murine TLR7 cDNA (AY035889).
- 15 SEQ ID NO:39 is the nucleotide sequence of murine TLR7 splice variant
(NM_133211).
- SEQ ID NO:40 is the nucleotide sequence of murine TLR7 splice variant (AF334942).
SEQ ID NO:41 is the amino acid sequence of murine TLR7 protein (AAK62676).
SEQ ID NO:42 is the amino acid sequence of murine TLR7 protein (AAL73191).
- 20 SEQ ID NO:43 is the amino acid sequence of murine TLR7 protein (AAL73192).
SEQ ID NO:44 is the amino acid sequence of murine TLR7 protein (NP_573474).
SEQ ID NO:45 is the amino acid sequence of murine TLR7 protein (P58681).
SEQ ID NO:46 is the nucleotide sequence of human TLR8 cDNA (AF245703).
SEQ ID NO:47 is the nucleotide sequence of human TLR8 cDNA (AF246971).
- 25 SEQ ID NO:48 is the nucleotide sequence of human TLR8 cDNA (NM_138636).
SEQ ID NO:49 is the nucleotide sequence of human TLR8 cDNA (NM_016610).
SEQ ID NO:50 is the amino acid sequence of human TLR8 protein (AAF78036).
SEQ ID NO:51 is the amino acid sequence of human TLR8 protein (AAF64061).
SEQ ID NO:52 is the amino acid sequence of human TLR8 protein (Q9NR97).
- 30 SEQ ID NO:53 is the amino acid sequence of human TLR8 protein (NP_619542).
SEQ ID NO:54 is the amino acid sequence of human TLR8 protein (NP_057694).
SEQ ID NO:55 is the nucleotide sequence of murine TLR8 cDNA (AY035890).
SEQ ID NO:56 is the nucleotide sequence of murine TLR8 cDNA (NM_133212).

- 15 -

- SEQ ID NO:57 is the amino acid sequence of murine TLR8 protein (AAK62677).
SEQ ID NO:58 is the amino acid sequence of murine TLR8 protein (NP_573475).
SEQ ID NO:59 is the amino acid sequence of murine TLR8 protein (P58682).
SEQ ID NO:60 is the nucleotide sequence of human TLR9 cDNA (AF245704).
5 SEQ ID NO:61 is the nucleotide sequence of human TLR9 cDNA (AB045180).
SEQ ID NO:62 is the amino acid sequence of human TLR9 protein (AAF78037).
SEQ ID NO:63 is the amino acid sequence of human TLR9 protein (AAF72189).
SEQ ID NO:64 is the amino acid sequence of human TLR9 protein (AAG01734).
SEQ ID NO:65 is the amino acid sequence of human TLR9 protein (AAG01735).
10 SEQ ID NO:66 is the amino acid sequence of human TLR9 protein (AAG01736).
SEQ ID NO:67 is the amino acid sequence of human TLR9 protein (BAB19259).
SEQ ID NO:68 is the nucleotide sequence of murine TLR9 cDNA (AF348140).
SEQ ID NO:69 is the nucleotide sequence of murine TLR9 cDNA (AB045181).
SEQ ID NO:70 is the nucleotide sequence of murine TLR9 cDNA (AF314224).
15 SEQ ID NO:71 is the nucleotide sequence of murine TLR9 cDNA (NM_031178).
SEQ ID NO:72 is the amino acid sequence of murine TLR9 protein (AAK29625).
SEQ ID NO:73 is the amino acid sequence of murine TLR9 protein (AAK28488).
SEQ ID NO:74 is the amino acid sequence of murine TLR9 protein (BAB19260).
SEQ ID NO:75 is the amino acid sequence of murine TLR9 protein (NP_112455).
20 SEQ ID NO:76 is the nucleotide sequence of human TLR10 cDNA (AF296673).
SEQ ID NO:77 is the amino acid sequence of human TLR10 protein (AAK26744).
SEQ ID NO:78 is the nucleotide sequence of human TLR6 cDNA (AB020807).
SEQ ID NO:79 is the nucleotide sequence of human TLR6 mRNA (NM_006068).
SEQ ID NO:80 is the amino acid sequence of human TLR6 protein (BAA78631).
25 SEQ ID NO:81 is the amino acid sequence of human TLR6 protein (NP_006059).
SEQ ID NO:82 is the amino acid sequence of human TLR6 protein (Q9Y2C9).
SEQ ID NO:83 is the nucleotide sequence of murine TLR6 cDNA (AB020808).
SEQ ID NO:84 is the nucleotide sequence of murine TLR6 cDNA (NM_011604).
SEQ ID NO:85 is the nucleotide sequence of murine TLR6 cDNA (AF314636).
30 SEQ ID NO:86 is the amino acid sequence of murine TLR6 protein (BAA78632).
SEQ ID NO:87 is the amino acid sequence of murine TLR6 protein (AAG38563).
SEQ ID NO:88 is the amino acid sequence of murine TLR6 protein (NP_035734).
SEQ ID NO:89 is the amino acid sequence of murine TLR6 protein (Q9EPW9).

- 16 -

SEQ ID NO:90 is the nucleotide sequence of a consensus sequence for NF- κ B p50 subunit.

SEQ ID NO:91 is the nucleotide sequence of a consensus sequence for NF- κ B p65 subunit.

5 SEQ ID NO:92 is the nucleotide sequence of an example of an NF- κ B p65 subunit binding site.

SEQ ID NO:93 is the nucleotide sequence of an example of a murine CREB binding site.

10 SEQ ID NO:94 is the nucleotide sequence of an example of a murine AP-1 binding site.

SEQ ID NO:95 is the nucleotide sequence of an example of a murine AP-1 binding site.

SEQ ID NO:96 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:97 is the nucleotide sequence of an example of an ISRE.

15 SEQ ID NO:98 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:99 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:100 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:101 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:102 is the nucleotide sequence of an example of an ISRE.

20 SEQ ID NO:103 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:104 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:105 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:106 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:107 is the nucleotide sequence of an example of an NFAT binding site.

25 SEQ ID NO:108 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:109 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:110 is the nucleotide sequence of an example of a GAS.

SEQ ID NO:111 is the nucleotide sequence of a p53 binding site consensus sequence.

SEQ ID NO:112 is the nucleotide sequence of an example of a p53 binding site.

30 SEQ ID NO:113 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:114 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:115 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:116 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:117 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:118 is the nucleotide sequence of an example of a TARE (TNF- α response element).

SEQ ID NO:119 is the nucleotide sequence of an example of an SRF binding site.

5 SEQ ID NO:120 is the nucleotide sequence of an example of an SRF binding site.

SEQ ID NO:121 is the nucleotide sequence of the -620 to +50 promoter region of IFN- α 4.

SEQ ID NO:122 is the nucleotide sequence of the -140 to +9 promoter region of IFN- α 1.

10 SEQ ID NO:123 is the nucleotide sequence of the -140 to +9 promoter region of IFN- α 1 (point mutation, AL353732).

SEQ ID NO:124 is the nucleotide sequence of the -280 to +20 promoter region of IFN- β .

15 SEQ ID NO:125 is the nucleotide sequence of the -397 to +5 promoter region of human RANTES (AB023652).

SEQ ID NO:126 is the nucleotide sequence of the -751 to +30 promoter region of human IL-12 p40.

SEQ ID NO:127 is the nucleotide sequence of the -250 to +30 promoter region of human IL-12 p40.

20 SEQ ID NO:128 is the nucleotide sequence of the -288 to +7 promoter region of human IL-6.

SEQ ID NO:129 is the nucleotide sequence of the IL-6 gene promoter from -1174 to +7 (M22111).

25 SEQ ID NO:130 is the nucleotide sequence of the -734 to +44 promoter region derived from human IL-8.

SEQ ID NO:131 is the nucleotide sequence of the -162 to 44 promoter region of human IL-8.

SEQ ID NO:132 is the nucleotide sequence of the -615 to +30 promoter region of human TNF- α .

30 SEQ ID NO:133 is the nucleotide sequence of a promoter region of human TNF- β .

SEQ ID NO:134 is the nucleotide sequence of the -875 to +97 promoter region of human IP-10.

- 18 -

SEQ ID NO:135 is the nucleotide sequence of the -219 to +114 promoter region of human CXCL11 (IP-9).

SEQ ID NO:136 is the nucleotide sequence of the full length promoter region of human CXCL11 (IP-9).

5 SEQ ID NO:137 is the nucleotide sequence of the -289 to +217 promoter region of IGFBP4 (Insulin growth factor binding protein 4).

SEQ ID NO:138 is the nucleotide sequence of the full length promoter region of IGFBP4.

SEQ ID NO:139 is the nucleotide sequence of an immunostimulatory nucleic acid.

10 SEQ ID NO:140 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:141 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:142 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:143 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:144 is the nucleotide sequence of an immunostimulatory nucleic acid.

15 SEQ ID NO:145 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:146 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:147 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

SEQ ID NO:148 is the nucleotide sequence of an immunostimulatory methylated CpG 20 nucleic acid.

SEQ ID NO:149 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

SEQ ID NO:150 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

25 SEQ ID NO:151 is the nucleotide sequence of an immunoinhibitory nucleic acid.

SEQ ID NO:152 is the nucleotide sequence of a sense primer for human TLR3.

SEQ ID NO:153 is the nucleotide sequence of an antisense primer for human TLR3.

SEQ ID NO:154 is the nucleotide sequence of a GpC nucleic acid.

SEQ ID NO:155 is the nucleotide sequence of a CpG ODN.

30 SEQ ID NO:156 is the nucleotide sequence of a GpC ODN.

SEQ ID NO:157 is the nucleotide sequence of a Me-CpG ODN.

SEQ ID NO:158 is the nucleotide sequence of a TLR9 ligand.

SEQ ID NO:159 is the nucleotide sequence of a TLR9 ligand.

SEQ ID NO:160 is the nucleotide sequence of a TLR9 ligand.

SEQ ID NO:161 is the nucleotide sequence of a TLR9 ligand.

Detailed Description of the Invention

5 In its broadest sense, the invention relates to screening methods and tools to be used to identify and discriminate between newly discovered immunomodulatory molecules and to compare and standardize compositions of known immunomodulatory molecules. The immunomodulatory molecules are preferably TLR ligands.

Thus, the invention is based in part on the discovery that cell lines expressing
10 endogenous TLR respond to TLR ligands in a manner similar to the response of peripheral blood mononuclear cells (PBMC). PBMC respond to immunomodulatory TLR ligands by modulating one or more parameters including gene expression, cell surface marker expression, cytokine and/or chemokine production and secretion, cell cycle status, phosphorylation status, and the like. TLR ligands can be categorized and distinguished based
15 on the cellular changes they induce (i.e., their induction profiles). The ability of a TLR ligand to provide therapeutic or prophylactic benefit to a subject depends on its induction profile. The ability to screen new TLR ligands for a panel of response indicators or parameters allows for rapid discrimination and categorization of TLR ligands. Moreover, the similarity between the cell line responses and those observed after in vivo administration of the TLR ligand
20 indicates that the cell lines are suitable predictors of in vivo activity. The use of in vitro propagated cell lines additionally overcomes the variability encountered when using freshly isolated PBMC.

The TLR ligands identified according to the invention therefore can be used therapeutically or prophylactically in a more patient- or disorder-specific manner. The
25 invention allows for the tailoring of TLR ligands for particular patients or disorders.

The invention identifies a number of cell lines that can be used to identify TLR ligands based on endogenous TLR expression such as TLR3, TLR7 and TLR9 expression. As an example; the invention is premised in part on the discovery of TLR9 expression in a number of cell lines including RPMI 8226, Raji, RAMOS, THP-1, Nalm-6 and KG-1. Cell lines
30 RPMI 8226, Raji and RAMOS have been determined to express TLR7 according to the invention. Cell lines KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell have been discovered to express TLR3 according to the invention.

It is further premised in part on the discovery that RPMI 8226 cells respond to the imidazoquinoline compound R-848. Consistent with this latter finding, it was also discovered
5 that RPMI 8226 cells express TLR7.

The invention in other aspects provides for screening methods and tools for verifying and standardizing compositions containing known TLR ligands. These compositions may be for example commercial production lots to be used in a clinical setting. Accordingly, the invention provides methods for standardizing lots of known TLR ligands prior to distribution
10 and use clinically. In this way, production processes can be observed and controlled and substandard production lots can be identified and eliminated prior to shipment.

The methods of the instant invention can be used at any step in the preparation and production of clinical material, i.e., pharmaceutical product. In particular, the methods will find use in characterizing or validating raw materials, in-process materials, finished product
15 materials (e.g., pre-release materials), and post-production materials (e.g., post-release materials). The methods can also be used to validate existing process methods, as well as to validate new or changed process methods used in the production of the pharmaceutical product.

20 Screening Assays Generally

The screening assays provided herein may be used to identify immunomodulatory agents. Immunomodulatory agents are agents that either stimulate or inhibit immune responses in a subject. Accordingly, as used herein, immunomodulation embraces both immunostimulation and immunoinhibition.

25 The screening methods are used to identify TLR agonists and antagonists. The methods can also be used to identify compounds that enhance the immunostimulation induced by a TLR agonist. This latter set of compounds is referred to herein as "enhancers". A TLR agonist is a compound that stimulates TLR signaling activity. A TLR antagonist is a compound that inhibits TLR signaling activity. Agonists are generally referred to herein as
30 immunostimulatory compounds because stimulation of TLR is associated with immune stimulation. Antagonists are generally referred to herein as immunoinhibitory compounds because inhibition of TLR is associated with immune inhibition. TLR antagonists include compounds that reduce (or eliminate completely) the immunostimulation induced by a TLR

agonist. In some embodiments, the agonists, antagonists and enhancers are TLR ligands (i.e., they bind to a TLR). In other embodiments, the test compounds with agonist, antagonist or enhancer activity may act downstream or upstream of the TLR-TLR ligand interaction.

An "immunostimulatory compound" as used herein refers to a natural or synthetic compound that characteristically induces a TLR-mediated response when contacted with a suitable functional TLR polypeptide. In one embodiment the immunostimulatory compound is a natural or synthetic compound that induces a TLR-mediated response when contacted with a cell that naturally or artificially expresses a suitable functional TLR polypeptide. Depending on the aspect of the invention, the cell may be an experimental cell or a primary cell such as a PBMC.

Examples of immunostimulatory compounds include the following immunostimulatory nucleic acids, which are discussed in further detail below:

5'-TCGTCGTTTGTCTGTTTGTCTT-3'	(SEQ ID NO:1)
5'-TCGTCGTTTGACGTTTGTCTT-3'	(SEQ ID NO:139)
15 5'-TCGTCGTTTGTCTGTTTTTCGA-3'	(SEQ ID NO:140)
5'-TCGTCGTTTCGTCGTTTCGTCGTT-3'	(SEQ ID NO:141)
5'-TCGTCGTTTCGTCGTTTGTCTGTT-3'	(SEQ ID NO:142)
5'-TCGTCGTTTCGGTCGTTT-3'	(SEQ ID NO:143)
5'-TCGTCGTTTCGTGCGTTT-3'	(SEQ ID NO:144)
20 5'-TCGTCGTTTCGGCGGCCGCCG-3'	(SEQ ID NO:145)
5'-TCGTC_GTTTAC_GGCGCC_GTGCCG-3'	(SEQ ID NO:146)

Imidazoquinolines are immune response modifiers thought to induce expression of several cytokines including interferons (e.g., IFN- α and IFN- β), TNF- α and some interleukins (e.g., IL-1, IL-6 and IL-12) as well as chemokines (e.g., IP-10 and IL-8). Imidazoquinolines are capable of stimulating a Th1 immune response, as evidenced in part by their ability to induce increases in IgG2a levels. Imidazoquinoline agents reportedly are also capable of inhibiting production of Th2 cytokines such as IL-4, IL-5, and IL-13. Some of the cytokines induced by imidazoquinolines are produced by macrophages and dendritic cells. Some species of imidazoquinolines have been reported to increase NK cell lytic activity and to stimulate B cells proliferation and differentiation, thereby inducing antibody production and secretion. Imidazoquinoline mimics can also be tested using the screening methods.

An "immunoinhibitory compound" as used herein refers to a natural or synthetic compound that characteristically inhibits a TLR-mediated response when contacted with a suitable functional TLR polypeptide. In one embodiment the immunoinhibitory compound is a natural or synthetic compound that inhibits a TLR-mediated response when contacted with a 5 cell that naturally or artificially expresses a suitable functional TLR polypeptide.

In addition to the immunoinhibitory nucleic acids disclosed elsewhere herein, immunoinhibitory compounds and TLR antagonists encompass certain small molecules (chloroquine, quinacrine, 9-aminoacridines and 4-aminoquinolines, and derivatives thereof) described by Macfarlane and colleagues in U.S. Pat. 6,221,882; U.S. Pat. 6,399,630; U.S. Pat. 10 6,479,504; U.S. Pat. 6,521,637; and published U.S. Pat. application 2002/0151564, the contents of all of which are hereby incorporated by reference in their entirety.

The invention provides in part methods and tools that utilize cell lines, in modified or unmodified form, as surrogates for PBMC. Immunomodulation by TLR ligands can be assessed using one or preferably more parameters including but not limited to cytokine and 15 chemokine secretion, upregulation of cell surface markers, changes in cell proliferation, phosphorylation changes, and the like. These parameters may be native readouts or artificial readouts as described herein.

The cellular response to immunostimulatory nucleic acids by the cell lines described herein (e.g., RPMI 8226, Raji, RAMOS, and the like) so resembles that of PBMC that these 20 cells can be used to identify and differentiate between immunomodulatory compounds based on the extent of the induced response and the particular profile of that response. The invention provides a number of cell lines each with a particular endogenous TLR expression profile, as described herein.

The cell lines can be used to identify immunomodulatory compounds with particular 25 response profiles. As an example, the cell lines can be used to identify molecules that are mimics to known TLR ligands. The cell lines can also be used to identify TLR ligands that trigger some but not necessarily all of the responses induced by known TLR ligands. For example, the cell line can be used to distinguish between compounds based on individual or group cytokine or chemokine secretion, or based on upregulation of one, a subset or all cell 30 surface markers. As an example, in some therapeutic instances, it may be desirable to use a compound that induces the secretion of relatively high levels of chemokine such as IP-10, yet induces only relatively low levels of one or more other factors. The screening methods of the invention allow for the identification of such a compound with this type of induction profile.

It is to be understood that the screening method also can be used to determine effective amounts of known and newly identified immunomodulatory compounds. For example, the EC₅₀ value of a TLR ligand for the production of a particular cytokine or chemokine can be determined, thereby facilitating comparison between different nucleic acids.

5 Generally, these assays require the incubation of cells with a reference compound and a test compound, and an analysis of the readout. Depending on the embodiment, the same cells are exposed to the reference compound and the test compound. An example of this latter embodiment is a screening assay for compounds that enhance the immunostimulatory effects of a TLR agonist. Another example is a screening assay for compounds that inhibit the
10 immunostimulatory effects of a TLR agonist. In both examples, the reference compound is a positive reference compound (i.e., it is itself immunostimulatory).

In other embodiments, particularly those directed at identifying immunostimulatory compounds, separate aliquots from the same cell line (or from the same freshly harvested cell population) are exposed to either the reference compound or the test compound, and the
15 readouts from each are measured and compared to the other. If the reference compound is a negative reference compound (i.e., it is inert and neither immunostimulatory nor immuno inhibitory), then any test level that is greater than the reference level is indicative of a test compound that has at least some immunostimulatory capacity. Generally, the negative reference compound is used to set background levels of immunostimulation or
20 immuno inhibition observed in the absence of the test compound. If the reference compound is a positive reference compound (i.e., it is immunostimulatory), then it is possible to compare and contrast the induction profile of the test compound to that of the reference compound.

In some instances, separate reference assays individually containing a positive and a negative reference compound are performed alongside the test assay. For example, if the test
25 assay is a screen for an immunostimulatory TLR ligand, then reference assays can be a positive reference assay (in which the reference compound is immunostimulatory), a negative reference assay (in which the reference compound is immunologically inert or neutral), or both. A test compound is defined as immunostimulatory if it induces a response greater than that of the negative reference compound. The level and profile of the immunostimulatory
30 response can be compared to the level and profile induced by the positive reference compound. It is to be understood that a test compound that induces a level of immunostimulation less than that of the positive reference compound may still be considered immunostimulatory according to the invention. Modifications to these screening assays for a

desired readout will be apparent to those of ordinary skill in the art based on the teachings provided herein.

If the test assay is a screen for an immunoinhibitory TLR ligand, then the assay may generally involve co-incubation of the test compound and a positive reference compound.

- 5 The control assay may include co-incubation of the negative and positive reference compounds. As used herein, co-incubation embraces simultaneous or consecutive addition of the reference and test compounds. The test compound may be added before or after the positive reference compound. An immunoinhibitory test compound may be identified by a diminution of the immunostimulatory response induced by the positive reference compound
- 10 when in the presence of the test compound. If the level of the response is less in the presence of the test compound, this indicates that the test compound is capable of interfering with the immunostimulatory effects of the positive reference compound. As an example, simultaneous or consecutive addition of a putative immunoinhibitory test compound can reduce the amount of cytokines or chemokines secreted by cells in response to the positive reference compound
- 15 alone, indicating an inhibition of the immunostimulatory effects of the positive reference compound.

The reference immunoinhibitory compound can be used at one or more concentrations in conjunction with a selected or constant concentration of reference immunostimulatory compound. Under proper conditions, the immunostimulatory effect of the reference

20 immunostimulatory compound will be less in the presence of the immunoinhibitory substance than in the absence of the immunoinhibitory substance. Furthermore, under proper conditions, the immunostimulatory effect of the reference immunostimulatory compound will decrease with increasing concentration of the immunoinhibitory substance.

The breadth of response by the cell line to immunomodulatory compounds, and its

25 facile manipulation, allows for the identification of novel compounds. The cell line allows the rapid discovery of such compounds given that it lends itself to high throughput screening methods such as those provided herein. These methods and compositions are described in greater detail below. The invention therefore provides screening methods that utilize cell lines that either endogenous express TLRs such as the RPMI 8226 cell line as well as cell

30 lines that have been modified to express TLRs. The invention further provides compositions that comprise such cell lines.

The verification and standardization methods of the invention generally involve assays in which an isolated cell expressing a functional TLR is contacted with each of two

compositions, each composition containing a known ligand for the TLR. One composition is a reference composition, and the assay using the reference composition yields a reference activity. The second composition is a test composition, and the assay using the test composition yields a test activity. The two contacting steps can be performed on separate
5 cells that are alike, and typically will be performed on separate populations of cells that are alike. For example, the separate cells or the separate populations of cells can be drawn from a single population of cells. In typical usage according to this embodiment, the reference and test activities are measured essentially concurrently, although the use of historical reference activity is also contemplated by the methods of the invention. As an alternative, the two
10 contacting steps can be performed on a single cell or on a single population of cells, usually in an essentially concurrent manner when it is desirable to have competition between reference and test compositions. In one embodiment the known TLR ligand is a nucleic acid molecule.

The assays of the invention are performed under specific conditions so that comparison can be made between reference and test activities or levels. The results of the
15 comparison can be used as a basis upon which to accept or reject the test material as suitable for its intended use.

The biological characterization of the reference composition will generally entail a series of biological activity measurements of the reference composition using a single assay under defined conditions in order to define a range of inter-test variance. The range of inter-
20 test variance so obtained using reference composition can be used to define an acceptable range of variance within which a subsequent test measurement must fall in order to satisfy quality standards. Such a range of acceptable variance can serve as a basis for developing predetermined range of variance about the reference activity, i.e., acceptance criteria for a particular test composition or test lot. For example, a particular reference composition can be assayed under defined conditions in a number of independent measurements and found to yield a result expressed as 100 ± 5 units of activity. Under this same example, a subsequent test measurement of a test composition performed using the same assay and defined
25 conditions is found to yield 97 units of activity. The activity of the test composition under this example thus yielded a result that falls within the normal range of inter-test variance observed for the reference composition. Accordingly, the test material under this example could be selected on the basis of the test activity falling within a predetermined range of variance about the reference activity. In short, the test material can be deemed acceptable
30

provided the test activity falls within a predetermined range of activity that is related to the activity of the reference material.

In one embodiment, the methods of the invention provide for comparison between a reference lot of a particular TLR ligand and a test lot of the same particular TLR ligand. Such 5 comparison is useful for quality control assessment of the test lot of material, also referred to herein as validation, e.g., product validation. Such comparison is also useful for process validation.

In another embodiment, the methods of the invention provide for comparison between a reference lot of a particular TLR ligand and a test lot of a different TLR ligand. In a simple 10 example, where a test TLR ligand (T) is expected to have little or no activity characteristic of reference TLR ligand (R), comparison can be made between T and R to confirm the lack of R-like activity possessed by T. In a more complex example, where a test TLR ligand (C) is capable of exerting two different effects, wherein each effect is characteristic of one of two different classes of TLR ligand and is best characterized by one of two different reference 15 TLR ligands (A and B), the test TLR ligand (C) can be compared with either of the two reference TLR ligands (A or B). In this second example, test composition C could be found, for example, to possess 50 percent A-like activity compared with reference A and 70 percent B-like activity compared with reference B. Test composition C could thus independently meet or fail to meet predetermined standards for each of A-like activity and B-like activity. 20 Such comparison is also useful for quality control assessment of the test lot of material, e.g., product validation. Of course test TLR ligand C can alternatively or additionally be compared against reference TLR ligand C, as described in the preceding paragraph.

To facilitate the methods of the invention, certain conditions for carrying out the assays are standardized and used for measurements of both reference activity and test activity. 25 In this way direct comparison between reference activity and test activity can be made readily. Conditions that can be standardized and used in this manner can include, without limitation, readout, temperature, media characteristics, duration (time between introduction of reference composition or test composition and activity measurement), methods of sampling, etc. In some embodiments the methods of the invention can be at least partially automated in order to 30 increase throughput and/or to reduce inter-test variability. For example, robotic devices and workstations with the capacity to dispense and/or sample fluids in a set or programmable fashion are now well known in the art and can be used in performing the methods of the instant invention.

In one embodiment a standard curve of reference composition activity is employed. Typically the standard curve is generated by selecting conditions including concentration of the reference composition such that the dose-response curve is essentially linear (and the slope is non-zero) over a range of concentrations that includes the effective concentration at 5 which activity is 50 percent of maximum (EC50). In one embodiment the standard curve spans a range of concentrations defined by EC50 \pm 1 log concentration, e.g., 1×10^{-7} M – 1×10^{-5} M, where EC50 is 1×10^{-6} M. In another embodiment the standard curve spans a broader range of concentrations defined by EC50 \pm 2 log concentration, e.g., 1×10^{-8} M – 1×10^{-4} M, where EC50 is 1×10^{-6} M. In yet another embodiment the standard curve spans a narrower 10 range of concentrations defined by EC50 \pm 0.5 log concentration, e.g., 3.16×10^{-7} M – 3.16×10^{-6} M, where EC50 is 1×10^{-6} M. The foregoing embodiments are intended to be exemplary and not limiting in any way. One of skill in the art will be able to select, for a given reference 15 composition and without undue experimentation, an appropriate range of concentrations about some middle value in order to generate an essentially linear standard curve with a non-zero slope.

In one embodiment a non-linear standard curve of reference and test composition activity is employed. The standard curve can be generated by selecting conditions including concentrations of the reference composition such that the dose-response curve is sigmoidal and the EC50 value can be determined. Comparison of reference and test activity can be done 20 by comparing, e.g., the EC50 values of both curves. Concentration range is chosen to yield a complete sigmoidal response, e.g., concentration should include EC50 \pm 3 log concentration or EC50 \pm 4 log concentration. In the case of testing an inhibitory compound the value determined would be the IC50, i.e., concentration where inhibition of the stimulatory signal is half-maximal.

The methods of the invention can be adapted to be automated or at least partially 25 automated methods, as well as to parallel array or high throughput format methods. For example, the assays can be set up using multiwell plates in which cells are dispensed in individual wells and reagents are added in a systematic manner using a multiwell delivery device suited to the geometry of the multiwell plate. Manual and robotic multiwell delivery 30 devices suitable for use in a high throughput screening assay are known by those skilled in the art. Each well or array element can be mapped in a one-to-one manner to a particular test condition, such as the test compound. Readouts can also be performed in this multiwell array, preferably using a multiwell plate reader device or the like. Examples of such devices are

known in the art and are available through commercial sources. Sample and reagent handling can be automated to further enhance the throughput capacity of the screening assay, such that dozens, hundreds, thousands, or even millions of parallel assays can be performed in a day or in a week. Fully robotic systems are known in the art for applications such as generation and 5 analysis of combinatorial libraries of synthetic compounds. See, for example, U.S. Pat. Nos. 5,443,791 and 5,708,158.

Cell lines

The screening methods may use experimental cells. As used herein, an experimental 10 cell is a non-primary cell (i.e., it is not a cell that has been recently harvested from a subject). It excludes, for example, freshly harvested PBMCs. An experimental cell includes a cell from a cell line such as the RPMI 8226 cell line.

In certain embodiments, the cell naturally expresses a functional TLR. In one embodiment relating to the verification and standardization aspects of the invention, the cell 15 may be a PBMC, preferably a PBMC freshly harvested from a subject.

Cells that would be suitable for identification of TLR agonists, antagonists or enhancers according to the invention may possess one or more particular attributes. These attributes include but are not limited to being of human origin, being an immortalized stable 20 cell line, endogenously expressing at least one functional TLR or a combination of functional TLRs, having intact signaling mechanisms, having intact uptake mechanisms, being able to upregulate cytokines, chemokines or cell surface markers, deriving from normal human B cells or from myeloma or B cell leukemia, deriving from human plasmacytoid and myeloid dendritic cells, and readily activatable by TLR ligands such as TLR7 ligands, TLR8 ligands or 25 TLR9 ligands such as CpG nucleic acids or nucleic acids having other immunostimulatory sequence motifs or small molecules such as imidazoquinoline compounds.

In some embodiments, the cell line is the Raji cell line which expresses TLR3, TLR7 and TLR9. This latter cell line secretes, for example, IL-6 and IFN- α 2 upon CpG nucleic acid exposure. In other embodiments, the cell line is RPMI 8226 which expresses TLR7 and TLR9. Upon CpG nucleic acid exposure, this cell line expresses, produces and/or secretes IL- 30 8, IL-10, IP-10 and TNF- α . It also expresses at its cell surface CD86, HLA-DR and CD71. In yet other embodiments, the cell line is the RAMOS cell line which expresses TLR3, TLR7 and TLR9. This cell line at least induces CD80 cell surface expression in response to CpG nucleic acid exposure.

- 29 -

The cell lines have been observed to respond in a concentration dependent manner to TLR ligands such as but not limited to CpG nucleic acids and some non-CpG nucleic acids including T-rich nucleic acids, poly-T nucleic acids and poly-G nucleic acids. The highest responses have been observed using CpG nucleic acids.

5 The screening methods employ a variety of cell lines as shown in the Examples. These include A549 (human lung carcinoma, ATCC CCL-185), BeWo (human choriocarcinoma, ATCC CCL-98), HeLa (human cervix carcinoma, ATCC CCL-2), Hep-2 (human cervix carcinoma, ATCC CCL-23), KG-1 (human acute myeloid leukemia, ATCC CCL-246), MUTZ-3 (human acute myelomonocytic leukemia, German Collection of Cell 10 lines and Microorganisms (DSZM) ACC-295), Nalm-6 (human B cell precursor leukemia, DSZM ACC-128), NK-92 (human Natural killer cell line, ATCC CRL-2407), NK-92 MI (IL-2 independent human Natural killer cell line, ATCC CRL-2408), Raji (human B lymphocyte Burkitt's lymphoma, ATCC CCL-86), RAMOS (B lymphocyte Burkitt's lymphoma, ATCC CRL-1596), RPMI 8226 (human B lymphocyte multiple myeloma, ATCC CCL-155), THP-1 15 (human acute monocytic leukemia, ATCC TIB 202), U937 (human lymphoma, ATCC CRL-1593.2) and Jurkat (human T cell leukemia, ATCC TIB 152).

As shown in the Examples, each of the afore-mentioned cell lines has a particular endogenous TLR expression profile which dictates its suitability in a particular screening assay.

20 A cell that artificially expresses a functional TLR can be a cell that does not express the functional TLR but for a transfected TLR expression vector. For example, human 293 fibroblasts (ATCC CRL-1573) do not express TLR7, TLR8 or TLR9, and they express very little TLR3. As described in the examples below, such cells can be transiently or stably transfected with suitable expression vector (or vectors) so as to yield cells that do express 25 TLR3, TLR7, TLR8, TLR9, or any combination thereof. Alternatively, a cell that artificially expresses a functional TLR can be a cell that expresses the functional TLR at a significantly higher level with the TLR expression vector than it does without the TLR expression vector. Transfected cells are considered modified cells, as used herein.

30 A cell that artificially expresses an expression or reporter construct is preferably stably transfected.

RPMI

- 30 -

The RPMI 8226 cell line is a human multiple myeloma cell line. The cell line was established from the peripheral blood of a 61 year old man at the time of diagnosis for multiple myeloma (IgG lambda type). RPMI 8226 was previously reported as responsive to CpG nucleic acids as evidenced by the production and secretion of IL-6 protein and 5 production of IL-12p40 mRNA. (Takeshita et al. (2000), Eur. J. Immunol. 30, 108-116, and Takeshita et al. (2000) *Ibid.* 30, 1967-1976) Takeshita et al. however used the cell line solely to study promoter constructs in order to identify transcription factor binding sites important for CpG nucleic acid signaling. It is now known according to the invention that the cell line produces a number of other chemokines and cytokines including IL-8, IL-10 and IP-10. It has 10 also been discovered according to the invention that the cell line responds to immunostimulatory nucleic acids by upregulating cell surface expression of particular markers. Many of these markers, including CD71, CD86 and HLA-DR, are similarly upregulated in PBMCs exposed to immunostimulatory nucleic acids. This has been observed using flow cytometric analysis of the cell line following CpG nucleic acid exposure. In other 15 aspects of the invention, the cell line can be used in similar screening assays that involve secretion of IL-6, IL-12 and/or TNF- α .

It has recently been discovered that R-848 mediates its immunostimulatory effects via other TLR family members, namely TLR7 and TLR8. TLR7 has previously been found expressed on human B cells. It has now also been discovered according to the invention that 20 RPMI 8226 expresses TLR9 as well as TLR7, thus making it a suitable cell line for identifying immunostimulatory nucleic acid and/or imidazoquinoline (e.g., R-848) mimics or other small molecules that also signal through TLR7 and/or TLR9. Incubation of RPMI 8226 cells with the imidazoquinoline R-848 (Resiquimod) induces for example IL-8, IL-10 and IP-10 production.

25

Known TLR Ligands

Ligands for many but not all of the TLRs have been described. For instance, it has been reported that TLR1 and TLR2 signals in response to peptidoglycan and lipopeptides. Yoshimura A et al. (1999) *J Immunol* 163:1-5; Brightbill HD et al. (1999) *Science* 285:732-6; 30 Aliprantis AO et al. (1999) *Science* 285:736-9; Takeuchi O et al. (1999) *Immunity* 11:443-51; Underhill DM et al. (1999) *Nature* 401:811-5. TLR4 has been reported to signal in response to lipopolysaccharide (LPS). Hoshino K et al. (1999) *J Immunol* 162:3749-52; Poltorak A et al. (1998) *Science* 282:2085-8; Medzhitov R et al. (1997) *Nature* 388:394-7. Bacterial

flagellin has been reported to be a natural ligand for TLR5. Hayashi F et al. (2001) *Nature* 410:1099-1103. TLR6, in conjunction with TLR2, has been reported to signal in response to proteoglycan. Ozinsky A et al. (2000) *Proc Natl Acad Sci USA* 97:13766-71; Takeuchi O et al. (2001) *Int Immunol* 13:933-40.

5 TLR9 is a receptor for CpG DNA. Hemmi H et al. (2000) *Nature* 408:740-5. Other TLR9 ligands are described herein under "Immunostimulatory Nucleic Acids". Certain imidazoquinoline compounds having antiviral activity are ligands of TLR7 and TLR8. Imidazoquinolines are potent synthetic activators of immune cells with antiviral and antitumor properties. R-848 is a ligand for human TLR7 and TLR8. Jurk M et al. (2002) *Nat Immunol* 3:499. Ligands of TLR3 include poly(I:C) and double-stranded RNA (dsRNA). Alexopoulou et al. (2001) *Nature* 413:732-738. For purposes of this invention, poly(I:C) and double-stranded RNA (dsRNA) are classified as oligonucleotide molecules. TLR3 may have a role in host defense against viruses.

10 15 **Reference and Test Compounds**

A test and/or reference compound can be a nucleic acid such as an oligonucleotide or a polynucleotide, an oligopeptide, a polypeptide, a lipid such as a lipopolysaccharide, a carbohydrate such as an oligosaccharide or a polysaccharide, or a small molecule. Alternatively, these compounds may also comprise or be synthesized from elements such as 20 amino acids, carbohydrates, hormones, lipids, organic molecules, and the like.

Small molecules in general include naturally occurring, synthetic, and semisynthetic organic and organometallic compounds with molecular weight less than about 2.5 kDa. Examples of small molecules include most drugs, subunits of polymeric materials, and analogs and derivatives thereof.

25 Some specific examples of small molecules include the imidazoquinolines. As used herein, an imidazoquinolines include imidazoquinoline amines (imidazoquinolinamines), imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2 bridged imidazoquinoline amines. These compounds have been described in U.S. Pat. Nos. 4,689,338; 4,929,624; 5,238,944; 5,266,575; 5,268,376; 5,346,905; 5,352,784; 5,389,640; 30 5,395,937; 5,482,936; 5,494,916; 5,525,612; 6,039,969 and 6,110,929. Particular species of imidazoquinoline agents include resiquimod (R-848; S-28463; 4-amino-2 ethoxymethyl- α,α -dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol); and imiquimod (R-837; S-26308; 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinoline-4-amine). Further examples of specific small

molecules include 4-aminoquinoline and derivatives thereof, 9-aminoacridine and derivatives thereof, and additional compounds disclosed in U.S. Pat. Nos. 6,221,882; 6,399,630; 6,479,504; and 6,521,637; and published U.S. Pat. Application No. 2002/0151564 A1, the entire contents of which are hereby incorporated by reference.

5 The test and reference compounds may be formulated for pharmaceutical use or not. For example, a test compound not formulated for pharmaceutical use can be a compound (e.g., a lot or batch of the compound) under evaluation for possible use in preparing a pharmaceutical formulation of the compound.

A reference compound, as used herein, is a compound having a known activity in the
10 presence of a TLR. The reference compound may stimulate TLR signaling (and is therefore regarded as a positive reference compound), or it may be inert in the presence of a TLR (and is therefore regarded as a negative reference compound). If it is a positive reference compound, it need not be the best known stimulator of TLR signaling (i.e., it is possible that other reference compounds and even test compounds will stimulate TLR signaling to a greater
15 extent). The readout of the screening assay may simply be stated relative to the level of signaling that occurs in the presence of the reference compound. Preferably, the reference compound is analyzed prior to the screening assay in order to determine its level of activity on a TLR. In some aspects of the invention, the reference compound and the test compound will be assayed separately (i.e., in separate wells); in other aspects, the reference compound and
20 the test compound will be assayed together (i.e., in the same well). These latter aspects are designed to measure the ability of a test compound to modulate the activity of the reference compound. The activity of the test compound and the reference compound combined (i.e., when assayed together in the same well) may be the same as that of the positive reference compound alone, indicating at a minimum that the test compound is not inhibitory; or it may be less than that of the positive reference compound, indicating at a minimum that it is inhibitory to the effect of the reference compound; or it may be additive or synergistic possibly indicating that the test compound is an enhancer. The effect of an enhance may be due to its ability to stimulate TLR signaling independently of the positive reference compound.
25

30 A "reference composition" as used herein refers to a composition that includes a reference compound and optionally another agent, e.g., a pharmaceutically acceptable carrier and/or another biologically active agent. A reference compound may be an immunostimulatory compound or it may be an immunoinhibitory compound.

As discussed further below, in some aspects of the invention the reference compositions include both finished products, e.g., finished pharmaceutical products, as well as raw materials and other in-process materials used for the preparation of such finished products, all of which contain a known TLR ligand. As used herein, a "production lot" shall refer to a batch or lot of a completed product prepared for release as clinical material, e.g., a pharmaceutical product. As used herein, an "in-process lot" shall refer to a batch or lot of unfinished product that is prepared in the course of making a production lot; an "in-process lot" shall also refer to a batch or lot of raw material provided for use in the production of a production lot.

In some aspects of the invention, the reference compositions of the invention are highly characterized in terms of their chemical, physical, and biological properties. A reference composition will be a specific composition previously determined to have a specific activity, or range of specific activity, of the particular known TLR ligand present in the composition. As used herein, "specific activity" refers to an amount of activity per unit mass or per unit volume of the reference composition as a whole, as determined using a defined assay under defined conditions. In one embodiment the reference composition is a representative sample of a particular lot or batch of a specific TLR ligand. In one embodiment the reference composition is a representative sample of a particular lot or batch of a specific TLR ligand formulated for pharmaceutical use, e.g., a sterile solution of the TLR ligand at a determined concentration or activity.

At least the following parameters are typically very well defined for a given reference composition: chemical formula of the active ingredient TLR ligand (e.g., nucleobase sequence and type of backbone of a nucleic acid; structural formula of a small molecule); concentration; diluent composition; and purity. Such parameters as purity and concentration can be determined using any appropriate physicochemical method, e.g., optical spectroscopy including absorbance at one or more specified wavelengths; nuclear magnetic resonance (NMR) spectroscopy; mass spectrometry (MS), including matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS); melting point; specific gravity; chromatography including as appropriate high pressure liquid chromatography (HPLC), one- and two-dimensional polyacrylamide gel electrophoresis (PAGE), capillary electrophoresis, and the like; as well as other methods known to those of skill in the art.

Reference compositions can also be very well characterized in terms of their biological activity, independent of the methods of the invention, although the methods of the

invention generally include such characterization, at least in part. A reference composition can be very well characterized in terms of its biological activity by characterizing, both qualitatively and quantitatively, the response by sensitive cells to the reference composition under defined conditions. For example, a reference composition can be a specific CpG 5 oligonucleotide such as SEQ ID NO:1 which in a specific assay and under specific conditions of temperature, concentration, duration of contact between the CpG oligonucleotide and a population of TLR9-expressing cells, and particular readout, reliably yields a specific result or range of results. Results can be expressed in any suitable manner, but can include results expressed on a per-cell basis, e.g., picograms of particular cytokine per cell per hour of 10 contact with the reference composition. Reference compositions can be very well characterized in terms of their biological activity according to one or more parameters, for example, according to their capacity to induce each of a plurality of cytokines.

The methods of the invention also involve measurement of a test activity of a test composition containing a known TLR ligand. A "test composition" as used herein refers to a 15 composition that includes a test compound and optionally another agent, e.g., a pharmaceutically acceptable carrier and/or another biologically active agent. A test compound can be an immunostimulatory compound or it can be an immunoinhibitory compound. In some aspects of the invention, the test compound is a known TLR ligand. Test compositions of the invention may comprise known TLR agonist or TLR antagonist 20 compounds, generally but not necessarily nominally the same as the reference compositions against which comparison is to be made according to some aspects of the invention. Thus test compositions may encompass immunostimulatory compounds, immunoinhibitory compounds, known TLR ligands, finished pharmaceutical products, and raw materials and other in-process materials used for the preparation of such finished products.

Unlike a reference composition, a test composition is not characterized at all, or is 25 only partially characterized, or is not as well characterized as the reference composition, in terms of its chemical, physical, or (most particularly) biological properties. The methods of the invention permit further characterization of the test composition by comparison with a reference composition. In some aspects, a test composition will be a specific composition 30 previously determined to be a ligand of a specific TLR. In one embodiment the test composition is a representative sample of a particular lot or batch of a specific TLR ligand. In one embodiment the test composition is a representative sample of a particular lot or batch of

a specific TLR ligand formulated for pharmaceutical use, e.g., a sterile solution of the TLR ligand at a determined concentration or activity.

Immunostimulatory and Immunoinhibitory Nucleic Acids

5 Nucleic acids useful as reference compounds and as test compounds in the methods of the invention include single- and double-stranded natural and synthetic nucleic acids, including those with phosphodiester, stabilized, and chimeric backbones. Also encompassed are at least the following classes of nucleic acids, which are described in detail below: immunostimulatory CpG nucleic acids (CpG nucleic acids), including but not limited to types
10 A, B, and C; immunostimulatory non-CpG nucleic acids, including without limitation methylated CpG nucleic acids, T-rich nucleic acids, TG-motif nucleic acids, CpI motif nucleic acids, and poly-G nucleic acids; and immunoinhibitory nucleic acids. Nucleic acids useful as reference compounds and as test compounds in the methods of the invention also include nucleic acids with modified backbones, including "soft" and "semi-soft" oligonucleotides as
15 described herein. As will be appreciated from the descriptions below, certain of these various classes of nucleic acids can coexist in a given nucleic acid molecule.

A "nucleic acid" as used herein with respect to test compounds and reference compounds used in the methods of the invention, shall refer to any polymer of two or more individual nucleoside or nucleotide units. Typically individual nucleoside or nucleotide units
20 will include any one or combination of deoxyribonucleosides, ribonucleosides, deoxyribonucleotides, and ribonucleotides. The individual nucleotide or nucleoside units of the nucleic acid can be naturally occurring or not naturally occurring. For example, the individual nucleotide units can include deoxyadenosine, deoxycytidine, deoxyguanosine, thymidine, and uracil. In addition to naturally occurring 2'-deoxy and 2'-hydroxyl forms,
25 individual nucleosides also include synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g., as described in Uhlmann E et al. (1990) *Chem Rev* 90:543-84. The linkages between individual nucleotide or nucleoside units can be naturally occurring or not naturally occurring. For example, the linkages can be phosphodiester, phosphorothioate, phosphorodithioate, phosphoramidate, as well as peptide linkages and other
30 covalent linkages, known in the art, suitable for joining adjacent nucleoside or nucleotide units. The linkages can also be mixed in a single polymer (e.g., a semi-soft backbone). The nucleic acid test compounds and nucleic acid reference compounds typically range in size from 3-4 units to a few tens of units, e.g., 18-40 units.

In some embodiments the nucleic acids are oligonucleotides made up of 2 to about 100 nucleotides, and more typically 4 to about 40 nucleotides. Oligonucleotides composed exclusively of deoxynucleotides are termed oligodeoxyribonucleotides or, equivalently, oligodeoxynucleotides (ODN).

5 A CpG nucleic acid is an immunostimulatory nucleic acid which contains a cytosine-guanine (CG) dinucleotide, the C residue of which is unmethylated. The effects of CpG nucleic acids on immune modulation have been described extensively in U.S. Pat. Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068; and published patent applications, such as PCT/US95/01570 (WO 96/02555); PCT/US98/04703 (WO 98/40100);
10 and PCT/US99/09863 (WO 99/56755). The entire contents of each of these patents and published patent applications is hereby incorporated by reference. The entire immunostimulatory nucleic acid can be unmethylated or portions can be unmethylated, but at least the C of the 5'-CG-3' must be unmethylated. The CpG nucleic acid sequences of the invention include, without limitation, those broadly described above as well as those disclosed
15 in U.S. Pat. Nos. 6,207,646 and 6,239,116.

In one embodiment the CpG nucleic acid has a base sequence provided by
5'-TCGTCGTTTGTCTTGTCTGTT-3' (SEQ ID NO:1).

In one embodiment the CpG nucleic acid has a base sequence provided by
5'-TCGTCGTTTGACGTTTGTCTGTT-3' (SEQ ID NO:139).

20 In one embodiment the CpG nucleic acid has a base sequence provided by
5'-TCGTCGTTTGTCTGTTTTTCGA-3' (SEQ ID NO:140).

In one embodiment the CpG nucleic acid has a base sequence provided by
5'-TCGTCGTTCGTCGTTCGTCTGTT-3' (SEQ ID NO:141).

25 In one embodiment the CpG nucleic acid has a base sequence provided by
5'-TCGTCGTTTCGTCGTTTGTCTGTT-3' (SEQ ID NO:142).

In one embodiment the CpG nucleic acid has a base sequence provided by
5'-TCGTCGTTTCGGTCGTTT-3' (SEQ ID NO:143).

In one embodiment the CpG nucleic acid has a base sequence provided by
5'-TCGTCGTTTCGTGCGTTT-3' (SEQ ID NO:144).

30 In one embodiment the CpG nucleic acid has a base sequence provided by
5'-TCGTCGTTTCGGCGGCCGCG-3' (SEQ ID NO:145).

In one embodiment the CpG nucleic acid has a base sequence provided by
5'-TCGTC_GTTTAC_GGCGCC_GTGCCG-3' (SEQ ID NO:146).

The oligonucleotides described by SEQ ID NOs: 1, 139-145 are fully stabilized phosphorothioate backbone ODN. The oligonucleotide of SEQ ID NO:146 has a chimeric backbone in which all internucleoside linkages are phosphorothioate except for those indicated by “_”, which are phosphodiester.

- 5 CpG nucleic acids have been further classified by structure and function into at least the following three types, all of which are intended to be encompassed within the methods of the instant invention: Type B CpG nucleic acids such as SEQ ID NO:1 include the earliest described CpG nucleic acids and characteristically activate B cells but do not induce or only weakly induce expression of IFN- α . Type B nucleic acids are described in U.S. Patents
- 10 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068. Type A CpG nucleic acids, described in published international application PCT/US00/26527 (WO 01/22990), incorporate a CpG motif, include a hybrid phosphodiester/phosphorothioate backbone, and characteristically induce plasmacytoid dendritic cells to express large amounts of IFN- α but do not activate or only weakly activate B cells. Type C oligonucleotides incorporate a CpG,
- 15 include a chimeric backbone, include a GC-rich palindromic or nearly-palindromic region, and are capable of both activating B cells and inducing expression of IFN- α . These have been described, for example, in copending U.S. Pat. application Ser. No. 10/224,523, filed August 19, 2002. Exemplary sequences of A, B and C class nucleic acids are described in the afore-mentioned references, patents and patent applications, the entire contents of which are
- 20 hereby incorporated by reference herein.

- In other embodiments of the invention, a non-CpG nucleic acid is used. A non-CpG nucleic acid is an immunostimulatory nucleic acid which either does not have a CpG motif in its sequence, or has a CpG motif which contains a methylated C residue. In some instances, the non-CpG nucleic acid may still be immunostimulatory by virtue of its having other immunostimulatory motifs such as those described herein and known in the art. In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid. In some instances the non-CpG nucleic acid is still immunostimulatory despite methylation of the C of the CpG motif, even without having another non-CpG immunostimulatory motif described herein and known in the art.

- 30 In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-TZGTZGTTTGTZGTTTG TZGTT-3' (SEQ ID NO:147), wherein Z represents 5-methylcytosine.

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-TZGTZGZTGTZTZGZTTZTTGZZ-3' (SEQ ID NO:148), wherein Z represents 5-methylcytosine.

5 In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-GZGTTGZTZTZTGTGZG-3' (SEQ ID NO:149), wherein Z represents 5-methylcytosine.

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-GZZZAAGZTGGZATZZGTZA-3' (SEQ ID NO:150), wherein Z represents 5-methylcytosine.

10 Non-CpG nucleic acids include T-rich immunostimulatory nucleic acids. The T-rich immunostimulatory nucleic acids include those disclosed in published PCT patent application PCT/US00/26383 (WO 01/22972), the entire contents of which are incorporated herein by reference. In some embodiments, T-rich nucleic acids 24 bases in length are used. A T-rich nucleic acid is a nucleic acid which includes at least one poly T sequence and/or which has a 15 nucleotide composition of greater than 25% T nucleotide residues. A nucleic acid having a poly-T sequence includes at least four Ts in a row, such as 5'-TTTT-3'. In some embodiments the T-rich nucleic acid includes more than one poly T sequence. In important embodiments, the T-rich nucleic acid may have 2, 3, 4, or more poly T sequences, such as SEQ ID NO:1.

20 Non-CpG nucleic acids also include poly-G immunostimulatory nucleic acids. A variety of references describe the immunostimulatory properties of poly-G nucleic acids. Pisetsky DS et al. (1993) *Mol Biol Reports* 18:217-221; Krieger M et al. (1994) *Ann Rev Biochem* 63:601-637; Macaya RF et al. (1993) *Proc Natl Acad Sci USA* 90:3745-3749; Wyatt JR et al. (1994) *Proc Natl Acad Sci USA* 91:1356-1360; Rando and Hogan, 1998, In *Applied Antisense Oligonucleotide Technology*, Krieg and Stein, eds., pp. 335-352; Kimura Y et al. 25 (1994) *J Biochem (Tokyo)* 116:991-994.

The immunostimulatory nucleic acids of the invention can also be those which do not possess CpG, methylated CpG, T-rich, or poly-G motifs.

Exemplary immunostimulatory nucleic acid sequences include but are not limited to those immunostimulatory sequences described and listed in U.S. Non-Provisional Pat. 30 Application No. 09/669,187, filed on September 25, 2000, and in corresponding published PCT patent application PCT/US00/26383 (WO 01/22972).

Immuno inhibitory nucleic acids have been described in Lenert P et al. (2001) *Antisense Nucleic Acid Drug Dev* 11:247-56 and in Stunz L et al. (2002) *Eur J Immunol*

32:1212-22. These inhibitory phosphorothioate ODN (S-ODN) differ from stimulatory S-ODN by having 2-3 G substitutions in the central motif. As inhibitory S-ODN did not directly interfere with the NF- κ B DNA binding but prevented CpG-induced NF- κ B nuclear translocation of p50, p65, and c-Rel and blocked p105, I κ B α , and I κ B β degradation, Lenert et al. suggested that the putative target of immunoinhibitory ODN would lie upstream of inhibitory kinase (IKK) activation. Stunz et al. reported that replacing GCGTT or ACGTT with GCGGG or ACGGG converted a stimulatory 15-mer ODN into an inhibitory ODN. All inhibitory ODN had three consecutive G, and a fourth G increased inhibitory activity, but a deazaguanosine substitution to prevent planar stacking did not affect activity. Inhibitory ODN blocked apoptosis protection and cell-cycle entry induced by stimulatory ODN, but not that induced by lipopolysaccharide, anti-CD40 or anti-IgM+IL-4. ODN-driven up-regulation of cyclin D(2), c-Myc, c-Fos, c-Jun and Bcl(XL) and down-regulation of cyclin kinase inhibitor p27(kip1) were all blocked by inhibitory ODN. Stunz et al. also reported that interference with uptake of stimulatory ODN did not account for the inhibitory effects of the immunoinhibitory nucleic acids.

In one embodiment the immunoinhibitory nucleic acid has a base sequence provided by 5'-TCCTGGCAGGGAAAGT-3' (SEQ ID NO:151).

Immunoinhibitory nucleic acids have also been described in U.S. Pat. No. 6,194,388, issued to Krieg et al. The immunoinhibitory oligonucleotides disclosed by Krieg et al. are oligonucleotides with GCG trinucleotides at or near the ends of the oligonucleotide and are represented by the formula 5' GCGX_nGCG 3' in which X is a nucleotide and n is an integer between 0 and 50.

The nucleic acids used as either test or reference compounds can be double-stranded or single-stranded. They can be deoxyribonucleotide (DNA) or ribonucleotide (RNA) molecules. Generally, double-stranded molecules are more stable in vivo, while single-stranded molecules have increased immune activity. Thus in some the nucleic acid is single-stranded and in other embodiments the nucleic acid is double-stranded. In certain embodiments, while the nucleic acid is single-stranded, it is capable of forming secondary and tertiary structures (e.g., by folding back on itself, or by hybridizing with itself either throughout its entirety or at select segments along its length). Accordingly, while the primary structure of such a nucleic acid may be single-stranded, its higher order structures may be double- or triple-stranded.

For facilitating uptake into cells, the nucleic acids are preferably in the range of 6 to 100 bases in length. However, nucleic acids of any size equal to or greater than 6 nucleotides (even many kb long) are capable of inducing an immune response. Preferably the nucleic acid is in the range of between 8 and 100 and in some embodiments between 8 and 50 or 8 and 30 nucleotides in size.

The terms "nucleic acid" and "oligonucleotide" are used interchangeably to mean multiple nucleotides (i.e., molecules comprising a sugar (e.g., ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g., cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g., adenine (A) or guanine (G)). As used herein, the terms "nucleic acid" and "oligonucleotide" refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms "nucleic acid" and "oligonucleotide" shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acid molecules can be obtained from existing nucleic acid sources (e.g., genomic or cDNA), but are preferably synthetic (e.g., produced by nucleic acid synthesis).

The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with substitutions or modifications, such as in the bases and/or sugars. For example, they include nucleic acids having backbone sugars that are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 2' position and other than a phosphate group or hydroxy group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose or 2'-fluoroarabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide-nucleic acids (which have an amino acid backbone with nucleic acid bases). Other examples are described in more detail below.

The immunostimulatory and immunoinhibitory nucleic acids can encompass various chemical modifications and substitutions, in comparison to natural RNA and DNA, involving a phosphodiester internucleoside bridge, a β -D-ribose unit and/or a natural nucleoside base (adenine, guanine, cytosine, thymine, uracil). Examples of chemical modifications are known to the skilled person and are described, for example, in Uhlmann E et al. (1990) *Chem Rev* 90:543; "Protocols for Oligonucleotides and Analogs" Synthesis and Properties & Synthesis and Analytical Techniques, S. Agrawal, Ed, Humana Press, Totowa, USA 1993; Crooke ST et al. (1996) *Annu Rev Pharmacol Toxicol* 36:107-129; and Hunziker J et al. (1995) *Mod Synth*

Methods 7:331-417. An oligonucleotide according to the invention may have one or more modifications, wherein each modification is located at a particular phosphodiester internucleoside bridge and/or at a particular β -D-ribose unit and/or at a particular natural nucleoside base position in comparison to an oligonucleotide of the same sequence which is composed of natural DNA or RNA.

- For example, the oligonucleotides may comprise one or more modifications and wherein each modification is independently selected from:
- a) the replacement of a phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside by a modified internucleoside bridge,
 - 10 b) the replacement of phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a diphospho bridge,
 - c) the replacement of a sugar phosphate unit from the sugar phosphate backbone by another unit,
 - d) the replacement of a β -D-ribose unit by a modified sugar unit, and
 - 15 e) the replacement of a natural nucleoside base by a modified nucleoside base.

More detailed examples for the chemical modification of an oligonucleotide are as follows.

The oligonucleotides may include modified internucleotide linkages, such as those described in (a) or (b) above. These modified linkages may be partially resistant to degradation (e.g., are stabilized). A "stabilized oligonucleotide molecule" shall mean an oligonucleotide that is relatively resistant to *in vivo* degradation (e.g., via an exo- or endonuclease) resulting from such modifications. Oligonucleotides having phosphorothioate linkages, in some embodiments, may provide maximal activity and protect the oligonucleotide from degradation by intracellular exo- and endo-nucleases.

A phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside can be replaced by a modified internucleoside bridge, wherein the modified internucleoside bridge is for example selected from phosphorothioate, phosphorodithioate, NR¹R²-phosphoramidate, boranophosphate, α -hydroxybenzyl phosphonate, phosphate-(C₁-C₂₁)-O-alkyl ester, phosphate-[(C₆-C₁₂)aryl-(C₁-C₂₁)-O-alkyl]ester, (C₁-C₈)alkylphosphonate and/or (C₆-C₁₂)arylphosphonate bridges, (C₇-C₁₂)- α -hydroxymethyl-aryl (e.g., disclosed in WO 95/01363), wherein (C₆-C₁₂)aryl, (C₆-C₂₀)aryl and (C₆-C₁₄)aryl are optionally substituted by halogen, alkyl, alkoxy, nitro, cyano, and where R¹ and R² are, independently of each other, hydrogen, (C₁-C₁₈)-alkyl, (C₆-C₂₀)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl, preferably hydrogen,

- 42 -

(C₁-C₈)-alkyl, preferably (C₁-C₄)-alkyl and/or methoxyethyl, or R¹ and R² form, together with the nitrogen atom carrying them, a 5-6-membered heterocyclic ring which can additionally contain a further heteroatom from the group O, S and N.

The replacement of a phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge (dephospho bridges are described, for example, in Uhlmann E and Peyman A in "Methods in Molecular Biology", Vol. 20, "Protocols for Oligonucleotides and Analogs", S. Agrawal, Ed., Humana Press, Totowa, 1993, Chapter 16, pp. 355 ff), wherein a dephospho bridge is for example selected from the dephospho bridges formacetal, 3'-thioformacetal, methylhydroxylamine, oxime, methylenedimethyl-hydrazo, dimethylenesulfone and/or silyl groups.

A sugar phosphate unit (i.e., a β-D-ribose and phosphodiester internucleoside bridge together forming a sugar phosphate unit) from the sugar phosphate backbone (i.e., a sugar phosphate backbone is composed of sugar phosphate units) can be replaced by another unit, wherein the other unit is for example suitable to build up a "morpholino-derivative" oligomer (as described, for example, in Stinchak EP et al. (1989) *Nucleic Acids Res* 17:6129-41), that is, e.g., the replacement by a morpholino-derivative unit; or to build up a polyamide nucleic acid ("PNA"; as described for example, in Nielsen PE et al. (1994) *Bioconjug Chem* 5:3-7), that is, e.g., the replacement by a PNA backbone unit, e.g., by 2-aminoethylglycine. The oligonucleotide may have other carbohydrate backbone modifications and replacements, such as peptide nucleic acids with phosphate groups (PHONA), locked nucleic acids (LNA), and oligonucleotides having backbone sections with alkyl linkers or amino linkers. The alkyl linker may be branched or unbranched, substituted or unsubstituted, and chirally pure or a racemic mixture.

A β-ribose unit or a β-D-2'-deoxyribose unit can be replaced by a modified sugar unit, wherein the modified sugar unit is for example selected from β-D-ribose, α-D-2'-deoxyribose, L-2'-deoxyribose, 2'-F-2'-deoxyribose, 2'-F-arabinose, 2'-O-(C₁-C₆)alkyl-ribose, preferably 2'-O-(C₁-C₆)alkyl-ribose is 2'-O-methylribose, 2'-O-(C₂-C₆)alkenyl-ribose, 2'-[O-(C₁-C₆)alkyl-O-(C₁-C₆)alkyl]-ribose, 2'-NH₂-2'-deoxyribose, β-D-xylo-furanose, α-arabinofuranose, 2,4-dideoxy-β-D-erythro-hexo-pyranose, and carbocyclic (described, for example, in Froehler J (1992) *Am Chem Soc* 114:8320) and/or open-chain sugar analogs (described, for example, in Vandendriessche et al. (1993) *Tetrahedron* 49:7223) and/or bicyclosugar analogs (described, for example, in Tarkov M et al. (1993) *Helv Chim Acta* 76:481).

In some embodiments the sugar is 2'-O-methylribose, particularly for one or both nucleotides linked by a phosphodiester or phosphodiester-like internucleoside linkage.

In some embodiments, the nucleic acids may be soft or semi-soft nucleic acids. A soft nucleic acid is an immunostimulatory nucleic acid having a partially stabilized backbone, in which phosphodiester or phosphodiester-like internucleotide linkages occur only within and immediately adjacent to at least one internal pyrimidine-purine dinucleotide (YZ). Preferably YZ is YG, a pyrimidine-guanosine (YG) dinucleotide. The at least one internal YZ dinucleotide itself has a phosphodiester or phosphodiester-like internucleotide linkage. A phosphodiester or phosphodiester-like internucleotide linkage occurring immediately adjacent to the at least one internal YZ dinucleotide can be 5', 3', or both 5' and 3' to the at least one internal YZ dinucleotide.

In particular, phosphodiester or phosphodiester-like internucleotide linkages involve "internal dinucleotides". An internal dinucleotide in general shall mean any pair of adjacent nucleotides connected by an internucleotide linkage, in which neither nucleotide in the pair of nucleotides is a terminal nucleotide, i.e., neither nucleotide in the pair of nucleotides is a nucleotide defining the 5' or 3' end of the nucleic acid. Thus a linear nucleic acid that is n nucleotides long has a total of n-1 dinucleotides and only n-3 internal dinucleotides. Each internucleotide linkage in an internal dinucleotide is an internal internucleotide linkage. Thus a linear nucleic acid that is n nucleotides long has a total of n-1 internucleotide linkages and only n-3 internal internucleotide linkages. The strategically placed phosphodiester or phosphodiester-like internucleotide linkages, therefore, refer to phosphodiester or phosphodiester-like internucleotide linkages positioned between any pair of nucleotides in the nucleic acid sequence. In some embodiments the phosphodiester or phosphodiester-like internucleotide linkages are not positioned between either pair of nucleotides closest to the 5' or 3' end.

Preferably a phosphodiester or phosphodiester-like internucleotide linkage occurring immediately adjacent to the at least one internal YZ dinucleotide is itself an internal internucleotide linkage. Thus for a sequence N₁ YZ N₂, wherein N₁ and N₂ are each, independent of the other, any single nucleotide, the YZ dinucleotide has a phosphodiester or phosphodiester-like internucleotide linkage, and in addition (a) N₁ and Y are linked by a phosphodiester or phosphodiester-like internucleotide linkage when N₁ is an internal nucleotide, (b) Z and N₂ are linked by a phosphodiester or phosphodiester-like internucleotide linkage when N₂ is an internal nucleotide, or (c) N₁ and Y are linked by a phosphodiester or

phosphodiester-like internucleotide linkage when N₁ is an internal nucleotide and Z and N₂ are linked by a phosphodiester or phosphodiester-like internucleotide linkage when N₂ is an internal nucleotide.

Soft nucleic acids according to the instant invention are believed to be relatively 5 susceptible to nuclease cleavage compared to completely stabilized nucleic acids. Without meaning to be bound to a particular theory or mechanism, it is believed that soft nucleic acids of the invention are cleavable to fragments with reduced or no immunostimulatory activity relative to full-length soft nucleic acids. Incorporation of at least one nuclease-sensitive internucleotide linkage, particularly near the middle of the nucleic acid, is believed to provide 10 an "off switch" which alters the pharmacokinetics of the nucleic acid so as to reduce the duration of maximal immunostimulatory activity of the nucleic acid. This can be of particular value in tissues and in clinical applications in which it is desirable to avoid injury related to chronic local inflammation or immunostimulation, e.g., the kidney.

A semi-soft nucleic acid is an immunostimulatory nucleic acid having a partially 15 stabilized backbone, in which phosphodiester or phosphodiester-like internucleotide linkages occur only within at least one internal pyrimidine-purine (YZ) dinucleotide. Semi-soft nucleic acids generally possess increased immunostimulatory potency relative to corresponding fully stabilized immunostimulatory nucleic acids. Due to the greater potency 20 of semi-soft nucleic acids, semi-soft nucleic acids may be used, in some instances, at lower effective concentrations and have lower effective doses than conventional fully stabilized immunostimulatory nucleic acids in order to achieve a desired biological effect.

It is believed that the foregoing properties of semi-soft nucleic acids generally increase 25 with increasing "dose" of phosphodiester or phosphodiester-like internucleotide linkages involving internal YZ dinucleotides. Thus it is believed, for example, that generally for a given nucleic acid sequence with five internal YZ dinucleotides, an nucleic acid with five internal phosphodiester or phosphodiester-like YZ internucleotide linkages is more immunostimulatory than an nucleic acid with four internal phosphodiester or phosphodiester-like YG internucleotide linkages, which in turn is more immunostimulatory than an nucleic acid with three internal phosphodiester or phosphodiester-like YZ internucleotide linkages, 30 which in turn is more immunostimulatory than an nucleic acid with two internal phosphodiester or phosphodiester-like YZ internucleotide linkages, which in turn is more immunostimulatory than an nucleic acid with one internal phosphodiester or phosphodiester-like YZ internucleotide linkage. Importantly, inclusion of even one internal phosphodiester or

phosphodiester-like YZ internucleotide linkage is believed to be advantageous over no internal phosphodiester or phosphodiester-like YZ internucleotide linkage. In addition to the number of phosphodiester or phosphodiester-like internucleotide linkages, the position along the length of the nucleic acid can also affect potency.

5 The soft and semi-soft nucleic acids will generally include, in addition to the phosphodiester or phosphodiester-like internucleotide linkages at preferred internal positions, 5' and 3' ends that are resistant to degradation. Such degradation-resistant ends can involve any suitable modification that results in an increased resistance against exonuclease digestion over corresponding unmodified ends. For instance, the 5' and 3' ends can be stabilized by the
10 inclusion thereof at least one phosphate modification of the backbone. In a preferred embodiment, the at least one phosphate modification of the backbone at each end is independently a phosphorothioate, phosphorodithioate, methylphosphonate, or methylphosphorothioate internucleotide linkage. In another embodiment, the degradation-resistant end includes one or more nucleotide units connected by peptide or amide linkages at
15 the 3' end.

A phosphodiester internucleotide linkage is the type of linkage characteristic of nucleic acids found in nature. The phosphodiester internucleotide linkage includes a phosphorus atom flanked by two bridging oxygen atoms and bound also by two additional oxygen atoms, one charged and the other uncharged. Phosphodiester internucleotide linkage
20 is particularly preferred when it is important to reduce the tissue half-life of the nucleic acid.

A phosphodiester-like internucleotide linkage is a phosphorus-containing bridging group that is chemically and/or diastereomerically similar to phosphodiester. Measures of similarity to phosphodiester include susceptibility to nuclease digestion and ability to activate RNase H. Thus for example phosphodiester, but not phosphorothioate, nucleic acids are susceptible to nuclease digestion, while both phosphodiester and phosphorothioate nucleic acids activate RNase H. In a preferred embodiment the phosphodiester-like internucleotide linkage is boranophosphate (or equivalently, boranophosphonate) linkage. U.S. Patent No. 5,177,198; U.S. Patent No. 5,859,231; U.S. Patent No. 6,160,109; U.S. Patent No. 6,207,819; Sergueev et al., (1998) *J Am Chem Soc* 120:9417-27. In another preferred embodiment the phosphodiester-like internucleotide linkage is diasteromerically pure Rp phosphorothioate. It is believed that diasteromerically pure Rp phosphorothioate is more susceptible to nuclease digestion and is better at activating RNase H than mixed or diastereomerically pure Sp phosphorothioate. Stereoisomers of CpG nucleic acids are the subject of co-pending U.S.

patent application 09/361,575 filed July 27, 1999, and published PCT application PCT/US99/17100 (WO 00/06588). It is to be noted that for purposes of the instant invention, the term "phosphodiester-like internucleotide linkage" specifically excludes phosphorodithioate and methylphosphonate internucleotide linkages.

- 5 As described above the soft and semi-soft nucleic acids of the invention may have phosphodiester like linkages between C and G. One example of a phosphodiester-like linkage is a phosphorothioate linkage in an Rp conformation. Nucleic acid p-chirality can have apparently opposite effects on the immune activity of a CpG nucleic acid, depending upon the time point at which activity is measured. At an early time point of 40 minutes, the R_p but not
10 the S_p stereoisomer of phosphorothioate CpG nucleic acid induces JNK phosphorylation in mouse spleen cells. In contrast, when assayed at a late time point of 44 hr, the S_p but not the R_p stereoisomer is active in stimulating spleen cell proliferation. This difference in the kinetics and bioactivity of the R_p and S_p stereoisomers does not result from any difference in cell uptake, but rather most likely is due to two opposing biologic roles of the p-chirality.
15 First, the enhanced activity of the Rp stereoisomer compared to the Sp for stimulating immune cells at early time points indicates that the Rp may be more effective at interacting with the CpG receptor, TLR9, or inducing the downstream signaling pathways. On the other hand, the faster degradation of the Rp PS-nucleic acids compared to the Sp results in a much shorter duration of signaling, so that the Sp PS-nucleic acids appear to be more biologically
20 active when tested at later time points.

A surprisingly strong effect is achieved by the p-chirality at the CpG dinucleotide itself. In comparison to a stereo-random CpG nucleic acid the congener in which the single CpG dinucleotide was linked in Rp was slightly more active, while the congener containing an Sp linkage was nearly inactive for inducing spleen cell proliferation.

- 25 Nucleic acids also include substituted purines and pyrimidines such as C-5 propyne pyrimidine and 7-deaza-7-substituted purine modified bases. Wagner RW et al. (1996) *Nat Biotechnol* 14:840-4. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, and thymine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties.

- 30 A modified base is any base which is chemically distinct from the naturally occurring bases typically found in DNA and RNA such as T, C, G, A, and U, but which share basic chemical structures with these naturally occurring bases. The modified nucleoside base may be, for example, selected from hypoxanthine, uracil, dihydrouracil, pseudouracil, 2-thiouracil,

- 47 -

4-thiouracil, 5-aminouracil, 5-(C₁-C₆)-alkyluracil, 5-(C₂-C₆)-alkenyluracil, 5-(C₂-C₆)-alkynyluracil, 5-(hydroxymethyl)uracil, 5-chlorouracil, 5-fluorouracil, 5-bromouracil, 5-hydroxycytosine, 5-(C₁-C₆)-alkylcytosine, 5-(C₂-C₆)-alkenylcytosine, 5-(C₂-C₆)-alkynylcytosine, 5-chlorocytosine, 5-fluorocytosine, 5-bromocytosine, N²-dimethylguanine,
5 2,4-diamino-purine, 8-azapurine, a substituted 7-deazapurine, preferably
7-deaza-7-substituted and/or 7-deaza-8-substituted purine, 5-hydroxymethylcytosine, N4-alkylcytosine, e.g., N4-ethylcytosine, 5-hydroxydeoxycytidine, 5-hydroxymethyldeoxycytidine, N4-alkyldeoxycytidine, e.g., N4-ethyldeoxycytidine, 6-thiodeoxyguanosine, and deoxyribonucleosides of nitropyrrole, C5-propynylpyrimidine, and
10 diaminopurine e.g., 2,6-diaminopurine, inosine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, hypoxanthine or other modifications of a natural nucleoside bases.
This list is meant to be exemplary and is not to be interpreted to be limiting.

Modified cytosines include but are not limited to 5-substituted cytosines (e.g., 5-methyl-cytosine, 5-fluoro-cytosine, 5-chloro-cytosine, 5-bromo-cytosine, 5-iodo-cytosine, 5-hydroxy-cytosine, 5-hydroxymethyl-cytosine, 5-difluoromethyl-cytosine, and unsubstituted or substituted 5-alkynyl-cytosine), 6-substituted cytosines, N4-substituted cytosines (e.g., N4-ethyl-cytosine), 5-aza-cytosine, 2-mercaptop-cytosine, isocytosine, pseudo-isocytosine, cytosine analogs with condensed ring systems (e.g., N,N'-propylene cytosine or phenoxazine), and uracil and its derivatives (e.g., 5-fluoro-uracil, 5-bromo-uracil, 5-bromovinyl-uracil, 4-thio-uracil, 5-hydroxy-uracil, 5-propynyl-uracil). In another embodiment, the cytosine base is substituted by a universal base (e.g., 3-nitropyrrole, P-base), an aromatic ring system (e.g., fluorobenzene or difluorobenzene) or a hydrogen atom (dSpacer).

Modified guanines include but are not limited to 7-deazaguanine, 7-deaza-7-substituted guanine (such as 7-deaza-7-(C₂-C₆)alkynylguanine), 7-deaza-8-substituted guanine, hypoxanthine, N2-substituted guanines (e.g., N2-methyl-guanine), 5-amino-3-methyl-3H,6H-thiazolo[4,5-d]pyrimidine-2,7-dione, 2,6-diaminopurine, 2-aminopurine, purine, indole, adenine, substituted adenines (e.g., N6-methyl-adenine, 8-oxo-adenine) 8-substituted guanine (e.g., 8-hydroxyguanine and 8-bromoguanine), and
30 6-thioguanine. In another embodiment, the guanine base is substituted by a universal base (e.g., 4-methyl-indole, 5-nitro-indole, and K-base), an aromatic ring system (e.g., benzimidazole or dichloro-benzimidazole, 1-methyl-1H-[1,2,4]triazole-3-carboxylic acid amide) or a hydrogen atom (dSpacer).

For use in the instant invention, the oligonucleotide reference compounds and test compounds can be synthesized *de novo* using any of a number of procedures well known in the art, for example, the β -cyanoethyl phosphoramidite method (Beaucage SL et al. (1981) *Tetrahedron Lett* 22:1859), or the nucleoside H-phosphonate method (Garegg et al. (1986) *Tetrahedron Lett* 27:4051-4; Froehler BC et al. (1986) *Nucleic Acids Res* 14:5399-407; Garegg et al (1986) *Tetrahedron Lett* 27:4055-8; Gaffney et al. (1988) *Tetrahedron Lett* 29:2619-22). These chemistries can be performed by a variety of automated nucleic acid synthesizers available in the market. These oligonucleotides are referred to as synthetic oligonucleotides. An isolated oligonucleotide generally refers to an oligonucleotide which is separated from components which it is normally associated with in nature. As an example, an isolated oligonucleotide may be one which is separated from a cell, from a nucleus, from mitochondria or from chromatin.

Modified backbones such as phosphorothioates can be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl-and alkyl-phosphonates can be made, e.g., as described in U.S. Pat. No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023,243 and European Pat. No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (e.g., Uhlmann E et al. (1990) *Chem Rev* 90:544; Goodchild J (1990) *Bioconjugate Chem* 1:165).

TLR expression

The cell lines can be used in their native state without any modification. For example, in the case of the RPMI 8226 cell line, it can be used to identify compounds that signal through at least TLR9 and/or TLR7. In other instances, however, the cell line can be modified to express a TLR that it does not naturally express. In still other instances, the cell to be used in the screening method may express one or more endogenous TLR and yet still be manipulated to express an additional TLR different from those it endogenously expresses. The cell may also be manipulated in order to increase or decrease the level of TLR that it endogenously expresses. The cells may be stably or transiently transfected.

A cell that does not naturally express a protein or polypeptide, but is genetically manipulated to do so is referred to as ectopically expressing the protein or polypeptide.

The basic screening method remains the same regardless of which TLR is expressed by the cell. However, the reference compound and the readout may vary depending upon the TLR(s) expressed. In the most simple aspect, the screening method is used to identify a compound that signals through a TLR such as for example TLR9. In this case, the positive 5 reference compound may be an immunostimulatory compound already known to act through TLR9 (e.g., CpG nucleic acid).

The methods of the invention involve, in part, contacting a functional TLR with a test composition. A functional TLR is a full-length TLR protein or a fragment thereof capable of inducing or inhibiting a signal in response to interaction with its ligand. Generally the 10 functional TLR will include at least a TLR ligand-binding fragment of the extracellular domain of the full-length TLR and at least a fragment of a TIR domain capable of interacting with another Toll homology domain-containing polypeptide, e.g., MyD88. In various embodiments the functional TLR is a full-length TLR selected from TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, and TLR10.

15 To date, there are eleven TLRs known. Nucleic acid and amino acid sequences for ten currently known human TLRs are available from public databases such as GenBank. Similarly, nucleic acid and amino acid sequences for various TLRs from numerous non-human species are also available from public databases including GenBank. For example, nucleic acid and amino acid sequences for human TLR9 (hTLR9) can be found as GenBank 20 accession numbers AF245704 (coding region spanning nucleotides 145-3243) (SEQ ID NO: 60) and AAF78037 (SEQ ID NO: 62), respectively. Nucleic acid and amino acid sequences for murine TLR9 (mTLR9) can be found as GenBank accession numbers AF348140 (coding region spanning nucleotides 40-3138) (SEQ ID NO: 68) and AAK29625 (SEQ ID NO: 72), respectively.

25 Nucleic acid and amino acid sequences for human TLR8 (hTLR8) can be found as GenBank accession numbers AF245703 (coding region spanning nucleotides 49-3174) (SEQ ID NO: 46) and AAF78036 (SEQ ID NO: 50), respectively. Nucleic acid and amino acid sequences for murine TLR8 (mTLR8) can be found as GenBank accession numbers AY035890 (coding region spanning nucleotides 59-3157) (SEQ ID NO: 55) and AAK62677 30 (SEQ ID NO: 57), respectively.

Nucleic acid and amino acid sequences for human TLR7 (hTLR7) can be found as GenBank accession numbers AF240467 (coding region spanning nucleotides 135-3285) (SEQ ID NO: 31) and AAF60188 (SEQ ID NO: 34), respectively. Nucleic acid and amino acid

- 50 -

sequences for murine TLR7 (mTLR7) can be found as GenBank accession numbers AY035889 (coding region spanning nucleotides 49-3201) (SEQ ID NO: 38) and AAK62676 (SEQ ID NO: 41), respectively.

Nucleic acid and amino acid sequences for human TLR3 (hTLR3) can be found as
5 GenBank accession numbers NM_003265 (coding region spanning nucleotides 102-2816)
(SEQ ID NO: 7) and NP_003256 (SEQ ID NO: 8), respectively. Nucleic acid and amino acid
sequences for murine TLR3 (hTLR3) can be found as GenBank accession numbers
AF355152 (coding region spanning nucleotides 44-2761) (SEQ ID NO: 9) and AAK26117
(SEQ ID NO: 10), respectively.

10 Nucleic acid and amino acid sequences for human TLR1 (hTLR1) can be found as
GenBank accession numbers NM_003263 and NP_003254, respectively. Nucleic acid and
amino acid sequences for murine TLR1 (mTLR1) can be found as GenBank accession
numbers NM_030682 and NP_109607, respectively.

The functional TLR also is not limited to native TLR polypeptides. As used herein, a
15 native TLR is one that is naturally occurring. The TLR may be a non-native (or non-naturally
occurring TLR). An example is a chimeric TLR having an extracellular domain and the
cytoplasmic domain derived from TLRs from different species. Such chimeric TLR
polypeptides can include, for example, a human TLR extracellular domain and a murine TLR
cytoplasmic domain. In alternative embodiments, such chimeric TLR polypeptides can
20 include chimerae created with different TLR splice variants or allotypes.

TLR Signaling Pathways

The screening methods provided by the invention measure TLR signaling activity.
TLR signaling activity is activity that results from interaction of a TLR with a TLR ligand.
25 TLR signaling can be measured in a number of ways including but not limited to interaction
between a TLR and a protein or factor (such as an adaptor protein), interaction between
downstream proteins or factors (such as an adaptor protein) with each other, activation of
nuclear factors such as transcription factors or transcription complexes, up- or down-
regulation of genes, phosphorylation or dephosphorylation of proteins or factors in the
30 signaling cascade, expression, production and/or secretion of cytokines and/or chemokines,
changes in cell cycle status, up- or down-regulation of cell surface marker expression, and the
like. Those of ordinary skill in the art are familiar with assays for measuring these latter

events including but not limited to gel shift assays, immunoprecipitations, phosphorylation status analysis of proteins, Northern analysis, RT-PCR analysis, etc.

The following is an exemplary TLR signaling pathway or cascade. It is to be understood that this is meant to be illustrative and that different factors may be involved in the 5 signaling of particular TLR. One TLR signaling pathway is known to use the cytoplasmic Toll/IL-1 receptor (TIR) homology domain, present in all TLRs. This domain interacts (e.g., binds to) and thereby transduces a signal to a similar domain on an adapter protein (e.g., MyD88). This type of interaction is referred to as a like:like interaction of TIR domains. This interaction is followed by another interaction between the adapter protein and a 10 kinase, through their respective "death domains". In the case of at least TLR4 signaling, the kinase then interacts with tumor necrosis factor (TNF) receptor-associated factor-6 (TRAF6). Medzhitov R et al., *Mol Cell* 2:253 (1998); Kopp EB et al., *Curr Opin Immunol* 11:15 (1999). After TRAF6, two sequential kinase activation steps lead to phosphorylation of the inhibitory protein I kappa B and its dissociation from NF- κ B. The first kinase is a mitogen-activated 15 kinase kinase kinase (MAPKKK) known as NIK, for NF- κ B-inducing kinase. The target of this kinase is another kinase made up of two chains, called I kappa B kinase α (IKK α) and I kappa B kinase β (IKK β), that together form a heterodimer of IKK α :IKK β , which phosphorylates I kappa B. NF- κ B translocates to the nucleus to activate genes with kappa B binding sites in their promoters and enhancers such as the genes encoding IL-6, IL-8, the p40 20 subunit of IL-12, and the costimulatory molecule CD86. The signaling mechanisms of TLRs are not limited to this pathway; other signaling pathways exist and can be used in the screening readouts of the methods provided herein.

The screening assays employ a number of readouts (or parameters). The readouts can be native readouts. A native readout is one that does not rely on introduction of a reporter 25 construct into the cell of interest. The readouts can be artificial. An artificial readout is one that relies on introduction of a reporter construct into the cell of interest. Examples of both are provided herein. In still other embodiments, a given assay may measure one or more native readouts and one or more artificial readouts. Each readout whether native or artificial is related to signaling pathways that ensue after TLR engagement with a ligand.

30 Each cell line described herein will be associated with a particular set of native readouts which the invention seeks to determine in the screening assays provided. As an example, the response of the RPMI 8226 cell line to an immunomodulatory molecule can be assessed in terms of native readouts such as CD71 expression, CD86 expression, HLA-DR

expression, IL-8 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- α expression, TNF- α production and TNF- α secretion. RAMOS response can be assessed, inter alia, by CD80 cell surface expression. Raji response can be assessed, inter alia, by IL-6 secretion.

As described in greater detail herein, the cell line can be used in an unmodified form. In one respect, an unmodified cell line will naturally respond to a TLR ligand through a native readout system. For example, an RPMI 8226 cell exposed to an immunostimulatory TLR ligand may increase expression of IP-10 from the native gene locus. Alternatively, the cell line may be modified to contain a reporter construct that acts as a surrogate for the IP-10 gene locus. For example, the reporter construct may contain the TLR responsive promoter elements that are naturally found in the native IP-10 locus operably linked to a reporter coding sequence that encodes a gene product that is detectable and quantifiable. The structure and variability of suitable reporter constructs will be discussed in greater detail herein.

Readouts typically include the induction of a gene under control of a specific promoter such as a NF- κ B promoter. The gene under the control of the NF- κ B promoter can be a gene which naturally includes an NF- κ B promoter or it can be a gene in a construct in which an NF- κ B promoter has been inserted. Endogenous genes and transfected constructs which include the NF- κ B promoter include but are not limited to IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and TNF-luc.

Increases in cytokine levels can result from increased production, increased stability, increased secretion, or any combination of the forgoing, of the cytokine in response to the TLR-mediated signaling. Cytokines generally include, without limitation, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-11, IL-12, IL-13, IL-15, IL-18, IFN- α , IFN- β , IFN- γ , TNF- α , GM-CSF, G-CSF, M-CSF. Th1 cytokines include but are not limited to IL-2, IFN- γ , and IL-12. Th2 cytokines include but are not limited to IL-4, IL-5, and IL-10.

Increases in chemokine levels can result from increased production, increased stability, increased secretion, or any combination of the forgoing, of the chemokine in response to the TLR-mediated signaling. Chemokines of particular significance in the invention include but are not limited to CCL5 (RANTES), CXCL9 (Mig), CXCL10 (IP-10), CXCL11 (I-TAC), IL-8, and MCP-1.

TLR signaling activity can also be measured by phosphorylation, such as total cellular phosphorylation or phosphorylation of specific factors such as but not limited to IRAK, ERK, MyD88, TRAF6, p38, NF- κ B subunits, c-Jun and c-Fos.

5 TLR signaling activity can be measured by changes in gene expression. The expression of CD71, CD86, CD80, CD69, CD54, HLA-DR, HLA class I, IL-6, IL-8, IL-10, IP-9, IP-10, IFN- α , TNF- α , and the like can be assessed as a measure of TLR signaling activity. Gene expression analysis may be performed using microarray techniques.

TLR signaling activity can also be measured by cell proliferation status or changes thereto.

10 TLR signaling activity can also be measured by cell surface marker expression such as the cell surface expression of markers such as but not limited to CD71, CD86, HLA-DR, CD80, HLA class I, CD54 and CD69.

TLR signaling activity can also be measured by antibody secretion such as but not limited to IgM secretion.

15

Reporter and Expression Constructs

The cells can be manipulated by the introduction of expression and/or reporter constructs. The expression constructs preferably comprise a TLR coding sequence, as described above. The reporter constructs can be used as surrogate measures of native TLR 20 signaling activity. These reporter constructs are intended to substitute for the "native" readouts capable with the cell line. In order to act as substitutes, the reporter constructs include a promoter element derived from a gene known to be modulated following TLR engagement with a TLR ligand. The reporter construct further includes a coding sequence linked to the promoter. The coding sequence is usually that of a reporter (i.e., a protein that is 25 detectable or quantifiable).

The reporter construct generally includes a promoter, a coding sequence and a polyadenylation signal. These nucleic acids shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, in addition to 30 promoter elements that are responsive to TLR signaling. The nucleic acid constructs may optionally include enhancer sequences or upstream activator sequences as desired.

The promoter in the reporter construct will include a TLR responsive promoter element, and will therefore be regarded as a TLR responsive promoter. As used herein, a

TLR responsive promoter is a promoter having an activity that is modulated (i.e., either activated or inhibited) by signaling through a TLR (e.g., by TLR interaction with its ligand). In order to be modulated by TLR signaling, the promoter contains sites that are bound by transcription factors modulated by TLR signaling. The factors may be activated or inhibited by TLR signaling. Activation of the transcription factor includes increases in the activity of the transcription factor per se, increases in its ability to interact with other factors or with DNA that serve to increase its activity, and increases in its transcription and translation (i.e., increased mRNA and protein levels of the transcription factor). Conversely, inhibition of the transcription factor includes decreases in the activity of the transcription factor per se, 5 decreases in its ability to interact with other factors or with DNA that serve to decrease its activity, and decreases in its transcription and translation (i.e., decreased mRNA and protein levels of the transcription factor). The effect on the transcription factor is usually the downstream result of other interactions in the signaling pathway. The expression of coding sequences linked to such promoters will therefore be modulated by TLR signaling events, and 10 it is the level of expression of these coding sequences that can be used as a readout of TLR signaling in the screening methods provided herein.

15

The TLR responsive promoter may comprise a transcription factor binding site selected from the group consisting of a NF- κ B binding site, an AP-1 binding site, a CRE, a SRE, an interferon-stimulated response element (ISRE), a GAS, an ATF2 binding site, an 20 IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE, among others. These binding sites and their sequences are known in the art. Below is a exemplary list of these sequences.

W = A or T, R = A or G, Y = C or T

25 NF- κ B Binding site:

Consensus p50 subunit
5' GGGGATYCCC 3' (SEQ ID NO:90)

30 Consensus p65 subunit
5' GGGRNTTCC 3' (SEQ ID NO:91)

Example of p65 subunit binding site
5' AGT TGA GGG GAC TTT CCC AGG C 3' (SEQ ID NO:92)

35 CREB Binding site:
5'AGA GAT TGC CTG ACG TCA GAG AGC TAG 3' (SEQ ID NO:93)

- 55 -

AP-1 Binding site:

- 5'- CGC TTG ATG AGT CAG CCG GAA -3' (SEQ ID NO:94)
- 5'- CGC ATG AGT CAG ACA -3' (SEQ ID NO:95)

5 **ISRE :**

- 5'- TGCAGAAGTGAAACTGAGG-3' (SEQ ID NO:96)
- 5'- AGAACGAAACA-3' (SEQ ID NO:97)
- 5'- GAGAACGTGAAAGTGG-3' (SEQ ID NO:98)
- 5'- TAAGAACATGAAACTGAA-3' (SEQ ID NO:99)
- 10 5'- ATGAAAACATGAAAGTA-3' (SEQ ID NO:100)
- 5'- TGAAAACCGAAAGCGC-3' (SEQ ID NO:101)
- 5'- AGAAAATGGAAAGT-3' (SEQ ID NO:102)

SRE

- 15 5'- TCACCCCCAC-3' (SEQ ID NO:103)
 5'- CTCACCCCCAC-3' (SEQ ID NO:104)
 5'- GCCACCCTAC-3' (SEQ ID NO:105)

NFAT:

- 20 5'- TATGAAACAGTTTCC -3' (SEQ ID NO:106)
 5'- AGGAAACTC -3' (SEQ ID NO:107)
 5'- ARGARATTCC -3' (SEQ ID NO:108)
 5'- CCAGTTGAGGCCAGAGA -3' (SEQ ID NO:109)

25 **GAS:**

- 5'- CTTTCAGTTCATATTACTCTAAATCCATT -3' (SEQ ID NO:110)

p53 Binding Site :

- 30 **p53 Consensus site:**
 5'- RRRCWWGYYY -3' (SEQ ID NO:111)

Examples of p53 binding sites:

- 35 5'- AGGCATGCCT -3' (SEQ ID NO:112)
 5'- GGGCTTGCCC -3' (SEQ ID NO:113)
 5'- GGGCTTGCTT -3' (SEQ ID NO:114)
 5'- GCCTGGACTTGCC -3' (SEQ ID NO:115)
 5'- GGACATGCCCGGGCATGTCC -3' (SEQ ID NO:116)
 5'- GTAGCATTAGCCCCAGACATGTCC -3' (SEQ ID NO:117)

40 **TARE (TNF- α response element):**

e.g. from the COL1A1 promoter
 5'GAGGTATGCAGACAAGAGTCAGAGTTCCCCTGAA 3' (SEQ ID
 NO:118)

45 **SRF**

- 5'- CCWWWWWWGG -3' (SEQ ID NO:119)
- 5'- CCAAATAAGGC -3' (SEQ ID NO:120)

The TLR responsive promoter element can be derived from the promoter of a naturally occurring (i.e., an endogenous) gene that is activated or inhibited by TLR signaling (such as the IL-6 gene, the IL-8 gene, the IL-10 gene, the IL-12 p40 gene, the IP-9 gene, the IP-10 gene, the type 1 IFN gene, the IFN- α 4 gene, the IFN- β gene, the TNF- α gene, the TNF- β gene, the RANTES gene, the ITAC gene, the IGFBP4 gene, the CD54 gene, the CD69 gene, the CD71 gene, the CD80 gene, the CD86 gene, the HLA-DR gene, the HLA class I gene, and the like). The afore-mentioned genes are genes that are known to be activated in response to TLR interaction with its ligand.

Suitable promoter regions are described in the Examples. Briefly, the upstream (5') – 10 620 to +50 promoter region of IFN- α 4 or the upstream (5') –140 to +9 promoter region of IFN- α 1 can be used. In one embodiment, the IFN- α 4 sequence is cloned into the *Sma*I site of the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') promoter region of IFN- α 4.

The promoter can also be the upstream (5') –280 to +20 promoter region of IFN- β .

15 The promoter can also be the upstream (5') –397 to +5 promoter region of RANTES. In one embodiment, the RANTES promoter sequence is cloned into the *Nhe*I site (filled in with Klenow) of the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') –397 to +5 promoter region of RANTES.

20 The promoter can also be the upstream truncated (-250 to +30) and full length (-860 to +30) promoter regions derived from human IL-12 p40 genomic DNA. In one embodiment, the truncated IL-12 p40 promoter was cloned as a *Kpn*I-*Xho*I insert into p β gal-Basic (Promega) resulting in an expression vector that includes a β gal gene under the control of the upstream (5') –250 to +30 promoter region of human IL-12 p40. In another embodiment, the full length IL-12 p40 promoter was cloned as a *Kpn*I-*Xho*I insert into p β gal-Basic (Promega) resulting in an expression vector that includes a β gal gene under the control of the upstream (5') –751 to +30 promoter region of human IL-12 p40. In another embodiment, the truncated –250 to +30 promoter region of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control 25 of the upstream (5') –250 to +30 promoter region of human IL-12 p40. In yet another embodiment, the full length IL-12 p40 promoter of human IL-12 p40 was cloned into the

pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') -751 to +30 promoter region of human IL-12 p40.

The promoter can also be the upstream (5') -288 to +7 promoter region derived from human IL-6 genomic DNA. The promoter can also be derived from the full-length promoter region of the IL-6 gene from -1174 to + 7 (Accession No M22111, SEQ ID NO:129).

5 The promoter can also be the upstream (5') -734 to +44 or the upstream (5') -162 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71.

10 The promoter can also be derived from the -615 to +30 promoter region of human TNF- α .

The promoter can also be derived from a promoter region of human TNF- β .

15 The promoter can also be derived from the -875 to +97 promoter region of human IP-10.

The promoter can also be derived from the -219 to +114 promoter region of human CXCL11 (IP9). The promoter can also be derived from the full length (-934 to +114) promoter region of human CXCL11 (IP9).

20 The promoter can also be derived from the -289 to +217 promoter region of human IGFBP4 (Insulin growth factor binding protein 4). The promoter can also be derived from the full length (-836 to +217) promoter region of human IGFBP4.

25 The promoter response element generally will be present in multiple copies, e.g., as tandem repeats. For example, in one reporter construct, coding sequence for luciferase is under control of an upstream 6X tandem repeat of NF- κ B response element. In another example, an ISRE-luciferase reporter construct useful in the invention is available from Stratagene (catalog no. 219092) and includes a 5x ISRE tandem repeat joined to a TATA box upstream of a luciferase reporter gene.

30 The reporter construct coding sequence is preferably any nucleotide sequence that codes for a protein capable of detection or quantification. The protein can be an enzyme (e.g., luciferase, alkaline phosphatase, β -galactosidase, chloramphenicol acetyltransferase (CAT), secreted alkaline phosphatase, etc.), a bioluminescence marker (e.g., green fluorescent protein (GFP, U.S. Pat. No. 5,491,084), etc.), blue fluorescent protein (BFP, e.g., U.S. Pat. No. 6,486,382), etc.), a surface-expressed molecule (e.g., CD25, CD80, CD86), a secreted molecule (e.g., IL-1, IL-6, IL-8, IL-12 p40, TNF- α), a hapten or antigen, and other detectable protein products known to those of skill in the art. For assays relying on enzyme activity

readout, substrate can be supplied as part of the assay, and detection can involve measurement of chemiluminescence, fluorescence, color development, incorporation of radioactive label, drug resistance, or other marker of enzyme activity. For assays relying on surface expression of a molecule, detection can be accomplished using flow cytometry (FACS) analysis or 5 functional assays. Secreted molecules can be assayed using enzyme-linked immunosorbent assay (ELISA) or bioassays. Many of these and other suitable readout systems are well known in the art and are commercially available. Preferably, the coding sequence encodes a protein having a level or an activity that is quantifiable, preferably with a wide linear range.

The expression construct coding sequence is preferably a TLR coding sequence 10 derived from the sequences listed herein. Preferably, the expression construct promoter is a constitutive promoter, although in some embodiments it may be inducible. Those of ordinary skill in the art are familiar with such promoters.

As used herein, a coding sequence and the regulatory sequences (such as promoters) are said to be operably linked when they are covalently linked in such a way as to place the 15 expression or transcription and/or translation of the coding sequence under the influence or control of the regulatory sequence. Two DNA sequences are said to be operably linked if induction of a promoter in the 5' regulatory sequence results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter 20 region to direct the transcription of the coding sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a regulatory sequence would be operably linked to a coding sequence if the gene expression sequence were capable of effecting transcription of that coding sequence such that the resulting transcript is translated into the desired protein or polypeptide.

25 Methods for nucleic acid introduction into cells are known in the art.

The nucleic acid may be delivered to the cells alone or in association with a vector. In its broadest sense, a vector is any vehicle capable of facilitating the transfer of the nucleic acid to the cells so that the reporter can be expressed. The vector generally transports the nucleic acid to the cells with reduced degradation relative to the extent of degradation that would 30 result in the absence of the vector. In general, the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the antigen nucleic acid sequences. Viral vectors are a preferred type of vector and include, but are not limited

to, nucleic acid sequences from the following viruses: retrovirus, such as Moloney murine leukemia virus, Harvey murine sarcoma virus, murine mammary tumor virus, and Rous sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA 5 virus such as a retrovirus. One can readily employ other vectors not named but known in the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral 10 RNA into DNA with subsequent proviral integration into host cellular DNA. Retroviruses have been approved for human gene therapy trials. Most useful are those retroviruses that are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard 15 protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., Gene Transfer and Expression, A Laboratory Manual W.H. Freeman C.O., New York (1990) and Murray, E.J. Methods in Molecular Biology, vol. 7, 20 Humana Press, Inc., Clifton, New Jersey (1991).

A preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication 25 -deficient and is capable of infecting a wide range of cell types and species. It further has advantages such as, heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages, including hemopoietic cells; and lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, wild-type adeno-associated virus manifest some preference for integration sites into human cellular DNA, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression 30 characteristic of retroviral infection. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

Recombinant adeno-associated viruses that lack the replicase protein apparently lack this integration sequence specificity.

Other vectors include plasmid vectors. Plasmid vectors have been extensively described in the art and are well-known to those of skill in the art. See e.g., Sambrook et al.,

- 5 Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. In the last few years, plasmid vectors have been found to be particularly advantageous for delivering genes to cells *in vivo* because of their inability to replicate within and integrate into a host genome. These plasmids, however, having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid.
- 10 Some commonly used plasmids include pBR322, pUC18, pUC19, pRc/CMV, SV40, and pBlueScript. Other plasmids are well-known to those of ordinary skill in the art. Additionally, plasmids may be custom designed using restriction enzymes and ligation reactions to remove and add specific fragments of DNA.

In general, the vectors useful in the invention are divided into two classes: biological 15 vectors and chemical/physical vectors. Biological vectors and chemical/physical vectors are useful in the delivery and/or uptake of reporter constructs of the invention.

Most biological vectors are used for delivery of nucleic acids and thus would be most appropriate in the delivery of nucleic acids.

As used herein, a "chemical/physical vector" refers to a natural or synthetic molecule, 20 other than those derived from bacteriological or viral sources, capable of delivering the reference and test compound.

A preferred chemical/physical vector of the invention is a colloidal dispersion system. Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, 25 micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a liposome. Liposomes are artificial membrane vessels which are useful as a delivery vector *in vivo* or *in vitro*. It has been shown that large unilamellar vessels (LUV), which range in size from 0.2 - 4.0 μm can encapsulate large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., *Trends Biochem. Sci.*, (1981) 6:77).

30 Liposomes may be targeted to a particular tissue by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to an immune cell include, but are not limited to, intact or fragments of molecules which interact with immune cell specific receptors and molecules,

such as antibodies, which interact with the cell surface markers of immune cells. Such ligands may easily be identified by binding assays well known to those of skill in the art. In still other embodiments, the liposome may be targeted to the cancer by coupling it to a one of the immunotherapeutic antibodies discussed earlier. Additionally, the vector may be coupled 5 to a nuclear targeting peptide, which will direct the vector to the nucleus of the host cell.

Lipid formulations for transfection are commercially available from QIAGEN, for example, as EFFECTENETTM (a non-liposomal lipid with a special DNA condensing enhancer) and SUPERFECTTM (a novel acting dendrimeric technology).

Liposomes are commercially available from Gibco BRL, for example, as 10 LIPOFECTINTTM and LIPOFECTACETM, which are formed of cationic lipids such as N-[1-(2, 3 dioleyloxy)-propyl]-N, N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications. Liposomes also have been reviewed by Gregoriadis, G. in *Trends in Biotechnology*, (1985) 3:235-241. In some preferred 15 embodiments, the method of choice for delivering DNA (for transfection) to the cells is electroporation, particularly where a stably transfected cell line is sought.

The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting.

20

Examples

Example 1. Biological Activity of Production Lot of CpG ODN (SEQ ID NO:1) Assayed Using Cells Stably Transfected with hTLR9 Expression Vector

CpG ODN (SEQ ID NO:1) is currently in preclinical and clinical trials for a number of 25 clinical applications. SEQ ID NO:1 has been discovered to induce signaling through TLR9. In order to assess different lots of clinical material, the methods of the invention are employed, using a highly characterized lot of SEQ ID NO:1 as a reference.

In a TLR9 assay, the CpG-non-responsive human embryonal kidney cell line HEK293 (e.g., ATCC CRL-1573) was stably transfected with a hTLR9 expression construct and found 30 to express full-length human TLR9 constitutively. The cells also contained a genomic copy of a reporter construct with a 6x NF- κ B binding site and a luciferase gene reporter cassette. Incubation of the cells with CpG ODN (SEQ ID NO:1) activates NF- κ B driven expression of luciferase, while incubation with medium alone (negative control) does not. The cells are

then lysed and activity of the luciferase protein determined by its catalytic activity of luciferin oxidation which is measured in a luminometer. Results are expressed as fold induction above medium control.

Assay set-up includes a reference standard material which is highly pure and well characterized. The reference material is used to create a standard curve within a defined range where the dose-response curve is linear (e.g., in the range of the EC50 value for SEQ ID NO:1, 70-100 nM). The test material is dissolved for testing and assayed at a defined concentration. Activity of the test material is calculated using the standard curve of the reference material. Quality of the tested material is deemed acceptable if activity of the test material compared to activity of the reference material falls within predetermined limits.

Example 2. Biological Activity of Production Lot of CpG ODN (SEQ ID NO:1) Assayed Using RPMI 8226 Cells

The assay of Example 1 is performed using RPMI 8226 cells (ATCC CCL-155) in place of the stably transfected HEK cells of Example 1. RPMI 8226 cells naturally express human TLR9. The cells are stably transfected with a 6x NF- κ B-luciferase reporter construct. It is to be understood that the assay could also be carried out by measuring a native readout such as IL-10 secretion.

20 Example 3. Expression Vectors for Human TLR3 (hTLR3) and Murine TLR3 (mTLR3)

To create an expression vector for human TLR3, human TLR3 cDNA was amplified by the polymerase chain method (PCR) from a cDNA made from human 293 cells using the primers 5'-GAAACTCGAGGCCACCATGAGACAGACTTGCCTGTATCTAC-3' (sense, SEQ ID NO:152) and 5'-GAAAGAATTCTTAATGTACAGAGTTTGATCCAAG-3' (antisense, SEQ ID NO:153). The primers introduce *Xho*I and *Eco*RI restriction endonuclease sites at their 5' ends for use in subsequent cloning into the expression vector. The resulting amplification product fragment was cloned into pGEM-T Easy vector (Promega), isolated, cut with *Xho*I and *Eco*RI restriction endonucleases, ligated into an *Xho*I/*Eco*RI-digested pcDNA3.1 expression vector (Invitrogen). The insert was fully sequenced and translated into protein. The cDNA sequence corresponds to the published cDNA sequence for hTLR3, available as GenBank accession no. NM_003265 (SEQ ID NO:7). The open reading frame codes for a protein 904 amino acids long, having the sequence corresponding to GenBank accession no. NP_003256 (SEQ ID NO:8).

Corresponding nucleotide and amino acid sequences for murine TLR3 (mTLR3) are known. The nucleotide sequence of mTLR3 cDNA has been reported as GenBank accession no. AF355152 (SEQ ID NO:9), and the amino acid sequence of mTLR3 has been reported as GenBank accession no. AAK26117 (SEQ ID NO:10).

5

Example 4. Reconstitution of TLR3 Signaling in 293 Fibroblasts

Human TLR3 cDNA and murine TLR3 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the *EcoRI* site. The resulting expression vectors mentioned above were transfected into

- 10 CpG-DNA non-responsive human 293 fibroblast cells (ATCC, CRL-1573) using the calcium phosphate method. Utilizing a "gain of function" assay it was possible to reconstitute human TLR3 (hTLR3) and murine TLR3 (mTLR3) signaling in 293 fibroblast cells.

Since NF- κ B activation is central to the IL-1/TLR signal transduction pathway (Medzhitov R et al. (1998) *Mol Cell* 2:253-8; Muzio M et al. (1998) *J Exp Med*

- 15 187:2097-101), in a first set of experiments human 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and an NF- κ B-driven luciferase reporter construct.

Likewise, in a second set of experiments, 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and an IFN- α 4-driven luciferase reporter 20 construct (described in Example 8 below).

In a third group of experiments, 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and a RANTES-driven luciferase reporter construct (described in Example 14 below).

- 25 **Example 5. Reconstitution of TLR7 Signaling**

Methods for cloning murine and human TLR7 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated herein by reference. Human TLR7 cDNA and murine TLR7 cDNA in pT-Adv 30 vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the *EcoRI* site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR7 (hTLR7) and murine TLR7 (mTLR7) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors

mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

Example 6. Reconstitution of TLR8 Signaling

5 Methods for cloning murine and human TLR8 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated by reference. Human TLR8 cDNA and murine TLR8 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from
10 Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR8 (hTLR8) and murine TLR8 (mTLR8) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

15

Example 7. Reconstitution of TLR9 Signaling in 293 Fibroblasts

Methods for cloning murine and human TLR9 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated by reference. Human TLR9 cDNA and murine TLR9 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from
20 Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR9 (hTLR9) and murine TLR9 (mTLR9) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors
25 mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

To generate stable clones expressing human TLR9, murine TLR9, or either TLR9 with the NF- κ B-luc reporter plasmid, 293 cells were transfected in 10 cm plates (2×10^6 cells/plate) with 16 μ g of DNA and selected with 0.7 mg/ml G418 (PAA Laboratories GmbH, Cöln, Germany). Clones were tested for TLR9 expression by RT-PCR, for example as shown in Fig. 21. The clones were also screened for IL-8 production or NF- κ B-luciferase activity after stimulation with ODN. Four different types of clones were generated.

293-hTLR9-luc: expressing human TLR9 and 6x NF- κ B-luciferase reporter
293-mTLR9-luc: expressing murine TLR9 and 6x NF- κ B-luciferase reporter
293-hTLR9: expressing human TLR9
293-mTLR9: expressing murine TLR9

5

Human 293 fibroblast cells were transiently transfected with hTLR9 and a 6x NF- κ B-luciferase reporter plasmid (NF- κ B-luc, kindly provided by Patrick Baeuerle, Munich, Germany) (Fig. 18A) or with hTLR9 alone (Fig. 18B). After stimulus with CpG-ODN (2 μ M, TCGTCGTTTGTGCTTTGTCGTT, SEQ ID NO:1), GpC-ODN (2 μ M, TGCTGCTTTGTGCTTTGTGCTT, SEQ ID NO:154), LPS (100 ng/ml) or media, NF- κ B activation by luciferase readout (8h, Fig. 18A) or IL-8 production by ELISA (48h, Fig. 18B) was monitored. Results are representative of three independent experiments. Fig. 18 shows that cells expressing hTLR9 responded to CpG-DNA but not to LPS.

Human 293 fibroblast cells were transiently transfected with mTLR9 and the NF- κ B-luc construct. Similar data was obtained for IL-8 production (not shown). Thus expression of TLR9 (human or mouse) in 293 cells results in a gain of function for CpG DNA stimulation similar to hTLR4 reconstitution of LPS responses.

Figs. 19 and 20 demonstrate the responsiveness of a stable 293-mTLR9-luc and 293-hTLR9-luc clones after stimulation with CpG-ODN (2 μ M, SEQ ID NO:1), GpC-ODN (2 μ M, SEQ ID NO:154), Me-CpG-ODN (2 μ M; TZGTZGTTTGTZGTTTGTZGTT, Z = 5-methylcytidine, SEQ ID NO:147), LPS (100 ng/ml) or media, as measured by monitoring NF- κ B activation. Similar results were obtained utilizing IL-8 production with the stable clones. These results demonstrate that CpG-DNA non-responsive cell lines can be stably genetically complemented with TLR9 to become responsive to CpG DNA in a motif-specific manner.

Example 8. Method of Making IFN- α 4 Reporter Vector

A number of reporter vectors may be used in the practice of the invention. Some of the reporter vectors are commercially available, e.g., the luciferase reporter vectors pNF- κ B-Luc (Stratagene) and pAP1-Luc (Stratagene). These two reporter vectors place the luciferase gene under control of an upstream (5') promoter region derived from genomic DNA for NF- κ B or AP1, respectively. Other reporter vectors can be constructed following standard

methods using the desired promoter and a vector containing a suitable reporter, such as luciferase, β -galactosidase (β -gal), chloramphenicol acetyltransferase (CAT), and other reporters known by those skilled in the art. Following are some examples of reporter vectors constructed for use in the present invention.

5 IFN- α 4 is an immediate-early type 1 IFN. Sequence-specific PCR products for the –620 to +50 promoter region of IFN- α 4 were derived from genomic DNA of human 293 cells and cloned into the *Sma*I site of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') –620 to +50 promoter region of IFN- α 4. The sequence of the –620 to +50 promoter region of IFN- α 4 is provided as
10 SEQ ID NO:121.

Example 9. Method of Making IFN- α 1 Reporter Vector

IFN- α 1 is a late type 1 IFN. Sequence-specific PCR products for the –140 to +9 promoter region of IFN- α 1 were derived from genomic DNA of human 293 cells and cloned
15 into *Sma*I site of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') –140 to +9 promoter region of IFN- α 1. A sequence of the –140 to +9 promoter region of IFN- α 1 is provided as SEQ ID NO:122.

Example 10. Method of Making IFN- β Reporter Vector

20 IFN- β is an immediate-early type 1 IFN. The –280 to +20 promoter region of IFN- β was derived from the pUC β 26 vector (Algarté M et al. (1999) *J Virol* 73:2694-702) by restriction at *Eco*RI and *Taq*I sites. The 300 bp restriction fragment was filled in by Klenow enzyme and cloned into *Nhe*I-digested and filled in pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') –280
25 to +20 promoter region of IFN- β . A sequence of the –280 to +20 promoter region of IFN- β is provided as SEQ ID NO:123.

Example 11. Method of Making Human IL-6 Reporter Vectors

Reporter constructs are made using the –285 to +7 promoter region derived from
30 human IL-6 genomic DNA. (Takeshita et al. *Eur. J. Immunol.* 2000. 30: 108–116.) In one reporter construct the IL-6 promoter region is cloned as a *Kpn*I-*Xho*I insert into pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of

- 67 -

an upstream (5') -288 to +7 promoter region derived from human IL-6 genomic DNA. A sequence of the -288 to +7 promoter region of human IL-6 is provided as SEQ ID NO:128.

The promoter can also be derived from the full-length promoter region of the IL-6 gene from -1174 to + 7 (GenBank Accession No M22111) as shown below as SEQ ID
5 NO:129.

Example 12. Method of Making Human IL-8 Reporter Vectors

Reporter constructs have been made using a -546 to +44 and a truncated -133 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71. In each reporter construct the IL-8 promoter region was cloned as a *Kpn*I-*Xho*I insert into pGL3-Basic Vector (Promega). One of the resulting expression vectors includes a luciferase gene under control of an upstream (5') -546 to +44 promoter region derived from human IL-8 genomic DNA. Another of the resulting expression vectors includes a luciferase gene under control of an upstream (5') -133 to +44 promoter region derived from human IL-8 genomic DNA.

The promoter can also be the upstream (5') -734 to +44 or the upstream (5') -162 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71. A sequence of the -734 to +44 promoter region derived from human IL-8 is provided below as SEQ ID NO: 130.

Example 13. Method of Making Human IL-12 p40 Reporter Vectors

Reporter constructs have been made using truncated (-250 to +30, SEQ ID NO:127) and full length (-751 to +30, SEQID NO:126) promoter regions derived from human IL-12 p40 genomic DNA. (Takeshita et al. *Eur. J. Immunol.* 2000. 30: 108–116.) In one reporter construct the truncated IL-12 p40 promoter was cloned as a *Kpn*I-*Xho*I insert into p β gal-Basic (Promega). The resulting expression vector includes a β gal gene under control of an upstream (5') -250 to +30 promoter region of human IL-12 p40. In a second reporter construct the full length IL-12 p40 promoter was cloned as a *Kpn*I-*Xho*I insert into p β gal-Basic (Promega). The resulting expression vector includes a β gal gene under control of an upstream (5') -751 to +30 promoter region of human IL-12 p40. In a third reporter construct the truncated -250 to +30 promoter region of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -250 to +30 promoter region of human IL-12 p40. In a

fourth reporter construct the full length IL-12 p40 promoter of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -751 to +30 promoter region of human IL-12 p40. A sequence of the -751 to +30 promoter region of human IL-12 p40 is provided as SEQ ID NO:

5 126.

Example 14. Method of Making RANTES Reporter Vector

Transcription of the chemokine RANTES is believed to be regulated at least in part by IRF3 and by NF- κ B. Lin R et al. (1999) *J Mol Cell Biol* 19(2):959-66; Genin P et al. (2000) *J Immunol* 164:5352-61. A 483 bp sequence-specific PCR product including the -397 to +5 promoter region of RANTES was derived from genomic DNA of human 293 cells, restricted with *Pst*I and cloned into pCAT-Basic Vector (Promega) using *Hind*III (filled in with Klenow) and *Pst*I sites (filled in). The -397 to +5 promoter region of RANTES was then isolated from the resulting RANTES/chloramphenicol acetyltransferase (CAT) reporter

10 plasmid by restriction with *Bgl*II and *Sal*I, filled in with Klenow enzyme, and cloned into the *Nhe*I site (filled in with Klenow) of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -397 to +5 promoter region of RANTES. Comparison of the insert sequence -397 to +5 of Genin P et al. (2000) *J Immunol* 164:5352-61 and GenBank accession no. AB023652 (SEQ ID NO:125)

15 20 revealed two point deletions (at positions 105 and 273 of SEQ ID NO:125) which do not create new restriction sites. A sequence of the -397 to +5 promoter region of RANTES is provided as SEQ ID NO:125.

Example 15. RT-PCR Analysis of Cell Lines for TLR Expression

25 TLR expression was determined using total RNA of cells prepared by standard methods (QIAGEN). RNA was transcribed to cDNA using AMV Reverse Transcriptase (Roche). Quantitative PCR was performed with TLR-gene specific primer sets using a LightCycler Instrument (Roche). Controls for genomic DNA impurities were performed by a similar PCR method using RNA (but without reverse transcriptase).

30 A variety of cell lines was screened for their expression of TLR3, 7, 8 and 9. These cell lines are A549 (human lung carcinoma), BeWo (human choriocarcinoma), HeLa (human cervix carcinoma), Hep-2 (human cervix carcinoma), KG-1 (human acute myeloid leukemia), MUTZ-3 (human acute myelomonocytic leukemia), Nalm-6 (human B cell precursor

leukemia), NK-92 (human Natural killer cell line), NK-92 MI (human Natural killer cell line, IL-2 independent), Raji (human Burkitt's lymphoma, B lymphocyte), RAMOS (Burkitt's lymphoma, B lymphocyte), RPMI 8226 (human multiple myeloma, B lymphocyte), THP-1 (human acute monocytic leukemia), U937 (human lymphoma) and Jurkat (human T cell leukemia).

All B cell lines express, as determined by Real Time-PCR (RT-PCR), endogenous TLR9. In addition, all lines except NALM co-express TLR7. Nevertheless, none of the other cell lines appeared to express TLR7, whereas low TLR9 expression on the mRNA level was observed for KG-1 and THP-1. TLR3 appeared to be expressed in most of these cell lines, 5 with the highest mRNA levels for example in the NK cell lines (e.g., NK-92).

Raji cells contain high levels of TLR9 mRNA and low levels of TLR3 and TLR7 mRNA suggesting high expression of TLR9 protein and lower levels of TLR3 and TLR7 protein.

These results indicate that the cell lines expressing TLR9 can be used to screen 15 potential new TLR9 ligands (CpG ODN, etc.), cell lines expressing TLR7 to screen potential new TLR7 ligands (ORN (oligoribonucleotides), small molecules, etc.), and cell lines expressing both receptors may be used to screen for "hybrid" TLR7 and 9 agonists. In addition, cell lines lacking TLR8 expression (i.e., all cell lines tested) can be used to confirm the specificity of a TLR7 versus a TLR8 ligand (i.e., the latter should not be able to stimulate 20 TLR7-expressing cells). In contrast, cell lines expressing TLR3 (e.g., Raji cells) may be used to screen for potential new TLR3 ligands (dsRNA, etc.).

Example 16. Screening of Various Cell Lines for Responses to TLR Ligands

Except where otherwise indicated, the following general methods were used.

25 Cells were plated at 5×10^5 /ml in 48 well plates in RPMI medium with 10% FBS. Stimulation was performed by addition of the oligonucleotides or other compounds diluted to the test concentrations in TE. Cells were incubated for 24 or 48h and the supernatants were taken to analyse for the presence of cytokines or chemokines.

The TLR ligands used are as follows:

30 TLR3: Poly I:C

TLR7, TLR8: R-848

TLR9:

T*C*C*A*G*G*A*C*T*T*C*T*C*T*C*A*G*G*T*T (SEQ ID NO: 2);

- 70 -

* phosphorothioate linkage; — phosphodiester linkage.

Increased expression of cell surface markers was determined using cells stimulated as described above and then stained with different monoclonal antibody combinations specific for the cell surface markers. Analysis of the cells was performed by flow cytometry.

Changes in reporter gene activity were determined using cells transfected with a NF- κ B reporter construct (Stratagene) and a β -galactosidase reporter control plasmid (Invitrogen) using electroporation. For NF- κ B analysis, a 5x NF- κ B-Luciferase Vector (Stratagene) was used. The amount of DNA transfected as well as cell concentration was varied. Stimulation was performed 24h after transfection. Cells were stimulated with the indicated amounts of ODN, R-848, LPS, TNF- α , or IL-1 β for the indicated incubation times. Cell extracts were prepared by lysing the cells in 100 μ l reporter lysis buffer (Promega) using the freeze-thaw method. All data were normalized for β -galactosidase expression.

Stimulation indices were calculated in reference to luciferase activity of medium without addition of ODN.

Stimulation of the Raji cell line with a TLR9 ligand (CpG ODN), a TLR3 ligand (poly I:C) or a TLR7 ligand (R-848) results in the ligand-specific secretion of cytokines. Figs. 14 and 15 show IL-6 production of Raji cells upon stimulation with ODN, poly I:C or R-848.

Fig. 16 shows IFN- α 2 production of Raji cells upon stimulation with ODN, poly I:C or R-848. In all assays, cells were incubated with Na-Butyrate for 48h before stimulation with TLR ligands. CpG stimulation of the RAMOS cell lines can result in the CpG-specific up-regulation of cell surface markers such as CD80, as shown in Fig. 17.

30 Example 17. Inhibition of a Positive Reference Compound Response with an Inhibitory Test Compound

Inhibition of CpG mediated chemokine production was determined using RPMI 8226 cells incubated with increasing amounts of SEQ ID NO:1 in the presence of an

- 71 -

immunoinhibitory ODN (SEQ ID NO: 151). IP-10 production was measured 24h later by ELISA (Fig. 9).

Equivalents

5 The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described
10 herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference.

15

We claim:

Claims

1. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising
 - contacting an RPMI 8226 cell that expresses a TLR with a test compound and
 - 5 measuring a test level of TLR signaling activity,
 - wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and
 - 10 wherein the TLR signaling activity is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- α expression, TNF- α production and TNF- α secretion.
2. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising
 - 15 contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,
 - wherein a test level that is positive is indicative of an immunostimulatory compound, and
 - 20 wherein the cell is a Raji cell, a RAMOS cell, a Nalm cell, a THP-1 cell, or a KG-1 cell.
3. The method of claim 1 or 2, wherein the test level is positive relative to a reference level determined by contacting the cell with a reference compound and measuring a reference TLR signaling activity.
 - 25
4. The method of claim 3, wherein the reference compound is a positive reference compound
 - 30
5. The method of claim 4, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an imidazoquinoline compound.

6. The method of claim 3, wherein the reference compound is a negative reference compound.

7. The method of claim 6, wherein the negative reference compound is
5 medium alone.

8. The method of claim 5, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

10

9. The method of claim 5, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

15 10. The method of claim 1 or 2, wherein the test compound is a nucleic acid.

11. The method of claim 10, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif.

20

12. The method of claim 10, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

25

13. The method of claim 10, wherein the nucleic acid is a DNA, an RNA or a DNA-RNA hybrid.

14. The method of claim 1 or 2, wherein the test compound is a non-nucleic acid small molecule.

30

15. The method of claim 1 or 2, wherein the test compound comprises an amino acid, a carbohydrate, a lipid, or a hormone.

16. The method of claim 15, wherein the carbohydrate is a polysaccharide.

17. The method of claim 1 or 2, wherein the test compound is derived from
a molecular library.
- 5 18. The method of claim 1, wherein the cell is transfected with a nucleic
acid.
- 10 19. The method of claim 18, wherein the nucleic acid encodes a TLR or a
reporter construct.
- 15 20. The method of claim 2, wherein the cell is transfected with a nucleic
acid.
- 20 21. The method of claim 20, wherein the nucleic acid encodes a TLR or a
reporter construct.
22. The method of claim 19 or 21, wherein the TLR is selected from the
group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and
TLR10.
23. The method of claim 22, wherein the TLR is a human TLR.
24. The method of claim 19 or 21, wherein the reporter construct is
selected from the group consisting of a luciferase reporter construct, a β -galactosidase reporter
construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein
reporter construct, and a secreted alkaline phosphatase construct.
- 25 25. The method of claim 19 or 21, wherein the reporter construct comprises
a TLR responsive promoter.
- 30 26. The method of claim 25, wherein the TLR responsive promoter
comprises a transcription factor binding site selected from the group consisting of a NF- κ B
binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an

IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

27. The method of claim 25, wherein the TLR responsive promoter is a
5 promoter region selected from the group consisting of an IL-1 promoter region, an IL-6 promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter region, an IFN- α 1 promoter region, an IFN- α 4 promoter region, an IFN- β promoter region, an IFN- γ promoter region, a TNF- α promoter region, a TNF- β promoter region, an IP-9 promoter region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a
10 MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

28. The method of claim 18 or 20, wherein the cell is stably transfected.
15

29. The method of claim 1 or 2, wherein the TLR signaling activity is measured by cytokine secretion or chemokine secretion.

30. The method of claim 1, wherein the TLR signaling activity is selected
20 from the group consisting of IL-8 secretion, IL-10 secretion, IP-10 secretion and TNF- α secretion.

31. The method of claim 2, wherein the TLR signaling activity is selected
from the group consisting of IL-6 expression, IL-6 production, IL-6 secretion, IL-8
25 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, IL-12 expression, IL-12 production, IL-12 secretion, TNF- α expression, TNF- α production and TNF- α secretion.

32. The method of claim 2, wherein the TLR signaling activity is measured
30 by phosphorylation.

33. The method of claim 32, wherein phosphorylation is total cellular phosphorylation.

34. The method of claim 32, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NFkB subunits, c-Jun and c-Fos.

5

35. The method of claim 1 or 2, wherein the TLR signaling activity is measured by gene expression.

10 36. The method of claim 1, wherein the TLR signaling activity is measured by gene expression selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-10 expression, IP-10 expression, and TNF- α expression.

15 37. The method of claim 35, wherein TLR signaling activity is measured by microarray techniques.

38. The method of claim 2, wherein the TLR signaling activity is measured by cell proliferation.

20 39. The method of claim 1 or 2, wherein TLR signaling activity is measured by cell surface marker expression.

40. The method of claim 1, wherein TLR signaling activity is measured by cell surface expression of CD71, CD86 or HLA-DR.

25

41. The method of claim 2, wherein TLR signaling activity is measured by CD71 cell surface expression, CD86 cell surface expression, HLA-DR cell surface expression, CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

30

42. The method of claim 2, wherein TLR signaling activity is measured by antibody secretion.

- 77 -

43. The method of claim 42, wherein the antibody secretion is IgM secretion.

44. A composition comprising
an RPMI 8226 cell stably transfected with a nucleic acid encoding a TLR
5 polypeptide, or a fragment thereof.

45. The composition of claim 44, further comprising a reporter construct
comprising a promoter and a reporter sequence wherein the promoter is a TLR responsive
promoter.

10

46. The composition of claim 45, wherein the TLR responsive promoter
comprises a nucleic acid sequence selected from the group consisting of an NF- κ B binding
site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3
binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding
15 site, and a TARE.

47. The composition of claim 45, wherein the reporter sequence is selected
from the group consisting of a luciferase sequence, a β -galactosidase sequence, a green
fluorescent protein sequence, a secreted alkaline phosphatase sequence and a chloramphenicol
20 transferase sequence.

48. The composition of claim 44, wherein the TLR polypeptide or fragment
thereof is a human TLR polypeptide or fragment thereof.

25 49. The composition of claim 44, wherein the TLR polypeptide or fragment
thereof is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6,
TLR7, TLR8, TLR9 and TLR10.

30 50. The composition of claim 44, wherein the TLR polypeptide or fragment
thereof is a human TLR polypeptide.

51. A screening method for identifying agonists of Toll-like receptor (TLR)
signaling activity, comprising

contacting an cell that ectopically expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

5 wherein the cell that ectopically expresses a TLR is selected from the group consisting of RPMI 8226, RAMOS, Raji, Nalm, THP-1, KG-1 and 293 HEK.

10 52. The method of claim 51, wherein the test level is positive relative to a reference level determined by contacting the cell with a reference compound and measuring a reference TLR signaling activity.

53. The method of claim 52, wherein the reference compound is a positive reference compound.

15 54. The method of claim 53, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an imidazoquinoline compound.

20 55. The method of claim 54, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

56. The method of claim 54, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

25 57. The method of claim 52, wherein the reference compound is negative reference compound.

30 58. The method of claim 57, wherein the negative reference compound is medium alone.

59. The method of claim 51, wherein the test compound is a nucleic acid.

60. The method of claim 59, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif.

5 61. The method of claim 59, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

62. The method of claim 59, wherein the nucleic acid is a DNA, an RNA, or a DNA-RNA hybrid.

10

63. The method of claim 51, wherein the test compound is a non-nucleic acid small molecule.

15

64. The method of claim 51, wherein the test compound comprises an amino acid, a carbohydrate, a lipid, or a hormone.

65. The method of claim 64, wherein the carbohydrate is a polysaccharide.

20
66. The method of claim 51, wherein the test compound is derived from a molecular library.

25
67. The method of claim 51, wherein the TLR signaling activity is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-6 expression, IL-6 production, IL-6 secretion, IL-8 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IL-12 expression, IL-12 production, IL-12 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- α expression, TNF- α production and TNF- α secretion.

30 68. The method of claim 51, wherein the TLR is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.

69. The method of claim 51, wherein the TLR is a human TLR.

70. The method of claim 51, wherein the cell is transfected with a reporter construct.

71. The method of claim 70, wherein the reporter construct is selected from 5 the group consisting of a luciferase reporter construct, a β -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.

72. The method of claim 71, wherein the TLR signaling activity is 10 measured by luciferase expression, β -galactosidase expression, chloramphenicol expression, acetyltransferase expression, green fluorescent protein expression, alkaline phosphatase expression and alkaline phosphatase secretion.

73. The method of claim 71, wherein the reporter construct comprises a 15 TLR responsive promoter.

74. The method of claim 25 or 73, wherein the TLR responsive promoter is a TLR1 responsive promoter, a TLR2 responsive promoter, a TLR3 responsive promoter, a 20 TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter and a TLR10 responsive promoter.

75. The method of claim 73, wherein the TLR responsive promoter comprises a transcription factor binding site selected from the group consisting of an NF- κ B 25 binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

76. The method of claim 73, wherein the TLR responsive promoter is a 30 promoter region selected from the group consisting of an IL-1 promoter region, an IL-6 promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter region, an IFN- α 1 promoter region, an IFN- α 4 promoter region, an IFN- β promoter region, an IFN- γ promoter region, a TNF- α promoter region, a TNF- β promoter region, an IP-9 promoter

region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

5

77. The method of claim 51, wherein the cell is stably transfected with a TLR nucleic acid.

10 78. The method of claim 70, wherein the cell is stably transfected with the reporter construct.

79. The method of claim 51, wherein the TLR signaling activity is measured by cytokine secretion or chemokine secretion.

15 80. The method of claim 79, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-8 secretion, TNF- α secretion, IL-10 secretion and IP-10 secretion.

20 81. The method of claim 79, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-6 secretion and IL-12 secretion.

82. The method of claim 51, wherein the TLR signaling activity is measured by phosphorylation.

25 83. The method of claim 82, wherein phosphorylation is total cellular phosphorylation.

30 84. The method of claim 82, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NF- κ B subunits, c-Jun and c-Fos.

85. The method of claim 51, wherein the TLR signaling activity is measured by gene expression.

86. The method of claim 85, wherein the gene expression is selected from the group consisting of IL-8 expression, IL-10 expression, IP-10 expression, CD71 expression, CD86 expression and HLA-DR expression.

5

87. The method of claim 85, wherein the gene expression is selected from the group consisting of IL-6 expression, IL-12 expression and TNF- α expression.

88. The method of claim 51, wherein the TLR signaling activity is
10 measured by microarray techniques.

89. The method of claim 51, wherein the TLR signaling activity is measured by cell proliferation.

15 90. The method of claim 51, wherein the TLR signaling activity is measured by cell surface marker expression.

20 91. The method of claim 90, wherein the cell surface marker expression is selected from the group consisting of CD71 cell surface expression, CD86 cell surface expression and HLA-DR cell surface expression.

92. The method of claim 90, wherein the cell surface marker expression is selected from the group consisting of CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

25

93. The method of claim 51, wherein the TLR signaling activity is measured by antibody secretion.

30 94. The method of claim 93, wherein the antibody secretion is IgM secretion.

95. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

5 wherein a test level that is less than a reference level is indicative of test compound that is a TLR antagonist, and

wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell, a Raji cell, a THP-1 cell, a Nalm cell and a KG-1 cell.

10 96. The method of claim 95, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an immunostimulatory imidazoquinoline compound.

15 97. The method of claim 96, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

98. The method of claim 96, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

20 99. The method of claim 95, wherein the test compound is a nucleic acid.

100. The method of claim 99, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a 25 poly-G motif.

101. The method of claim 99, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

30 102. The method of claim 99, wherein the nucleic acid is a DNA, an RNA or a DNA-RNA hybrid.

103. The method of claim 95, wherein the test compound is a non-nucleic acid small molecule.

104. The method of claim 95, wherein the test compound comprises an
5 amino acid, a carbohydrate, a lipid, or a hormone.

105. The method of claim 104, wherein the carbohydrate is a polysaccharide.

10 106. The method of claim 95, wherein the test compound is derived from a molecular library.

107. The method of claim 95, wherein the experimental cell is transfected with a nucleic acid.

15 108. The method of claim 107, wherein the nucleic acid encodes a TLR or a reporter construct.

20 109. The method of claim 108, wherein the TLR is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.

110. The method of claim 108, wherein the TLR is a human TLR.

25 111. The method of claim 108, wherein the reporter construct is selected from the group consisting of a luciferase reporter construct, a β -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.

30 112. The method of claim 111, wherein the TLR signaling activity is selected from the group consisting of luciferase expression, β -galactosidase expression, chloramphenicol acetyltransferase expression, green fluorescent protein expression, alkaline phosphatase expression and alkaline phosphatase secretion.

- 85 -

113. The method of claim 108, wherein the reporter construct comprises a TLR responsive promoter.

114. The method of claim 113, wherein the TLR responsive promoter
5 comprises a transcription factor binding site selected from the group consisting of an NF- κ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

10 115. The method of claim 113, wherein the TLR responsive promoter is a promoter region selected from the group consisting of an IL-1 promoter region, an IL-6 promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter region, an IFN- α 1 promoter region, an IFN- α 4 promoter region, an IFN- β promoter region, an IFN- γ promoter region, a TNF- α promoter region, a TNF- β promoter region, an IP-9 promoter
15 region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

20 116. The method of claim 113, wherein the TLR responsive promoter is selected from the group consisting of a TLR1 responsive promoter, TLR2 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter and a TLR10 responsive promoter.

25

117. The method of claim 107, wherein the cell is stably transfected with the nucleic acid.

30 118. The method of claim 95, wherein the TLR signaling activity is measured by cytokine secretion or chemokine secretion.

119. The method of claim 118, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-6 secretion, IL-12 secretion and TNF- α secretion.

5 120. The method of claim 118, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-8 secretion, IL-10 secretion and IP-10 secretion.

10 121. The method of claim 95, wherein the TLR signaling activity is measured by phosphorylation.

122. The method of claim 121, wherein phosphorylation is total cellular phosphorylation.

15 123. The method of claim 122, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NF- κ B subunits, c-Jun and c-Fos.

20 124. The method of claim 95, wherein the TLR signaling activity is measured by gene expression.

125. The method of claim 124, wherein the gene expression is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-10 expression and IP-10 expression.

25 126. The method of claim 124, wherein the gene expression is selected from the group consisting of IL-6 expression, IL-12 expression and TNF- α expression.

127. The method of claim 95, wherein the TLR signaling activity is measured by microarray techniques.

30 128. The method of claim 95, wherein the TLR signaling activity is measured by cell proliferation.

129. The method of claim 95, wherein the TLR signaling activity is measured by cell surface marker expression.

5 130. The method of claim 129, wherein the cell surface marker expression is selected from the group consisting of CD71 cell surface expression, CD86 cell surface expression and HLA-DR MHC class II cell surface expression.

10 131. The method of claim 129, wherein the cell surface marker expression is selected from the group consisting of CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

132. The method of claim 95, wherein the TLR signaling activity is measured by antibody secretion.

15 133. The method of claim 132, wherein the antibody secretion is IgM secretion.

20 134. The method of claim 95, wherein the cell is contacted to the positive reference compound and the test compound simultaneously.

135. The method of claim 95, wherein the cell is contacted to the positive reference compound prior to contact with the test compound.

25 136. The method of claim 95, wherein the cell is contacted to the test compound prior to contact with the positive reference compound.

137. A method for quality assessment of a test composition containing a known Toll like receptor (TLR) ligand, comprising:

30 measuring a reference activity of a reference composition comprising a known TLR ligand, wherein the known TLR ligand is a nucleic acid molecule; measuring a test activity of a test composition comprising the known TLR ligand; and comparing the test activity to the reference activity.

138. The method of claim 137, further comprising selecting the test composition if the test activity falls within a predetermined range of variance about the reference activity.

5

139. The method of claim 1, wherein the reference composition is a first production lot of a pharmaceutical composition comprising the known TLR ligand, and wherein the test composition is a second production lot of a pharmaceutical composition comprising the known TLR ligand.

10

140. The method of claim 137, wherein the reference composition is a first in-process lot of a composition comprising the known TLR ligand, and wherein the test composition is a second in-process lot of a composition comprising the known TLR ligand.

15

141. The method of claim 137, wherein the measuring the reference activity comprises contacting the reference composition with an isolated cell expressing a TLR responsive to the known TLR ligand, and wherein the measuring the test activity comprises contacting the test composition with the isolated cell expressing a TLR responsive to the known TLR ligand.

20

142. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand comprises an expression vector for the TLR responsive to the known TLR ligand.

25

143. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand naturally expresses the TLR responsive to the known TLR ligand.

30

144. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226.

145. The method of claim 137, wherein the measuring the reference activity and the measuring the test activity each comprise measuring signaling activity mediated by a TLR responsive to the known TLR ligand.

5 146. The method of claim 145, wherein the signaling activity is activity of a reporter construct under control of NF- κ B response element.

147. The method of claim 145, wherein the signaling activity is activity of a reporter construct under control of interferon-stimulated response element (ISRE).

10

148. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IFN- α promoter.

15

149. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IFN- β promoter.

150. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-6 promoter.

20

151. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-8 promoter.

152. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-12 p40 promoter.

25

153. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of a RANTES promoter.

30

154. The method of claim 137, wherein the known TLR ligand is a TLR9 ligand.

155. The method of claim 137, wherein the known TLR ligand is a TLR3 ligand.

156. The method of claim 137, wherein the known TLR ligand is a TLR7
ligand.

5 157. The method of claim 137, wherein the known TLR ligand is a TLR8
ligand.

158. The method of claim 137, wherein the known TLR ligand is an
immunostimulatory nucleic acid.

10 159. The method of claim 137, wherein the known TLR ligand is a CpG
nucleic acid.

15 160. The method of claim 137, wherein the known TLR ligand is an
immunoinhibitory nucleic acid.

161. A method for quality assessment of a test lot of a pharmaceutical
product containing a known TLR9 ligand, comprising:

20 measuring a reference activity of a reference lot of a pharmaceutical product
comprising a known TLR9 ligand, wherein the known TLR9 ligand is a nucleic acid
molecule;

measuring a test activity of a test lot of a pharmaceutical product comprising
the known TLR9 ligand;

25 comparing the test activity to the reference activity; and
rejecting the test lot if the test activity falls outside of a predetermined range of
variance about the reference activity.

162. The method of claim 161, wherein the known TLR9 ligand is an
oligonucleotide comprising a base sequence TCGTCGTTTGTCTGTTTGTCTGTT (SEQ ID
30 NO:1).

163. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTGACGTTTGTGCGTT-3' (SEQ ID NO:139).

5 164. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTGTCGTTTTTCGA-3' (SEQ ID NO:140).

10 165. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTCGTCGTTCGT-3' (SEQ ID NO:141).

15 166. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTCGTCGTTTGTGCGTT-3' (SEQ ID NO:142).

20 167. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGGTCGTTT-3' (SEQ ID NO:143).

168. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGTGCGTTT-3' (SEQ ID NO:144).

25 169. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGGCGGCCGCG-3' (SEQ ID NO:145).

30 170. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTC_GTTTAC_GGCGCC_GTGCCG-3' (SEQ ID NO:146), wherein every internucleoside linkage is phosphorothioate except for those indicated by “_”, which are phosphodiester.

- 92 -

171. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

5 wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

wherein the cell is a Raji cell, a RAMOS cell, a Nalm cell, a THP-1 cell, or a KG-1 cell, and the TLR is TLR9.

10 172. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

15 wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

wherein the cell is a Raji cell or a RAMOS cell, and the TLR is TLR7.

173. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

20 contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

25 wherein the cell is a Raji cell, a RAMOS cell, a KG-1 cell, a Nalm-6 cell, a Jurkat cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell, and the TLR is TLR3.

174. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

30 contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell, a Raji cell, a THP-1 cell, a Nalm cell and a KG-1 cell, and the TLR is TLR9.

5

175. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

10

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell and a Raji cell, and the TLR is TLR7.

15

175. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

20

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

25

wherein the cell is selected from the group consisting of a Raji cell, a RAMOS cell, a KG-1 cell, a Nalm-6 cell, a Jurkat cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell and an NK-92 MI cell, and the TLR is TLR3.

30

176. A screening method for identifying an enhancer of a Toll-like receptor (TLR) agonist, comprising

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity, and

contacting a cell with the positive reference compound and a test compound and measuring a test level of TLR signaling activity,

wherein the positive reference compound is a TLR agonist, and a test level that is greater than the reference level is indicative of a test compound that is an enhancer of a TLR
5 agonist.

177. The method of claim 176, wherein the positive reference compound is an immunostimulatory nucleic acid.

10 178. The method of claim 176, wherein the positive reference compound is an imidazoquinoline compound.


15 180. The method of claim 176, wherein the cell is selected from the group consisting of a KG-1 cell, a Nalm-6 cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell and an NK-92 MI cell, and the TLR is TLR3.

20 181. The method of claim 176, wherein the cell is selected from the group consisting of a KG-1 cell, a Nalm-6 cell, a Raji cell, an RPMI 8226 cell, a RAMOS cell, and a THP-1 cell, and the TLR is TLR9.

182. The method of claim 176, wherein the cell is selected from the group consisting of a Raji cell, an RPMI 8226 cell and a RAMOS cell, and the TLR is TLR7.

25 183. The method of claim 1, wherein the TLR is TLR7 or TLR9.

184. The method of claim 172-175 or 176, wherein the cell is unmodified.

**Fig. 1****SUBSTITUTE SHEET (RULE 26)**

2/15




Fig. 2

SUBSTITUTE SHEET (RULE 26)

3/15




Fig. 3

4/15




Fig. 4

5/15




Fig. 5

6/15




Fig. 6

7/15




Fig. 7

SUBSTITUTE SHEET (RULE 26)

8/15




Fig. 8

9/15




Fig. 9

10/15




Fig. 10




Fig. 11

11/15




Fig. 12

12/15




Fig. 13




Fig. 14

13/15




Fig. 15





Fig. 16

Fig. 17
SUBSTITUTE SHEET (RULE 26)

14/15




Fig. 18A




Fig. 18B

15/15




Fig. 19





Fig. 20

Fig. 21
SUBSTITUTE SHEET (RULE 26)

SEQUENCE LISTING

<110> COLEY PHARMACEUTICAL GmbH
COLEY PHARMACEUTICAL GROUP INC.

<120> METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT OF TLR LIGANDS

<130> C1041.70024W000

<140> not yet assigned

<141> 2004-04-22

<150> US 60/464,586
<151> 2003-04-22

<150> US 60/464,588
<151> 2003-04-22

<160> 161

<170> PatentIn version 3.2

<210> 1
<211> 24
<212> DNA
<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 1
tcgtcgaaaa gtcgttttgtt cgtt

24

<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 2
tccaggactt ctctcaggtt

20

<210> 3
<211> 2600
<212> DNA
<213> Homo sapiens

<400> 3
ggatccaaag gagacctata gtgactccca ggagctctta gtgaccaagt gaaggtaacct 60
gtggggctca ttgtgccat tgctcttca ctgcattcaa ctggtagttg tgggttgaag 120
cactggacaa tgccacatac tttgtggatg gtgtgggtct tgggggtcat catcagcctc 180
tccaaggaag aatcctccaa tcaggcttct ctgtttgtg accgcaatgg tatctgcaag 240

ggcagctcag gatctttaaa ctccattccc tcagggctca cagaagctgt aaaaagcctt 300
gacctgtcca acaacaggat cacctacatt agcaacagtg acctacagag gtgtgtgaac 360
ctccaggctc tggtgctgac atccaatgga attaacacaa tagaggaaga ttcttttct 420
tccctggca gtcttgaaca ttttagactta tcctataatt acttatctaa tttatcgct 480
tcctggttca agcccctttc ttcttaaca ttcttaaact tactggaaa tccttacaaa 540
accctagggg aaacatctct ttttctcat ctcacaaaat tgcaaattct gagagtggaa 600
aatatggaca ccttcactaa gattcaaaga aaagattttg ctggacttac cttcctttag 660
gaacttgaga ttgatgttca agatctacag agctatgagc caaaaagttt gaagtcaatt 720
cagaacgtaa gtcatctgat ctttcataatg aagcagcata ttttactgct ggagatttt 780
gtagatgttca caagttccgt ggaatgtttt gaactgcgag atactgattt ggacactttc 840
cattttcag aactatccac tggtaaaaca aattcattga ttaaaaaagtt tacattttaga 900
aatgtgaaaa tcaccgatga aagtttgtt caggttatga aacttttggaa tcagatttct 960
ggattgttag aatttagagtt tgatgactgt acccttaatg gagttggtaa ttttagagca 1020
tctgataatg acagagttat agatccaggt aaagtggaaa cgtaacaat ccggaggctg 1080
catattccaa ggttttactt attttatgat ctgagactt tatattcaat tacagaaaga 1140
gttaaaaagaa tcacagttaga aaacagtaaa gttttctgg ttccctgttt actttcacaa 1200
catttaaaat cattagaata cttggatctc agtggaaatt tgatggtaa agaatacttg 1260
aaaaatttcag cctgtgagga tgcctggccc tctctacaaa cttaatttt aaggcaaaat 1320
catttggcat cattggaaaa aaccggagag actttgctca ctctgaaaaa cttgactaac 1380
attgatatca gtaagaatag ttttcattct atgcctgaaa cttgtcagtg gccagaaaag 1440
atgaaatatt tgaacttatac cagcacacga atacacagtg taacaggctg cattcccaag 1500
acactggaaa ttttagatgt tagcaacaac aatctcaatt tattttcttt gaatttgcgg 1560
caactcaaag aactttatata ttccagaaaat aagttgatga ctctaccaga tgcctccctc 1620
ttacccatgt tactagtatt gaaaatcagt aggaatgcaaa taactacgtt ttcttaaggag 1680
caacttgact catttcacac actgaagact ttggaaagctg gtggcaataa cttcatttgc 1740
tcctgtgaat tcctctcctt cactcaggag cagcaagcac tggccaaagt cttgattgat 1800
tggccagcaa attacctgtg tgactctcca tcccatgtgc gtggccagca ggttcaggat 1860
gtccgcctct cgggtgtcgga atgtcacagg acagcaactgg tgtctggcat gtgctgtgt 1920
ctgttcctgc tgatcctgct cacgggggtc ctgtgccacc gtttccatgg cctgtggat 1980
atgaaaatga tggggcctg gctccaggcc aaaaggaagc ccaggaaagc tcccagcagg 2040
aacatctgct atgatgcatt tgtttcttac agtggcgaaa atgcctactg ggtggagaac 2100

cttatggtcc aggagctgga gaacttaat ccccccttca agttgtgtct tcataaggcg 2160
 gacttcattc ctggcaagtg gatcattgac aatatcattg actccattga aaagagccac 2220
 aaaactgtct ttgtgtttc tgaaaacttt gtgaagagtg agtggtgcaa gtatgaactg 2280
 gacttctccc atttccgtct ttttgaagag aacaatgatg ctgccattct cattttctg 2340
 gagccattg agaaaaaaagc cattccccag cgcttctgca agctgcggaa gataatgaac 2400
 accaagacct acctggagtg gcccatggac gaggctcagc gggaggatt ttgggtaaat 2460
 ctgagagctg cgataaaagtc ctaggttccc atattaaga ccagtcttg tctagttggg 2520
 atcttatgt cactagttat agttaagttc attcagacat aattatataa aaactacgtg 2580
 gatgtaccgt catttgagga 2600

<210> 4
 <211> 784
 <212> PRT
 <213> Homo sapiens

<400> 4

Met	Pro	His	Thr	Leu	Trp	Met	Val	Trp	Val	Leu	Gly	Val	Ile	Ile	Ser
1				5				10					15		
Leu	Ser	Lys	Glu	Glu	Ser	Ser	Asn	Gln	Ala	Ser	Leu	Ser	Cys	Asp	Arg
		20				25						30			
Asn	Gly	Ile	Cys	Lys	Gly	Ser	Ser	Gly	Ser	Leu	Asn	Ser	Ile	Pro	Ser
	35					40						45			
Gly	Leu	Thr	Glu	Ala	Val	Lys	Ser	Leu	Asp	Leu	Ser	Asn	Asn	Arg	Ile
	50				55					60					
Thr	Tyr	Ile	Ser	Asn	Ser	Asp	Leu	Gln	Arg	Cys	Val	Asn	Leu	Gln	Ala
65				70			75				80				
Leu	Val	Leu	Thr	Ser	Asn	Gly	Ile	Asn	Thr	Ile	Glu	Glu	Asp	Ser	Phe
			85				90				95				
Ser	Ser	Leu	Gly	Ser	Leu	Glu	His	Leu	Asp	Leu	Ser	Tyr	Asn	Tyr	Leu
		100				105					110				
Ser	Asn	Leu	Ser	Ser	Ser	Trp	Phe	Lys	Pro	Leu	Ser	Ser	Leu	Thr	Phe
	115				120			125							
Leu	Asn	Leu	Leu	Gly	Asn	Pro	Tyr	Lys	Thr	Leu	Gly	Glu	Thr	Ser	Leu
	130			135				140							
Phe	Ser	His	Leu	Thr	Lys	Leu	Gln	Ile	Leu	Arg	Val	Gly	Asn	Met	Asp
145					150				155			160			
Thr	Phe	Thr	Lys	Ile	Gln	Arg	Lys	Asp	Phe	Ala	Gly	Leu	Thr	Phe	Leu
	165					170						175			
Glu	Glu	Leu	Glu	Ile	Asp	Ala	Ser	Asp	Leu	Gln	Ser	Tyr	Glu	Pro	Lys
				180			185				190				

Ser Leu Lys Ser Ile Gln Asn Val Ser His Leu Ile Leu His Met Lys
195 200 205

Gln His Ile Leu Leu Leu Glu Ile Phe Val Asp Val Thr Ser Ser Val
210 215 220

Glu Cys Leu Glu Leu Arg Asp Thr Asp Leu Asp Thr Phe His Phe Ser
225 230 235 240

Glu Leu Ser Thr Gly Glu Thr Asn Ser Leu Ile Lys Lys Phe Thr Phe
245 250 255

Arg Asn Val Lys Ile Thr Asp Glu Ser Leu Phe Gln Val Met Lys Leu
260 265 270

Leu Asn Gln Ile Ser Gly Leu Leu Glu Leu Glu Phe Asp Asp Cys Thr
275 280 285

Leu Asn Gly Val Gly Asn Phe Arg Ala Ser Asp Asn Asp Arg Val Ile
290 295 300

Asp Pro Gly Lys Val Glu Thr Leu Thr Ile Arg Arg Leu His Ile Pro
305 310 315 320

Arg Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Leu Tyr Ser Leu Thr Glu
325 330 335

Arg Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro
340 345 350

Cys Leu Leu Ser Gln His Leu Lys Ser Leu Glu Tyr Leu Asp Leu Ser
355 360 365

Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Glu Asp
370 375 380

Ala Trp Pro Ser Leu Gln Thr Leu Ile Leu Arg Gln Asn His Leu Ala
385 390 395 400

Ser Leu Glu Lys Thr Gly Glu Thr Leu Leu Thr Leu Lys Asn Leu Thr
405 410 415

Asn Ile Asp Ile Ser Lys Asn Ser Phe His Ser Met Pro Glu Thr Cys
420 425 430

Gln Trp Pro Glu Lys Met Lys Tyr Leu Asn Leu Ser Ser Thr Arg Ile
435 440 445

His Ser Val Thr Gly Cys Ile Pro Lys Thr Leu Glu Ile Leu Asp Val
450 455 460

Ser Asn Asn Asn Leu Asn Leu Phe Ser Leu Asn Leu Pro Gln Leu Lys
465 470 475 480

Glu Leu Tyr Ile Ser Arg Asn Lys Leu Met Thr Leu Pro Asp Ala Ser
485 490 495

Leu Leu Pro Met Leu Leu Val Leu Lys Ile Ser Arg Asn Ala Ile Thr
500 505 510

Thr Phe Ser Lys Glu Gln Leu Asp Ser Phe His Thr Leu Lys Thr Leu

	515	520	525
Glu Ala Gly Gly Asn Asn Phe Ile Cys Ser Cys Glu Phe Leu Ser Phe			
	530	535	540
Thr Gln Glu Gln Gln Ala Leu Ala Lys Val Leu Ile Asp Trp Pro Ala			
	545	550	555
			560
Asn Tyr Leu Cys Asp Ser Pro Ser His Val Arg Gly Gln Gln Val Gln			
	565	570	575
Asp Val Arg Leu Ser Val Ser Glu Cys His Arg Thr Ala Leu Val Ser			
	580	585	590
Gly Met Cys Cys Ala Leu Phe Leu Leu Leu Leu Thr Gly Val Leu			
	595	600	605
Cys His Arg Phe His Gly Leu Trp Tyr Met Lys Met Met Trp Ala Trp			
	610	615	620
Leu Gln Ala Lys Arg Lys Pro Arg Lys Ala Pro Ser Arg Asn Ile Cys			
	625	630	635
			640
Tyr Asp Ala Phe Val Ser Tyr Ser Glu Arg Asp Ala Tyr Trp Val Glu			
	645	650	655
Asn Leu Met Val Gln Glu Leu Glu Asn Phe Asn Pro Pro Phe Lys Leu			
	660	665	670
Cys Leu His Lys Arg Asp Phe Ile Pro Gly Lys Trp Ile Ile Asp Asn			
	675	680	685
Ile Ile Asp Ser Ile Glu Lys Ser His Lys Thr Val Phe Val Leu Ser			
	690	695	700
Glu Asn Phe Val Lys Ser Glu Trp Cys Lys Tyr Glu Leu Asp Phe Ser			
	705	710	715
			720
His Phe Arg Leu Phe Glu Glu Asn Asn Asp Ala Ala Ile Leu Ile Leu			
	725	730	735
Leu Glu Pro Ile Glu Lys Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu			
	740	745	750
Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Met Asp Glu			
	755	760	765
Ala Gln Arg Glu Gly Phe Trp Val Asn Leu Arg Ala Ala Ile Lys Ser			
	770	775	780

<210> 5
<211> 2824
<212> DNA
<213> murine

<400> 5	
gccccccatg gccatatggg caccggggag cggcggtgg aggactccta ggctcctggg	60
caggcggtca catggcagaa gatgtgtccg caatcatagt ttctgtatggt gaagggttga	120
cggcagtctc tgcgacacctag aagtggaaaa gatgtcggttc aaggagggtgc ggactgtttc	180

cttctgacca ggatcttggt tctgagtgta ggggcttcac ttctctgctt ttcgttcatc	240
tctggagcat ccgaattgca tcaccgtca gaaaacaact taccgaaacc tcagacaag	300
cgtcaaatct cagaggatgc tacgagctct ttggctcttc tggatcttgg tggccataac	360
agtccctttc agcaaacgct gttctgctca ggagtctctg tcatgtgatg cttctgggt	420
gtgtgatggc cgctccaggt ct当地caccc tattccctcc ggactcacag cagccatgaa	480
aagccttgac ctgtctttca acaagatcac ctacattggc catggtgacc tccgagcgtg	540
tgcgaacctc caggttctga ttttgaagtc cagcagaatc aatacaatag agggagacgc	600
cttttattct ctgggcagtc ttgaacattt ggatttgtct gataatcacc tatctagttt	660
atcttcctcc tggttcgggc cccttcctc tttgaaatac taaaacttaa tggaaatcc	720
ttaccagaca ctggggtaa catcgctttt tcccaatctc acaaatttac aaaccctcag	780
gataggaaat gttagagactt tcagtgagat aaggagaata gattttgctg ggctgacttc	840
tctcaatgaa ctgaaatta aggcatthaag tctccggaat tatcagtccc aaagtctaaa	900
gtcgatccgc gacatccatc acctgactct tcacttaagc gagtctgctt tcctgctgga	960
gattttgca gatattctga gttctgtgag atatttagaa ctaagagata ctaacttggc	1020
caggttccag ttttaccac tgccctaga tgaagtcagc tcaccgatga agaagctggc	1080
attccgaggc tcggttctca ctgatgaaag ctttaacgag ctcctgaagc tggcgat	1140
catcttgaa ctgtcgagg tagagttcga cgactgtacc ctcaatggc tcggcgat	1200
caaccctcg gagtcagacg tagtgagcga gctggtaaa gtagaaacag tcactatccg	1260
gaggttgcatttccact tctattttttt ttatgacctg agtactgtct attccctct	1320
ggagaaggtg aagcgaatca cagtagagaa cagcaaggc ttcctgggtc cctgctcgat	1380
ctccccagcat taaaatcat tagaattctt agacccatc gaaaatctga tgggtgaaga	1440
atatttgaag aactcagcct gtaagggagc ctggccttct ctacaaacct tagtttgag	1500
ccagaatcat ttgagatcaa tgcaaaaaac aggagagatt ttgctgactc tgaaaaacct	1560
gacctccctt gacatcagca ggaacacttt tcacccatg cccgacagct gtcagtgcc	1620
agaaaatgt cgcttcctga atttgcctcag tacagggatc cgggtggtaa aaacgtgcatt	1680
tcctcagacg ctggaggtgt tggatgttag taacaacaat cttgactcat tttctttgtt	1740
cttgcctcgg ctgcaagagc tctatatttc cagaaataag ctgaaaacac tcccagatgc	1800
ttcggttgc cctgtgttgc tggcatgaa aatcagagag aatgcagtaa gtactttctc	1860
taaagaccaa cttgggttctt ttcccaaact ggagactctg gaagcaggcg acaaccactt	1920
tgtttgcctt tgcgaactcc tatacatttac tatggagacg ccagctctgg ctcaaatcct	1980
ggttgactgg ccagacagct acctgtgtga ctctccgcct cgcctgcacg gccacaggct	2040
tcaggatgcc cggccctccg tcttgaaatg tcaccaggct gcactgggtt ctggagtctg	2100

ctgtgccctt	ctcctgttga	tcttgctcg	aggtgccctg	tgccaccatt	tccacgggct	2160
gtggcacctg	agaatgatgt	ggcgctggct	ccaggccaag	aggaagccca	agaaagctcc	2220
ctgcaggac	gtttgctatg	atgcctttgt	tccctacagt	gagcaggatt	cccattgggt	2280
ggagaacctc	atggtccagc	agctggagaa	ctctgacccg	cccttaagc	tgtgtctcca	2340
caagcggac	ttcggtccgg	gcaaattggat	cattgacaac	atcatcgatt	ccatcgaaaa	2400
gagccacaaa	actgtgttcg	tgcttctga	gaacttcgta	cggagcggagt	ggtgcaagta	2460
cgaactggac	ttctcccaact	tcaggctctt	tgacgagaac	aacgacgcgg	ccatccttgt	2520
tttgcggag	cccattgaga	ggaaagccat	tccccagcgc	ttctgcaaac	tgcgcaagat	2580
aatgaacacc	aagacctacc	tggagtggcc	cttggatgaa	ggccagcagg	aagtgttttg	2640
ggtaaatctg	agaactgcaa	taaagtcccta	ggttctccac	ccagttcctg	acttccttaa	2700
ctaaggcttt	tgtgacacaa	actgtaacaa	agtttataag	taacatagaa	ttgtattatt	2760
gaggatatta	actatgggtt	ttgtctgaa	tactgtata	taaatatgtg	acatcaggct	2820
tttag						2824

<210> 6
<211> 784
<212> PRT
<213> murine

<400> 6

Met Leu Arg Ala Leu Trp Leu Phe Trp Ile Leu Val Ala Ile Thr Val
1 5 10 15

Leu Phe Ser Lys Arg Cys Ser Ala Gln Glu Ser Leu Ser Cys Asp Ala
20 25 30

Ser Gly Val Cys Asp Gly Arg Ser Arg Ser Phe Thr Ser Ile Pro Ser
35 40 45

Gly Leu Thr Ala Ala Met Lys Ser Leu Asp Leu Ser Phe Asn Lys Ile
50 55 60

Thr Tyr Ile Gly His Gly Asp Leu Arg Ala Cys Ala Asn Leu Gln Val
65 70 75 80

Ile Ile Leu Lys Ser Ser Arg Ile Asn Thr Ile Glu Gly Asp Ala Phe
85 90 95

Tyr Ser Leu Gly Ser Leu Glu His Leu Asp Leu Ser Asp Asn His Leu
100 105 110

Ser Ser Leu Ser Ser Ser Trp Phe Gly Pro Leu Ser Ser Leu Lys Tyr
115 120 125

Leu Asn Leu Met Gly Asn Pro Tyr Gln Thr Leu Gly Val Thr Ser Leu
130 135 140

Phe Pro Asn Leu Thr Asn Leu Gln Thr Leu Arg Ile Gly Asn Val Glu
145 150 155 160

Thr Phe Ser Glu Ile Arg Arg Ile Asp Phe Ala Gly Leu Thr Ser Leu
165 170 175

Asn Glu Leu Glu Ile Lys Ala Leu Ser Leu Arg Asn Tyr Gln Ser Gln
180 185 190

Ser Leu Lys Ser Ile Arg Asp Ile His His Leu Thr Leu His Leu Ser
195 200 205

Glu Ser Ala Phe Leu Leu Glu Ile Phe Ala Asp Ile Leu Ser Ser Val
210 215 220

Arg Tyr Leu Glu Leu Arg Asp Thr Asn Leu Ala Arg Phe Gln Phe Ser
225 230 235 240

Pro Leu Pro Val Asp Glu Val Ser Ser Pro Met Lys Lys Leu Ala Phe
245 250 255

Arg Gly Ser Val Leu Thr Asp Glu Ser Phe Asn Glu Leu Leu Lys Leu
260 265 270

Leu Arg Tyr Ile Leu Glu Leu Ser Glu Val Glu Phe Asp Asp Cys Thr
275 280 285

Leu Asn Gly Leu Gly Asp Phe Asn Pro Ser Glu Ser Asp Val Val Ser
290 295 300

Glu Leu Gly Lys Val Glu Thr Val Thr Ile Arg Arg Leu His Ile Pro
305 310 315 320

Gln Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Val Tyr Ser Leu Leu Glu
325 330 335

Lys Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro
340 345 350

Cys Ser Phe Ser Gln His Leu Lys Ser Leu Glu Phe Leu Asp Leu Ser
355 360 365

Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Lys Gly
370 375 380

Ala Trp Pro Ser Leu Gln Thr Leu Val Leu Ser Gln Asn His Leu Arg
385 390 395 400

Ser Met Gln Lys Thr Gly Glu Ile Leu Leu Thr Leu Lys Asn Leu Thr
405 410 415

Ser Leu Asp Ile Ser Arg Asn Thr Phe His Pro Met Pro Asp Ser Cys
420 425 430

Gln Trp Pro Glu Lys Met Arg Phe Leu Asn Leu Ser Ser Thr Gly Ile
435 440 445

Arg Val Val Lys Thr Cys Ile Pro Gln Thr Leu Glu Val Leu Asp Val
450 455 460

Ser Asn Asn Asn Leu Asp Ser Phe Ser Leu Phe Leu Pro Arg Leu Gln

465	470	475	480
Glu Leu Tyr Ile Ser Arg Asn Lys Leu Lys	Thr Leu Pro Asp Ala Ser		
485	490	495	
Leu Phe Pro Val Leu Leu Val Met Lys Ile Arg Glu Asn Ala Val Ser			
500	505	510	
Thr Phe Ser Lys Asp Gln Leu Gly Ser Phe Pro Lys Leu Glu Thr Leu			
515	520	525	
Glu Ala Gly Asp Asn His Phe Val Cys Ser Cys Glu Leu Leu Ser Phe			
530	535	540	
Thr Met Glu Thr Pro Ala Leu Ala Gln Ile Leu Val Asp Trp Pro Asp			
545	550	555	560
Ser Tyr Leu Cys Asp Ser Pro Pro Arg Leu His Gly His Arg Leu Gln			
565	570	575	
Asp Ala Arg Pro Ser Val Leu Glu Cys His Gln Ala Ala Leu Val Ser			
580	585	590	
Gly Val Cys Cys Ala Leu Leu Leu Ile Leu Leu Val Gly Ala Leu			
595	600	605	
Cys His His Phe His Gly Leu Trp Tyr Leu Arg Met Met Trp Ala Trp			
610	615	620	
Leu Gln Ala Lys Arg Lys Pro Lys Lys Ala Pro Cys Arg Asp Val Cys			
625	630	635	640
Tyr Asp Ala Phe Val Ser Tyr Ser Glu Gln Asp Ser His Trp Val Glu			
645	650	655	
Asn Leu Met Val Gln Gln Leu Glu Asn Ser Asp Pro Pro Phe Lys Leu			
660	665	670	
Cys Leu His Lys Arg Asp Phe Val Pro Gly Lys Trp Ile Ile Asp Asn			
675	680	685	
Ile Ile Asp Ser Ile Glu Lys Ser His Lys Thr Val Phe Val Leu Ser			
690	695	700	
Glu Asn Phe Val Arg Ser Glu Trp Cys Lys Tyr Glu Leu Asp Phe Ser			
705	710	715	720
His Phe Arg Leu Phe Asp Glu Asn Asn Asp Ala Ala Ile Leu Val Leu			
725	730	735	
Leu Glu Pro Ile Glu Arg Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu			
740	745	750	
Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Leu Asp Glu			
755	760	765	
Gly Gln Gln Glu Val Phe Trp Val Asn Leu Arg Thr Ala Ile Lys Ser			
770	775	780	

<210> 7
<211> 3029
<212> DNA

<213> Homo sapiens
<400> 7

gcggccgcgt cgacgaaatg tctggatttg gactaaagaa aaaaggaaag gctagcagtc	60
atccaacaga atcatgagac agactttgcc ttgtatctac ttttgggggg gcctttgcc	120
ctttggatg ctgtgtcat cctccaccac caagtgcact gttagccatg aagttgtga	180
ctgcagccac ctgaagttga ctcaggtacc cgatgatcta cccacaaaaca taacagtgtt	240
gaaccttacc cataatcaac tcagaagatt accagccgc aacttcacaa ggtatagcca	300
gctaactagc ttggatgttag gatttaacac catctaaaa ctggagccag aattgtgcc	360
gaaaacctccc atgttaaaag ttttgaacct ccagcacaat gagctatetc aactttctga	420
taaaacccctt gccttctgca cgaatttgac tgaactccat ctcatgtcca actcaatcca	480
gaaaattaaa aataatccct ttgtcaagca gaagaattta atcacattag atctgtctca	540
taatggcttg tcatctacaa aatttaggaac tcaggttcag ctggaaaatc tccaagagct	600
tctattatca aacaataaaaa ttcaagcgct aaaaagtgaa gaactggata tctttgccaa	660
ttcatcttta aaaaaattag agttgtcatc gaatcaaatt aaagagttt ctccagggtg	720
tttacagcga attggaagat tatttggcct ctttctgaac aatgtccagc tgggtcccag	780
ccttacagag aagctatgtt tggaatttagc aaacacaagc attcggaaatc tgtctctgag	840
taacagccag ctgtccacca ccagcaatac aactttcttg ggactaaaagt ggacaaaatct	900
cactatgctc gatcttcct acaacaactt aaatgtggtt ggtaacgatt cctttgcttg	960
gcttccacaa ctagaatatt tttcctaga gtataataat atacagcatt tgtttctca	1020
ctctttgcac gggctttca atgtgaggta cctgaatttg aaacggtctt ttactaaaca	1080
aagtatttcc ctgcctcac tccccaaatg tgatgatttt tctttcagt ggctaaaatg	1140
tttggagcac ctaaacatgg aagataatga tattccaggc ataaaaagca atatgttcac	1200
aggattgata aacctgaaat acttaagtct atccaactcc tttacaagtt tgcgaacttt	1260
gacaaatgaa acatttgtat cacttgctca ttctccctta cacatactca acctaaccas	1320
gaataaaaatc tcaaaaaatag agagtgtatc tttctcttgg ttgggccacc tagaagtact	1380
tgacctgggc ctaaatgaaa ttgggcaaga actcacaggc caggaatgga gaggtctaga	1440
aaatatttcc gaaatctatc ttctctacaa caagtacctg cagctgacta ggaactcctt	1500
tgccttggtc ccaagccttc aacgactgtat gctccgaagg gtggccctta aaaatgtgga	1560
tagctctct tcaccattcc agcctttcg taacttgacc attctggatc taagcaacaa	1620
caacatagcc aacataaaatg atgacatgtt ggagggtctt gagaaactag aaattctcg	1680
tttgcaagcat aacaacttag cacggctctg gaaacacgc aaccctggtg gtcccattta	1740
tttcttaaag ggtctgtctc acctccacat ctttaacttg gagtccaacg gctttgacga	1800

<210> 8
<211> 904
<212> PRT
<213> *Homo sapiens*

<400> 8

Met Arg Gln Thr Leu Pro Cys Ile Tyr Phe Trp Gly Gly Leu Leu Pro
1 5 10 15

Phe Gly Met Leu Cys Ala Ser Ser Thr Thr Lys Cys Thr Val Ser His
 20 25 30

Glu Val Ala Asp Cys Ser His Leu Lys Leu Thr Gln Val Pro Asp Asp
35 40 45

Leu Pro Thr Asn Ile Thr Val Leu Asn Leu Thr His Asn Gln Leu Arg
50 55 60

Arg Leu Pro Ala Ala Asn Phe Thr Arg Tyr Ser Gln Leu Thr Ser Leu

65 Asp Val Gly Phe Asn Thr Ile Ser Lys Leu Glu Pro Glu Leu Cys Gln	70 85	75 90	80 95
Lys Leu Pro Met Leu Lys Val Leu Asn Leu Gln His Asn Glu Leu Ser			
	100	105	110
Gln Leu Ser Asp Lys Thr Phe Ala Phe Cys Thr Asn Leu Thr Glu Leu			
	115	120	125
His Leu Met Ser Asn Ser Ile Gln Lys Ile Lys Asn Asn Pro Phe Val			
	130	135	140
Lys Gln Lys Asn Leu Ile Thr Leu Asp Leu Ser His Asn Gly Leu Ser			
	145	150	155
Ser Thr Lys Leu Gly Thr Gln Val Gln Leu Glu Asn Leu Gln Glu Leu			
	165	170	175
Leu Leu Ser Asn Asn Lys Ile Gln Ala Leu Lys Ser Glu Glu Leu Asp			
	180	185	190
Ile Phe Ala Asn Ser Ser Leu Lys Lys Leu Glu Leu Ser Ser Asn Gln			
	195	200	205
Ile Lys Glu Phe Ser Pro Gly Cys Phe His Ala Ile Gly Arg Leu Phe			
	210	215	220
Gly Leu Phe Leu Asn Asn Val Gln Leu Gly Pro Ser Leu Thr Glu Lys			
	225	230	235
Leu Cys Leu Glu Leu Ala Asn Thr Ser Ile Arg Asn Leu Ser Leu Ser			
	245	250	255
Asn Ser Gln Leu Ser Thr Thr Ser Asn Thr Phe Leu Gly Leu Lys			
	260	265	270
Trp Thr Asn Leu Thr Met Leu Asp Leu Ser Tyr Asn Asn Leu Asn Val			
	275	280	285
Val Gly Asn Asp Ser Phe Ala Trp Leu Pro Gln Leu Glu Tyr Phe Phe			
	290	295	300
Leu Glu Tyr Asn Asn Ile Gln His Leu Phe Ser His Ser Leu His Gly			
	305	310	315
Leu Phe Asn Val Arg Tyr Leu Asn Leu Lys Arg Ser Phe Thr Lys Gln			
	325	330	335
Ser Ile Ser Leu Ala Ser Leu Pro Lys Ile Asp Asp Phe Ser Phe Gln			
	340	345	350
Trp Leu Lys Cys Leu Glu His Leu Asn Met Glu Asp Asn Asp Ile Pro			
	355	360	365
Gly Ile Lys Ser Asn Met Phe Thr Gly Leu Ile Asn Leu Lys Tyr Leu			
	370	375	380
Ser Leu Ser Asn Ser Phe Thr Ser Leu Arg Thr Leu Thr Asn Glu Thr			
	385	390	395
Phe Val Ser Leu Ala His Ser Pro Leu His Ile Leu Asn Leu Thr Lys			

405	410	415
Asn Lys Ile Ser Lys Ile Glu Ser Asp Ala Phe Ser Trp Leu Gly His		
420	425	430
435	440	445
Gly Gln Glu Trp Arg Gly Leu Glu Asn Ile Phe Glu Ile Tyr Leu Ser		
450	455	460
Tyr Asn Lys Tyr Leu Gln Leu Thr Arg Asn Ser Phe Ala Leu Val Pro		
465	470	475
Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val Asp		
485	490	495
Ser Ser Pro Ser Pro Phe Gln Pro Leu Arg Asn Leu Thr Ile Leu Asp		
500	505	510
Leu Ser Asn Asn Ile Ala Asn Ile Asn Asp Asp Met Leu Glu Gly		
515	520	525
Leu Glu Lys Leu Glu Ile Leu Asp Leu Gln His Asn Asn Leu Ala Arg		
530	535	540
Leu Trp Lys His Ala Asn Pro Gly Gly Pro Ile Tyr Phe Leu Lys Gly		
545	550	555
Leu Ser His Leu His Ile Leu Asn Leu Glu Ser Asn Gly Phe Asp Glu		
565	570	575
Ile Pro Val Glu Val Phe Lys Asp Leu Phe Glu Leu Lys Ile Ile Asp		
580	585	590
Leu Gly Leu Asn Asn Leu Asn Thr Leu Pro Ala Ser Val Phe Asn Asn		
595	600	605
Gln Val Ser Leu Lys Ser Leu Asn Leu Gln Lys Asn Leu Ile Thr Ser		
610	615	620
Val Glu Lys Lys Val Phe Gly Pro Ala Phe Arg Asn Leu Thr Glu Leu		
625	630	635
Asp Met Arg Phe Asn Pro Phe Asp Cys Thr Cys Glu Ser Ile Ala Trp		
645	650	655
Phe Val Asn Trp Ile Asn Glu Thr His Thr Asn Ile Pro Glu Leu Ser		
660	665	670
Ser His Tyr Leu Cys Asn Thr Pro Pro His Tyr His Gly Phe Pro Val		
675	680	685
Arg Leu Phe Asp Thr Ser Ser Cys Lys Asp Ser Ala Pro Phe Glu Leu		
690	695	700
Phe Phe Met Ile Asn Thr Ser Ile Leu Ile Phe Ile Phe Ile Val		
705	710	715
Leu Leu Ile His Phe Glu Gly Trp Arg Ile Ser Phe Tyr Trp Asn Val		
725	730	735
Ser Val His Arg Val Leu Gly Phe Lys Glu Ile Asp Arg Gln Thr Glu		

740	745	750
Gln Phe Glu Tyr Ala Ala Tyr Ile Ile His Ala Tyr Lys Asp Lys Asp		
755	760	765
Trp Val Trp Glu His Phe Ser Ser Met Glu Lys Glu Asp Gln Ser Leu		
770	775	780
Lys Phe Cys Leu Glu Glu Arg Asp Phe Glu Ala Gly Val Phe Glu Leu		
785	790	800
Glu Ala Ile Val Asn Ser Ile Lys Arg Ser Arg Lys Ile Ile Phe Val		
805	810	815
Ile Thr His His Leu Leu Lys Asp Pro Leu Cys Lys Arg Phe Lys Val		
820	825	830
His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile Ile		
835	840	845
Leu Val Phe Leu Glu Glu Ile Pro Asp Tyr Lys Leu Asn His Ala Leu		
850	855	860
Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile Leu Asn Trp Pro		
865	870	875
Val Gln Lys Glu Arg Ile Gly Ala Phe Arg His Lys Leu Gln Val Ala		
885	890	895
Leu Gly Ser Lys Asn Ser Val His		
900		

<210> 9
 <211> 3310
 <212> DNA
 <213> murine

<400> 9	
tagaatatga tacagggatt gcaccataa tctggctga atcatgaaag ggtgttcctc	60
ttatctaattt tactcctttt gggactttt gtccctatgg attcttctgg tgtcttccac	120
aaaccaatgc actgtgagat acaacgttagc tgactgcagc catttgaagc taacacacat	180
acctgatgat cttccctcta acataacagt gttaatctt actcacaacc aactcagaag	240
attaccacct accaacttta caagatacag ccaacttgct atcttggatg caggatttaa	300
ctccatttca aaactggagc cagaactgtg ccaaatactc cctttgttga aagtattgaa	360
cctgcaacat aatgagctct ctcagatttc tgatcaaacc tttgtttct gcacgaacct	420
gacagaactc gatctaatgt ctaactcaat acacaaaatt aaaagcaacc ctttcaaaaa	480
ccagaagaat ctaatcaaat tagatttgc tcataatggc ttatcatcta caaagttggg	540
aacgggggtc caactggaga acctccaaga actgctctt gcaaaaaata aaatcctgc	600
gttgcgaagt gaagaacttg agtttcttgg caattcttct ttacgaaagt tggacttgc	660
atcaaatcca cttaaagagt tctccccggg gtgtttccag acaattggca agttattcgc	720

cctccttgc aacaacgccc aactgaaccc ccacacctaca gagaagcttt gctggaaact	780
ttcaaacaca agcatccaga atctctctct ggctaacaac cagctgctgg ccaccagcga	840
gagcactttc tctgggctga agtggacaaa tctcacccag ctcgatctt cctacaacaa	900
cctccatgtat gtcggcaacg gtcccttctc ctatctccca agcctgaggt atctgtctct	960
ggagtacaac aatatacagc gtctgtcccc tcgctcttt tatggactct ccaacactgag	1020
gtacctgagt ttgaagcgag catttactaa gcaaagtgtt tcacttgctt cacatccaa	1080
cattgacgat tttcctttaa aatggttaaa atatttggaa tatctcaaca tggatgacaa	1140
taatattcca agtacccaaa gcaatacctt cacgggattt gtgagtcgtt agtacctaag	1200
tctttccaaa actttcacaa gtttgcaaac tttaacaaat gaaacatttgc tgtaacttgc	1260
tcatttctccc ttgctcactc tcaacttaac gaaaaatcac atctcaaaaaa tagcaaatgg	1320
tactttctct tggttaggcc aactcaggat acttgatctc ggccttaatg aaattgaaca	1380
aaaactcagc ggccaggaat ggagaggtct gagaaatata tttgagatct acctatccta	1440
taacaaatac ctccaaactgt ctaccagttc cttgcattt gtcggccagcc ttcaaaagact	1500
gatgctcagg agggtggccc ttaaaaatgt ggatatctcc ctttcaccc ttccggctct	1560
tcgtaaacttgc accattctgg acttaagcaa caacaacata gccaacataa atgaggactt	1620
gctggagggt ctgagaatc tagaaatcct ggattttcag cacaataact tagccaggct	1680
ctggaaacgc gcaaaccggc gtggcccgt taatttcttgc aaggggctgt ctcacccctca	1740
catcttgaat ttagagtcca acggcttaga tgaaatccca gtcggggttt tcaagaactt	1800
attcgaacta aagagcatca atctaggact gaataactt aacaaacttgc aaccattcat	1860
ttttgatgac cagacatctc taaggtcact gaaccccttgc aagaacctca taacatctgt	1920
tgagaaggat gtttcgggc cgccctttca aaacctgaac agtttagata tgcgttcaa	1980
tccgttcgac tgacgtgtg aaagtatttc ctgggtttttt aactggatca accagacccca	2040
cactaatatc tttgagctgt ccactcaacta cctctgttac actccacatc attattatgg	2100
cttcccccttgc aagctttcg atacatcatc ctgtttttttt aactggatca accagacccca	2160
cttcataatc agcaccagta tgctccttgtt tttatactt gtggacttgc tcattcacat	2220
cgagggctgg aggtctttttt tttactggaa tgtttcagtg catcgatttgc ttgggttcaa	2280
ggaaatagac acacaggctg agcagtttga atatacagcc tacataatttgc atgcccataa	2340
agacagagac tgggtctggg aacatttctc cccaaatggaa gaacaagacc aatctctcaa	2400
attttgccta gaagaaaggg actttgaagg aggccgttgc ttggacttgc caattgtttaa	2460
tagcatcaaa agaagccgaa aaatcattttt cgttatcaca caccatatttgc taaaagaccc	2520
tctgtgcaga agattcaagg tacatcacgc agttcagcaa gctattgacaaa aatctctggaa	2580
ttcaattata ctgatttttc tccagaatata tccagatttgc aaactaaacc atgcactctg	2640

tttgcgaaga ggaatgttta aatctcattg catcttgaac tggccagttc agaaagaacg	2700
gataaatgcc tttcatcata aattgcaagt agcacttgga tctcgaaatt cagcacatta	2760
aactcatttg aagatttgg a gtcggtaaag ggatagatcc aatttataaa ggtccatcat	2820
gaatctaagt ttacttgaa agttttgtat atttatttat atgtatagat gatgatatta	2880
catcacaatc caatctcagt tttgaaatat ttccggcttat ttcatggaca tctggttat	2940
tcactccaaa taaacacatg ggcagttaaa aacatcctct attaatagat tacccattaa	3000
ttcttgaggt gtatcacagc tttaagggt tttaaatatt ttatataaa taagactgag	3060
agttttataa atgtaatttt tttaaaactcg agtcttactg tgtagctcag aaaggcctgg	3120
aaattaatat attagagagt catgtcttga acttatttat ctctgcctcc ctctgtctcc	3180
agagtgtgc tttaaggc atgttagcacc acacccagct atgtacgtgt gggattttat	3240
aatgctcatt ttgagacgt ttatagaata aaagataatt gctttatgg tataaggcta	3300
cttgaggtaa	3310

<210> 10
<211> 905
<212> PRT
<213> murine

<400> 10

Met Lys Gly Cys Ser Ser Tyr Leu Met Tyr Ser Phe Gly Gly Leu Leu			
1	5	10	15
Ser Leu Trp Ile Leu Leu Val Ser Ser Thr Asn Gln Cys Thr Val Arg			
20	25	30	
Tyr Asn Val Ala Asp Cys Ser His Leu Lys Leu Thr His Ile Pro Asp			
35	40	45	
Asp Leu Pro Ser Asn Ile Thr Val Leu Asn Leu Thr His Asn Gln Leu			
50	55	60	
Arg Arg Leu Pro Pro Thr Asn Phe Thr Arg Tyr Ser Gln Leu Ala Ile			
65	70	75	80
Leu Asp Ala Gly Phe Asn Ser Ile Ser Lys Leu Glu Pro Glu Leu Cys			
85	90	95	
Gln Ile Leu Pro Leu Leu Lys Val Leu Asn Leu Gln His Asn Glu Leu			
100	105	110	
Ser Gln Ile Ser Asp Gln Thr Phe Val Phe Cys Thr Asn Leu Thr Glu			
115	120	125	
Leu Asp Leu Met Ser Asn Ser Ile His Lys Ile Lys Ser Asn Pro Phe			
130	135	140	
Lys Asn Gln Lys Asn Leu Ile Lys Leu Asp Leu Ser His Asn Gly Leu			
145	150	155	160

Ser Ser Thr Lys Leu Gly Thr Gly Val Gln Leu Glu Asn Leu Gln Glu
165 170 175

Leu Leu Leu Ala Lys Asn Lys Ile Leu Ala Leu Arg Ser Glu Glu Leu
180 185 190

Glu Phe Leu Gly Asn Ser Ser Leu Arg Lys Leu Asp Leu Ser Ser Asn
195 200 205

Pro Leu Lys Glu Phe Ser Pro Gly Cys Phe Gln Thr Ile Gly Lys Leu
210 215 220

Phe Ala Leu Leu Leu Asn Asn Ala Gln Leu Asn Pro His Leu Thr Glu
225 230 235 240

Lys Leu Cys Trp Glu Leu Ser Asn Thr Ser Ile Gln Asn Leu Ser Leu
245 250 255

Ala Asn Asn Gln Leu Leu Ala Thr Ser Glu Ser Thr Phe Ser Gly Leu
260 265 270

Lys Trp Thr Asn Leu Thr Gln Leu Asp Leu Ser Tyr Asn Asn Leu His
275 280 285

Asp Val Gly Asn Gly Ser Phe Ser Tyr Leu Pro Ser Leu Arg Tyr Leu
290 295 300

Ser Leu Glu Tyr Asn Asn Ile Gln Arg Leu Ser Pro Arg Ser Phe Tyr
305 310 315 320

Gly Leu Ser Asn Leu Arg Tyr Leu Ser Leu Lys Arg Ala Phe Thr Lys
325 330 335

Gln Ser Val Ser Leu Ala Ser His Pro Asn Ile Asp Asp Phe Ser Phe
340 345 350

Gln Trp Leu Lys Tyr Leu Glu Tyr Leu Asn Met Asp Asp Asn Asn Ile
355 360 365

Pro Ser Thr Lys Ser Asn Thr Phe Thr Gly Leu Val Ser Leu Lys Tyr
370 375 380

Leu Ser Leu Ser Lys Thr Phe Thr Ser Leu Gln Thr Leu Thr Asn Glu
385 390 395 400

Thr Phe Val Ser Leu Ala His Ser Pro Leu Leu Thr Leu Asn Leu Thr
405 410 415

Lys Asn His Ile Ser Lys Ile Ala Asn Gly Thr Phe Ser Trp Leu Gly
420 425 430

Gln Leu Arg Ile Leu Asp Leu Gly Leu Asn Glu Ile Glu Gln Lys Leu
435 440 445

Ser Gly Gln Glu Trp Arg Gly Leu Arg Asn Ile Phe Glu Ile Tyr Leu
450 455 460

Ser Tyr Asn Lys Tyr Leu Gln Leu Ser Thr Ser Ser Phe Ala Leu Val
465 470 475 480

Pro Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val

	485	490	495
Asp Ile Ser Pro Ser Pro Phe Arg Pro Leu Arg Asn Leu Thr Ile Leu			
	500	505	510
Asp Leu Ser Asn Asn Asn Ile Ala Asn Ile Asn Glu Asp Leu Leu Glu			
	515	520	525
Gly Leu Glu Asn Leu Glu Ile Leu Asp Phe Gln His Asn Asn Leu Ala			
	530	535	540
Arg Leu Trp Lys Arg Ala Asn Pro Gly Gly Pro Val Asn Phe Leu Lys			
	545	550	555
			560
Gly Leu Ser His Leu His Ile Leu Asn Leu Glu Ser Asn Gly Leu Asp			
	565	570	575
Glu Ile Pro Val Gly Val Phe Lys Asn Leu Phe Glu Leu Lys Ser Ile			
	580	585	590
Asn Leu Gly Leu Asn Asn Leu Asn Lys Leu Glu Pro Phe Ile Phe Asp			
	595	600	605
Asp Gln Thr Ser Leu Arg Ser Leu Asn Leu Gln Lys Asn Leu Ile Thr			
	610	615	620
Ser Val Glu Lys Asp Val Phe Gly Pro Pro Phe Gln Asn Leu Asn Ser			
	625	630	635
			640
Leu Asp Met Arg Phe Asn Pro Phe Asp Cys Thr Cys Glu Ser Ile Ser			
	645	650	655
Trp Phe Val Asn Trp Ile Asn Gln Thr His Thr Asn Ile Phe Glu Leu			
	660	665	670
Ser Thr His Tyr Leu Cys Asn Thr Pro His His Tyr Tyr Gly Phe Pro			
	675	680	685
Leu Lys Leu Phe Asp Thr Ser Ser Cys Lys Asp Ser Ala Pro Phe Glu			
	690	695	700
Leu Leu Phe Ile Ile Ser Thr Ser Met Leu Leu Val Phe Ile Leu Val			
	705	710	715
			720
Val Leu Leu Ile His Ile Glu Gly Trp Arg Ile Ser Phe Tyr Trp Asn			
	725	730	735
Val Ser Val His Arg Ile Leu Gly Phe Lys Glu Ile Asp Thr Gln Ala			
	740	745	750
Glu Gln Phe Glu Tyr Thr Ala Tyr Ile Ile His Ala His Lys Asp Arg			
	755	760	765
Asp Trp Val Trp Glu His Phe Ser Pro Met Glu Glu Gln Asp Gln Ser			
	770	775	780
Leu Lys Phe Cys Leu Glu Glu Arg Asp Phe Glu Ala Gly Val Leu Gly			
	785	790	795
			800
Leu Glu Ala Ile Val Asn Ser Ile Lys Arg Ser Arg Lys Ile Ile Phe			
	805	810	815
Val Ile Thr His His Leu Leu Lys Asp Pro Leu Cys Arg Arg Phe Lys			

820	825	830
Val His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile		
835	840	845
Ile Leu Ile Phe Leu Gln Asn Ile Pro Asp Tyr Lys Leu Asn His Ala		
850	855	860
Leu Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile Leu Asn Trp		
865	870	875
Pro Val Gln Lys Glu Arg Ile Asn Ala Phe His His Lys Leu Gln Val		
885	890	895
Ala Leu Gly Ser Arg Asn Ser Ala His		
900	905	

<210> 11
<211> 3811
<212> DNA
<213> Homo sapiens

<400> 11	acagggccac tgctgctcac agaagcagtg aggatgatgc caggatgatg tctgcctcgc	60
	gcctggctgg gactctgatc ccagccatgg ctttcctctc ctgcgtgaga ccagaaaagct	120
	gggagccctg cgtggagact tggccctaaa ccacacagaa gagctggcat gaaacccaga	180
	gtttttagac tccggagcct cagcccttca ccccgattcc attgcttctt gctaatgct	240
	gccgttttat cacggaggtg gttcctaata ttacttatca atgcattggag ctgaatttct	300
	acaaaatccc cgacaacctc cccttctcaa ccaagaacct ggacctgagc ttaatcccc	360
	tgaggcattt aggcagctat agcttcttca gtttcccaga actgcaggtg ctggattttat	420
	ccaggtgtga aatccagaca attgaagatg gggcatatca gagcctaagc cacctctcta	480
	ccttaatatt gacaggaaac cccatccaga gtttagccct gggagcctt tctggactat	540
	caagtttaca gaagctggtg gctgtggaga caaatctagc atctctagag aacttcccc	600
	ttggacatct caaaactttt aagaactta atgtggctca caatcttatac caatcttca	660
	aattacctga gtatTTTCT aatctgacca atcttagagca cttggacctt tccagcaaca	720
	agattcaaag tatTTATTG acagacttgc gggttctaca tcaaattcccc ctactcaatc	780
	tctctttaga cctgtccctg aaccctatga actttatcca accaggtgca tttaaaagaaa	840
	ttaggcttca taagctgact ttaagaaata atttttagat tttaaatgta atgaaaactt	900
	gtattcaagg tctggctggt ttagaagtcc atcgTTTGGT tctgggagaa tttagaaatg	960
	aaggaaaactt ggaaaagttt gacaaatctg ctctagaggg cctgtgcaat ttgaccattg	1020
	aagaattccg attagcatac ttagactact acctcgatga tattattgac ttatTTAATT	1080
	ttttgacaaa tggTTCTCA tttccctgg tgagtgtgac tattgaaagg gtAAAAGACT	1140
	tttcttataa ttccggatgg caacatttag aattagttaa ctgtaaattt ggacagttc	1200

ccacattgaa actcaaatct ctcaaaaggc ttactttcac ttccaacaaa ggtggaaatg	1260
cttttcaga agttgatcta ccaagcctt agtttctaga tctcagtata aatggcttga	1320
gtttcaaagg ttgctgttct caaagtgatt ttgggacaac cagcctaaag tatttagatc	1380
tgagcttcaa tggtgttatt accatgagtt caaacttctt gggcttagaa caactagaac	1440
atctggattt ccagcattcc aatttggaaac aaatgagtga gttttcagta ttcctatcac	1500
tcagaaacct catttacctt gacatttctc atactcacac cagagttgct ttcaatggca	1560
tcttcaatgg cttgtccagt ctcgaagtct tgaaaatggc tggcaattct ttccaggaaa	1620
acttccttcc agatatcttc acagagctga gaaacttgac cttectggac ctctctcagt	1680
gtcaactgga gcagttgtct ccaacagcat ttaactcaact ctccagtc tt caggtaaa	1740
atatgagcca caacaacttc ttttcaattgg atacgtttcc ttataagtgt ctgaactccc	1800
tccagttct tgattacagt ctcaatcaca taatgacttc caaaaaacag gaactacagc	1860
attttccaag tagtcttagct ttcttaatc ttactcagaa tgactttgct tgtacttgc	1920
aacaccagag ttccctgcaa tggatcaagg accagaggca gctcttggtg gaagttgaac	1980
gaatggaatg tgcaacaccc tcagataagc agggcatgcc tgtgctgagt ttgaatatca	2040
cctgtcagat gaataagacc atcattggtg tgccgtcct cagtgtgc tt ctagtatctg	2100
ttgttagcagt tctggcttat aagttctatt ttcacctgat gcttcttgct ggctgcataa	2160
agtatggtag aggtgaaaac atctatgatg cctttgtt ctactcaagc caggatgagg	2220
actggtaag gaatgagcta gtaaagaatt tagaagaagg ggtgcctcca tttcagctct	2280
gccttcacta cagagacttt attcccggtg tggccattgc tgccaaacatc atccatgaag	2340
gtttccataa aagccgaaag gtgattttg tggatccca gcacttcatc cagagccgt	2400
ggtgtatctt tgaatatgag attgctcaga cctggcagtt tctgagcagt cgtgtggta	2460
tcatcttcat tgcctgcag aaggtggaga agaccctgct caggcagcag gtggagctgt	2520
accgccttct cagcaggaac acttacctgg agtgggagga cagtgtcctg gggccgcaca	2580
tcttctggag acgactcaga aaagccctgc tggatggtaa atcatggaaat ccagaaggaa	2640
cagtgggtac aggatgcaat tggcaggaag caacatctat ctgaagagga aaaataaaaa	2700
cctcctgagg catttcttgc ccagctgggt ccaacacttg ttcatgttaat aagtattaaa	2760
tgctgccaca tgcaggcct tatgctaagg gtgagtaatt ccatggtgca ctatgtatgc	2820
agggctgcta atctcaagga gcttccagtg cagagggaaat aaatgctaga ctaaaataca	2880
gagtcttcca ggtgggcatt tcaaccaact cagtcaagga acccatgaca aagaaagtca	2940
tttcaactct tacctcatca agttgaataa agacagagaa aacagaaaga gacattgttc	3000
ttttcctgag tctttgaat ggaaattgta ttatgtata gccatcataa aaccattttg	3060

gtagtttga ctgaactggg ttttcacttt ttcccttttg attgaataca atttaaattc	3120
tacttgcata ctgcagtcgt caaggggctc ctgatgcaag atgccccttc catttaagt	3180
ctgttcctt acagagggtta aagtctaattt gctaaatttctt aaggaaacctt gattaacaca	3240
tgctcacaac catcctggtc attctcgAAC atgttctatt tttaactaa tcacccctga	3300
tatattttta ttttatata tccagtttc atttttttac gtcttgccta taagctaata	3360
tcataaataa ggttgtttaa gacgtgcTTT aaatatccat attaaccactt atttttcaag	3420
gaagtatgga aaagtacact ctgtcacttt gtcactcgat gtcattccaa agttattgcc	3480
tactaagtaa tgactgtcat gaaagcagca ttgaaataat ttgtttaaag gggcactct	3540
tttaaacggg aagaaaattt ccgcttcctg gtcttatcat ggacaatttggc ggctataggc	3600
atgaaggaag tgggattacc tcaggaagtc accctttctt gattccagaa acatatggc	3660
tgataaaccc ggggtgacctt catgaaatga gttcagcag atgttttattt tttcagaac	3720
aagtgtatgtt tgatggacctt atgaatctat ttagggagac acagatggctt gggatccctc	3780
ccctgtaccc ttctcactga caggagaact a	3811

<210> 12
<211> 2845
<212> DNA
<213> Homo sapiens

<400> 12	
cctctcaccc tttagccccag aactgttttgc aatacaccaa ttgctgtggg gcccgtcgag	60
gaagagaaga caccagtgc tcagaaactg ctcggcaga cggtgatagc gagccacgca	120
ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatgt atgtctgcct	180
cgcgcctggc tgggactctg atcccagcca tggccttcct ctcctgcgtg agaccagaaa	240
gctgggagcc ctgcgtggag gtgtgaaatc cagacaattt aagatggggc atatcagagc	300
ctaagccacc tctctaccc ttatattgaca ggaaacccca tccagagttt agccctggga	360
gcctttctg gactatcaag ttacagaag ctggggctg tggagacaaa tctagcatct	420
ctagagaact tccccattgg acatctaaa actttgaaag aacttaatgt ggctcacaat	480
cttatccaaat cttccaaattt acctgagttt ttttctaattc tgaccaatctt agagcacttg	540
gacctttcca gcaacaagat tcaaagtatt tattgcacag acttgcgggt tctacatcaa	600
atgcccctac tcaatcttc tttagacctg tccctgaacc ctatgaactt tatccaaacca	660
ggtgcatatca aagaaattttt gcttcataag ctgactttaa gaaataattt tgatagttt	720
aatgtatgaa aaacttgtat tcaaggctgt gctggtttag aagtccatcg tttggttctg	780
ggagaattta gaaatgaagg aaacttggaa aagtttgaca aatctgctct agagggcctg	840

tgcaatttga ccattgaaga attccgatta gcatacttag actactacct cgatgatatt 900
attgacttat ttaattgttt gacaaatgtt tcttcatttt ccctggtag tgtgactatt 960

gaaagggtaa aagacttttc ttataatttc ggatggcaac atttagaatt agttaactgt 1020
aaatttggac agtttcccac attgaaactc aaatctctca aaaggcttac tttcaattcc 1080
aacaaaggtg ggaatgcttt ttcagaagtt gatctaccaa gccttgagtt tctagatctc 1140
agtagaaatg gcttgagttt caaaggttgc tgttctaaa gtgattttgg gacaaccagc 1200
ctaaagtatt tagatctgag cttcaatggt gttattacca tgagttcaaa cttcttggc 1260
ttagaacaac tagaacatct ggatttccag cattccaatt tgaaacaaat gagtgagttt 1320
tcagtattcc tatcaactcag aaacctcatt taccttgaca tttctcatac tcacaccaga 1380
gttgcttca atggcatctt caatggcttg tccagtctcg aagtcttgaa aatggctggc 1440
aattcttcc aggaaaactt cttccagat atttcacag agctgagaaa ctggaccttc 1500
ctggacctct ctcagtgtca actggagcag ttgtctccaa cagcatttaa ctcactctcc 1560
agtcttcagg tactaaatat gagccacaac aacttcttt cattggatac gtttccttat 1620
aagtgtctga actccctcca gtttcttgat tacagtctca atcacataat gacttccaaa 1680
aaacaggaac tacagcattt tccaaagtat ctagcttct taaatcttac tcagaatgac 1740
tttgcttgta ctgtgaaca ccagagttt ctgcaatgga tcaaggacca gaggcagctc 1800
ttggtggaaag ttgaacgaat ggaatgtgca acaccttcag ataagcaggg catgcctgtg 1860
ctgagtttga atatcacctg tcagatgaat aagaccatca ttggtgtgtc ggtcctcagt 1920
gtgctttagt tatctgttgt agcagttctg gtctataagt tctatcttca cctgatgctt 1980
cttgctggct gcataaaagta tggtagaggt gaaaacatct atgatgcctt tgttatctac 2040
tcaagccagg atgaggactg ggtaaggaat gagctagtaa agaatttaga agaaggggtg 2100
cctccatttc agctctgcct tcactacaga gactttattc ccgggtgtggc cattgctgcc 2160
aacatcatcc atgaagggtt ccataaaagc cgaaaggtga ttgttgtggt gtcccagcac 2220
ttcatccaga gccgctggtg tatcttgaa tatgagattt ctcagacctg gcagttctg 2280
agcagtcgtg ctggtatcat cttcattgtc ctgcagaagg tggagaagac cctgctcagg 2340
cagcaggtgg agctgtaccg cttctcagc aggaacactt acctggagtg ggaggacagt 2400
gtcctggggc ggcacatctt ctggagacga ctcagaaaag ccctgctgga tggtaaatca 2460
tggaatccag aaggaacagt gggtagacca tgcaattggc aggaagcaac atctatctga 2520
agagaaaaaa taaaaacctc ctgaggcatt tcttgccag ctgggtccaa cacttggatca 2580
gttaataagt attaaatgct gccacatgtc aggctttagt ctaagggtga gtaattccat 2640
ggtagacttag atatgcaggg ctgctaatttca agggagttt ccagtgcaga gggataaaat 2700
gctagactaa aatacagagt cttccaggtg ggcatttcaa ccaactcagt caaggaaccc 2760

atgacaaaaga aagtcatttc aactcttacc tcatcaagtt gaataaagac agagaaaaca	2820
aaaaaaaaaaa aaaaaaaaaaa aaaaaa	2845

<210> 13
<211> 3767
<212> DNA
<213> Homo sapiens

<400> 13	
cctctcaccc tttagccccag aactgctttg aatacaccaa ttgctgtggg gcggctcgag	60
gaagagaaga caccagtgcc tcagaaactg ctgggtcaga cggtgatagc gagccacgca	120
ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct	180
cgcgcttggc tgggactctg atcccagcca tggccttcct ctcctgcgtg agaccagaaa	240
gctgggagcc ctgcgtggag acttggccct aaaccacaca gaagagctgg catgaaaccc	300
agagctttca gactccggag ctcagccct tcaccccgat tccattgttt cttgttaaat	360
gctgccgttt tatcacggag gtgtgaaatc cagacaattt aagatggggc atatcagagc	420
ctaagccacc tctctacctt aatattgaca ggaaacccca tccagagttt agccctggga	480
gcctttctg gactatcaag tttacagaag ctgggtggctg tggagacaaa tctagcatct	540
ctagagaact tccccattgg acatctaaa acttgaaag aacttaatgt ggctcacaat	600
cttatccaaat ctttcaaatt acctgagttt ttttctaattc tgaccaatct agagacttg	660
gacctttcca gcaacaagat tcaaaggattt tattgcacag acttgcgggt tctacatcaa	720
atgcccctac tcaatctctc tttagacctg tccctgaacc ctatgaactt tatccaacca	780
ggtcattta aagaaatttgc gtttcataag ctgactttaa gaaataattt tgatagttt	840
aatgtatga aaacttgtat tcaaggtctg gctggtttag aagtccatcg tttggttctg	900
ggagaatttgc gaaatgaagg aaacttgaa aagtttgc aatctgctct agaggcctg	960
tgcaatttgc ccattgaaga attccgatta gcatacttag actactaccc cgatgatatt	1020
attgacttat ttaattgttt gacaaatgtt tcttcatttt ccctggtgag tgtgactatt	1080
gaaaggtaa aagacttttc ttataatttc ggatggcaac atttagaatt agttaactgt	1140
aaatttggac agtttccac attgaaactc aaatctctca aaaggcttac tttcaattcc	1200
aacaaaggta ggaatgcttt ttcagaagtt gatctaccaa gccttgagtt tctagatctc	1260
agtagaaatg gcttgagttt caaagggtgc tgttctcaaa gtgattttgg gacaaccagc	1320
ctaaagtatt tagatctgag cttcaatggt gttattacca tgagttcaaa cttcttggc	1380
ttagaacaac tagaacatct ggatttccag cattccaatt tgaacaaat gagtgagttt	1440
tcagtattcc tatcaactcag aaacctcatt taccttgaca tttctcatac tcacaccaga	1500

gttgctttca atggcatctt caatggcttg tccagtcctcg aagtcttcaa aatggctggc	1560
aattcttccc aggaaaactt ccttccagat atcttcacag agctgagaaa cttgaccttc	1620
ctggacctct ctcagtgtca actggagcag ttgtctccaa cagcatttaa ctcactctcc	1680
agtcttcagg tactaaatat gagccacaac aacttctttt cattggatac gtttccttat	1740
aagtgtctga actccctcca ggttcttgat tacagtctca atcacataat gacttccaaa	1800
aaacaggaac tacagcattt tccaagtagt cttagttct taaatcttac tcagaatgac	1860
tttgcttgta cttgtgaaca ccagagttc ctgcaatgga tcaaggacca gaggcagctc	1920
ttggtggaaag ttgaacgaat ggaatgtgca acacccctcag ataagcaggg catgcctgtg	1980
ctgagttga atatcacctg tcagatgaat aagaccatca ttggtgtgtc ggtcctcagt	2040
tgctttagt tatctgttgc agcagttctg gtctataagt tctatccat cctgatgttt	2100
cttgctggct gcataaaagta tggttagaggt gaaaacatct atgatgcctt tgttatctac	2160
tcaagccagg atgaggactg ggtaaggaat gagctagtaa agaatttaga agaaggggtg	2220
cctccatttc agctctgcct tcactacaga gactttattc ccgggtgtggc cattgctgcc	2280
aacatcatcc atgaaggttt ccataaaagc cgaaagggtga ttgttgtggt gtcccagcac	2340
ttcatccaga gccgctggtg tatcttgaa tatgagattt ctcagacctg gcagttctg	2400
agcagtcgtg ctggtatcat cttcatgtc ctgcagaagg tggagaagac cctgctcagg	2460
cagcaggtgg agctgtaccg cttctcagc aggaacactt acctggagtg ggaggacagt	2520
gtcctggggc ggcacatctt ctggagacga ctcagaaaag ccctgctgga tggtaaatca	2580
tggaatccag aaggaacagt gggtacagga tgcaattggc aggaagcaac atctatctga	2640
agagaaaaaa taaaacctc ctgaggcatt tcttgcccag ctgggtccaa cacttggta	2700
gttaataagt attaaatgct gccacatgtc aggccttatg ctaagggtga gtaattccat	2760
ggtgcaactg atatgcaggg ctgctaattt caaggagtt ccagtgcaaga gggaaataat	2820
gctagactaa aatacagagt cttccaggtg ggcatttcaa ccaactcagt caaggaaccc	2880
atgacaaaga aagtcatctt aactcttacc tcatcaagtt gaataaagac agagaaaaca	2940
gaaagagaca ttgttctttt cctgagtc ttgaatggaa attgtattat gttatagcca	3000
tcataaaacc attttggtag ttttgactga actgggtgtt cacttttcc ttttgatttgc	3060
aatacaattt aaattctact tgatgactgc agtcgtcaag gggctcctga tgcaagatgc	3120
cccttccatt ttaagtctgt ctccttacag aggttaaagt cttagtggcta attcctaagg	3180
aaacctgatt aacacatgct cacaaccatc ctggtcattt tcgagcatgt tctatccat	3240
aactaatcac ccctgatata tttttatccat tatatatccaa gttttcattt ttttacgtct	3300
tgcctataag ctaatatcat aaataagggtt gtttaagacg tgcttcaat atccatatta	3360
accactatcc ttcaaggaag tatggaaaag tacactctgt cactttgtca ctgcgtgtca	3420

ttccaaagtt attgcctact aagtaatgac tgtcatgaaa gcagcattga aataatttgt	3480
ttaaaggggg cactcttta aacgggaaga aaattccgc ttcctggct tatcatggac	3540
aatttggct agaggcagga aggaagtggg atgacctcg gaggtcacct tttcttgatt	3600
ccagaaacat atgggctgat aaaccgggg tgacctcatg aaatgagttg cagcagaagt	3660
ttatTTTTT cagaacaagt gatgttgat ggacctctga atctcttag ggagacacag	3720
atggctggga tccctcccct gtacccttct cactgccagg agaacta	3767

<210> 14
<211> 3814
<212> DNA
<213> Homo sapiens

<400> 14	
cctctcaccc tttagcccaag aactgctttg aatacaccaa ttgctgtggg gcccgtcgag	60
gaagagaaga caccagtgc tcagaaactg ctgggtcaga cggtgatagc gagccacgca	120
ttcacaggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct	180
cgcgcctggc tggactctg atcccccca tggcttcct ctcctgcgtg agaccagaaa	240
gctgggagcc ctgcgtggag gtggttccta atattactta tcaatgcatg gagctgaatt	300
tctacaaaat ccccgacaac ctcccccttca aaccaagaa cctggaccccg agcttaatc	360
ccctgaggca tttaggcage tatacgcttct tcagttccc agaactgcag gtgctggatt	420
tatccaggtg tgaaatccag acaattgaag atggggcata tcagagccctt agccacctct	480
ctaccttaat attgacagga aaccccatcc agagtttgc cctggagcc ttttctggac	540
tatcaagttt acagaagctg gtggctgtgg agacaaatctt agcatctcta gagaacttcc	600
ccattggaca tctcaaaaact ttgaaagaac ttaatgtggc tcacaatctt atccaatctt	660
tcaaattacc tgagtatttt tctaattctga ccaatctaga gcacttggac ctttccagca	720
acaagattca aagtattttat tgcacagact tgccggttct acatcaaattt cccctactca	780
atctctctttt agacctgtcc ctgaaccctt tgaactttat ccaaccaggt gcattaaag	840
aaatttaggct tcataagctg actttaaagaa ataattttga tagtttaat gtaatgaaaa	900
cttgtattca aggtctggct ggttttagaag tccatcgttt gggtctggga gaatttagaa	960
atgaaggaaa cttggaaaag tttgacaaat ctgctctaga gggcctgtgc aatttgcacca	1020
ttgaagaatt ccgatttagca tacttagact actacctcgat tgcattttt gactttat	1080
attgtttgac aaatgtttct tcattttccc tggtgagtgt gactattgaa agggtaaaag	1140
acttttctta taatttcgga tggcaacatt tagaatttagt taactgtaaa tttggacagt	1200
ttccccacatt gaaactcaaa tctctcaaaa ggcttacttt cacttccaaac aaaggtggga	1260

atgcttttc agaagttgat ctaccaaagcc ttgagttct agatctcagt agaaatggct 1320
tgagttcaa agttgctgt tctcaaagtg atttgggac aaccagccta aagtatttag 1380

atctgagctt caatggtggtt attaccatga gttcaaactt cttgggctta gaacaactag 1440
aacatctgga tttccagcat tccaaatttga aacaaatgag tgagtttca gtattcctat 1500
caactcagaaa cctcatttac cttgacattt ctcatactca caccagagtt gcttcaatg 1560
gcacatccaa tggcttgc tggcttgc tggcttgc tggcttgc 1620
aaaacttcct tccagatatac ttcacagagc tgagaaactt gacccctcctg gacccctc 1680
agtgtcaact ggaggcagttt tctccaacag catttaactc actctccagt cttcaggtac 1740
taaatatgag ccacaacaac ttctttcat tggatacggt tccttataag tgtctgaact 1800
ccctccagg tcttgcattt acgtctcaatc acataatgac ttccaaaaaa caggaactac 1860
agcattttcc aagtagtcta gctttcttaa atcttactca gaatgacttt gcttgcattt 1920
gtgaacacca gagtttccctg caatggatca aggaccagag gcagctctt gttggaaatgg 1980
aacgaatgg aatgtcaaca ctttcagata agcagggcat gcctgtgctg agttgaata 2040
tcacctgtca gatgaataag accatcattt gtgtgtcggt ctcagtgctg cttgtat 2100
ctgttgcattt agttctggc tataagttct atttcacct gatgcttctt gctggctgca 2160
taaaatgg tagaggtgaa aacatctatg atgcctttgt tatctactca agccaggatg 2220
aggactgggt aaggaatgag ctagtaaaga atttagaaga aggggtgcct ccatttc 2280
tctgccttca ctacagagac ttattcccg gtgtggccat tgctgccaaatc atcatccatg 2340
aaggtttcca taaaagccga aagggttattt ttgtgggtgc ccagcacttc atccagagcc 2400
gttgggttat ctgttgcattt gagattgctc agacctggca gtttctgagc agtcgtgctg 2460
gtatcatctt cattgtcctg cagaagggtt agaagaccct gtcaggcag cagggtggc 2520
tgtaccgcct ttcagcagg aacacttacc tggagtggga ggacagtgtc ctggggcggc 2580
acatcttctt gagacgactc agaaaagccc tgctggatgg taaatcatgg aatccagaag 2640
gaacagtggg tacaggatgc aattggcagg aagcaacatc tatctgaaga ggaaaaataa 2700
aaaccttcctt aggcatctt tgeccagctg ggtccaaacac ttgttcagtt aataagtatt 2760
aaatgtgcc acatgtcagg ctttatgcta agggtgagta attccatgtt gcactagata 2820
tgcagggtctt ctaatctcaa ggagcttcca gtgcagaggg aataaatgtc agactaaaat 2880
acagagtctt ccaggtggc atttcaacca actcagtc aaacccatg acaaagaaag 2940
tcatttcaac tcttacctca tcaagttgaa taaagacaga gaaaacagaa agagacattt 3000
ttctttccctt gagtcttttgc aatggaaatt gtattatgtt atagccatca taaaaccattt 3060
ttggtagttt tgactgaact ggggtttcac ttttccctt ttgattgaat acaatttaaa 3120
ttctacttgc tgcactgcagt cgtcaagggg ctccgtatgc aagatgcccc ttccattttt 3180

agtctgtctc	cttacagagg	ttaaagtcta	gtggctaatt	cctaaggaaa	cctgattaac	3240		
acatgctcac	aaccatcctg	gtcattctcg	agcatgttct	attttttaac	taatcacc	3300		
tgatatat	ttat	tttat	atatccagtt	ttcattttt	tacgtctgc	ctataagcta	3360	
atatcataaa	taaggttgtt	taagacgtgc	ttcaaatac	catattaacc	actat	tttc	3420	
aaggaagtat	ggaaaagtac	actctgtcac	tttgtca	ctc	gatgtcattc	caaagttatt	3480	
gcctactaag	taatgactgt	catgaaagca	gcattgaaat	aatttgttta	aagggggcac	3540		
tctttaaac	ggaagaaaaa	tttccgc	tttc	ctgg	tctt	catggacaat	ttgggctaga	3600
ggcaggaagg	aagtgggatg	acctcaggag	gtcac	ctt	tgattcca	gaaacatatg	3660	
ggctgataaa	cccgggtga	cctcatgaaa	tgagttgcag	cagaagtttta	ttttttcag	3720		
aacaagtat	gtttgatgga	cctctgaatc	tctttaggga	gacacagatg	gctgggatcc	3780		
ctccccgt	ta	cccttctcac	tgccaggaga	acta		3814		

<210> 15
<211> 3934
<212> DNA
<213> Homo spaiens

<400> 15							
cctctcaccc	tttagcccag	aactgctttg	aatacaccaa	ttgctgtggg	gcggctcgag	60	
gaagagaaga	caccagtgcc	tcagaaactg	ctcggtcaga	cggtgatagc	gagccacgca	120	
ttcacaggc	cactgctgct	cacagaagca	gtgaggatga	tgccaggatg	atgtctgcct	180	
cgcgcctggc	tggactctg	atcccagcca	tggcttcct	ctcctgcgtg	agaccagaaa	240	
gctggagcc	ctgcgtggag	acttggccct	aaaccacaca	gaagagctgg	catgaaaccc	300	
agagcttca	gactccggag	cctcagccct	tcaccccgat	tccattgctt	cttgctaaat	360	
gctgccgtt	tatcacggag	gtggttctta	atattactta	tcaatgcatg	gagctgaatt	420	
tctacaaaat	ccccgacaac	ctccccctct	caaccaagaa	cctggacctg	agctttaatc	480	
ccctgaggca	tttaggcagc	tatagcttct	tcagttccc	agaactgcag	gtgctggatt	540	
tatccagg	tgaaatccag	acaattgaag	atggggcata	tcagagccta	agccacctct	600	
ctaccttaat	attgacagga	aacccatcc	agagtttagc	cctggagcc	ttttctggac	660	
tatcaagttt	acagaagctg	gtggctgtgg	agacaaatct	agcatctcta	gagaacttcc	720	
ccattggaca	tctcaaaact	ttgaaagaac	ttaatgtggc	tcacaatctt	atccaatctt	780	
tcaaattacc	tgagtat	tttt	tctaatctga	ccaatctaga	gcacttggac	ctttccagca	840
acaagattca	aagtat	ttt	tgcacagact	tgccggttct	acatcaa	atg cccctactca	900
atctctctt	agac	ctgtcc	ctgaacccta	tgaactttat	ccaaccaggt	gcattaaag	960

aaattaggct tcataagctg actttaagaa ataattttga tagtttaaat gtaatgaaaa	1020
cttgtattca aggtctggct ggtttagaag tccatcggtt gggtctggga gaatttagaa	1080
atgaaggaaa cttggaaaag tttgacaaat ctgctctaga gggcctgtgc aatttgacca	1140
ttgaagaatt ccgatttagca tacttagact actacctcgta tgatattatt gacttattta	1200
attgtttgac aaatgtttct tcattttccc tggtgagtgt gactattgaa agggtaaaag	1260
acttttctta taatttcgga tggcaacatt tagaatttagt taactgtaaa tttggacagt	1320
ttccccacatt gaaactcaaa tctctcaaaa ggcttacttt cacttccaac aaagggtggga	1380
atgcttttc agaagttgat ctaccaagcc ttgagttct agatctcagt agaaatggct	1440
tgagttcaa aggttgctgt tctcaaagtg attttggac aaccagccta aagtatttag	1500
atctgagctt caatggtggtt attaccatga gttcaaactt cttgggctta gaacaactag	1560
aacatctgga tttccagcat tccaaatttga aacaaatgag tgagtttca gtattcctat	1620
cactcagaaa cctcatttac cttgacattt ctcatactca caccagagtt gctttcaatg	1680
gcatcttcaa tggcttgcgtc agtctcgaaat tcttggcaat ggctggcaat tctttccagg	1740
aaaacttcct tccagatatac ttcacagagc tgagaaactt gaccttcctg gacctctctc	1800
agtgtcaact ggagcagttg tctccaacag catttactc actctccagt cttcaggtac	1860
taaatatgag ccacaacaac ttctttcat tggatacggtt tccttataag tgtctgaact	1920
ccctccaggt tcttgattac agtctcaatc acataatgac ttccaaaaaaaa caggaactac	1980
agcattttcc aagtagtcta gctttcttaa atcttactca gaatgacttt gcttgtactt	2040
gtgaacaccca gagtttcctg caatggatca aggaccagag gcagctctt gtggaaagttg	2100
aacgaatgga atgtgcaaca ctttcagata agcagggcat gcctgtgctg agttgaata	2160
tcacctgtca gatgaataag accatcattt gtgtgtcggt cctcagtgtg ctttagtat	2220
ctgttgtagc agttctggtc tataaggctt atttcacct gatgcttctt gctggctgca	2280
taaagatgg tagaggtgaa aacatctatg atgcctttgt tatctactca agccaggatg	2340
aggactgggt aaggaatgag ctagtaaaga atttagaaga aggggtgcct ccatttcagc	2400
tctgccttca ctacagagac tttattcccg gtgtggccat tgctgccaac atcatccatg	2460
aaggtttcca taaaagccga aaggtgattt ttgtgggtgc ccagcacttc atccagagcc	2520
gctgggtgtat cttgaatat gagattgctc agacctggca gtttctgagc agtcgtgctg	2580
gtatcatctt cattgtcctg cagaagggtgg agaagaccct gctcaggcag caggtggagc	2640
tgtaccgcct tctcagcagg aacacttacc tggagtggga ggacagtgtc ctggggcggc	2700
acatcttctg gagacgactc agaaaagccc tgctggatgg taaatcatgg aatccagaag	2760
gaacagtggg tacaggatgc aattggcagg aagcaacatc tatctgaaga ggaaaaataa	2820
aaacctcctg aggcatatct tgcccagctg ggtccaaacac ttgttcagtt aataagtatt	2880

aaatgctgcc acatgtcagg ccttatgcta agggtgagta attccatggt gcactagata	2940
tgcagggctg ctaatctcaa ggagcttcca gtgcagaggg aataaatgct agactaaaat	3000
acagagtctt ccaggtggc atttcaacca actcagtcaa ggaacccatg acaaagaaag	3060
tcatttcaac tcttacctca tcaagttgaa taaagacaga gaaaacagaa agagacattg	3120
ttctttcct gagtctttg aatggaaatt gtattatgtt atagccatca taaaaccatt	3180
ttggtagttt tgactgaact ggggtttcac ttttccctt ttgattgaat acaatttaaa	3240
ttctacttga tgactgcagt cgtcaagggg ctccgtatgc aagatgcccc ttccatTTTA	3300
agtctgtctc cttacagagg ttaaagtcta gtggctaatt cctaaggaaa cctgattaac	3360
acatgctcac aaccatcctg gtcattctcg agcatgttct atttttAAC taatCACCCC	3420
tgatatatTTT ttatTTTAT atatccagtt ttcattttt tacgtcttgc ctataagcta	3480
atatcataAA TAAGGTTGTT taagacgtgc ttcaaatac catattaacc actatTTTC	3540
aaggaagtat ggaaaagtac actctgtcac tttgtcaactc gatgtcatTC caaagttatt	3600
gcctactaag taatgactgt catgaaagca gcattgaaat aatttGTTTA aaggGGGcAC	3660
tctttAAAC gggaaagaaaa tttccgcttc ctggctttat catggacaat ttggctaga	3720
ggcaggaagg aagtggatg acctcaggag gtcacccTTT cttgattCCA gaaacatATG	3780
ggctgataAA CCGGGGTGA CCTCATGAAA tgagttgcag cagaagtTTA tttttTCAG	3840
aacaagtgtat gtttcatggc cctctgaatC tctttagggA gacacagatg gctggatCC	3900
ctcccctgtA cccttctcac tgccaggaga actA	3934

<210> 16
<211> 839
<212> PRT
<213> Homo sapiens

<400> 16

Met Met Ser Ala Ser Arg Leu Ala Gly Thr Leu Ile Pro Ala Met Ala
1 5 10 15

Phe Leu Ser Cys Val Arg Pro Glu Ser Trp Glu Pro Cys Val Glu Val
20 25 30

Val Pro Asn Ile Thr Tyr Gln Cys Met Glu Leu Asn Phe Tyr Lys Ile
35 40 45

Pro Asp Asn Leu Pro Phe Ser Thr Lys Asn Leu Asp Leu Ser Phe Asn
50 55 60

Pro Leu Arg His Leu Gly Ser Tyr Ser Phe Phe Ser Phe Pro Glu Leu
65 70 75 80

Gln Val Leu Asp Leu Ser Arg Cys Glu Ile Gln Thr Ile Glu Asp Gly
85 90 95

Ala Tyr Gln Ser Leu Ser His Leu Ser Thr Leu Ile Leu Thr Gly Asn
100 105 110

Pro Ile Gln Ser Leu Ala Leu Gly Ala Phe Ser Gly Leu Ser Ser Leu
115 120 125

Gln Lys Leu Val Ala Val Glu Thr Asn Leu Ala Ser Leu Glu Asn Phe
130 135 140

Pro Ile Gly His Leu Lys Thr Leu Lys Glu Leu Asn Val Ala His Asn
145 150 155 160

Leu Ile Gln Ser Phe Lys Leu Pro Glu Tyr Phe Ser Asn Leu Thr Asn
165 170 175

Leu Glu His Leu Asp Leu Ser Ser Asn Lys Ile Gln Ser Ile Tyr Cys
180 185 190

Thr Asp Leu Arg Val Leu His Gln Met Pro Leu Leu Asn Leu Ser Leu
195 200 205

Asp Leu Ser Leu Asn Pro Met Asn Phe Ile Gln Pro Gly Ala Phe Lys
210 215 220

Glu Ile Arg Leu His Lys Leu Thr Leu Arg Asn Asn Phe Asp Ser Leu
225 230 235 240

Asn Val Met Lys Thr Cys Ile Gln Gly Leu Ala Gly Leu Glu Val His
245 250 255

Arg Leu Val Leu Gly Glu Phe Arg Asn Glu Gly Asn Leu Glu Lys Phe
260 265 270

Asp Lys Ser Ala Leu Glu Gly Leu Cys Asn Leu Thr Ile Glu Glu Phe
275 280 285

Arg Leu Ala Tyr Leu Asp Tyr Tyr Leu Asp Asp Ile Ile Asp Leu Phe
290 295 300

Asn Cys Leu Thr Asn Val Ser Ser Phe Ser Leu Val Ser Val Thr Ile
305 310 315 320

Glu Arg Val Lys Asp Phe Ser Tyr Asn Phe Gly Trp Gln His Leu Glu
325 330 335

Leu Val Asn Cys Lys Phe Gly Gln Phe Pro Thr Leu Lys Leu Lys Ser
340 345 350

Leu Lys Arg Leu Thr Phe Thr Ser Asn Lys Gly Gly Asn Ala Phe Ser
355 360 365

Glu Val Asp Leu Pro Ser Leu Glu Phe Leu Asp Leu Ser Arg Asn Gly
370 375 380

Leu Ser Phe Lys Gly Cys Cys Ser Gln Ser Asp Phe Gly Thr Thr Ser
385 390 395 400

Leu Lys Tyr Leu Asp Leu Ser Phe Asn Gly Val Ile Thr Met Ser Ser
405 410 415

Asn Phe Leu Gly Leu Glu Gln Leu Glu His Leu Asp Phe Gln His Ser

	420	425	430												
Asn	Leu	Lys	Gln	Met	Ser	Glu	Phe	Ser	Val	Phe	Leu	Ser	Leu	Arg	Asn
	435			440							445				
Leu	Ile	Tyr	Leu	Asp	Ile	Ser	His	Thr	His	Thr	Arg	Val	Ala	Phe	Asn
	450			455						460					
Gly	Ile	Phe	Asn	Gly	Leu	Ser	Ser	Leu	Glu	Val	Leu	Lys	Met	Ala	Gly
	465			470					475			480			
Asn	Ser	Phe	Gln	Glu	Asn	Phe	Leu	Pro	Asp	Ile	Phe	Thr	Glu	Leu	Arg
	485				490						495				
Asn	Leu	Thr	Phe	Leu	Asp	Leu	Ser	Gln	Cys	Gln	Leu	Glu	Gln	Leu	Ser
	500				505						510				
Pro	Thr	Ala	Phe	Asn	Ser	Leu	Ser	Ser	Leu	Gln	Val	Leu	Asn	Met	Ser
	515				520					525					
His	Asn	Asn	Phe	Phe	Ser	Leu	Asp	Thr	Phe	Pro	Tyr	Lys	Cys	Leu	Asn
	530				535					540					
Ser	Ile	Gln	Val	Leu	Asp	Tyr	Ser	Leu	Asn	His	Ile	Met	Thr	Ser	Lys
	545				550					555			560		
Lys	Gln	Glu	Leu	Gln	His	Phe	Pro	Ser	Ser	Leu	Ala	Phe	Leu	Asn	Leu
	565				570					575					
Thr	Gln	Asn	Asp	Phe	Ala	Cys	Thr	Cys	Glu	His	Gln	Ser	Phe	Leu	Gln
	580				585					590					
Trp	Ile	Lys	Asp	Gln	Arg	Gln	Leu	Leu	Val	Glu	Val	Glu	Arg	Met	Glu
	595				600					605					
Cys	Ala	Thr	Pro	Ser	Asp	Lys	Gln	Gly	Met	Pro	Val	Leu	Ser	Leu	Asn
	610				615					620					
Ile	Thr	Cys	Gln	Met	Asn	Lys	Thr	Ile	Ile	Gly	Val	Ser	Val	Leu	Ser
	625				630				635			640			
Val	Leu	Val	Val	Ser	Val	Val	Ala	Val	Leu	Val	Tyr	Lys	Phe	Tyr	Phe
	645				650				655						
His	Leu	Met	Leu	Leu	Ala	Gly	Cys	Ile	Lys	Tyr	Gly	Arg	Gly	Glu	Asn
	660				665				670						
Ile	Tyr	Asp	Ala	Phe	Val	Ile	Tyr	Ser	Ser	Gln	Asp	Glu	Asp	Trp	Val
	675				680				685						
Arg	Asn	Glu	Leu	Val	Lys	Asn	Leu	Glu	Glu	Gly	Val	Pro	Pro	Phe	Gln
	690				695				700						
Leu	Cys	Leu	His	Tyr	Arg	Asp	Phe	Ile	Pro	Gly	Val	Ala	Ile	Ala	Ala
	705				710				715			720			
Asn	Ile	Ile	His	Glu	Gly	Phe	His	Lys	Ser	Arg	Lys	Val	Ile	Val	Val
	725				730				735						
Val	Ser	Gln	His	Phe	Ile	Gln	Ser	Arg	Trp	Cys	Ile	Phe	Glu	Tyr	Glu
	740				745				750						
Ile	Ala	Gln	Thr	Trp	Gln	Phe	Leu	Ser	Ser	Arg	Ala	Gly	Ile	Ile	Phe

755	760	765
Ile Val Leu Gln Lys Val Glu	Lys Thr Leu Leu Arg	Gln Gln Val Glu
770	775	780
Leu Tyr Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Ser		
785	790	795
Val Leu Gly Arg His Ile Phe Trp Arg Arg Leu Arg Lys Ala Leu Leu		
805	810	815
Asp Gly Lys Ser Trp Asn Pro Glu Gly Thr Val Gly Thr Gly Cys Asn		
820	825	830
Trp Gln Glu Ala Thr Ser Ile		
835		

<210> 17
<211> 782
<212> PRT
<213> Homo sapiens

<400> 17

Met Lys Pro Arg Ala Phe Arg Leu Arg Ser Leu Ser Pro Ser Pro Arg		
1	5	10
		15
Phe His Cys Phe Leu Leu Asn Ala Ala Val Leu Ser Arg Arg Cys Glu		
20	25	30
Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu Ser		
35	40	45
Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly Ala		
50	55	60
Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr Asn		
65	70	75
80		
Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu Lys		
85	90	95
Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro Glu		
100	105	110
Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser Asn		
115	120	125
Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln Met		
130	135	140
Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn Phe		
145	150	155
160		
Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr Leu		
165	170	175
Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln Gly		
180	185	190
Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg Asn		
195	200	205

Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu Cys
210 215 220

Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr Leu
225 230 235 240

Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser Phe
245 250 255

Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr Asn
260 265 270

Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln Phe
275 280 285

Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser Asn
290 295 300

Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu Phe
305 310 315 320

Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser Gln
325 330 335

Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe Asn
340 345 350

Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu Glu
355 360 365

His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe Ser
370 375 380

Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His Thr
385 390 395 400

His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser Leu
405 410 415

Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu Pro
420 425 430

Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser Gln
435 440 445

Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser Ser
450 455 460

Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp Thr
465 470 475 480

Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser Leu
485 490 495

Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro Ser
500 505 510

Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr Cys
515 520 525

Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu Leu

530	535	540
Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln Gly		
545	550	555
		560
Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr Ile		
565	570	575
Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala Val		
580	585	590
Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys Ile		
595	600	605
Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr Ser		
610	615	620
Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu Glu		
625	630	635
		640
Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe Ile		
645	650	655
Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His Lys		
660	665	670
Ser Arg Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser Arg		
675	680	685
Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu Ser		
690	695	700
Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys Thr		
705	710	715
		720
Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn Thr		
725	730	735
Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp Arg		
740	745	750
Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu Gly		
755	760	765
Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile		
770	775	780

<210> 18
<211> 799
<212> PRT
<213> Homo sapiens

<400> 18

Met Glu Leu Asn Phe Tyr Lys Ile Pro Asp Asn Leu Pro Phe Ser Thr		
1	5	10
		15
Lys Asn Leu Asp Leu Ser Phe Asn Pro Leu Arg His Leu Gly Ser Tyr		
20	25	30
Ser Phe Phe Ser Phe Pro Glu Leu Gln Val Leu Asp Leu Ser Arg Cys		
35	40	45

Glu Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu
 50 55 60

Ser Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly
 65 70 75 80

Ala Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr
 85 90 95

Asn Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu
 100 105 110

Lys Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro
 115 120 125

Glu Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser
 130 135 140

Asn Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln
 145 150 155 160

Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn
 165 170 175

Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr
 180 185 190

Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln
 195 200 205

Gly Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg
 210 215 220

Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu
 225 230 235 240

Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr
 245 250 255

Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser
 260 265 270

Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr
 275 280 285

Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln
 290 295 300

Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser
 305 310 315 320

Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu
 325 330 335

Phe Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser
 340 345 350

Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe
 355 360 365

Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu

370 375 380
Glu His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe
385 390 395 400

Ser Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His
405 410 415

Thr His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser
420 425 430

Leu Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu
435 440 445

Pro Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser
450 455 460

Gln Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser
465 470 475 480

Ser Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp
485 490 495

Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser
500 505 510

Leu Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro
515 520 525

Ser Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr
530 535 540

Cys Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu
545 550 555 560

Leu Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln
565 570 575

Gly Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr
580 585 590

Ile Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala
595 600 605

Val Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys
610 615 620

Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr
625 630 635 640

Ser Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu
645 650 655

Glu Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe
660 665 670

Ile Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His
675 680 685

Lys Ser Arg Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser
690 695 700

Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu

705 710 715 720
 Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys
 725 730 735

Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn
 740 745 750

Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp
 755 760 765

Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu
 770 775 780

Gly Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile
 785 790 795

<210> 19
<211> 639
<212> PRT
<213> Homo sapiens

<400> 19

Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn
 1 5 10 15

Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr
 20 25 30

Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln
 35 40 45

Gly Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg
 50 55 60

Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu
 65 70 75 80

Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr
 85 90 95

Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser
 100 105 110

Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr
 115 120 125

Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln
 130 135 140

Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser
 145 150 155 160

Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu
 165 170 175

Phe Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser
 180 185 190

Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe
 195 200 205

Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu
210 215 220

Glu His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met ,Ser Glu Phe
225 230 235 240

Ser Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His
245 250 255

Thr His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser
260 265 270

Leu Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu
275 280 285

Pro Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser
290 295 300

Gln Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser
305 310 315 320

Ser Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp
325 330 335

Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser
340 345 350

Leu Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro
355 360 365

Ser Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr
370 375 380

Cys Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu
385 390 395 400

Leu Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln
405 410 415

Gly Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr
420 425 430

Ile Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala
435 440 445

Val Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys
450 455 460

Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr
465 470 475 480

Ser Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu
485 490 495

Glu Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe
500 505 510

Ile Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His
515 520 525

Lys Ser Arg Lys Val Ile Val Val Ser Gln His Phe Ile Gln Ser

530	535	540
Arg Trp Cys Ile Phe Glu	Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu	
545	550	555
Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys		
565	570	575
Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn		
580	585	590
Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp		
595	600	605
Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu		
610	615	620
Gly Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile		
625	630	635

<210> 20
<211> 3866
<212> DNA
<213> murine

<400> 20	60
ctgggtgcag aaaatgccag gatgatgcct ccctggctcc tggctaggac tctgatcatg	60
gcactgttct tctcctgcct gacaccagga agcttgaatc cctgcataga ggttagttcct	120
aatattacct accaatgcat ggatcagaaa ctcagcaaag tccctgatga cattccttct	180
tcaaccaaga acatagatct gagcttcaac cccttgaaga tcttaaaaaag ctatacgccc	240
tccaaatttt cagaacttca gtggctggat ttatccagggt gtgaaattga aacaattgaa	300
gacaaggcat ggcattggctt acaccaccc tc当地atgtga tactgacagg aaaccctatc	360
cagagttttt ccccaggaag tttctctgga ctaacaagtt tagagaatct ggtggctgtg	420
gagacaaaaat tggcctctct agaaagcttc cctattggac agcttataac ct当地agaaaa	480
ctcaatgtgg ctcacaattt tatacattcc tgtaagttac ct当地atctt ttccaatctg	540
acgaacctag tacatgtgga tctttcttat aactatattc aaactattac tgtcaacgac	600
ttacagtttc tacgtgaaaa tccacaagtc aatctcttt tagacatgtc tttgaaccca	660
attgacttca ttcaagacca agcctttcag ggaattaagc tccatgaact gactctaaga	720
ggtaattttt atagctaaa tataatgaaa acttgccctc aaaacctggc tggtttacac	780
gtccatcggt tgatcttggg agaattaaa gatgaaagga atctggaaat ttttgaaccc	840
tctatcatgg aaggactatg tgatgtgacc attgatgagt tcaggtaac atatacaaatt	900
gatTTTcag atgatattgt taagttccat tgcttggcga atgtttctgc aatgtctctg	960
gcaggtgtat ctataaaaata tctagaagat gttccctaaac atttcaaattg gcaatcctta	1020
tcaatcatta gatgtcaact taagcagttt ccaactctgg atctaccctt tcttaaaaagt	1080

ttgactttaa ctatgaacaa agggcttatac agttttaaaa aagtggccctt accaagtctc	1140
agctatctag atcttagtag aaatgcactg agcttttagtg gttgctgttc ttattctgat	1200
ttggaaacaa acagcctgag acacttagac ctcagcttca atggtgccat cattatgagt	1260
gccaaattca tgggtctaga agagctgcag cacctggatt ttcagcactc tactttaaaa	1320
agggtcacag aattctcagc gttcttatcc cttgaaaagc tactttacct tgacatctct	1380
tatactaaca cccaaattga cttcgatggt atatttcttg gcttgaccag tctcaacaca	1440
ttaaaaatgg ctggcaattc ttcaaagac aacacccttt caaatgtctt tgcaaacaca	1500
acaaacttga cattcctgga tctttctaaa tgtcaattgg aacaaatatac ttggggggta	1560
tttgacacccc tccatagact tcaatttatta aatatgagtc acaacaatct attgttttg	1620
gattcatccc attataacca gctgtattcc ctcagcactc ttgattgcag tttcaatcgc	1680
atagagacat ctaaaggaat actgcaacat tttccaaaga gtctagcctt cttcaatctt	1740
actaacaatt ctgttgctt tatatgtgaa catcagaaat tcctgcagtg ggtcaaggaa	1800
cagaagcagt tcttggtgaa tggtgaacaa atgacatgtg caacacctgt agagatgaat	1860
accccttag tggggattt taataattct acctgttata tgtacaagac aatcatcagt	1920
gtgtcagtgg tcagtgtgat tggttatcc actgttagcat ttctgatata ccacttctat	1980
ttcacctga tacttattgc tggctgtaaa aagtacagca gaggagaaag catctatgat	2040
gcatttgta tctactcgag tcagaatgag gactgggtga gaaatgagct ggtaaagaat	2100
ttagaagaag gagtcccccg ctttcaccc tcgccttact acagagactt tattcctggt	2160
gtagccatttgc ctgccaacat catccaggaa ggcttccaca agagccggaa ggttattgtg	2220
gtagtgtcta gacactttat tcagagccgt tggttatct ttgaatatga gattgctcaa	2280
acatggcagt ttctgagcag ccgctctggc atcatcttca ttgtccttga gaagggttag	2340
aagtccctgc tgaggcagca ggtggattt ttcgccttc ttgcagaaaa cacctacctg	2400
aatggggagg acaatccctt gggggggcac atcttctgga gaagacttaa aaatgcctt	2460
ttggatggaa aagcctcgaa tcctgagcaa acagcagagg aagaacaaga aacggcaact	2520
tggacctgag gagaacaaaa ctctggggcc taaacccagt ctgttgcaaa ttaataatg	2580
ctacagctca cctggggctc tgctatggac cgagagccca tggaaacacat ggctgctaa	2640
ctatagcatg gaccttaccg ggcagaagga agtagcactg acacccctt ttccagggt	2700
atgaattacc taactcgaaa aaagaaacat aatccagaat cttaacccctt aatctgaagg	2760
agaagaggct aaggccttagt gagaacagaa aggagaacca gtcttactg ggcctttga	2820
atacaagcca tgtcatgttc tggtttcag ttgcattttaga agagtattga tagttcaac	2880
tgaactgaac ggtttcttac ttccctttt ttctactgaa tgcaatatta aatagcttt	2940
tttgagaggt ctccattcca atttcatctt ccattttatg tcattttctt ttctttttt	3000

tttttatcta attctataag aaatatgatt gatacacgct cacagatgc ctggccaatc	3060
ctaagaatgc tatatttatt aaatacaatt cctagtatac ttttactttt ataaattcag	3120
ttatcgaaaa tcatacgcttg actataaact aatatacataa ataagattgt tacaggtatg	3180
ctaagaaggc ccataattga ctataatttt ttaagaaagt atataaaata tactttgtca	3240
tattgtcact gaatgtcattt cttaagttat tacctaagtt atggatgtca cagagtcagt	3300
gttaaaaata atttgggtga tagaaatatt tttaatcagg agggaaaagt ggagaggggt	3360
gcaggaacag aaatcatgat ttcatcattt attcttgatt tttccggaag ttcacatagc	3420
tgaatgacaa gactacatat gctgcaactg atgttccttc tcatcaagga tactctctga	3480
acttgagaac attttgggaa ggaagaaagg tctaacatcc ttttcattca tcattctcat	3540
ttctggacat gccttgtgag atggatcaat gttggagta cacatttctg ctttcacctt	3600
atttcagtca gcatgaacac tgaatataat atgtcatttc acagtgtgtg tgtgttgtgt	3660
atgtacatat atgaaccctgt acatgtgttt aagtttaaag agaaaatagt gtacagagca	3720
ggtgtatatt tgtgataggg cttaaatag ttgagcta at ctagaaaagt atggaggttt	3780
cttggtaaac caaacaaaaa gtagaatcat tacaagatct aacaataaaaa attttgaaaaa	3840
aaaaaaaaaaaa aaaaaaaaaa aaaaaaa	3866

<210> 21
<211> 2520
<212> DNA
<213> murine

<400> 21	
atgatgcctc cctggctcct ggcttaggact ctgatcatgg cactgttctt ctccgcctg	60
acaccaggaa gcttgaatcc ctgcataagag gtagttccta atattaccta ccaatgcatt	120
gatcagaaac tcagcaaagt ccctgtatgac attccttctt caaccaagaa catagatctg	180
agcttcaacc ccttgaagat cttaaaaagc tataccttctt ccaattttc agaacttcag	240
tggctggatt tatccaggtg tgaaattgaa acaattgaag acaaggcatg gcatggctta	300
caccacctct caaacttgat actgacagga aaccctatcc agagttttc cccaggaagt	360
ttctctggac taacaagttt agagaatctg gtggctgtgg agacaaaatt ggcctctcta	420
gaaagcttcc ctattggaca gcttataacc taaaagaaac tcaatgtggc tcacaatttt	480
atacattcct gtaagttacc tgcatatttt tccaaatctga cgaacctagt acatgtggat	540
ctttcttata actatattca aactattact gtcaacgact tacagttct acgtgaaaat	600
ccacaagtca atctctcttt agacatatct ttgaacccaa ttgacttcat tcaagaccaa	660
gccttcagg gaattaagct ccatgaactg actctaagag gtaattttaa tagctcaaatt	720

ataataaaa cttgccttca aaacctggct ggtttacaca tccatcggtt gatcttggga	780
gaatttaag atgaaaggaa tctggaaatt tttgaaccct ctatcatgga aggactatgt	840
gatgtgacca ttgatgagtt caggttaaca tatacaaatg attttcaga tgatattgtt	900
aagttccatt gcttggcgaa tgtttctgca atgtctctgg caggtgtatc tataaaatat	960
ctagaagatg ttccctaaaca tttcaaattgg caatccttat caatcattag atgtcaactt	1020
aagcagttc caactctgga tctacccttt cttaaaaagtt tgactttaac tatgaacaaa	1080
gggtctatca gttttaaaaa agtggcccta ccaagtctca gctatctaga tcttagtaga	1140
aatgcactga gcttttagtgg ttgctgttct tattctgatt tgggaacaaa cagcctgaga	1200
cacttagacc tcagcttcaa tggtgccatc attatgagtg ccaatttcat gggtctagaa	1260
gagctgcagc acctggattt tcagcactct actttaaaaa gggtcacaga attctcagcg	1320
ttcttatccc ttgaaaagct actttacctt gacatctctt atactaacac caaaattgac	1380
ttcgatggta tatttcttgg cttgaccagt ctcaacacat taaaaatggc tggcaattct	1440
ttcaaaagaca acaccctttc aaatgtcttt gcaaacacaaa caaaacttgac attcctggat	1500
ctttctaaat gtcaatttgg acaaataatct tgggggtat ttgacaccct ccatagactt	1560
caattattaa atatgagtca caacaatcta ttgttttgg attcatccca ttataaccag	1620
ctgtattccc tcagcactct tgattgcagt ttcaatcgca tagagacatc taaaggaata	1680
ctgcaacatt ttccaaagag tctagccttc ttcaatctta ctaacaattc tgttgcttgt	1740
atatgtgaac atcagaaaatt cctgcagtgg gtcaaggacc agaaggcgtt cttggtaat	1800
gttgaacaaa tgacatgtgc aacacctgta gagatgaata cctccttagt gttggatttt	1860
aataattcta cctgttatat gtacaagaca atcatcagtg tgtcagtggc cagtgtgatt	1920
gtggtatcca ctgtagcatt tctgatatac cacttctatt ttcacctgat acttattgct	1980
ggctgtaaaa agtacagcag aggagaaaagc atctatgatg catttgcgtt ctactcgagt	2040
cagaatgagg actgggtgag aaatgagctg gtaaaaggatt tagaagaagg agtgcggcgc	2100
ttcacctct gccttcacta cagagacttt attcctggc tagccattgc tgccaatatc	2160
atccaggaag gcttccacaa gagccggaag gttattgtgg tagtgtctag acactttatt	2220
cagagccgtt ggtgtatctt tgaatatgag attgctaaa catggcgtt tctgagcagc	2280
cactctggca tcacatctcat tgccttgag aaggttgaga agtcccgtt gaggcagcag	2340
gtggaaattgt atcgccttct tagcagaaac acctacctgg aatgggagga caatcctctg	2400
gggaggcaca tcttctggag aagactaaa aatgccctat tggatggaaa agcctcgaat	2460
cctgagcaaa cagcagagga agaacaagaa acggcaactt ggacctgagg agaaccgcgg	2520

<212> DNA
<213> murine

<400> 22

ctggttgcag	aaaatgccag	gatgatgcct	ccctggctcc	tggctaggac	tctgatcatg	60
gcactgttct	tctcctgcct	gacaccagga	agcttgaatc	cctgcataaga	ggtagttcct	120
aatattacct	accaatgcat	ggatcagaaa	ctcagcaaag	tccctgatga	cattccttct	180
tcaacccaaga	acatagatct	gagcttcaac	cccttgaaga	tcttaaaaag	ctatagcttc	240
tccaattttt	cagaacttca	gtggctggat	ttatccaggt	gtgaaattga	aacaattgaa	300
gacaaggcat	ggcatggctt	acaccacctc	tcaaacttga	tactgacagg	aaaccctatc	360
cagagttttt	ccccaggaag	tttctctgga	ctaacaagtt	tagagaatct	ggtggctgtg	420
gagacaaaat	tggcctctct	agaaagcttc	cctattggac	agttataac	cttaaagaaa	480
ctcaatgtgg	ctcacaattt	tatacattcc	tgtaagttac	ctgcataattt	ttccaatctg	540
acgaacctag	tacatgtgga	tcttttttat	aactatattc	aaactattac	tgtcaacgac	600
ttacagtttc	tacgtgaaaa	tccacaagtc	aatctctctt	tagacatgtc	tttgaaccca	660
attgacttca	ttcaagacca	agcctttcag	ggaattaagc	tccatgaact	gactctaaga	720
ggtaatttta	atagctaaa	tataatgaaa	actgccttc	aaaacctggc	tggttcacac	780
gtccatcggt	tgatcttggg	agaatttaaa	gatgaaagga	atctggaaat	tttgaacccc	840
tctatcatgg	aaggactatg	tgatgtgacc	attgatgagt	tcaggttaac	atatacaaat	900
gattttcag	atgatattgt	taagttccat	tgcttggcga	atgtttctgc	aatgtctctg	960
gcaggtgtat	ctataaaata	tctagaagat	gttcctaaac	atttcaaatg	gcaatcctta	1020
tcaatcatta	gatgtcaact	taagcagttt	ccaaactctgg	atctaccctt	tctaaaaagt	1080
ttgactttaa	ctatgaacaa	agggtctatc	agttttaaaa	aagtggccct	accaagtctc	1140
agctatctag	atcttagtag	aaatgcactg	agcttttagtg	gttgctgttc	ttattctgat	1200
ttgggaacaa	acagcctgag	acacttagac	ctcagcttca	atggtgccat	cattatgagt	1260
gccaatttca	tgggtctaga	agagctgcag	cacctggatt	ttcagcactc	tactttaaaa	1320
agggtcacag	aattctcagc	gttcttatcc	cttggaaaagc	tactttacct	tgacatctct	1380
tatactaaca	ccaaaattga	cttcgatggt	atatttcttg	gcttgaccag	tctcaacaca	1440
ttaaaaatgg	ctggcaattc	tttcaaagac	aacacccttt	caaatgtctt	tgcaaacaca	1500
acaaaacttga	cattcctgga	tctttctaaa	tgtcaattgg	aacaaatatc	ttggggggta	1560
tttgacaccc	tccatagact	tcaatttatta	aatatgagtc	acaacaatct	attgtttttg	1620
gattcatccc	attataacca	gctgtattcc	ctcagcactc	ttgattgcag	tttcaatcgc	1680
atagagacat	ctaaaggaat	actgcaacat	tttccaaaga	gtctagcctt	cttcaatctt	1740

actaacaaatt ctgttgcttg tatatgtgaa catcagaaaat tcctgcagtg ggtcaaggaa 1800
cagaaggcagt tcttggatcc ttataattct acctgttata tgtacaagac aatcatcagt 1860
accccttag tggtggatcc taataattct acctgttata tgtacaagac aatcatcagt 1920
gtgtcagtgg tcagtgtgat tgtggtatcc actgttagcat ttctgatata ccacttctat 1980
tttcacctga tacttattgc tggctgtaaa aagtacagca gaggagaaag catctatgat 2040
gcatttgtga tctactcgag tcagaatgag gactgggtga gaaatgagct ggtaaagaat 2100
ttagaagaag gagtgcggcg ctttcaccc tcgccttact acagagactt tattcctgg 2160
gtagccattg ctgccaacat catccaggaa ggcttccaca agagccggaa ggttattgtg 2220
gtagtgtcta gacactttat tcagagccgt tggtgtatct ttgaatatga gattgctcaa 2280
acatggcagt ttctgagcag ccgctctggc atcatcttca ttgtccttga gaaggttgag 2340
aagtccctgc tgaggcagca ggtggattt tattgccttc ttagcagaaa cacctacctg 2400
gaatggagg acaatccctt ggggaggcac atcttctgga gaagacttaa aaatgcccta 2460
ttggatggaa aagcctcgaa tcctgagcaa acagcagagg aagaacaaga aacggcaact 2520
tggacctgag gagaacaaaa ctctggggcc taaacccagt ctgtttgcaa ttaataaatg 2580
ctacagctca cctggggctc tgctatggac cgagagccca tggAACACAT ggctgctaag 2640
ctatacgatg gaccttaccg ggcagaagga agtagcactg acaccccttctt ttccagggg 2700
atgaattacc taactcgaaa aaagaaacat aatccagaat ctttaccttt aatctgaagg 2760
agaagaggct aaggcctagt gagaacagaa aggagaacca gtcttcactg ggcctttga 2820
atacaagcca tgtcatgttc tgtgtttcag ttgctttaga agagtattga tagttcaac 2880
tgaactgaac ggtttcttac ttccctttt ttctactgaa tgcaatatta aatacgctt 2940
tttgagaggt ctcatccat atttcatctt ccattttatg tcattttctt ttctttttg 3000
tttttatcta attctataag aaatatgatt gatacagct cacagatgc ctggccaatc 3060
ctaagaatgc tatatttatt aaatacaatt cctagtatac ttttactttt ataaattcag 3120
ttatcgaaaa tcatgccttgc actataaact aatatcataa ataagattgt tacaggtatg 3180
ctaagaaggc ccatatttga ctataatttt ttaagaaaagt atataaaata tactttgtca 3240
tattgtcact gaatgtcatt cttaagttt tacctaagtt atggatgtca cagagtcagt 3300
gttaaaaata atttgggttga tagaaatatt tttaatcagg agggaaaagt ggagaggg 3360
gcaggaacag aaatcatgat ttcatcattt atttttgcatttttttccatccatgc 3420
tgaatgacaa gactacatat gctgcaactg atttgccttc tcatcaagga tactctctg 3480
acttgagaac attttggggaa ggaagaaaagg tcttaacatcc ttcccttca tcattctcat 3540
ttctggacat gccttgcgtatc atggatcaat gttggggatca cacatttctg ctttcaccc 3600
atttcagtca gcatgaacac tgaatatata atgtcatttc acagtgtgtg tgggtttgtgt 3660

atgtacatat atgaacctgt acatgtgtt aagtttaag agaaaatagt gtacagagca	3720
ggtgtatatt tgtgataggg ctttaaatag ttgagcta atcagaaaatgt atggaggttt	3780
cttggtaaac caaacaaaaa gtagaatcat tacaagatct aacaataaaa attttgaaaa	3840
aaaaaaaaaa aaaaaaaaaa aaaaaa	3866

<210> 23
<211> 835
<212> PRT
<213> murine

<400> 23

Met Met Pro Pro Trp Leu Leu Ala Arg Thr Leu Ile Met Ala Leu Phe			
1	5	10	15
Phe Ser Cys Leu Thr Pro Gly Ser Leu Asn Pro Cys Ile Glu Val Val			
20	25	30	
Pro Asn Ile Thr Tyr Gln Cys Met Asp Gln Lys Leu Ser Lys Val Pro			
35	40	45	
Asp Asp Ile Pro Ser Ser Thr Lys Asn Ile Asp Leu Ser Phe Asn Pro			
50	55	60	
Leu Lys Ile Leu Lys Ser Tyr Ser Phe Ser Asn Phe Ser Glu Leu Gln			
65	70	75	80
Trp Leu Asp Leu Ser Arg Cys Glu Ile Glu Thr Ile Glu Asp Lys Ala			
85	90	95	
Trp His Gly Leu His His Leu Ser Asn Leu Ile Leu Thr Gly Asn Pro			
100	105	110	
Ile Gln Ser Phe Ser Pro Gly Ser Phe Ser Gly Leu Thr Ser Leu Glu			
115	120	125	
Asn Leu Val Ala Val Glu Thr Lys Leu Ala Ser Leu Glu Ser Phe Pro			
130	135	140	
Ile Gly Gln Leu Ile Thr Leu Lys Lys Leu Asn Val Ala His Asn Phe			
145	150	155	160
Ile His Ser Cys Lys Leu Pro Ala Tyr Phe Ser Asn Leu Thr Asn Leu			
165	170	175	
Val His Val Asp Leu Ser Tyr Asn Tyr Ile Gln Thr Ile Thr Val Asn			
180	185	190	
Asp Leu Gln Phe Leu Arg Glu Asn Pro Gln Val Asn Leu Ser Leu Asp			
195	200	205	
Met Ser Leu Asn Pro Ile Asp Phe Ile Gln Asp Gln Ala Phe Gln Gly			
210	215	220	
Ile Lys Leu His Glu Leu Thr Leu Arg Gly Asn Phe Asn Ser Ser Asn			
225	230	235	240

Ile Met Lys Thr Cys Leu Gln Asn Leu Ala Gly Leu His Val His Arg
245 250 255

Leu Ile Leu Gly Glu Phe Lys Asp Glu Arg Asn Leu Glu Ile Phe Glu
260 265 270

Pro Ser Ile Met Glu Gly Leu Cys Asp Val Thr Ile Asp Glu Phe Arg
275 280 285

Leu Thr Tyr Thr Asn Asp Phe Ser Asp Asp Ile Val Lys Phe His Cys
290 295 300

Leu Ala Asn Val Ser Ala Met Ser Leu Ala Gly Val Ser Ile Lys Tyr
305 310 315 320

Leu Glu Asp Val Pro Lys His Phe Lys Trp Gln Ser Leu Ser Ile Ile
325 330 335

Arg Cys Gln Leu Lys Gln Phe Pro Thr Leu Asp Leu Pro Phe Leu Lys
340 345 350

Ser Leu Thr Leu Thr Met Asn Lys Gly Ser Ile Ser Phe Lys Lys Val
355 360 365

Ala Leu Pro Ser Leu Ser Tyr Leu Asp Leu Ser Arg Asn Ala Leu Ser
370 375 380

Phe Ser Gly Cys Cys Ser Tyr Ser Asp Leu Gly Thr Asn Ser Leu Arg
385 390 395 400

His Leu Asp Leu Ser Phe Asn Gly Ala Ile Ile Met Ser Ala Asn Phe
405 410 415

Met Gly Leu Glu Glu Leu Gln His Leu Asp Phe Gln His Ser Thr Leu
420 425 430

Lys Arg Val Thr Glu Phe Ser Ala Phe Leu Ser Leu Glu Lys Leu Leu
435 440 445

Tyr Leu Asp Ile Ser Tyr Thr Asn Thr Lys Ile Asp Phe Asp Gly Ile
450 455 460

Phe Leu Gly Leu Thr Ser Leu Asn Thr Leu Lys Met Ala Gly Asn Ser
465 470 475 480

Phe Lys Asp Asn Thr Leu Ser Asn Val Phe Ala Asn Thr Thr Asn Leu
485 490 495

Thr Phe Leu Asp Leu Ser Lys Cys Gln Leu Glu Gln Ile Ser Trp Gly
500 505 510

Val Phe Asp Thr Leu His Arg Leu Gln Leu Leu Asn Met Ser His Asn
515 520 525

Asn Leu Leu Phe Leu Asp Ser Ser His Tyr Asn Gln Leu Tyr Ser Leu
530 535 540

Ser Thr Leu Asp Cys Ser Phe Asn Arg Ile Glu Thr Ser Lys Gly Ile
545 550 555 560

Leu Gln His Phe Pro Lys Ser Leu Ala Phe Phe Asn Leu Thr Asn Asn

	565	570	575
Ser Val Ala Cys Ile Cys Glu His Gln Lys Phe Leu Gln Trp Val Lys			
	580	585	590
Glu Gln Lys Gln Phe Leu Val Asn Val Glu Gln Met Thr Cys Ala Thr			
	595	600	605
Pro Val Glu Met Asn Thr Ser Leu Val Leu Asp Phe Asn Asn Ser Thr			
	610	615	620
Cys Tyr Met Tyr Lys Thr Ile Ile Ser Val Ser Val Val Ser Val Ile			
	625	630	635
Val Val Ser Thr Val Ala Phe Leu Ile Tyr His Phe Tyr Phe His Leu			
	645	650	655
Ile Leu Ile Ala Gly Cys Lys Lys Tyr Ser Arg Gly Glu Ser Ile Tyr			
	660	665	670
Asp Ala Phe Val Ile Tyr Ser Ser Gln Asn Glu Asp Trp Val Arg Asn			
	675	680	685
Glu Leu Val Lys Asn Leu Glu Glu Gly Val Pro Arg Phe His Leu Cys			
	690	695	700
Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala Asn Ile			
	705	710	715
Ile Gln Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val Val Ser			
	725	730	735
Arg His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala			
	740	745	750
Gln Thr Trp Gln Phe Leu Ser Ser Arg Ser Gly Ile Ile Phe Ile Val			
	755	760	765
Leu Glu Lys Val Glu Lys Ser Leu Leu Arg Gln Gln Val Glu Leu Tyr			
	770	775	780
Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Asn Pro Leu			
	785	790	795
Gly Arg His Ile Phe Trp Arg Arg Leu Lys Asn Ala Leu Leu Asp Gly			
	805	810	815
Lys Ala Ser Asn Pro Glu Gln Thr Ala Glu Glu Glu Gln Glu Thr Ala			
	820	825	830
Thr Trp Thr			
	835		

<210> 24
<211> 835
<212> PRT
<213> murine

<400> 24

Met Met Pro Pro Trp Leu Leu Ala Arg Thr Leu Ile Met Ala Leu Phe
1 5 10 15

Phe Ser Cys Leu Thr Pro Gly Ser Leu Asn Pro Cys Ile Glu Val Val
 20 25 30

Pro Asn Ile Thr Tyr Gln Cys Met Asp Gln Lys Leu Ser Lys Val Pro
 35 40 45

Asp Asp Ile Pro Ser Ser Thr Lys Asn Ile Asp Leu Ser Phe Asn Pro
 50 55 60

Leu Lys Ile Leu Lys Ser Tyr Ser Phe Ser Asn Phe Ser Glu Leu Gln
 65 70 75 80

Trp Leu Asp Leu Ser Arg Cys Glu Ile Glu Thr Ile Glu Asp Lys Ala
 85 90 95

Trp His Gly Leu His His Leu Ser Asn Leu Ile Leu Thr Gly Asn Pro
 100 105 110

Ile Gln Ser Phe Ser Pro Gly Ser Phe Ser Gly Leu Thr Ser Leu Glu
 115 120 125

Asn Leu Val Ala Val Glu Thr Lys Leu Ala Ser Leu Glu Ser Phe Pro
 130 135 140

Ile Gly Gln Leu Ile Thr Leu Lys Lys Leu Asn Val Ala His Asn Phe
 145 150 155 160

Ile His Ser Cys Lys Leu Pro Ala Tyr Phe Ser Asn Leu Thr Asn Leu
 165 170 175

Val His Val Asp Leu Ser Tyr Asn Tyr Ile Gln Thr Ile Thr Val Asn
 180 185 190

Asp Leu Gln Phe Leu Arg Glu Asn Pro Gln Val Asn Leu Ser Leu Asp
 195 200 205

Ile Ser Leu Asn Pro Ile Asp Phe Ile Gln Asp Gln Ala Phe Gln Gly
 210 215 220

Ile Lys Leu His Glu Leu Thr Leu Arg Gly Asn Phe Asn Ser Ser Asn
 225 230 235 240

Ile Met Lys Thr Cys Leu Gln Asn Leu Ala Gly Leu His Ile His Arg
 245 250 255

Leu Ile Leu Gly Glu Phe Lys Asp Glu Arg Asn Leu Glu Ile Phe Glu
 260 265 270

Pro Ser Ile Met Glu Gly Leu Cys Asp Val Thr Ile Asp Glu Phe Arg
 275 280 285

Leu Thr Tyr Thr Asn Asp Phe Ser Asp Asp Ile Val Lys Phe His Cys
 290 295 300

Leu Ala Asn Val Ser Ala Met Ser Leu Ala Gly Val Ser Ile Lys Tyr
 305 310 315 320

Leu Glu Asp Val Pro Lys His Phe Lys Trp Gln Ser Leu Ser Ile Ile
 325 330 335

Arg Cys Gln Leu Lys Gln Phe Pro Thr Leu Asp Leu Pro Phe Leu Lys

340 345 350
Ser Leu Thr Leu Thr Met Asn Lys Gly Ser Ile Ser Phe Lys Lys Val
355 360 365

Ala Leu Pro Ser Leu Ser Tyr Leu Asp Leu Ser Arg Asn Ala Leu Ser
370 375 380

Phe Ser Gly Cys Cys Ser Tyr Ser Asp Leu Gly Thr Asn Ser Leu Arg
385 390 400

His Leu Asp Leu Ser Phe Asn Gly Ala Ile Ile Met Ser Ala Asn Phe
405 410 415

Met Gly Leu Glu Glu Leu Gln His Leu Asp Phe Gln His Ser Thr Leu
420 425 430

Lys Arg Val Thr Glu Phe Ser Ala Phe Leu Ser Leu Glu Lys Leu Leu
435 440 445

Tyr Leu Asp Ile Ser Tyr Thr Asn Thr Lys Ile Asp Phe Asp Gly Ile
450 455 460

Phe Leu Gly Leu Thr Ser Leu Asn Thr Leu Lys Met Ala Gly Asn Ser
465 470 480

Phe Lys Asp Asn Thr Leu Ser Asn Val Phe Ala Asn Thr Thr Asn Leu
485 490 495

Thr Phe Leu Asp Leu Ser Lys Cys Gln Leu Glu Gln Ile Ser Trp Gly
500 505 510

Val Phe Asp Thr Leu His Arg Leu Gln Leu Leu Asn Met Ser His Asn
515 520 525

Asn Leu Leu Phe Leu Asp Ser Ser His Tyr Asn Gln Leu Tyr Ser Leu
530 535 540

Ser Thr Leu Asp Cys Ser Phe Asn Arg Ile Glu Thr Ser Lys Gly Ile
545 550 560

Leu Gln His Phe Pro Lys Ser Leu Ala Phe Phe Asn Leu Thr Asn Asn
565 570 575

Ser Val Ala Cys Ile Cys Glu His Gln Lys Phe Leu Gln Trp Val Lys
580 585 590

Asp Gln Lys Gln Phe Leu Val Asn Val Glu Gln Met Thr Cys Ala Thr
595 600 605

Pro Val Glu Met Asn Thr Ser Leu Val Leu Asp Phe Asn Asn Ser Thr
610 615 620

Cys Tyr Met Tyr Lys Thr Ile Ile Ser Val Ser Val Val Ser Val Ile
625 630 640

Val Val Ser Thr Val Ala Phe Leu Ile Tyr His Phe Tyr Phe His Leu
645 650 655

Ile Leu Ile Ala Gly Cys Lys Lys Tyr Ser Arg Gly Glu Ser Ile Tyr
660 665 670

Asp Ala Phe Val Ile Tyr Ser Ser Gln Asn Glu Asp Trp Val Arg Asn

675	680	685
Glu Leu Val Lys Asn Leu Glu	Gly Val Pro Arg	Phe His Leu Cys
690	695	700
Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala Asn Ile		
705	710	720
Ile Gln Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val Val Ser		
725	730	735
Arg His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala		
740	745	750
Gln Thr Trp Gln Phe Leu Ser Ser His Ser Gly Ile Ile Phe Ile Val		
755	760	765
Leu Glu Lys Val Glu Lys Ser Leu Leu Arg Gln Gln Val Glu Leu Tyr		
770	775	780
Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Asn Pro Leu		
785	790	800
Gly Arg His Ile Phe Trp Arg Arg Leu Lys Asn Ala Leu Leu Asp Gly		
805	810	815
Lys Ala Ser Asn Pro Glu Gln Thr Ala Glu Glu Glu Gln Glu Thr Ala		
820	825	830
Thr Trp Thr		
	835	

<210> 25
<211> 3431
<212> DNA
<213> Homo sapiens

<400> 25		
ggcttatagg gctcgagcgg ccgccccggc aggtatagaa ttcagcggcc gctgaattct	60	
agggtttca ggagcccgag cgagggcgcc gctttgcgt ccgggaggag ccaaccgtgg	120	
cgcaggcggc gcggggaggc gtcccagagt ctcaactctgc cgcccaggtt ggactgcagt	180	
gacacaatct cggctgactg caaccactgc ctccagggtt caagcgattc tcttgccatca	240	
gcctcccaag tagctggat tacagattga tttcatgtt cttggactca ctacaagatt	300	
catactcctg atgctactga caacgtggct tctccacagt caccaaaccg gggatgctat	360	
actggacttc cctactctca tctgctccag cccctgacc ttatagttgc ccagctttcc	420	
tggcaattga ctttgcctat caatacacag gathtagcat ccagggaga tgctggagcc	480	
ttagatgtta atttctaat tgagaatgtt ggcgtgtcc gaacctggag acagaaaaac	540	
aaaaagtcct ttctcctgat tcacaaaaaa ataaaatact gactaccatc actgtgatga	600	
gattcctata gtctcaggaa ctgaagtctt taaaacaacca gggaccctct gcccctagaa	660	
taagaacata ctagaagtcc cttctgttag gacaacgagg atcatggag accacctgga	720	

ccttcctcta ggagtgggtgc tcatggccgg tcctgtgttt ggaattcctt cctgctcctt	780
tgatggccga atagcctttt atcggttctg caacctcacc caggtcccc aggtcctcaa	840
caccactgag aggctcctgc tgagcttcaa ctatatcagg acagtcactg cttcatcctt	900
ccccttctg gaacagctgc agctgctgga gctcgggagc cagtataccc ccttgactat	960
tgacaaggag gccttcagaa acctgccccaa ccttagaatc ttggacctgg gaagtagtaa	1020
gatatacttc ttgcacatccag atgctttca gggactgttc catctgtttg aacttagact	1080
gtatttctgt ggtctctctg atgctgtatt gaaagatggt tatttcagaa atttaaaggc	1140
tttaactcgc ttggatctat ccaaaaatca gattcgtags ctttaccttc atcccttcatt	1200
tgggaagttg aattccttaa agtccataga ttttccctcc aacccaaatat tccttgtatg	1260
tgaacatgag ctcgagcccc tacaaggaa aacgctctcc ttttttagcc tcgcagctaa	1320
tagcttgtat agcagagctc cagtgactg gggaaaatgt atgaacccat tcagaaacat	1380
ggtgctggag atactagatg tttctggaaa tggctggaca gtggacatca cagggaaactt	1440
tagcaatgcc atcagcaaaa gccaggcctt ctcttgatt cttgcccacc acatcatggg	1500
tgcggggtt ggcttcata acatcaaaga tcctgaccag aacacatttgc tggcctggc	1560
cagaagttca gtgagacacc tggatcttc acatgggtt gtcttctccc tgaactcacg	1620
agtcttgag acactcaagg atttgaaggt tctgaacctt gcctacaaca agataaataa	1680
gattgcagat gaagcattt acggacttga caacctccaa gttctcaatt tgtcatataa	1740
ccttcgggg gaactttaca gttcgaattt ctatggacta cctaaggtag cctacattga	1800
tttgc当地 aatcacattt caataattca agaccaaaca ttcaaattcc tggaaaaatt	1860
acagaccttgc gatctccgag acaatgttca tacaaccatt cattttatttca caagcatacc	1920
cgtatcttc ttgagtggca ataaaactagt gactttgcca aagatcaacc ttacagcgaa	1980
cctcatccac ttatcagaaa acaggctaga aaatcttagat attctctact ttcttctacg	2040
ggtacctcat ctccagattt tcattttaaa tcaaatcgc ttctcctcct gtagtggaga	2100
tcaaaccctt tcagagaatc ccagcttgc acagtttgc cttggagaaa atatgttgc	2160
acttgcttgc gaaactgagc tctgtggaa tggttttgc gggacttttc atcttcaagt	2220
tctgtatttgc aatcataact atcttaattt cttccacca ggagtttta ggcacatgtac	2280
tgcattaagg ggactaagcc tcaactccaa caggctgaca gttcttctc acaatgtttt	2340
acctgctaat tttagatcc tggacatatac caggaaccag ctccttagctc ctaatcctga	2400
tgtatttgc tcaacttagtg tcttgatattt aactcataac aagtttgc ttgaatgtga	2460
acttagcact ttatcattt ggcttaatca caccaatgtc actatagctg ggcctcctgc	2520
agacatataat tgggtgtacc ctgactcggtt ctctgggggtt tcccttcttct cttttccac	2580
ggaagggttgc gatgaagagg aagtcttaaaa gtcctaaag ttctccctt tcaattgtatg	2640

cactgtca	ctgactctgt	tcctcatgac	catcctcaca	gtcacaaagt	tccggggctt	2700
ctgtttatc	tgttataaga	cagcccagag	actggtgttc	aaggaccatc	cccagggcac	2760
agaacctgat	atgtacaaat	atgatgccta	tttgtgcttc	agcagcaaag	acttcacatg	2820
ggtcagaat	gcttgctca	aacacctgga	cactcaatac	agtgaccaaa	acagattcaa	2880
cctgtgctt	gaagaaagag	actttgtccc	aggagaaaac	cgcattgcc	atatccagga	2940
tgccatctgg	aacagtagaa	agatcgttt	tcttgtgagc	agacacttcc	ttagagatgg	3000
ctgggcctt	gaagccttca	gttatgccc	ggcaggtgc	ttatctgacc	ttaacagtgc	3060
tctcatcatg	gtggtggttg	ggtccttgc	ccagtaccag	ttgatgaaac	atcaatccat	3120
cagaggctt	gtacagaaac	agcagtattt	gaggtggcct	gaggatctcc	aggatgtgg	3180
ctggttctt	cataaactct	ctcaacagat	actaaagaaa	aaaaaagaaaa	agaagaaaaga	3240
caataacatt	ccgttgcaaa	ctgttagaac	catctcctaa	tcaaaggagc	aatttccaac	3300
ttatctcaag	ccacaaataa	ctcttactt	tgtatggca	ccaagttatc	atttggggt	3360
cctctctgga	ggtttttttt	ttcttttgc	tactatgaaa	acaacataaaa	tctctcaatt	3420
ttcgtatcaa	a					3431

<210> 26
<211> 858
<212> PRT
<213> Homo sapiens

<400> 26

Met	Gly	Asp	His	Leu	Asp	Leu	Leu	Gly	Val	Val	Leu	Met	Ala	Gly
1				5				10				15		

Pro	Val	Phe	Gly	Ile	Pro	Ser	Cys	Ser	Phe	Asp	Gly	Arg	Ile	Ala	Phe
				20				25				30			

Tyr	Arg	Phe	Cys	Asn	Leu	Thr	Gln	Val	Pro	Gln	Val	Leu	Asn	Thr	Thr
				35			40				45				

Glu	Arg	Leu	Leu	Leu	Ser	Phe	Asn	Tyr	Ile	Arg	Thr	Vál	Thr	Ala	Ser
				50			55				60				

Ser	Phe	Pro	Phe	Leu	Glu	Gln	Leu	Gln	Leu	Leu	Glu	Leu	Gly	Ser	Gln
65				70				75				80			

Tyr	Thr	Pro	Leu	Thr	Ile	Asp	Lys	Glu	Ala	Phe	Arg	Asn	Leu	Pro	Asn
				85			90				95				

Leu	Arg	Ile	Leu	Asp	Leu	Gly	Ser	Ser	Lys	Ile	Tyr	Phe	Leu	His	Pro
				100			105				110				

Asp	Ala	Phe	Gln	Gly	Leu	Phe	His	Leu	Phe	Glu	Leu	Arg	Leu	Tyr	Phe
				115			120				125				

Cys	Gly	Leu	Ser	Asp	Ala	Val	Leu	Lys	Asp	Gly	Tyr	Phe	Arg	Asn	Leu
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

130	135	140
Lys Ala Leu Thr Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu		
145	150	155
Tyr Leu His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp		
165	170	175
Phe Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro		
180	185	190
Leu Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu		
195	200	205
Tyr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg		
210	215	220
Asn Met Val Leu Glu Ile Leu Asp Val Ser Gly Asn Gly Trp Thr Val		
225	230	235
Asp Ile Thr Gly Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe		
245	250	255
Ser Leu Ile Leu Ala His His Ile Met Gly Ala Gly Phe Gly Phe His		
260	265	270
Asn Ile Lys Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser		
275	280	285
Ser Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn		
290	295	300
Ser Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala		
305	310	315
Tyr Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp		
325	330	335
Asn Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Tyr		
340	345	350
Ser Ser Asn Phe Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln		
355	360	365
Lys Asn His Ile Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu		
370	375	380
Lys Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His		
385	390	395
Phe Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val		
405	410	415
Thr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu		
420	425	430
Asn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro		
435	440	445
His Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser		
450	455	460
Gly Asp Gln Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu		

465	470	475	480													
Gly	Glu	Asn	Met	Leu	Gln	Leu	Ala	Trp	Glu	Thr	Glu	Leu	Cys	Trp	Asp	
485									490						495	
Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu Asn His Asn																
				500					505					510		
Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu Thr Ala Leu																
				515					520					525		
Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu Ser His Asn																
				530					535					540		
Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln Leu																
				545					550					555		
Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val Leu Asp Ile																
				565					570					575		
Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr Phe Ile Asn																
				580					585					590		
Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro Ala Asp Ile																
				595					600					605		
Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu Phe Ser Leu																
				610					615					620		
Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser Leu Lys Phe																
				625					630					635		
Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe Leu Met Thr																
				645					650					655		
Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys																
				660					665					670		
Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr Glu Pro																
				675					680					685		
Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys Asp Phe																
				690					695					700		
Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr Gln Tyr Ser																
				705					710					715		
720																
Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe Val Pro																
				725					730					735		
Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg																
				740					745					750		
Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly Trp Cys																
				755					760					765		
Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn																
				770					775					780		
Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln Tyr Gln Leu																
				785					790					795		
Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu																

805	810	815
Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu		
820	825	830

835	840	845
Ser Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Asp Asn Asn		

Ile Pro Leu Gln Thr Val Ala Thr Ile Ser		
850	855	

<210> 27
<211> 858
<212> PRT
<213> Homo sapiens

<400> 27

Met Gly Asp His Leu Asp Leu Leu Gly Val Val Leu Met Ala Gly		
1	5	10
		15

Pro Val Phe Gly Ile Pro Ser Cys Ser Phe Asp Gly Arg Ile Ala Phe		
20	25	30

Tyr Arg Phe Cys Asn Leu Thr Gln Val Pro Gln Val Leu Asn Thr Thr		
35	40	45

Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Arg Thr Val Thr Ala Ser		
50	55	60

Ser Phe Pro Phe Leu Glu Gln Leu Gln Leu Leu Glu Leu Gly Ser Gln		
65	70	75
		80

Tyr Thr Pro Leu Thr Ile Asp Lys Glu Ala Phe Arg Asn Leu Pro Asn		
85	90	95

Leu Arg Ile Leu Asp Leu Gly Ser Ser Lys Ile Tyr Phe Leu His Pro		
100	105	110

Asp Ala Phe Gln Gly Leu Phe His Leu Phe Glu Leu Arg Leu Tyr Phe		
115	120	125

Cys Gly Leu Ser Asp Ala Val Leu Lys Asp Gly Tyr Phe Arg Asn Leu		
130	135	140

Lys Ala Leu Thr Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu		
145	150	155
		160

Tyr Leu His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp		
165	170	175

Phe Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro		
180	185	190

Leu Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu		
195	200	205

Tyr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg		
210	215	220

Asn Met Val Leu Glu Ile Val Asp Val Ser Gly Asn Gly Trp Thr Val		
225	230	235
		240

Asp Ile Thr Gly Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe
245 250 255

Ser Leu Ile Leu Ala His His Ile Met Gly Ala Gly Phe Gly Phe His
260 265 270

Asn Ile Lys Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser
275 280 285

Ser Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn
290 295 300

Ser Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala
305 310 315 320

Tyr Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp
325 330 335

Asn Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Cys
340 345 350

Ser Ser Asn Phe Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln
355 360 365

Lys Asn His Ile Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu
370 375 380

Lys Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His
385 390 395 400

Phe Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val
405 410 415

Thr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu
420 425 430

Asn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro
435 440 445

His Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser
450 455 460

Gly Asp Gln Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu
465 470 475 480

Gly Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Glu Leu Cys Trp Asp
485 490 495

Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu Asn His Asn
500 505 510

Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu Thr Ala Leu
515 520 525

Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu Ser His Asn
530 535 540

Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln Leu
545 550 555 560

Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val Leu Asp Ile

	565	570	575
Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr Phe Ile Asn			
	580	585	590
Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro Ala Asp Ile			
	595	600	605
Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu Phe Ser Leu			
	610	615	620
Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser Leu Lys Phe			
	625	630	635
Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe Leu Met Thr			
	645	650	655
Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys			
	660	665	670
Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr Glu Pro			
	675	680	685
Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys Asp Phe			
	690	695	700
Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr Gln Tyr Ser			
	705	710	715
			720
Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe Val Pro			
	725	730	735
Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg			
	740	745	750
Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly Trp Cys			
	755	760	765
Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn			
	770	775	780
Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln Tyr Gln Leu			
	785	790	795
			800
Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu			
	805	810	815
Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu			
	820	825	830
Ser Gln Gln Ile Leu Lys Lys Glu Lys Lys Lys Lys Asp Asn Asn			
	835	840	845
Ile Pro Leu Gln Thr Val Ala Thr Ile Ser			
	850	855	

<210> 28
<211> 365
<212> PRT
<213> Homo sapiens

<400> 28

Cys Trp Asp Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu
1 5 10 15

Asn His Asn Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu
20 25 30

Thr Ala Leu Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu
35 40 45

Ser His Asn Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg
50 55 60

Asn Gln Leu Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val
65 70 75 80

Leu Asp Ile Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr
85 90 95

Phe Ile Asn Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro
100 105 110

Ala Asp Ile Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu
115 120 125

Phe Ser Leu Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser
130 135 140

Leu Lys Phe Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe
145 150 155 160

Leu Met Thr Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile
165 170 175

Cys Tyr Lys Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly
180 185 190

Thr Glu Pro Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser
195 200 205

Lys Asp Phe Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr
210 215 220

Gln Tyr Ser Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp
225 230 235 240

Phe Val Pro Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp
245 250 255

Asn Ser Arg Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp
260 265 270

Gly Trp Cys Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser
275 280 285

Asp Leu Asn Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln
290 295 300

Tyr Gln Leu Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln
305 310 315 320

Gln Tyr Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu

325	330	335
His Lys Leu Ser Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Lys		
340	345	350
Asp Asn Asn Ile Pro Leu Gln Thr Val Ala Thr Ile Ser		
355	360	365

<210> 29
<211> 4286
<212> DNA
<213> murine

<400> 29	60
ttgaaatctc acagcccggt tggttgcagt gaccacttc gttgaacata ttcttcctaa	60
tccttagtact ttcaatttgc tctattccct ggtgtctatg catttaaatc gactatgggg	120
ccattttcc ttgaaccacc acagaagaca ttagctctt gggatccttg ttaatttttt	180
ctcctttac atagcaccta cgcttggAAC atatgccaga cacatctgtg agacacccct	240
tgccgctgca gctcatggat ggatgctgag ttccccacg caccacactt cagcagggtgg	300
gtgtatttct gcttcacatt atactcccac acggccatgc atgtcaggca tggagcaggc	360
tcataaccca cttaaattaag gtgatccatat cagatccttt atcaagatgc atagagtgt	420
cagtgcctgt actatgatct cggtattttggagatggggc tagatagagt ctggacacaga	480
atacagcaga gaaaccgata tgtttattgt ccgatcatca gctaagcttc tggagctag	540
gaatggggct ccttggatga acagaagtaa aaatgcctcg tctttatgac tttcaacttc	600
cctcagcagg tctggaatgg gtgaacaaac actgcctgca tgggtgataa atagccttt	660
tttgcgtctt gttgcgtct tttatggttc tggagggaa cctagaacct agcacatgct	720
agacaagtcc tctagcactg agctatctcc ccagcttggta tgaaatatct gtaaagtact	780
ggtgcccggt tgtaaaaatgc accattaa gtgtcaaga agaaaagact gggcatttct	840
gttccaccaa gacaagaaga atctgcacgc agaatgtttggc cgcagtcatt tgagcaaagg	900
ggtccaagggg acagtaccct ccagtgcgtgg ggacccatgt gccgagcctc aggctgtgat	960
gtgggttgtt ttttaattct ctctttccat ataggatcat ggcatgtcaa cttgacttgc	1020
tcataggtgt gatcttcatg gccagccccg tgggttaat atctccctgt tcttcagacgc	1080
gcaggatagc cttttccatggc ggctgttaacc tcacccagat tccctggatc ctcaatacta	1140
ccactgagag gctcctgctc agcttcaact atatcagtat ggtgggtgcc acatcatttc	1200
cactcctggta gcccgtccag ttgctggagc tggggaccca gtatgttaac ttgaccattg	1260
gtccaggggc tttcagaaac ctgccccatc ttaggatctt ggacttgggc caaagccaga	1320
tcgaagtctt gaatcgagat gccttcaag gtctggccca tctcttgaa cttcggctgt	1380
tttcctgtgg actctccagt gctgtgtttaa gtgacggtaa cttcagaaat ctatattcat	1440

tagctcgctt agacctatct ggcaaccaga ttcacagcct ccgcctccat tcttcattcc ggaactgaa ttcccttaagc gacgtaaatt ttgcttcaa ccaaataatc actatatgtg	1500 1560
aagatgaact cgagcctctg cagggcaaaa cactgtcttt ctttggcctc aaattaacta	1620
agctgttcag cagagtctct gtgggctggg agacatgcag gaacccttc agaggcgtga	1680
ggctagaaaac tctagatctt tctgaaaatg gctggacggt ggacatcaca aggaacttca	1740
gcaacatcat ccagggaaagc cagattcct ctttgattct taaacaccac atcatgggtc	1800
ctggcttgg ctcccagaac atcagagatc ctgaccagag cacatttgcc agcctggcca	1860
gaagttcggt gctgcaactg gaccttcgc acggcttat ctttccttg aatcctcgac	1920
tgtttggac actgaaggat ttgaagatgc tgaaccttgc cttcaacaag ataaacaaga	1980
ttggagagaa tgccctttat gggcttgaca gcctccaggt tctcaatcta tcctataatc	2040
ttttggggaa actctataat tccaacttct atgggcttcc tagagtagcc tacgttgacc	2100
ttcaaaggaa ccacattggg atcattcaag accaaacatt cagattatta aaaacgttac	2160
aaaccttaga tctccgtgac aatgctctt agccattgg tttattcca agcatacaga	2220
tggtcctcct gggaggcaat aagctggtcc atttgccaca catccacttt actgccaact	2280
tccttagagtt atctgaaaac aggctagaaa acctgtccga cctctacttc ctcctgcgag	2340
tccccagct ccagttctc atcttgaatc agaatgcct ttcgtcatgc aaggcagccc	2400
acactccctc ggagaaccca agcttagaac agctttcct tacagagaat atgctgcagc	2460
tggcctggga gaccggcctc tggtggatg ttttcaagg ccttccgc ctccagattc	2520
tttacctgag taataactac cttaatttcc ttccacctgg gatatttaac gacgtggttg	2580
cattacggat gcttagtctt agtgctaaca agctgaccgt gctctctccg ggcagttac	2640
ctgctaattt agagattctc gacatatcta gaaatcagct tttgtgtcct gaccctgctt	2700
tgtttcttc gttcgtgtt ttggacataa ctcataacga gttcgtctgc aactgtgaac	2760
tttagcacttt tatctcctgg ctcaacaaaa ccaacgtcac cctgttcggc tctcctgcag	2820
acgtgtattg catgtaccct aactcaactgc tagggggctc cctctacaac atatccaccg	2880
aagactgcga tgaagaggaa gccatgcggt ccctaaagtt ttccctttc atcctgtca	2940
cggtcacttt gactctattc ctcgtcatca ccctttagt cataaagttc cggggatct	3000
gtttcctgtg ctataagacc atccagaagc tggtgttcaa ggacaaggc tggagttgg	3060
aacctgggtc atatagatat gatgcctact tctgcttcag cagcaaagac tttgaatggg	3120
cacagaatgc tttgctcaaa cacctggatg ctcactacag ttcccgaac aggctcaggc	3180
tatgctttga agaaagagac ttcattccgg gggaaaacca tatctccaac atccaggcgg	3240
ctgtctgggg cagcaggaag acggtgtgtc tagtgagcag acacttcctg aaggatggtt	3300
ggtcctggga ggccttcagg tatgcccaga gccggagtct gtctgaccc tc aagagcattc	3360

tcatcggtt ggtgggtggga tcgctgtccc agtatcagct gatgagacat gagaccatca	3420
gagggtttct gcaaaagcaa cagtacttga ggtggcctga agacctccag gatgttggct	3480
ggtttctcga taaaactctcc ggatgcattc taaaggaaga aaaaggaaag aaaagaagca	3540
gttccatcca gttgcgaacc atagcaacca ttctcttagca ggagcgcctc ctagcagaag	3600
tgcaagcatc gtagataact ctccacgctt tatccgcaca gcccgtgggg gtccttcct	3660
ggagtcattt ttctgacaat gaaaacaaca ccaatctctt gatTTTcat gtcaacaggg	3720
agctttgtct tcactgtttt ccaaattggaa agtaagaggt ccagaaagct gcctctaagg	3780
gctctcacct gccattgatg tcctttcagg cccaatgaca tggtttccct ccattctatt	3840
gcgtactgtc tgctacccag gtggcaagag caccttggga gaagttacag gcagcttcat	3900
gctttctgtg ctgttcagtt caaaagcagg tgccttgaga atcctgaatt caagcactct	3960
gtagaacatg gacagacaag atgggtcctt ctctggccat aggcatgagg gccagttgct	4020
gaggactgct ctcactacac ctaagtgcac aagtgataag aagttggaca gatagacaga	4080
tagcagcagt cccattgctg tagccagaat gcacttattt cctgttctga ccctgcaggc	4140
ccagcttttg gggaccacag ccatgttctg cacggaccc ctcaacctgg cattcatgcc	4200
ctttcacgac ttagcaccgg cctgccttc ttcttcccc acaactatac aagagctgtt	4260
gcaaccactg aaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa	4286

<210> 30
<211> 859
<212> PRT
<213> murine

<400> 30

Met Ala Cys Gln Leu Asp Leu Leu Ile Gly Val Ile Phe Met Ala Ser
1 5 10 15

Pro Val Leu Val Ile Ser Pro Cys Ser Ser Asp Gly Arg Ile Ala Phe
20 25 30

Phe Arg Gly Cys Asn Leu Thr Gln Ile Pro Trp Ile Leu Asn Thr Thr
35 40 45

Thr Glu Arg Leu Leu Ser Phe Asn Tyr Ile Ser Met Val Val Ala
50 55 60

Thr Ser Phe Pro Leu Leu Glu Arg Leu Gln Leu Leu Glu Leu Gly Thr
65 70 75 80

Gln Tyr Ala Asn Leu Thr Ile Gly Pro Gly Ala Phe Arg Asn Leu Pro
85 90 95

Asn Leu Arg Ile Leu Asp Leu Gly Gln Ser Gln Ile Glu Val Leu Asn
100 105 110

Arg Asp Ala Phe Gln Gly Leu Pro His Leu Leu Glu Leu Arg Leu Phe
 115 120 125
 Ser Cys Gly Leu Ser Ser Ala Val Leu Ser Asp Gly Tyr Phe Arg Asn
 130 135 140
 Leu Tyr Ser Leu Ala Arg Leu Asp Leu Ser Gly Asn Gln Ile His Ser
 145 150 155 160
 Leu Arg Leu His Ser Ser Phe Arg Glu Leu Asn Ser Leu Ser Asp Val
 165 170 175
 Asn Phe Ala Phe Asn Gln Ile Phe Thr Ile Cys Glu Asp Glu Leu Glu
 180 185 190
 Pro Leu Gln Gly Lys Thr Leu Ser Phe Phe Gly Leu Lys Leu Thr Lys
 195 200 205
 Leu Phe Ser Arg Val Ser Val Gly Trp Glu Thr Cys Arg Asn Pro Phe
 210 215 220
 Arg Gly Val Arg Leu Glu Thr Leu Asp Leu Ser Glu Asn Gly Trp Thr
 225 230 235 240
 Val Asp Ile Thr Arg Asn Phe Ser Asn Ile Ile Gln Gly Ser Gln Ile
 245 250 255
 Ser Ser Leu Ile Leu Lys His His Ile Met Gly Pro Gly Phe Gly Phe
 260 265 270
 Gln Asn Ile Arg Asp Pro Asp Gln Ser Thr Phe Ala Ser Leu Ala Arg
 275 280 285
 Ser Ser Val Leu Gln Leu Asp Leu Ser His Gly Phe Ile Phe Ser Leu
 290 295 300
 Asn Pro Arg Leu Phe Gly Thr Leu Lys Asp Leu Lys Met Leu Asn Leu
 305 310 315 320
 Ala Phe Asn Lys Ile Asn Lys Ile Gly Glu Asn Ala Phe Tyr Gly Leu
 325 330 335
 Asp Ser Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu
 340 345 350
 Tyr Asn Ser Asn Phe Tyr Gly Leu Pro Arg Val Ala Tyr Val Asp Leu
 355 360 365
 Gln Arg Asn His Ile Gly Ile Ile Gln Asp Gln Thr Phe Arg Leu Leu
 370 375 380
 Lys Thr Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Lys Ala Ile
 385 390 395 400
 Gly Phe Ile Pro Ser Ile Gln Met Val Leu Leu Gly Gly Asn Lys Leu
 405 410 415
 Val His Leu Pro His Ile His Phe Thr Ala Asn Phe Leu Glu Leu Ser
 420 425 430
 Glu Asn Arg Leu Glu Asn Leu Ser Asp Leu Tyr Phe Leu Leu Arg Val

435 440 445
Pro Gln Leu Gln Phe Leu Ile Leu Asn Gln Asn Arg Leu Ser Ser Cys
450 455 460

Lys Ala Ala His Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe
465 470 475 480

Leu Thr Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Gly Leu Cys Trp
485 490 495

Asp Val Phe Gln Gly Leu Ser Arg Leu Gln Ile Leu Tyr Leu Ser Asn
500 505 510

Asn Tyr Leu Asn Phe Leu Pro Pro Gly Ile Phe Asn Asp Leu Val Ala
515 520 525

Leu Arg Met Leu Ser Leu Ser Ala Asn Lys Leu Thr Val Leu Ser Pro
530 535 540

Gly Ser Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln
545 550 555 560

Leu Leu Cys Pro Asp Pro Ala Leu Phe Ser Ser Leu Arg Val Leu Asp
565 570 575

Ile Thr His Asn Glu Phe Val Cys Asn Cys Glu Leu Ser Thr Phe Ile
580 585 590

Ser Trp Leu Asn Gln Thr Asn Val Thr Leu Phe Gly Ser Pro Ala Asp
595 600 605

Val Tyr Cys Met Tyr Pro Asn Ser Leu Leu Gly Gly Ser Leu Tyr Asn
610 615 620

Ile Ser Thr Glu Asp Cys Asp Glu Glu Ala Met Arg Ser Leu Lys
625 630 635 640

Phe Ser Leu Phe Ile Leu Cys Thr Val Thr Leu Thr Leu Phe Leu Val
645 650 655

Ile Thr Leu Val Val Ile Lys Phe Arg Gly Ile Cys Phe Leu Cys Tyr
660 665 670

Lys Thr Ile Gln Lys Leu Val Phe Lys Asp Lys Val Trp Ser Leu Glu
675 680 685

Pro Gly Ala Tyr Arg Tyr Asp Ala Tyr Phe Cys Phe Ser Ser Lys Asp
690 695 700

Phe Glu Trp Ala Gln Asn Ala Leu Leu Lys His Leu Asp Ala His Tyr
705 710 715 720

Ser Ser Arg Asn Arg Leu Arg Leu Cys Phe Glu Glu Arg Asp Phe Ile
725 730 735

Pro Gly Glu Asn His Ile Ser Asn Ile Gln Ala Ala Val Trp Gly Ser
740 745 750

Arg Lys Thr Val Cys Leu Val Ser Arg His Phe Leu Lys Asp Gly Trp
755 760 765

Cys Leu Glu Ala Phe Arg Tyr Ala Gln Ser Arg Ser Leu Ser Asp Leu

770	775	780
Lys Ser Ile Leu Ile Val Val Val Val Gly Ser	Leu Ser Gln Tyr Gln	
785	790	795
Leu Met Arg His Glu Thr Ile Arg Gly Phe Leu Gln Lys Gln Gln Tyr		
805	810	815
Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu Asp Lys		
820	825	830
Leu Ser Gly Cys Ile Leu Lys Glu Glu Lys Gly Lys Lys Arg Ser Ser		
835	840	845
Ser Ile Gln Leu Arg Thr Ile Ala Thr Ile Ser		
850	855	

<210> 31
<211> 3373
<212> DNA
<213> Homo sapiens

<400> 31	agctggctag cgtttaaacg ggccctctag actcgagcgg ccgcgaattc actagtgatt	60
	cacctctcat gctctgtctt cttcaaccag acctctacat tccatTTTgg aagaagacta	120
	aaaatggtgt ttccaatgtg gacactgaag agacaaattc ttatccttt taacataatc	180
	ctaatttcca aactccttgg ggcttagatgg tttctaaaa ctctgccctg tgatgtcact	240
	ctggatgttc caaagaacca tgtgatcgtg gactgcacag acaagcattt gacagaaatt	300
	cctggaggta ttcccacgaa caccacgaac ctcaccctca ccattaacca cataccagac	360
	atctccccag cgtccttca cagactggac catctggtag agatcgattt cagatgcaac	420
	tgtgtaccta ttccactggg gtcaaaaaac aacatgtgca tcaagaggct gcagattaa	480
	cccagaagct ttagtggact cacttattta aaatccctt acctggatgg aaaccagcta	540
	ctagagatac cgcagggcct cccgcctagc ttacagcttc tcagccttga ggccaacaac	600
	atctttcca tcagaaaaga gaatctaaca gaactggcca acatagaaat actctacctg	660
	ggccaaaact gttattatcg aaatccttgt tatgtttcat attcaataga gaaagatgcc	720
	ttcctaaact tgacaaaagtt aaaagtgttc tccctgaaag ataacaatgt cacagccgtc	780
	cctactgttt tgccatctac tttaacagaa ctatatctt acaacaacat gattgaaaa	840
	atccaagaag atgatTTAA taacctcaac caattacaaa ttcttgacct aagtggaaat	900
	tgcctcggtt gttataatgc cccatttcct tggcgccgt gtaaaaataa ttctccccata	960
	cagatccctg taaatgcttt tggatgtgtc acagaattaa aagtttacg tctacacagt	1020
	aactcttttc agcatgtgcc cccaaagatgg tttaagaaca tcaacaaact ccaggaactg	1080
	gatctgtccc aaaacttctt ggccaaagaa attggggatg ctaaatttctc gcattttctc	1140
	cccagcctca tccaatttggaa tctgtcttc aattttgaac ttcagggtcta tcgtgcacatct	1200

atgaatctat cacaaggcatt ttcttcactg aaaagcctga aaattctgcg gatcagagga 1260
tatgtctta aagagttgaa aagctttaac ctctcgccat tacataatct tcaaaatctt 1320
gaagttcttg atcttggcac taactttata aaaattgcta acctcagcat gttaaacaa 1380
tttaaaagac tgaaagtcat agatcttca gtgaataaaa tatcaccttc aggagattca 1440
agtgaagttg gcttctgctc aaatgccaga acttctgttag aaagttatga accccaggtc 1500
ctggaacaat tacattatTT cagatATGAT aagtATGCAA ggAGTTGCAg attcaaaaac 1560
aaagaggcTT cTTTcatgTC tgttaatgaa agctgctaca agtATGGCA gacTTggat 1620
ctaagtaaaa atagtatatt ttttgtcaag tcctctgatt ttcagcatct ttcttcctc 1680
aaatgcctga atctgtcagg aaatctcatt agccaaactc ttaatggcag tgaattccaa 1740
cctttagcag agctgagata tttggacttc tccaacaacc ggcttgattt actccattca 1800
acagcattt aagagcttca caaactggaa gttctggata taagcagtaa tagccattat 1860
tttcaatcag aaggaattac tcataATGCTA aactttacca agaacctaaa ggTTCTGCAG 1920
aaactgatga tgaacgacaa tgacatctt tcctccacca gcaggaccat ggagagttag 1980
tctcttagaa ctctggaatt cagagggaaat cacttagatg ttttatggag agaagggtat 2040
aacagatact tacaattatt caagaatctg ctAAAATTAG aggaattaga catctctaaa 2100
aattccctaa gtttcttgcc ttctggagtt tttgatggta tgcctccaaa tctaaagaat 2160
ctctctttgg ccaaaaatgg gctcaaATCTC ttcagttgga agaaactcca gtgtctaaag 2220
aacctggaaa ctttggacct cagccacaac caactgacca ctgtccctga gagattatcc 2280
aactgttcca gaagcctcaa gaatctgatt cttaagaata atcaaATCAG gagtctgacg 2340
aagtattttc tacaagatgc cttccagttg cgatatctgg atctcagctc aaataaaaatc 2400
cagatgatcc aaaagaccag cttcccagaa aatgtcctca acaatctgaa gatgttgctt 2460
ttgcatcata atcggtttct gtgcacctgt gatgctgtgt ggTTGTCTG gtgggttaac 2520
catacggagg tgactattcc ttacctggcc acagatgtga cttgtgtggg gccaggagca 2580
cacaaggGCC aaagtgtgat ctccctggat ctgtacacct gtgagttaga tctgactaac 2640
ctgattctgt ttcactttc catatctgta tctcttttc tcatggtgat gatgacagca 2700
agtcacctct atttctggta tttgtggat attaccatt tctgtaaaggc caagataaaag 2760
gggtatcagc gtctaatatc accagactgt tgctatgtg ctttattgt gtatgacact 2820
aaagacccag ctgtgacccga gtgggttttg gctgagctgg tggccaaact ggaagaccca 2880
agagagaaac attttaattt atgtctcgag gaaaggact gttaccagg gcagccagtt 2940
ctggaaaacc ttcccagag catacagctt agcaaaaaga cagtgtttgt gatgacagac 3000
aagtatgcaa agactgaaaa ttttaagata gcattttact tttccatca gaggctcatg 3060

gataaaaaaag ttgatgtat tatcttgata tttcttgaga agcctttca gaagtccaaag	3120
ttcctccaggc tccggaaaag gctctgtggg agttctgtcc ttgagtggcc aacaaacccg	3180
caagctcacc catacttctg gcagtgtcta aagaacgccc tggccacaga caatcatgtg	3240
gcctatagtc aggtgttcaa ggaaacggtc tagaatcgaa ttcccgcggc cgccactgtg	3300
ctggatatct gcagaattcc accacactgg actagtggat ccgagctcgg taccaagctt	3360
aagtttaaac cgc	3373

<210> 32
<211> 3416
<212> DNA
<213> Homo sapiens

<400> 32	
tccagatata ggatcaactcc atgccatcaa gaaagtttat gctattggc ccatctcaag	60
ctgatcttgg cacctctcat gctctgtct cttcaaccag acctctacat tccattttgg	120
aagaagacta aaaatggtgt ttccaatgtg gacactgaag agacaaattc ttatcctttt	180
taacataatc ctaatttcca aactccttgg ggcttagatgg ttccctaaaa ctctgcccctg	240
tgatgtcaact ctggatgttc caaagaacca tgtgatcgtg gactgcacag acaagcattt	300
gacagaaaatt cctggaggta ttcccacgaa caccacgaac ctcaccctca ccattaacca	360
cataccagac atctccccag cgtccttca cagactggac catctggtag agatcgattt	420
cagatgcaac tgtgtaccta ttccacttgg gtcaaaaaac aacatgtgca tcaagaggct	480
gcagattaaa cccagaagct ttagtgact cacttattta aaatccctt acctggatgg	540
aaaccagcta cttagagatac cgcagggcct cccgccttagc ttacagcttc tcagccttga	600
ggccaacaac atcttttcca tcagaaaaaga gaatctaaca gaactggcca acatagaaat	660
actctacctg ggccaaaact gttattatcg aaatccttgc tatgtttcat attcaataga	720
gaaagatgcc ttccctaaact tgacaaaagtt aaaagtgttc tccctgaaag ataacaatgt	780
cacagccgtc cctactgttt tgccatctac tttaacagaa ctatatctt acaacaacat	840
gattgcaaaa atccaagaag atgattttaa taacctcaac caattacaaa ttcttgacct	900
aagtggaaat tgccctcggtt gttataatgc cccatttcct tgtgcgcgt gtaaaaataa	960
ttctccctta cagatccctg taaatgttt tgatgcgtc acagaattaa aagttttacg	1020
tctacacagt aactcttcc agcatgtgcc cccaaagatgg tttaagaaca tcaacaaact	1080
ccaggaactg gatctgtccc aaaacttctt ggccaaagaa attggggatg ctaaatttct	1140
gcattttctc cccagcctca tccaaatttggaa tctgtcttc aattttgaac ttcaaggctca	1200
tcgtgcacatct atgaatctat cacaaggcatt ttcttcactg aaaaggctga aaattctg	1260

gatcagagga tatgtcttta aagagtggaa aagctttAAC ctctcgccat tacataatct	1320
tcaaaaatctt gaagttcttg atcttggcac taactttata aaaattgcta acctcagcat	1380
gtttaaacaa tttaaaagac tgaaagtcat agatcttca gtgaataaaa tatcaccttc	1440
aggagattca agtgaagttg gcttctgctc aaatgccaga acttctgttag aaagttatga	1500
accccaggTC ctggaacaat tacatttattt cagatatgtat aagtatgcaa ggagttgcag	1560
attcaaaaac aaagaggcTT ctttcatgtc tgttaatgaa agctgctaca agtatggca	1620
gaccttggat ctaagtaaaa atagtatatt ttttgtcaag tcctctgatt ttcagcatct	1680
ttcttcctc aaatgcctga atctgtcagg aaatctcatt agccaaactc ttaatggcag	1740
tgaattccaa ccttttagcag agttgagata tttggacttc tccaacaacc ggcttgattt	1800
actccattca acagcatttG aagagcttca caaactggaa gttctggata taagcagtaa	1860
tagccattat tttcaatcag aaggaattac tcatatgcta aactttacca agaacctaAA	1920
ggttctgcag aaactgatga tgaacgacaa tgacatctct tcctccacca gcaggaccat	1980
ggagagttag tctcttagaa ctctggaaatt cagaggaaat cacttagatg ttttatggag	2040
agaagggtat aacagataact tacaatttattt caagaatctg ctaaaaattttt aggaattttaga	2100
catctctaaa aattccctaa gtttcttgcc ttctggagtt tttgatggta tgcctccaaa	2160
tctaaagaat ctctctttgg ccaaaaatgg gctcaaatttctt tcagttggaa agaaactcca	2220
gtgtctaaag aacctggaaa ctttggacct cagccacaac caactgacca ctgtccctga	2280
gagattatcc aactgttcca gaagccacaa gaatctgatt cttaagaata atcaaattttag	2340
gagtccgacG aagtatttttG tacaagatgc ctccagtttG cgatatctgg atctcagctc	2400
aaataaaaatc cagatgtatcc AAAAGACCAG CTTCCAGAA AATGTCCTCA ACAATTGAA	2460
gatgttgctt ttgcataatc atcggtttctt gtgcacctgt gatgctgtgt ggtttgtctg	2520
gtgggttaac catacgagg tgactattcc ttacctggcc acagatgtga cttgtgtgg	2580
gccaggagca cacaaggGCC aaagtgtgat ctccctggat ctgtacaccc gtgagtttaga	2640
tctgactaac ctgattctgt tctcaatttcc catactgtta tctctctttc tcatgggtat	2700
gatgacagca agtcacccctt atttctggGA tgtgtggat atttaccatt tctgtaaaggc	2760
caagataaaag gggatcagc gtctaatatc accagactgt tgctatgatg ctttattgt	2820
gtatgacact aaagacccAG ctgtgaccGA gtgggttttG gctgagctgg tggccaaact	2880
ggaagaccca agagagaaAC attttaattt atgtctcgag gaaaggact ggttaccagg	2940
gcagccagtt ctggaaaacc ttcccagag catacagctt agaaaaaga cagtgtttgt	3000
gatgacagac aagtatgcaa agactgaaaa tttaagata gcattttact tgtcccatca	3060
gaggctcatG gatgaaaaAG ttgtatgtat tatcttgata tttcttgaga agccctttca	3120
gaagtccaaAG ttccctccagc tccggaaaAG gctctgtggg agttctgtcc ttgagtgcc	3180

aacaaacccg caagctcacc catacttctg gcagtgtcta aagaacgccc tggccacaga	3240
caatcatgtg gcctatagtc aggtgttcaa ggaaacggtc tagcccttct ttgcaaaaca	3300
caactgccta gtttaccaag gagaggcctg gctgtttaaa ttgtttcat atatatcaca	3360
ccaaaagcgt gtttgaaat tcttcaagaa atgagattgc ccataattca ggggag	3416

<210> 33
<211> 3418
<212> DNA
<213> Homo spaiens

<400> 33	
actccagata taggatcaact ccatgccatc aagaaagttg atgctattgg gcccatctca	60
agctgatctt ggcacctctc atgctctgct ctcttcaacc agacctctac attccatttt	120
ggaagaagac taaaaatggt gtttccaatg tggacactga agagacaaat tcttatcctt	180
tttaacataa tcctaatttc caaactcctt gggcttagat ggttcttaa aactctgccc	240
tgtgatgtca ctctggatgt tccaaagaac catgtgatcg tggactgcac agacaagcat	300
ttgacagaaa ttcttgagg tattccacg aacaccacga acctcacctt caccattaac	360
cacataccag acatctcccc agcgtcctt cacagactgg accatctggt agagatcgat	420
ttcagatgca actgtgtacc tattccactg gggtaaaaaa acaacatgtg catcaagagg	480
ctgcagatta aacccagaag cttagtgga ctcacttatt taaaatccct ttacctggat	540
ggaaaccagc tactagagat accgcagggc ctccgccta gtttacagct tctcagcctt	600
gaggccaaca acatcttttc catcagaaaa gagaatctaa cagaactggc caacatagaa	660
atacttacc tggccaaaa ctgttattat cgaaatcctt gttatgttc atattcaata	720
gagaaagatg ctttcctaaa cttgacaaag taaaagtgc tctccctgaa agataacaat	780
gtcacagccg tccctactgt ttgcctatct actttaacag aactataatct ctacaacaac	840
atgattgcaa aaatccaaga agatgattt aataacctca accaattaca aatttttgc	900
ctaagtggaa attgcctcg ttgttataat gcccatttc cttgtgcgc gtgtaaaaat	960
aattctcccc tacagatccc tgtaaatgct ttgtatgcgc tgacagaatt aaaagttta	1020
cgtctacaca gtaactctct tcagcatgtg ccccaagat ggtttaagaa catcaacaaa	1080
ctccaggaac tggatctgtc cccaaacttc ttggccaaag aaattgggaa tgctaaattt	1140
ctgcattttc tccccagcct catccaaattt gatctgttctt tcaattttga acttcaggtc	1200
tatcgatgcat ctatgaatct atcacaagca ttttcttcac tgaaaagcct gaaaattctg	1260
cggatcagag gatatgtctt taaagagttg aaaagcttta acctctgcgc attacataat	1320
cttcaaaatc ttgaagttct tgatcttggc actaacttta taaaaattgc taacctcagc	1380

atgtttaaac aattttaaaag actgaaagtc atagatctt cagtgaataa aatatcacct tcaggagatt caagtgaagt tggcttctgc tcaaatacgcc gaacttctgt agaaagttat	1440 1500
gaaccccagg tccttggaca attacattat ttccagatatg ataagtatgc aaggagttgc	1560
agattcaaaa acaaagaggc ttctttcatg tctgttaatg aaagctgcta caagtatggg	1620
cagaccttgg atctaagtaa aaatagtata ttttttgtca agtcctctga ttttcagcat	1680
ctttcttcc tcaaatacgct gaatctgtca ggaaatctca ttagccaaac tcttaatggc	1740
agtgaattcc aaccttttagc agagctgaga tatttggact tctccaacaa ccggccttgat	1800
ttactccatt caacagcatt tgaagagctt cacaaactgg aagttctgga tataagcagt	1860
aatagccatt atttcaatc agaaggaatt actcatatgc taaactttac caagaaccta	1920
aaggttctgc agaaaactgat gatgaacgac aatgacatct cttcctccac cagcaggacc	1980
atggagagtg agtctcttag aactctggaa ttccagaggaa atcacttaga tgtttatgg	2040
agagaaggta ataacagata cttacaatta ttcaagaatc tgctaaaatt agaggaatta	2100
gacatctcta aaaattccct aagttcttg cttctggag ttttgatgg tatgcctcca	2160
aatctaaaga atctctcttt ggccaaaaat gggctcaaat cttcagttg gaagaaactc	2220
cagtgtctaa agaacctgga aactttggac ctcagccaca accaactgac cactgtccct	2280
gagagattat ccaactgttc cagaagcctc aagaatctga ttcttaagaa taatcaaatc	2340
aggagtctga cgaagtattt tctacaagat gccttccagt tgcgatatct ggatctcagc	2400
tcaaataaaa tccagatgat cccaaagacc agttcccag aaaatgtcct caacaatctg	2460
aagatgtgc tttgcatca taatcggtt ctgtgcacct gtgatgctgt gtggttgtc	2520
tggtgggtta accatacggc ggtgactatt ctttacctgg ccacagatgt gacttgtgt	2580
ggccaggag cacacaaggg ccaaagtgtg atctccctgg atctgtacac ctgtgagtt	2640
gatctgacta acctgattct gttctactt tccatatctg tatctcttctt tctcatggtg	2700
atgatgacag caagtcaccc ctatttctgg gatgtgtggt atatttacca tttctgttaag	2760
gccaagataa aggggtatca gcgtctaata tcaccagact gttgctatga tgctttatt	2820
gtgtatgaca ctaaagaccc agctgtgacc gagtgggtt tggctgagct ggtggccaaa	2880
ctggaagacc caagagagaa acattttaat ttatgtctcg aggaaaggga ctggttacca	2940
ggccagccag ttctggaaaa ctttccctgg agcatacagc ttagcaaaaa gacagtgttt	3000
gtgatgacag acaagttatgc aaagactgaa aattttaaga tagcattttt cttgtcccat	3060
cagaggctca tggatgaaaa agttgtgtg attatcttgc tatttttttgc gaagcccttt	3120
cagaagtcca agttcctcca gctccggaaa aggctctgtg ggagttctgt ctttgagtgg	3180
ccaacaaacc cgcaagctca cccatacttc tggcagtgtc taaaagaacgc cctggccaca	3240
gacaatcatg tggcctatag tcaggtgttc aaggaaacgg tctagccctt ctttgcaaaa	3300

cacaactgcc tagtttacca aggagaggcc tggctgtta aattgtttc atatatatca 3360
 caccaaaagc gtgtttgaa attcttcaag aaatgagatt gccccatattt caggggag 3418

<210> 34
 <211> 1049
 <212> PRT
 <213> Homo sapiens

<400> 34

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe
 1 5 10 15

Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys
 20 25 30

Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile
 35 40 45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro
 50 55 60

Thr Asn Thr Thr Asn Leu Thr Ile Asn His Ile Pro Asp Ile
 65 70 75 80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe
 85 90 95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys
 100 105 110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr
 115 120 125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln
 130 135 140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile
 145 150 155 160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile
 165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser
 180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val
 195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro
 210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile
 225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu
 245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro

260	265	270
Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala		
275	280	285
Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His		
290	295	300
Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp		
305	310	315
Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu		
325	330	335
His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu		
340	345	350
Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser		
355	360	365
Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu		
370	375	380
Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu		
385	390	395
Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met		
405	410	415
Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys		
420	425	430
Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala		
435	440	445
Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His		
450	455	460
Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys		
465	470	475
Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln		
485	490	495
Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp		
500	505	510
Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu		
515	520	525
Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu		
530	535	540
Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr		
545	550	555
Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn		
565	570	575
Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr		
580	585	590
Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile		

595 600 605
Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu
610 615 620

Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn
625 630 635 640

Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp
645 650 655

Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly
660 665 670

Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys
675 680 685

Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu
690 695 700

Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn
705 710 715 720

Cys Ser Arg Ser Leu Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg
725 730 735

Ser Leu Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu
740 745 750

Asp Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro
755 760 765

Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg
770 775 780

Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His
785 790 795 800

Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly
805 810 815

Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr
820 825 830

Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser
835 840 845

Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe
850 855 860

Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly
865 870 875 880

Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val
885 890 895

Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu
900 905 910

Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu
915 920 925

Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser

930	935	940
Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys		
945	950	955
Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln		
965	970	975
Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu		
980	985	990
Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys		
995	1000	1005
Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro		
1010	1015	1020
Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His		
1025	1030	1035
Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val		
1040	1045	
<210>	35	
<211>	1049	
<212>	PRT	
<213>	Homo sapiens	
<400>	35	
Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe		
1	5	10
		15
Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys		
20	25	30
Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile		
35	40	45
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro		
50	55	60
Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile		
65	70	75
		80
Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe		
85	90	95
Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys		
100	105	110
Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr		
115	120	125
Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln		
130	135	140
Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile		
145	150	155
Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile		
165	170	175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro
210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile
225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro
260 265 270

Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His
290 295 300

Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp
305 310 315 320

Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu
325 330 335

His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu
340 345 350

Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser
355 360 365

Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu
370 375 380

Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met
405 410 415

Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys
420 425 430

Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala
435 440 445

Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His
450 455 460

Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys
465 470 475 480

Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln
485 490 495

Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp

500	505	510
Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu		
515	520	525
Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu		
530	535	540
Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr		
545	550	555
Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn		
565	570	575
Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr		
580	585	590
Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile		
595	600	605
Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu		
610	615	620
Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn		
625	630	635
Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp		
645	650	655
Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly		
660	665	670
Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys		
675	680	685
Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu		
690	695	700
Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn		
705	710	715
Cys Ser Arg Ser His Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg		
725	730	735
Ser Pro Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu		
740	745	750
Asp Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro		
755	760	765
Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg		
770	775	780
Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His		
785	790	795
Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly		
805	810	815
Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr		
820	825	830
Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser		

835	840	845
Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe		
850	855	860
Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly		
865	870	875
Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val		
885	890	895
Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu		
900	905	910
Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu		
915	920	925
Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser		
930	935	940
Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys		
945	950	955
Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln		
965	970	975
Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu		
980	985	990
Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys		
995	1000	1005
Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro		
1010	1015	1020
Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His		
1025	1030	1035
Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val		
1040	1045	
<210> 36		
<211> 1049		
<212> PRT		
<213> Homo spaiens		
<400> 36		
Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe		
1	5	10
15		
Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys		
20	25	30
Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile		
35	40	45
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro		
50	55	60
Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile		
65	70	75
80		

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe
85 90 95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys
100 105 110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr
115 120 125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln
130 135 140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile
145 150 155 160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile
165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro
210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile
225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro
260 265 270

Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His
290 295 300

Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp
305 310 315 320

Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu
325 330 335

His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu
340 345 350

Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser
355 360 365

Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu
370 375 380

Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met

405	410	415
Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys		
420	425	430
Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala		
435	440	445
Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His		
450	455	460
Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys		
465	470	475
Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln		
485	490	495
Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp		
500	505	510
Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu		
515	520	525
Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu		
530	535	540
Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr		
545	550	555
Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn		
565	570	575
Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr		
580	585	590
Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile		
595	600	605
Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu		
610	615	620
Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn		
625	630	635
Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Leu Asp		
645	650	655
Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly		
660	665	670
Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys		
675	680	685
Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu		
690	695	700
Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn		
705	710	715
Cys Ser Arg Ser Leu Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg		
725	730	735
Ser Leu Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu		

	740	745	750													
Asp	Leu	Ser	Ser	Asn	Lys	Ile	Gln	Met	Ile	Gln	Lys	Thr	Ser	Phe	Pro	
								755	760						765	
Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg																
								770	775						780	
Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His																
								785	790						795	800
Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly																
								805		810					815	
Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr																
								820		825					830	
Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser																
								835		840					845	
Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe																
								850		855					860	
Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly																
								865	870		875				880	
Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val																
								885		890					895	
Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu																
								900		905					910	
Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu																
								915		920					925	
Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser																
								930		935					940	
Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys																
								945		950					960	
Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln																
								965		970					975	
Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu																
								980		985					990	
Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys																
								995		1000					1005	
Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro																
								1010		1015					1020	
Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His																
								1025		1030					1035	
Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val																
								1040		1045						

<210> 37

<211> 1049

<212> PRT

<213> Homo sapiens

<400> 37

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe
1 5 10 15

Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys
20 25 30

Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile
35 40 45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro
50 55 60

Thr Asn Thr Thr Asn Leu Thr Ile Asn His Ile Pro Asp Ile
65 70 75 80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe
85 90 95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys
100 105 110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr
115 120 125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln
130 135 140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile
145 150 155 160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile
165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro
210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile
225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro
260 265 270

Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His
290 295 300

Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp
305 310 315 320

Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu
325 330 335

His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu
340 345 350

Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser
355 360 365

Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu
370 375 380

Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met
405 410 415

Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys
420 425 430

Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala
435 440 445

Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His
450 455 460

Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys
465 470 475 480

Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln
485 490 495

Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp
500 505 510

Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu
515 520 525

Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu
530 535 540

Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr
545 550 555 560

Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn
565 570 575

Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr
580 585 590

Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile
595 600 605

Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu
610 615 620

Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn
625 630 635 640

Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp

	645	650	655
Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly			
	660	665	670
Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys			
	675	680	685
Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu			
	690	695	700
Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn			
	705	710	715
Cys Ser Arg Ser Leu Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg			
	725	730	735
Ser Leu Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu			
	740	745	750
Asp Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro			
	755	760	765
Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg			
	770	775	780
Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His			
	785	790	795
Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly			
	805	810	815
Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr			
	820	825	830
Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser			
	835	840	845
Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe			
	850	855	860
Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly			
	865	870	875
Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val			
	885	890	895
Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu			
	900	905	910
Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu			
	915	920	925
Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser			
	930	935	940
Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys			
	945	950	955
Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln			
	965	970	975
Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu			

980	985	990
Lys Pro Phe Gln Lys Ser Lys Phe	Leu Gln Leu Arg Lys	Arg Leu Cys
995	1000	1005
Gly Ser Ser Val Leu Glu Trp	Pro Thr Asn Pro Gln	Ala His Pro
1010	1015	1020
Tyr Phe Trp Gln Cys Leu Lys	Asn Ala Leu Ala Thr	Asp Asn His
1025	1030	1035
Val Ala Tyr Ser Gln Val Phe	Lys Glu Thr Val	
1040	1045	

<210> 38
<211> 3243
<212> DNA
<213> murine

<400> 38	attctcctcc accagacactc ttgattccat tttgaaagaa aactgaaaat ggtgtttcg	60
	atgtggacac ggaagagaca aattttgatc tttttaata tgctcttagt ttcttagatgc	120
	tttgggttcc gatggttcc taaaactcta ctttgtaaag tttaaagtaaa tatcccagag	180
	gcccatgtga tcgtggactg cacagacaag catttgacag aaatccctga gggcattccc	240
	actaacacca ccaatcttac ctttaccatc aaccacatac caagcatctc tccagattcc	300
	ttccgttaggc tgaaccatct ggaagaaatc gattnaagat gcaattgtgt acctgttcta	360
	ctggggtcca aagccaatgt gtgtaccaag aggctgcaga tttagacctgg aagctttagt	420
	ggactctctg acttaaaagc ctttacctg gatggaaacc aacttctgga gataccacag	480
	gatctgccat ccagcttaca tcttctgagc ctgaggcta acaacatctt ctccatcacg	540
	aaggagaatc taacagaact ggtcaacatt gaaacactct acctgggtca aaactgttat	600
	tatcgaaatc ctgtcaatgt ttcctattct attgaaaaag atgctttcct agttatgaga	660
	aatttgaagg ttctctcact aaaagataac aatgtcacag ctgtccccac cacttgcca	720
	cctaatttac tagagctcta tctttataac aatatcatta agaaaatcca agaaaatgtat	780
	ttaataacc tcaatgagtt gcaagttctt gacctaagtg gaaattgcc tcgatgttat	840
	aatgtccccat atccgtgtac accgtgtgaa aataattccc ctttacagat ccatgacaat	900
	gttttcaattt cattgacaga attaaaagtt ttacgtttac acagtaattc ttttcagcat	960
	gtgcccccaa catggtttaa aaacatgaga aacccagg aactagaccc tccccaaac	1020
	tacttggcca gagaaattga ggaggccaaa ttttgcatt ttcttccaa ctttgtttag	1080
	ttggattttt cttaatttca tgagctgcag gtctaccatg catctataac tttaccatc	1140
	tcactcttctt cattggaaaaa cttgaaaattt ctgcgtgtca aggggtatgt cttaaagag	1200
	ctgaaaaactt ccagtcttcc ttttgcac aagcttccca ggctgaaatg tcttgacctt	1260

ggcactaact tcataaaaaat tgctgacctc aacatattca aacatttga aaacctcaa	1320
ctcatagacc ttcagtcaa taagatatct cttcagaag agtcaagaga agttggctt	1380
tgtcctaattg ctcaaaacttc tgttagaccgt catggggccc aggtccttga ggccttacac	1440
tatttccgat acgatgaata tgcacggagc tgcaggttca aaaacaaaga gccaccttct	1500
ttcttgccctt tgaatgcaga ctgccacata tatggcaga ccttagactt aagtagaaat	1560
aacatatttt ttattaaacc ttctgatttt cagcatctt cattcctcaa atgcctcaac	1620
ttatcaggaa acaccattgg ccaaactctt aatggcagtg aactctggcc gttgagagag	1680
ttgcggtaact tagacttctc caacaaccgg ctgttattac tctactcaac agccttggaa	1740
gagotccaga gtcttgaagt tctggatcta agtagtaaca gccactattt tcaagcagaa	1800
ggaattactc acatgctaaa ctttaccaag aaattacggc ttctggacaa actcatgatg	1860
aatgataatg acatctctac ttccggccagc aggaccatgg aaagtgactc tcttcgaatt	1920
ctggagttca gaggcaacca ttttagatgtt ctatggagag ccggtgataa cagatacttg	1980
gacttcttca agaattttgtt caatttagag gtattagata tctccagaaa ttccctgaat	2040
tccttgccctc ctgagggttt tgagggtatg ccggccaaatc taaaagaatct ctccctggcc	2100
aaaaatgggc tcaaatacttt cttttggac agactccagt tactgaagca tttggaaatt	2160
ttggacctca gccataacca gctgacaaaaa gtacctgaga gattggccaa ctgttccaaa	2220
agtctcacaa cactgattct taagcataat caaatcaggc aattgacaaa atattttcta	2280
gaagatgctt tgcaattgcg ctatctagac atcagttcaa ataaaatcca ggtcattcag	2340
aagactagct tccccagaaaaa tgcctcaac aatctggaga tgggggtttt acatcacaat	2400
cgtttcttt gcaactgtga tgctgtgtgg tttgtctggt gggtaacca tacagatgtt	2460
actattccat acctggccac tgatgtact tgttaggtc caggagcaca caaaggtaa	2520
agtgtcatat cccttgatct gtatacgtgt gagttagatc tcacaaacct gattctgttc	2580
tcaagttcca tatcatcagt cctctttctt atggtagtta tgacaacaag tcacctctt	2640
ttctggata tgggtacat ttatttttt tgaaaagcaa agataaagggg gtatcagcat	2700
ctgcaatcca tggagtcttg ttatgtgtc tttattgtgt atgacactaa aaactcagct	2760
gtgacagaat gggtttgca ggagctggtg gcaaaattgg aagatccaaag agaaaaacac	2820
ttcaatttgt gtctagaaga aagagactgg ctaccaggac agccagttct agaaaacctt	2880
tccccagagca tacagctcag caaaaagaca gtgtttgtga tgacacagaa atatgctaag	2940
actgagagtt ttaagatggc attttatgg tctcatcaga ggctcctgga tgaaaaagtg	3000
gatgtgatta tcttgatatt cttggaaaag cctcttcaga agtctaagtt tcttcagctc	3060
aggaagagac tctgcaggag ctctgtccctt gagtggcctg caaatccaca ggctcacccca	3120
tacttctggc agtgcctgaa aaatgccctg accacagaca atcatgtggc ttatagtcaa	3180

atgttcaagg aaacagtcta gctctctgaa gaatgtcacc acctaggaca tgccttgaat 3240
cga 3243
<210> 39
<211> 3747
<212> DNA
<213> murine

<400> 39
gagctcaaag gctctgcgag tctcggttt ctgttgccct ctctctgtct cagaggactc 60
catctataga accactctat gccttcaaga aagatgtcct tggetccctt ctcaggatga 120
tcctggccta tctctgactc tcttctccctc caccagacct ctgttccca ttttggaaaaga 180
aaactgaaaa tggtgtttc gatgtggaca cggaagagac aaattttgtat ctttttaaat 240
atgtcttag tttcttagagt ctgggggtt cgatggttt ctaaaactct accttggaa 300
gttaaagtaa atatcccaga ggcccatgtg atcgtggact gcacagacaa gcatttgaca 360
aaaatccctg agggcattcc cactaacacc accaatctta cccttaccat caaccacata 420
ccaagcatct ctccagattc ctcccgtagg ctgaaccatc tggaaagaaat cgattnaaga 480
tgcaattgtg tacctgttct actgggggtcc aaagccaatg tgtgttaccaa gaggctgcag 540
attagacctg gaagctttag tggactctct gactttaaag cccttacact ggatggaaac 600
caacttctgg agataccaca ggatctgccca tccagcttac atcttctgag ctttgaggct 660
aacaacatct tctccatcac gaaggagaat ctaacagaac tggtaacat tgaaacactc 720
tacctgggtc aaaactgtta ttatcgaaat ccttgcataatg tttcttattt tattgaaaaaa 780
gatgctttcc tagttatgag aaatttgaag gttctctcac taaaagataa caatgtcaca 840
gtgtccccca ccactttgcc acctaatttta cttagactct atcttataaa caatatcatt 900
aagaaaatcc aagaaaatga ttttataaac ctcaatgagt tgcaagttct tgacctaaatg 960
ggaaattgcc ctctatgtta taatgtccccca tatccgtgtta caccgtgtga aaataattcc 1020
cccttacaga tccatgacaa tgctttcaat tcattgacag aattttaaatg tttacgttta 1080
cacagtaatt ctcttcagca tggccccca acatggttta aaaaacatgag aaacctccag 1140
gaactagacc tctccaaaaa ctacttggcc agagaaaatttggaggccaa atttttgcatt 1200
tttcttccca accttggatgttcaatttcttcaattt atgagactgca ggtctaccat 1260
gcatttataaa ctttaccaca ttcactctct tcattggaaa acttgaaaat tctgcgtgtc 1320
aaggggatgttcaattttaaaaac tccagttttt ctgttattgca caagcttccccca 1380
aggctggaaatg ttcttgacacttggcactaac ttcataaaaaa ttgctgacacttcaacatattc 1440
aaacatttttggaaatgaaaacactcatagaccttccgtgttaataagatatc tcccttcgaaat 1500

gaggtaagag aagtggctt ttgtccta at gctcaaac tt ctgttagaccg tcatggcc c
caggtcctt aggccattaca ctat tccga tacgatgaat atgcacggag ctgcagggttc 1560
aaaaacaaag agccaccc tt ttttgctt ttgaatgcag actgccacat atatggcgag 1620
accttagact taat tagaaaa taacatattt ttat taaac cttctgattt tcagcatctt 1680
tcattccca aatgcctcaa ctat cagga aacaccattt gcca aaaaactct taatggcagt 1740
gaactctggc cggtgagaga gttgcggta ctttactt ccaacaaccg gctt gat tta 1800
ctctactcaa cagccttga agagctccag agtcttgaag ttctggatct aagtagtaac 1860
agccactatt ttcaaggcaga aggaattact cacatgctt aa actttaccaaa gaaattacgg 1920
cttctggaca aactcatgat gaatgataat gacatctcta cttcggccag caggaccatg 1980
gaaagtgact ctcttcgaat tctggagttc agaggcaacc atttagatgt tctatggaga 2040
gccgggtgata acagataactt ggacttcttc aagaatttgt tcaat ttaga ggtatttagat 2100
atctccagaa attccctgaa ttccctgctt cctgagg tttt ttgagggtat gccgccaat 2160
ctaaagaatc tcccttggc caaaaatggg ctcaaatctt tcttttgggaa cagactccag 2220
ttactgaagc atttggaaat ttggaccc agccataacc agctgacaaa agtacccctgag 2280
agattggcca actgttccaa aagtctcaca acactgattt ttaagcataa tcaaattcagg 2340
caattgacaa aatattttctt agaagatgt ttgcaattgc gctatctaga catcaggatca 2400
aataaaatcc aggtcattca gaagacttagc ttcccagaaa atgtcctcaa caatctggag 2460
atgttggttt tacatcacaa tcgcttctt tgcaactgtg atgctgtgtg gtttgc tgg 2520
tgggttaacc atacagatgt tactattcca tacctggcca ctgatgtgac ttgtgttaggt 2580
ccaggagcac acaaaggta aagtgtcata tcccttgatc tgtatctgt tgagttagat 2640
ctcacaaacc tgattctgtt ctcagttcc atatcatcag tcctcttct tatggtagtt 2700
atgacaacaa gtcacctt tttctggat atgtggtaca tttatttattt ttggaaagca 2760
aagataaaagg ggtatcagca tctgcaatcc atggagtctt gttatgtgc ttttattgtg 2820
tatgacacta aaaactcagc tgtgacagaa tgggtttgc aggagctgg ggcaaaattg 2880
gaagatccaa gagaaaaaaca cttcaatttgc tgc ttagaag aagagactg gctaccagga 2940
cagccagttc tagaaaaccc ttcccagagc atacagctca gcaaaaagac agtgtttgtg 3000
atgacacaga aatatgctt aactgagatgt tttaagatgg cattttattt gtctcatcag 3060
aggctcctgg atgaaaaagt ggtatgtgatt atcttgat tcttggaaaa gcctcttcag 3120
aagtctaaatgtt ctcagttccat caggaagaga ctctgcaggaa gctctgtcct tgagtggcct 3180
gcaaatccac aggctcaccc atacttctgg cagtgcctga aaaatgcctt gaccacagac 3240
aatcatgtgg cttatagtc aatgttcaag gaaacagtctt agtctcttga agaatgtcact 3300
cacctaggac atgccttggt acctgaagtt ttcataaaagg tttccataaa tgaaggtctg 3360
3420

aattttcct aacagttgtc atggctcaga ttggtggaa atcatcaata tatggctaag	3480
aaattaagaa ggggagactg atagaagata atttcttct tcatgtgcc a gctcagtt	3540
aatatccc ctagctcaa tctgaaaaac tgtgcctagg agacaacaca aggctttgat	3600
ttatctgcat acaattgata agagccacac atctgcctg aagaagtact agtagttta	3660
gtagtagggt aaaaattaca caagcttct ctctctga tactgaactg taccagagtt	3720
caatgaaata aaagcccaga gaacttc	3747

<210> 40
<211> 3449
<212> DNA
<213> murine

<400> 40	
gcgagtctcg gtttctgtt gccttctctc tgtctcagag gactccatct atagaaccac	60
tctatgcctt caagaaagat gtccttgct cccttctcag gatgatcctg gcctatctct	120
gactctcttc tcctccacca gacctcttga ttccattttg aaagaaaact gaaaatggtg	180
tttcgatgt ggacacggaa gagacaaatt ttgattttt taaaatatgtctt cttagttct	240
agagtctttg ggttcgatg gttcctaaa actctacctt gtgaagttaa agtaaatatc	300
ccagaggccc atgtgatcgt ggactgcaca gacaaggcatt tgacagaaat ccctgaggc	360
attcccaacta acaccaccaa tcttaccctt accatcaacc acataccaag catctctcca	420
gattccttcc gtaggctgaa ccatctggaa gaaatcgatt taagatgaa ttgtgtacct	480
gttctactgg ggtccaaagc caatgtgtgtt accaagaggc tgcagattag acctggaagc	540
ttagtggac tctctgactt aaaagccctt tacctggatg gaaaccaact tctggagata	600
ccacaggatc tgccatccag cttacatctt ctgagccttg aggctaacaa catctctcc	660
atcacgaagg agaatctaactc agaactggtc aacattgaaa cactctaccc gggtaaaaac	720
tgttattatc gaaatccttcaatgtttcc tattctattt gaaaagatgc tttcttagtt	780
atgagaaatt tgaagggtct ctcactaaaa gataacaatg tcacagctgt cccccaccact	840
ttgccaccta atttactaga gctctatctt tataacaata tcattaagaa aatccaagaa	900
aatgatttttataaacctcaa tgagttgaa gttcttgacc taagtggaaa ttgcctcgat	960
tgttataatg tcccatatcc gtgtacaccg tgtgaaaata attccccctt acagatccat	1020
gacaatgtt tcaattcatt gacagaatta aaagttttac gtttacacag taattctt	1080
cagcatgtgc ccccaacatg gtttaaaaac atgagaaacc tccaggaact agacccctcc	1140
caaaaactact tggccagaga aattgaggag gccaaatttt tgcattttct tcccaacctt	1200
gtttagttgg atttttcttt caattatgag ctgcaggctt accatgcata tataacttta	1260

ccacattcac tcttttcatt ggaaaacttg aaaattctgc gtgtcaaggg gtatgtctt	1320
aaagagctga aaaactccag tctttctgta ttgcacaagc ttcccaggct ggaagttctt	1380
gaccctggca ctaacttcat aaaaattgct gacctaaca tattcaaaca ttttggaaac	1440
ctcaaactca tagaccttgc agtgaataag atatctcctt cagaagagtc aagagaagtt	1500
ggctttgtc ctaatgctca aacttctgta gaccgtcatg ggccccaggct ccttgaggcc	1560
ttacactatt tccgatacga tgaatatgca cggagctgca ggttcaaaaa caaagagcca	1620
ccttctttct tgcccttgaa tgcagactgc cacatatatg ggcagacctt agacttaagt	1680
agaaataaca tatttttat taaaccttct gatttcagc atctttcatt cctcaaattgc	1740
ctcaacttat cagggaaacac cattggccaa actcttaatg gcagtgaact ctggccgttgc	1800
agagagttgc ggtacttaga cttctccaac aaccggcttgc atttactcta ctcaacagcc	1860
tttgaagagc tccagagtct tgaagttctg gatctaagta gtaacagcca ctatttcaa	1920
gcagaaggaa ttactcacat gctaaacttt accaagaaat tacggcttct ggacaaaactc	1980
atgatgaatg ataatgacat ctctacttgc gccagcagga ccatggaaag tgactcttct	2040
cgaattctgg agttcagagg caaccattta gatgttctat ggagagccgg tgataacaga	2100
tacttggact tcttcaagaa tttgttcaat ttagaggtat tagatatctc cagaaattcc	2160
ctgaattcct tgcctcctga ggttttgag ggtatgccgc caaatctaaa gaatctctcc	2220
ttggccaaaa atgggctcaa atctttctt tggcacagac tccagttact gaagcatttg	2280
gaaattttgg acctcagccaa taaccagctg acaaaagtac ctgagagatt ggccaactgt	2340
tccaaaagtc tcacaacact gattcttaag cataatcaaa tcaggcaatt gacaaaataat	2400
tttctagaag atgccttgca attgcgttat ctagacatca gttcaaataa aatccaggc.	2460
attcagaaga cttagttccc agaaaatgtc ctcaacaatc tggagatgtt ggttttacat	2520
cacaatcgct ttctttgcaa ctgtgatgt gttgtgggg tctgggtgggt taaccataca	2580
gatgttacta ttccatacct ggccactgat gtgacttgc taggtccagg agcacacaaa	2640
ggtcaaagtg tcatatccct tgatctgtat acgtgtgagt tagatctcac aaacctgatt	2700
ctgttctcag tttccatatac atcagtcctc tttcttatgg tagttatgac aacaagtac	2760
ctcttttct gggatatgtg gtacatttat tattttggaa aagcaaagat aaaggggtat	2820
cagcatctgc aatccatgga gtcttgatgt gatgctttta ttgtgtatga cactaaaaac	2880
ttagctgtga cagaatgggt tttgcaggag ctggtgccaa aattggaaga tccaagagaa	2940
aaacacttca atttgtgtct agaagaaaaga gactggctac caggacagcc agttctagaa	3000
aacctttccc agagcataca gtcagcaaa aagacagtgt ttgtgtatgac acagaaat	3060
gctaagactg agagtttaa gatggcattt tatttgcattc atcagaggct cctggatgaa	3120
aaagtggatg tgattatctt gatattctt gaaaagcctc ttcagaagtc taagttctt	3180

cagctcagga agagactctg caggagctct gtccttgagt ggcctgcaaa tccacaggct	3240
caccatact tctggcagtg cctgaaaaat gccctgacca cagacaatca tgtggcttat	3300
agtcaaatgt tcaaggaaac agtctagctc tctgaagaat gtcaccacct aggacatgcc	3360
ttgg tacctg aagtttcat aaaggttcc ataaatgaag gtctgaattt ttcc taacag	3420
ttgtcatggc tcagatttgtt gggaaatca	3449

<210> 41
<211> 1050
<212> PRT
<213> murine

<400> 41

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu			
1	5	10	15

Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys		
20	25	30

Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile		
35	40	45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro		
50	55	60

Thr Asn Thr Thr Asn Leu Thr Ile Asn His Ile Pro Ser Ile			
65	70	75	80

Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu		
85	90	95

Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys		
100	105	110

Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp		
115	120	125

Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln		
130	135	140

Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile			
145	150	155	160

Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr		
165	170	175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser		
180	185	190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val		
195	200	205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro		
210	215	220

Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile

225	230	235	240												
Gln	Glu	Asn	Asp	Phe	Asn	Asn	Leu	Asn	Glu	Leu	Gln	Val	Leu	Asp	Leu
245									250						255
Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro															
260		265		270											
Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser															
275		280		285											
Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His															
290		295		300											
Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp															
305		310		315		320									
Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu															
325		330		335											
His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu															
340		345		350											
Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser															
355		360		365											
Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu															
370		375		380											
Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu															
385		390		395		400									
Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile															
405		410		415											
Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys															
420		425		430											
Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala															
435		440		445											
Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His															
450		455		460											
Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys															
465		470		475		480									
Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly															
485		490		495											
Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser															
500		505		510											
Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn															
515		520		525											
Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu															
530		535		540											
Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser															
545		550		555		560									
Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser															

565	570	575
Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe		
580	585	590
Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp		
595	600	605
Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile		
610	615	620
Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp		
625	630	635
Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu		
645	650	655
Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu		
660	665	670
Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu		
675	680	685
Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile		
690	695	700
Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala		
705	710	715
Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile		
725	730	735
Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr		
740	745	750
Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe		
755	760	765
Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn		
770	775	780
Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn		
785	790	795
His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val		
805	810	815
Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr		
820	825	830
Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile		
835	840	845
Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe		
850	855	860
Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys		
865	870	875
Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile		
885	890	895
Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu		

900	905	910
Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys		
915	920	925
Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu		
930	935	940
Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln		
945	950	955
Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His		
965	970	975
Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu		
980	985	990
Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu		
995	1000	1005
Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His		
1010	1015	1020
Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn		
1025	1030	1035
His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val		
1040	1045	1050

<210> 42
 <211> 1050
 <212> PRT
 <213> murine

 <400> 42

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu		
1	5	10
		15
Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys		
20	25	30
Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile		
35	40	45
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro		
50	55	60
Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile		
65	70	75
		80
Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu		
85	90	95
Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys		
100	105	110
Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp		
115	120	125
Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln		
130	135	140

Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile
 145 150 155 160
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr
 165 170 175
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser
 180 185 190
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val
 195 200 205
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro
 210 215 220
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile
 225 230 235 240
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu
 245 250 255
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro
 260 265 270
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser
 275 280 285
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His
 290 295 300
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp
 305 310 315 320
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu
 325 330 335
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu
 340 345 350
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser
 355 360 365
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu
 370 375 380
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu
 385 390 395 400
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile
 405 410 415
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys
 420 425 430
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala
 435 440 445
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His
 450 455 460
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys

465	470	475	480
Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly			
485	490	495	
Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser			
500	505	510	
Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn			
515	520	525	
Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu			
530	535	540	
Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser			
545	550	555	560
Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser			
565	570	575	
Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe			
580	585	590	
Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp			
595	600	605	
Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile			
610	615	620	
Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp			
625	630	635	640
Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu			
645	650	655	
Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu			
660	665	670	
Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu			
675	680	685	
Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile			
690	695	700	
Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala			
705	710	715	720
Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile			
725	730	735	
Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr			
740	745	750	
Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe			
755	760	765	
Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn			
770	775	780	
Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn			
785	790	795	800
His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val			

	805	810	815
Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr			
	820	825	830
Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile			
	835	840	845
Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe			
	850	855	860
Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys			
	865	870	875
Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile			
	885	890	895
Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu			
	900	905	910
Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys			
	915	920	925
Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu			
	930	935	940
Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln			
	945	950	955
Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His			
	965	970	975
Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu			
	980	985	990
Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu			
	995	1000	1005
Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His			
	1010	1015	1020
Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn			
	1025	1030	1035
His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val			
	1040	1045	1050
<210> 43			
<211> 1050			
<212> PRT			
<213> murine			
<400> 43			
Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu			
	1	5	10
			15
Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys			
	20	25	30
Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile			
	35	40	45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro
50 55 60

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile
65 70 75 80

Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu
85 90 95

Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys
100 105 110

Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp
115 120 125

Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln
130 135 140

Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile
145 150 155 160

Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr
165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro
210 215 220

Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile
225 230 235 240

Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro
260 265 270

Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His
290 295 300

Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp
305 310 315 320

Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu
325 330 335

His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu
340 345 350

Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser
355 360 365

Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu

370	375	380
Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu		
385	390	400
Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile		
405	410	415
Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys		
420	425	430
Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala		
435	440	445
Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His		
450	455	460
Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys		
465	470	480
Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly		
485	490	495
Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser		
500	505	510
Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn		
515	520	525
Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu		
530	535	540
Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser		
545	550	560
Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser		
565	570	575
Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe		
580	585	590
Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp		
595	600	605
Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile		
610	615	620
Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp		
625	630	640
Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu		
645	650	655
Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu		
660	665	670
Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu		
675	680	685
Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile		
690	695	700
Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala		

705 710 715 720
Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile
 725 730 735

Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr
 740 745 750

Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe
 755 760 765

Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn
 770 775 780

Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn
785 790 795 800

His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val
 805 810 815

Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr
 820 825 830

Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile
 835 840 845

Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe
 850 855 860

Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys
865 870 875 880

Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile
 885 890 895

Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu
 900 905 910

Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys
 915 920 925

Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu
 930 935 940

Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln
945 950 955 960

Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His
 965 970 975

Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu
 980 985 990

Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu
 995 1000 - 1005

Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His
1010 1015 1020

Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn
1025 1030 1035

His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val

1040	1045	1050
<210> 44		
<211> 1050		
<212> PRT		
<213> murine		
<400> 44		
Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu		
1	5	10
		15
Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys		
20	25	30
Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile		
35	40	45
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro		
50	55	60
Thr Asn Thr Asn Leu Thr Ile Asn His Ile Pro Ser Ile		
65	70	75
		80
Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu		
85	90	95
Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys		
100	105	110
Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp		
115	120	125
Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln		
130	135	140
Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile		
145	150	155
		160
Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr		
165	170	175
Leu Tyr Leu Gly Gln Asn Cys Tyr Arg Asn Pro Cys Asn Val Ser		
180	185	190
Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val		
195	200	205
Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro		
210	215	220
Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile		
225	230	235
		240
Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu		
245	250	255
Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro		
260	265	270
Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser		
275	280	285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His
290 295 300

Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp
305 310 315 320

Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu
325 330 335

His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu
340 345 350

Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser
355 360 365

Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu
370 375 380

Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile
405 410 415

Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys
420 425 430

Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala
435 440 445

Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His
450 455 460

Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys
465 470 475 480

Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly
485 490 495

Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser
500 505 510

Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn
515 520 525

Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu
530 535 540

Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser
545 550 555 560

Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser
565 570 575

Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe
580 585 590

Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp
595 600 605

Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile

610	615	620
Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp		
625	630	635
Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu		
645	650	655
Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu		
660	665	670
Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu		
675	680	685
Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile		
690	695	700
Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala		
705	710	715
Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile		
725	730	735
Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr		
740	745	750
Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe		
755	760	765
Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn		
770	775	780
Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn		
785	790	795
800		
His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val		
805	810	815
Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr		
820	825	830
Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile		
835	840	845
Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe		
850	855	860
Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys		
865	870	875
880		
Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile		
885	890	895
Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu		
900	905	910
Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys		
915	920	925
Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu		
930	935	940
Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln		

945	950	955	960
Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His			
965	970	975	
Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu			
980	985	990	
Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu			
995	1000	1005	
Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His			
1010	1015	1020	
Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn			
1025	1030	1035	
His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val			
1040	1045	1050	
<210> 45			
<211> 1050			
<212> PRT			
<213> murine			
<400> 45			
Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu			
1	5	10	15
Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys			
20	25	30	
Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile			
35	40	45	
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro			
50	55	60	
Thr Asn Thr Thr Asn Leu Thr Ile Asn His Ile Pro Ser Ile			
65	70	75	80
Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu			
85	90	95	
Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys			
100	105	110	
Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp			
115	120	125	
Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln			
130	135	140	
Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile			
145	150	155	160
Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr			
165	170	175	
Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser			
180	185	190	

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro
210 215 220

Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile
225 230 235 240

Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro
260 265 270

Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His
290 295 300

Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp
305 310 315 320

Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu
325 330 335

His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu
340 345 350

Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser
355 360 365

Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu
370 375 380

Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile
405 410 415

Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys
420 425 430

Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala
435 440 445

Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His
450 455 460

Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys
465 470 475 480

Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly
485 490 495

Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser
500 505 510

Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn

515	520	525
Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu		
530	535	540
Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser		
545	550	555
560		
Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser		
565	570	575
Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe		
580	585	590
Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp		
595	600	605
Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile		
610	615	620
Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp		
625	630	635
640		
Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu		
645	650	655
Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu		
660	665	670
Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu		
675	680	685
Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile		
690	695	700
Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala		
705	710	715
720		
Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile		
725	730	735
Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr		
740	745	750
Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe		
755	760	765
Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn		
770	775	780
Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn		
785	790	795
800		
His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val		
805	810	815
Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr		
820	825	830
Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile		
835	840	845
Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe		

850	855	860
Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys		
865	870	875
Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile		
885	890	895
Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu		
900	905	910
Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys		
915	920	925
Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu		
930	935	940
Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln		
945	950	955
Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His		
965	970	975
Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu		
980	985	990
Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu		
995	1000	1005
Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His		
1010	1015	1020
Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn		
1025	1030	1035
His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val		
1040	1045	1050

<210> 46
 <211> 3311
 <212> DNA
 <213> Homo sapiens

<400> 46	
ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca acagaaacat ggaaaaacatg	60
tcccttcagt cgtcaatgct gacctgcatt ttcctgctaa tatctgggtc ctgtgagttt	120
tgcgccgaag aaaatttttc tagaagctat ccttgtatg agaaaaagca aaatgactca	180
gttattgcag agtgcagcaa tcgtcgacta caggaagttc cccaaacggt gggcaaataat	240
gtgacagaac tagacctgtc tgataatttc atcacacaca taacgaatga atcatttcaa	300
gggctgcaaa atctcactaa aataaatcta aaccacaacc ccaatgtaca gcaccagaac	360
ggaaatcccc gtataacaatc aaatggcttg aatatcacag acggggcatt cctcaaccta	420
aaaaacctaa gggagttact gcttgaagac aaccagttac cccaaatacc ctctggtttgc	480
ccagagtctt tgacagaact tagtctaatt caaaacaata tataacaacat aactaaagag	540

ggcatttcaa gacttataaa cttgaaaaat ctctatttg cctggaaactg ctatTTAAC	600
aaagtttgcg agaaaaactaa catagaagat ggagtattt aaacgctgac aaatttggag	660
ttgctatcac tatcttcaa ttctcttca cacgtgccac ccaaactgcc aagctcccta	720
cgcaaactt ttctgagcaa cacccagatc aaatacatta gtgaagaaga tttcaaggga	780
ttgataaatt taacattact agatttaagc gggaaactgtc cgaggtgctt caatgccccca	840
tttccatgcg tgccTTgtga tggtgggtct tcaattaata tagatcgTT tgctttcaa	900
aacttgcaccc aacttcgata cctaaacctc tctagcactt ccctcaggaa gattaatgt	960
gcctggTTta aaaatatgcc tcatctgaag gtgctggatc ttgaattcaa ctatTTAGTG	1020
ggagaaaatag cctctggggc atttttaacg atgctgcccc gcttagaaat acttgacttg	1080
tcttttaact atataaaggg gagttatcca cagcatatta atatttccag aaacttctct	1140
aaacttttgt ctctacgggc attgcattta agaggttatg tgTTCCAGGA actcagagaa	1200
gatgatttcc agccctgat gcagcttcca aacttatcga ctatcaactt ggTTTATTAAT	1260
tttattaAGC aaatcgattt cAAACtttC cAAAAtttCT ccaatctgga aattatTTAC	1320
ttgtcagaaa acagaatato accgttggta aaagataccc ggcagagtta tgcaaatagt	1380
tcctcttttc aacgtcatat ccggaaacga cgctcaacag attttgagtt tgaccacat	1440
tcgaactttt atcatttcac ccgtcTTta ataaAGCCAC aatgtgctgc ttatggaaaa	1500
gccttagatt taagcctcaa cagtatttC ttcatGGGC caaaccaatt tgAAAATCTT	1560
cctgacattt cctgtttaaa tctgtctgca aatagcaatg ctcaagtgtt aagtggaaCT	1620
gaattttcag ccattcctca tgtcaaataat ttggatttga caaacaatAG actagacttt	1680
gataatgcta gtgctttac tgaatttgc GACTTGGAAAG ttctagatct cagctataat	1740
tcacactatt tcagaatago aggCGTAACA catcatctag aatttattca aaatttccaca	1800
aatctaaaAG ttttaaactt gagccacaac aacatttata cttaacaga taagtataac	1860
ctggaaAGCA agtccctggT agaatttagtt ttcatGGCA atcgcTTGA cattttgtgg	1920
aatgatgatG acaacaggtA tatctccatt ttCAAAGGTc tcaagaatct gacacgtctG	1980
gatttatCCC ttaataggct gaagcacatc ccaaATGAAG cattcTTAA tttGCCAGCG	2040
agtctcaCTG aactacatAT aaatgataat atgttAAAGT ttttaactG gacattactC	2100
cagcagttcc ctcgtctcgA gttgCTTGAC ttacgtggAA acAAactact ctTTTAact	2160
gatagcCTAT ctgactttac atcttccTTT cggacactgc tgctgagtca taacaggatt	2220
tcccacCTAC cctctggTT tctttctgaa gTCAGTAGTC tgaAGCACCT CGATTAAgt	2280
tccaaATCTGC taaaaacaat caacaaATCC GCACTGAAA ctaAGACCAC caccaaATTA	2340
tctatgttgg aactacacGG aaACCCCTTT gaatgcacCT gtgacattgg agatttCCGA	2400
agatggatgg atgaacatct gaatgtcaaA attcccAGAC tggtagatgt catttGTGCC	2460

agtccctgggg atcaaagagg gaagagtatt gtgagtctgg agctgacaac ttgtgtttca	2520
gatgtcactg cagtgatatt atttttcttc acgttctta tcaccaccat ggttatgttg	2580
gctgccctgg ctcaccattt gtttactgg gatgttttgtt tatatataaa tgtgtgttta	2640
gctaaggtaa aaggctacag gtctcttcc acatccaaa ctttctatga tgcttacatt	2700
tcttatgaca ccaaagatgc ctctgttact gactgggtga taaatgagct gcgctaccac	2760
cttgaagaga gccgagacaa aaacgttctc ctttgtctag aggagagggta ttgggaccgg	2820
ggattggcca tcatcgacaa cctcatgcag agcatcaacc aaagcaagaa aacagtattt	2880
gttttaacca aaaaatatgc aaaaagctgg aactttaaaa cagctttta cttggctttg	2940
cagaggctaa tggatgagaa catggatgtg attatattta tcctgctgga gccagtgtta	3000
cagcattctc agtatttgag gctacggcag cggatctgta agagctccat cctccagtgg	3060
cctgacaacc cgaaggcaga aggcttgtt tggcaaactc tgagaaatgt ggtcttgact	3120
aaaaatgatt cacggtataa caatatgtat gtcgattcca ttaagcaata ctaactgacg	3180
ttaagtcatg atttcgcgcc ataataaaaga tgcaaaggaa tgacatttct gtatttagtta	3240
tctattgcta tgtaacaaat tatccaaaaa cttagtggtt taaaacaaca catttgctgg	3300
ccccacagttt t	3311

<210> 47
<211> 3367
<212> DNA
<213> Homo spaiens

<400> 47	
ctcctgcata gagggtacca ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca	60
acagaaaacgt gtttctcttg acacttcagt gtttagggAAC atcagcaaga .cccacccag	120
gagaccttga aggaaggcctt tgaaaggag aatgaaggag tcatcttgc aaaatagctc	180
ctgcagcctg gaaaaggaga ctaaaaagga aaacatgttc cttcagtcgt caatgctgac	240
ctgcattttc ctgctaataat ctggttcctg tgagttatgc gccgaagaaa atttttctag	300
aagctatcct tggatgaga aaaagcaaaa tgactcagtt attgcagagt gcagcaatcg	360
tcgactacag gaagttcccc aaacgggtggg caaatatgtg acagaactag acctgtctga	420
taatttcatc acacacataa cgaatgaatc atttcaaggg ctgcaaaatc tcactaaaat	480
aaatctaaac cacaacccca atgtacagca ccagaacggaa aatcccggtt tacaatcaaa	540
tggcttgaat atcacagacg gggcattcct caacctaaaaa aacctaaggg agttactgct	600
tgaagacaac cagttacccc aaataccctc tggttgcca gagtctttga cagaacttag	660
tctaattcaa aacaatataat acaacataac taaagagggc atttcaagac ttataaaactt	720

gaaaaatctc tattggcct ggaactgcta tttAACAAA gtttgcgaga aaactaacat	780
agaagatgga gtatTTGAAA cgctgacaaa ttggagtt ctatcaactat ctttcaattc	840
tcttcacac gtgtcaccca aactgccaaag ctccctacgc aaacttttc tgagcaacac	900
ccagatcaaa tacatttagtg aagaagattt caagggattt ataaatttaa cattactaga	960
tttaagcggg aactgtccga ggtgcttcaa tgccccattt ccatgcgtgc cttgtgatgg	1020
tggtgcttca attaatatacg atcgTTTGC tttcaAAAC ttgacccaaac ttcgatacct	1080
aaacctctct agcacttccc tcaggaagat taatgctgcc tggtttaaaa atatgcctca	1140
tctgaaggta ctggatcttgc aattcaacta tttAGTGGGA gaaatAGCCT ctggggcatt	1200
tttaacgatg ctgccccgct tagaaatact tgacttgtct tttaactata taaaggggag	1260
ttatccacag catattaata ttccagaaa cttctctaaa cctttgtctc tacgggcatt	1320
gcatttaaga ggttatgtgt tccaggaact cagagaagat gatttccagc ccctgatgca	1380
gcttccaaac ttatcgacta tcaacttggg tattaatttt attaagcaaa tcgatttcaa	1440
acttttccaa aatttctcca atctggaaat tatttacttg tcagaaaaca gaatatcacc	1500
gttggtaaaa gatacccgac agagttatgc aaatagtTCC tctttcaac gtcatatccg	1560
gaaacgacgc tcaacagatt ttgagttga cccacattcg aacttttac tttcaccgg	1620
tcctttaata aagccacaat gtgctgctta tggAAAAGCC ttagatttaa gcctcaacag	1680
tatTTTCTTC attgggccaa accaatttga aaatTTTCTC gacattgcct gtttaatct	1740
gtctgcaaattt agcaatgctc aagtgttaag tggAACTGAA ttTCAGCCA ttccTCTGT	1800
caaataTTTG gatttgacaa acaatagact agactttgat aatgcttagt ctcttactga	1860
attgtccgac ttggaagtTC tagatCTCAG ctataattca cactatttca gaatAGCAGG	1920
cgtAACACAT catctagaat ttattcaAAA ttTCACAAAT ctAAAAGTT taaACTTGAG	1980
ccacaacaac atttataCTT taACAGATAA gtataACCTG gaaAGCAAGT CCCTGGTAGA	2040
attagTTTC agtggcaatC gccttgacat ttgtggaaat gatgtgaca acaggatata	2100
ctccattttc aaaggTCTCA agaatCTGAC acgtctggat ttatCCCTTA ataggCTGAA	2160
gcacatcccc aatgaagcat tccttaattt gccagcgagt ctcactgaac tacatataaa	2220
tgataatATG ttaaAGTTT ttAACTGGAC attactCCAG cagTTTCTC gtctcgagtt	2280
gcttgactta cgtggaaACA aactactCTT ttAACTGAT agcctatCTG actttacatC	2340
ttcccttcgg acactgCTGC tgagtCATAA caggatttcc cacctaccct ctggCTTTCT	2400
ttctgaaAGTC agtagtCTGA agcacCTCGA ttAAAGTTCC aatCTGCTAA aaACATCTCAA	2460
caaATCCGCA ctgAAACTA agaccACCAC caaATTATCT atgttggAAC tacacggAAA	2520
ccccTTTGAAG tgcacCTGTG acattggAGA ttccGAAGA tggatggatG aacatCTGAA	2580
tgtcaAAATT cccAGACTGG tagatgtCAT ttgtGCCAGT CCTGGGGATC aaAGAGGGAA	2640

gagtattgtg agtctggagc taacaacttg tggatcgat gtcactgcag tgatattttt	2700
tttcttcacg ttcttttatca ccaccatggt tatgttggct gccctggctc accattttttt	2760
ttactggat gtttggttta tatataatgt gtgttagct aagataaaaag gctacaggc	2820
tctttccaca tcccaaactt tctatgatgc ttacatttct tatgacacca aagatgcctc	2880
tgtaactgac tgggtgataa atgagctgct ctaccacctt gaagagagcc gagacaaaaa	2940
cgttctcctt tgtcttagagg agagggattt ggaccggga ttggccatca tcgacaacct	3000
catgcagagc atcaacccaa gcaagaaaac agtattttttt ttaacccaaa aatatgcaaa	3060
aagctggaac tttaaaacag ctttttactt ggctttgcag aggctaatttgg atgagaacat	3120
ggatgtgatt atatttatcc tgctggagcc agtgttacag cattctcagt atttgggct	3180
acggcagcgg atctgtttaaga gctccatcct ccagtggcct gacaacccga aggccagaagg	3240
cttgggggg caaaactctga gaaatgtggt cttgactgaa aatgattcac ggtataacaa	3300
tatgtatgtc gattccatta agcaatacta actgacgttta agtcatgatt tcgcgccata	3360
ataaaaga	3367

<210> 48
<211> 4211
<212> DNA
<213> Homo spaiens

<400> 48	
ctcctgcata gagggtacca ttctgcgtc ctgcaagtta cggaatgaaa aattagaaca	60
acagaaaacat gggaaaacatg ttccttcagt cgtcaatgtt gacctgcatt ttcctgctaa	120
tatctggttc ctgtgagttt tgccggaaag aaaatttttc tagaagctat ctttgtatg	180
agaaaaaagca aaatgactca gttattgcag agtgcagcaa tcgtcgacta caggaagttc	240
cccaaacggg gggcaaatat gtgacagaac tagacctgtc tgataatttc atcacacaca	300
taacgaatga atcatttcaa gggctgaaa atctcactaa aataaatcta aaccacaacc	360
ccaaatgtaca gcaccagaac gggaaatcccg gtatataatc aaatggctt aatatcacag	420
acggggcatt cctcaaccta aaaaacctaa gggagttact gtttgaagac aaccagttac	480
cccaaataacc ctctggtttccagttttt tgacagaact tagtctaatt caaaacaata	540
tataacaat aactaaagag ggcatttcaa gacttataaa cttgaaaaat ctctattttgg	600
cctggaaactg ctatTTAAC aaagtttgcg agaaaaactaa catagaagat ggagtatttg	660
aaacgctgac aaatttggag ttgttatcac tatctttcaa ttctcttca cacgtgccac	720
ccaaactgccc aagctcccta cgccaaacttt ttctgagcaa cacccagatc aaatacatta	780
gtgaagaaga ttcaaggga ttgataaatt taacattact agatttaagc ggaaactgtc	840

cgaggtgcctt caatccccca	tttccatgcg	tgccttgtga	tggtggtgct	tcaattaata	900
tagatcgttt	tgctttcaa	aactgaccc	aacttcgata	cctaaacctc	960
ccctcaggaa	gatataatgct	gcctggttta	aaaatatgcc	tcatctgaag	1020
ttgaattcaa	ctattttagtg	ggagaaaatag	cctctggggc	attttaacg	1080
gcttagaaat	acttgacttg	tctttaact	atataaaggg	gagttatcca	1140
atatttccag	aaacttctct	aaactttgt	ctctacgggc	attgcattta	1200
tgttccagga	actcagagaa	gatgatttcc	agcccctgat	gcagcttcca	1260
ctatcaactt	gggttattaaat	tttattaagc	aaatcgattt	caaactttc	1320
ccaatctgga	aattatttac	ttgtcagaaa	acagaatatc	accgttggta	1380
ggcagagttt	tgcaaatagt	tcctctttc	aacgtcatat	ccggaaacga	1440
attttagtt	tgacccacat	tcgaactttt	atcatttcac	ccgtccttta	1500
aatgtgctgc	ttatggaaaa	gccttagatt	taagcctcaa	cagtatttc	1560
caaaccattt	tgaaaatctt	cctgacattt	cctgtttaaa	tctgtctgca	1620
ctcaagtgtt	aagtggaaact	gaattttcag	ccattcctca	tgtcaaataat	1680
caaacaatag	actagacttt	gataatgcta	gtgctttac	tgaattgtcc	1740
ttctagatct	cagctataat	tcacactatt	tcagaatagc	aggcgtaaca	1800
aatttattca	aaatttcaca	aatctaaaag	ttttaaactt	gagccacaac	1860
ctttaacaga	taagtataac	ctggaaagca	agtccctgg	agaatttagtt	1920
atcgcccttga	cattttgtgg	aatgatgatg	acaacaggta	tatctccatt	1980
tcaagaatct	gacacgtctg	gatttatccc	ttaataggct	gaagcacatc	2040
cattcccttaa	tttgcgcagcg	agtctcactg	aactacatat	aatgataat	2100
tttttaactg	gacattactc	cagcagtttc	ctcgctcga	gttgcttgc	2160
acaaaactact	ctttttaact	gatagcctat	ctgactttac	atctccctt	2220
tgctgagtca	taacaggatt	tcccacctac	cctctggctt	tctttctgaa	2280
tgaagcacct	cgattnaagt	tccaaatctgc	taaaaacaat	caacaaatcc	2340
ctaagaccac	caccaaatta	tctatgttgg	aactacacgg	aaacccttt	2400
gtgacattgg	agattnccga	agatggatgg	atgaacatct	gaatgtcaaa	2460
tggtagatgt	catttgtgcc	agtccctgggg	atcaaagagg	gaagagtatt	2520
agctaacaac	tttgtttca	gatgtcactg	cagtgtatatt	attttcttc	2580
tcaccaccat	ggttatgttg	gctgcctgg	ctcaccat	gtttactgg	2640
ttatataaa	tgtgtttta	gctaaggtaa	aaggctacag	gtctttcc	2700
ctttctatga	tgcttacatt	tcttatgaca	ccaaagatgc	ctctgttact	2760

taaatgagct gcgcgtaccac cttgaagaga gccgagacaa aaacgttctc ctttgtctag	2820
aggagagggta ttggatccg ggattggcca tcatacgacaa cctcatgcag agcatcaacc	2880
aaagcaagaa aacagtatTTT gtttaacca aaaaatatgc aaaaagctgg aactttaaaa	2940
cagctttta ctggcttg cagaggctaa tggatgagaa catggatgtg attatattta	3000
tcctgctgga gccagtgtta cagcattctc agtattttag gctacggcag cgatctgta	3060
agagctccat cctccagtgg cctgacaacc cgaaggcaga aggcttgtt tggcaaactc	3120
ttagaaatgt ggtcttgact gaaaatgatt cacggtataa caatatgtat gtcgattcca	3180
ttaagcaata ctaactgacg ttaagtcatg atttcgcgcc ataataaaga tgcaaaggaa	3240
tgacatttct gtatttagtta tctattgcta tgtaacaaat tatccccaaa cttagtggtt	3300
taaaacaaca catttgctgg cccacagttt ttgagggtca ggagtccagg cccagcataa	3360
ctgggtcctc tgctcagggt gtctcagagg ctgcaatgta ggtgttcacc agagacatag	3420
gcatactgg ggtcacactc atgtgggtgt tttctggatt caattcctcc tgggttattg	3480
gccaaggct atactcatgt aagccatgctc agcctctccc acaaggcagc ttgcttcattc	3540
agagctagca aaaaagagag gttgctagca agatgaagtc acaatctttt gtaatcgaat	3600
caaaaaagtg atatctcatc actttggcca tattctattt gttagaagta aaccacaggt	3660
cccaccagct ccatggagt gaccacctca gtccaggaa aacagctgaa gaccaagatg	3720
gtgagctctg attgcttcag ttggtcatca actatTTTCC cttgactgct gtcctggat	3780
ggcctgctat cttgatgata gattgtgaat atcaggaggc agggatcaact gtggaccatc	3840
ttagcagttg acctaacaca tcttctttc aatatctaag aactttgcc actgtgacta	3900
atggtcctaa tattaagctg ttgttatTTT ttatcatata tctatggcta catggttata	3960
ttatgctgtg gttgcgttcg gttttattta cagttgcttt tacaaatatt tgctgtaaca	4020
tttgacttct aaggTTTtga tgccattaa gaactgagat ggatagctt taaagcatct	4080
tttacttctt accatTTTTT aaaagtatgc agctaaattc gaagctttg gtctatattg	4140
ttaattgcca ttgctgtaaa tcttaaaatg aatgaataaa aatgtttcat tttacaaaaa	4200
aaaaaaaaaa a	4211

<210> 49
<211> 3468
<212> DNA
<213> Homo sapiens

<400> 49 ctcctgcata gagggtaacca ttctgcgtc ctgcaagtta cgaaatgaaa aattagaaca	60
acagaaacat gtttctttt acacttcagt gttaggaaac atcagcaaga cccatcccag	120

gagaccttga aggaaggcctt tgaaagggag aatgaaggag tcatcttcgc aaaatagctc	180
ctgcagccgt gggaaaggaga ctaaaaagga aaacatgttc ctgcgtcgtaatgtac	240
ctgcattttc ctgctaataat ctggttccctg tgagttatgc gccgaagaaa atttttctag	300
aagctatcct tgtgtatgaga aaaagcaaaa tgactcagtt attgcagagt gcagcaatcg	360
tcgactacag gaagttcccc aaacgggtggg caaatatgtg acagaactag acctgtctga	420
taatttcatc acacacataa cgaatgaatc atttcaaggg ctgcaaaatc tcactaaaat	480
aaatctaaac cacaacccca atgtacagca ccagaacgga aatcccgta tacaatcaaa	540
tggcttgaat atcacagacg gggcattcct caacctaaaa aacctaaggg agttactgct	600
tgaagacaac cagttacccc aaataccctc tggtttgcga gagtcatttga cagaacttag	660
tctaattcaa aacaatataat acaacataac taaagagggc atttcaagac ttataaactt	720
aaaaaatctc tatttggcct ggaactgcta ttttaacaaa gtttgcgaga aaactaacat	780
agaagatgga gtatttgaaa cgctgacaaa tttggagttt ctatcactat ctttcaattc	840
tctttcacac gtgccaccca aactgccaag ctccctacgc aaacttttc tgagcaacac	900
ccagatcaaa tacatttagt aagaagattt caagggattt ataaattttaa cattactaga	960
tttaagcggg aactgtccga ggtgcttcaa tgccccattt ccatgcgtgc cttgtgatgg	1020
tggtgcttca attaatataat atcgaaaaatc tttcaaaaac ttgaccacac ttgcataacct	1080
aaacctctct agcacttccc tcaggaagat taatgctgcc tggttaaaa atatgcctca	1140
tctgaaggtg ctggatctt aattcaacta ttttagtggg gaaatagcct ctggggcatt	1200
tttaacgatg ctgccccgct tagaaataact tgacttgtct ttttaactata taaaggggag	1260
ttatccacag catattaata tttccagaaaa cttctctaaa cttttgtctc tacgggcatt	1320
gcatttaaga gtttatgtgt tccaggaact cagagaagat gattccagc ccctgatgca	1380
gttccaaac ttatcgacta tcaacttggg tattaatttt attaagcaaa tcgatttcaa	1440
actttccaa aatttctcca atctggaaat tatttacttg tcagaaaaca gaatatcacc	1500
gttggaaaa gataccggc agagttatgc aaatagttcc tctttcaac gtcatatccg	1560
gaaacgacgc tcaacagatt ttgagtttga cccacattcg aacttttac atttcacccg	1620
tcctttaata aagccacaat gtgctgctta tggaaaagcc ttagatttaa gcctcaacag	1680
tatTTTCTTC attggccaa accaatttga aaatcttcct gacattgcct gttttatct	1740
gtctgcaaat agcaatgctc aagtgttaag tggaaactgaa ttttcagcca ttccatgt	1800
caaataattt gatttgacaa acaatagact agactttgat aatgcttagt ctcttactga	1860
attgtccgac ttgaaagttc tagatctcag ctataattca cactattca gaatagcagg	1920
cgtaacacat catctagaat ttattcaaaa tttcacaaat ctaaaagtt taaacttgag	1980
ccacaacaac atttataactt taacagataa gtataaccctg gaaagcaagt ccctggtaga	2040

attagtttc agtggcaatc gccttgacat tttgtggaat gatgatgaca acaggtatat	2100
ctccattttc aaaggctca agaatctgac acgtctggat ttatccctta ataggctgaa	2160
gcacatccca aatgaagcat tccttaattt gccagcgagt ctcactgaac tacatataaa	2220
tgataatatg ttaaagtttt ttaactggac attactccag cagtttcctc gtctcgagtt	2280
gcttgactta cgtggaaaca aactactctt tttactgat agcctatctg actttacatc	2340
ttcccttcgg acactgctgc tgagtctaaa caggattcc cacctaccct ctggctttct	2400
ttctgaagtc agtagtctga agcacctcga tttaagttcc aatctgctaa aaacaatcaa	2460
caaatccgca cttgaaaacta agaccaccac caaattatct atgttggAAC tacacggaaa	2520
ccccttgaa tgcacctgtg acattggaga ttccgaaga tggatggatg aacatctgaa	2580
tgtcaaatt cccagactgg tagatgtcat ttgtgccagt cctggggatc aaagagggaa	2640
gagtattgtg agtctggagc taacaacttg ttttcagat gtcactgcag tgatattatt	2700
tttcttcacg ttcttatca ccaccatggt tatgtggct gccctggctc accattgtt	2760
ttactggat gtttggtta tatataatgt gtgttagct aaggtaaaag gctacaggc	2820
tcttcacaca tcccaaactt tctatgatgc ttacattct tatgacacca aagatgcctc	2880
tgttactgac tgggtgataa atgagctgcg ctaccacctt gaagagagcc gagacaaaaa	2940
cgttctcctt tgtcttagagg agagggattt ggatccggga ttggccatca tcgacaacct	3000
catgcagagc atcaaccaaa gcaagaaaac agtattgtt ttaaccaaaa aatatgcaaa	3060
aagctggaac ttaaaacag cttttactt ggcttgcag aggctaattgg atgagaacat	3120
ggatgtgatt atatttatcc tgctggagcc agtgttacag cattctcagt atttgggct	3180
acggcagcgg atctgtaaa gctccatcct ccagtggcct gacaacccga aggcagaagg	3240
cttgggggg caaactctga gaaatgtggt cttgactgaa aatgattcac ggtataacaa	3300
tatgtatgtc gattccatta agcaatacta actgacgtta agtcatgatt tcgcgccata	3360
ataaaagatgc aaaggaatga catttctgta ttagttatct attgctatgt aacaaattat	3420
ccccaaactt agtggttaa aacaacacat ttgctggccc acagtttt	3468

<210> 50
 <211> 1041
 <212> PRT
 <213> Homo sapiens

<400> 50

Met Glu Asn Met Phe Ile Gln Ser Ser Met Leu Thr Cys Ile Phe Leu
 1 5 10 15

Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg
 20 25 30

Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu
35 40 45

Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr
50 55 60

Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn
65 70 75 80

Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His
85 90 95

Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn
100 105 110

Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg
115 120 125

Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu
130 135 140

Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn
145 150 155 160

Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr
165 170 175

Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile
180 185 190

Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu
195 200 205

Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu
210 215 220

Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu
225 230 235 240

Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn
245 250 255

Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly
260 265 270

Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln
275 280 285

Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala
290 295 300

Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe
305 310 315 320

Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu
325 330 335

Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser
340 345 350

Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser

355 360 365
Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu
370 375 380

Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn
385 390 395 400

Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn
405 410 415

Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro
420 425 430

Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln
435 440 445

Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His
450 455 460

Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala
465 470 475 480

Ala Tyr Gly Lys Ala Ile Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile
485 490 495

Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu
500 505 510

Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe Ser Ala
515 520 525

Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe
530 535 540

Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp
545 550 555 560

Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His
565 570 575

Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser
580 585 590

His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys
595 600 605

Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp
610 615 620

Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn
625 630 635 640

Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn
645 650 655

Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn
660 665 670

Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro
675 680 685

Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr

690	695	700
Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser		
705	710	715
720		
His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser		
725 730 735		
Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr Ile Asn		
740 745 750		
Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met Leu Glu		
755 760 765		
Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp Phe Arg		
770 775 780		
Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu Val Asp		
785 790 795 800		
Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser		
805 810 815		
Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe		
820 825 830		
Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala		
835 840 845		
His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu		
850 855 860		
Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr		
865 870 875 880		
Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp		
885 890 895		
Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn		
900 905 910		
Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile		
915 920 925		
Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe		
930 935 940		
Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe		
945 950 955 960		
Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile		
965 970 975		
Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu		
980 985 990		
Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro		
995 1000 1005		
Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu		
1010 1015 1020		
Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile		

1025	1030	1035
Lys Gln Tyr		
1040		

<210> 51
<211> 1059
<212> PRT
<213> *Homo sapiens*

<400> 51

Met Lys Glu Ser Ser Leu Gln Asn Ser Ser Cys Ser Leu Gly Lys Glu
1 5 10 15

Thr Lys Lys Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile
20 25 30

Phe Leu Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe
 35 40 45

Ser Arg Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile
50 55 60

Ala Glu Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly
65 70 75 80

Lys Tyr Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile
85 90 95

Thr Asn Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu
100 105 110

Asn His Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln
115 120 125

Ser Asn Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn
 130 135 140

Leu Arg Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser
145 150 155 160

Gly Leu Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile
165 170 175

Tyr Asn Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn
 180 185 190

Leu Tyr Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr
 195 200 205

Asn Ile Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu
210 215 220

Ser Leu Ser Phe Asn Ser Leu Ser His Val Ser Pro Lys Leu Pro Ser
225 230 235 240

Ser Leu Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser
245 250 255

Glu Glu Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser
260 265 270

Gly Asn Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys
275 280 285

Asp Gly Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu
290 295 300

Thr Gln Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile
305 310 315 320

Asn Ala Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu
325 330 335

Glu Phe Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr
340 345 350

Met Leu Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys
355 360 365

Gly Ser Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Pro
370 375 380

Leu Ser Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu
385 390 395 400

Arg Glu Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr
405 410 415

Ile Asn Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe
420 425 430

Gln Asn Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile
435 440 445

Ser Pro Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser
450 455 460

Phe Gln Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp
465 470 475 480

Pro His Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln
485 490 495

Cys Ala Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe
500 505 510

Phe Ile Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu
515 520 525

Asn Leu Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe
530 535 540

Ser Ala Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu
545 550 555 560

Asp Phe Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val
565 570 575

Leu Asp Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr
580 585 590

His His Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn

595	600	605
Leu Ser His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu		
610	615	620
Ser Lys Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile		
625	630	635
640		
Leu Trp Asn Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu		
645	650	655
Lys Asn Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile		
660	665	670
Pro Asn Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His		
675	680	685
Ile Asn Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln		
690	695	700
Phe Pro Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe		
705	710	715
720		
Leu Thr Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu		
725	730	735
Leu Ser His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu		
740	745	750
Val Ser Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr		
755	760	765
Ile Asn Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met		
770	775	780
Leu Glu Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp		
785	790	795
800		
Phe Arg Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu		
805	810	815
Val Asp Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile		
820	825	830
Val Ser Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile		
835	840	845
Leu Phe Phe Phe Thr Phe Ile Thr Thr Met Val Met Leu Ala Ala		
850	855	860
Leu Ala His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val		
865	870	875
880		
Cys Leu Ala Lys Ile Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr		
885	890	895
Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr		
900	905	910
Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp		
915	920	925
Lys Asn Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu		

930	935	940
Ala Ile Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr		
945	950	955
Val Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr		
965	970	975
Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val		
980	985	990
Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu		
995	1000	1005
Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro		
1010	1015	1020
Asp Asn Pro Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn		
1025	1030	1035
Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val		
1040	1045	1050
Asp Ser Ile Lys Gln Tyr		
1055		

<210> 52
<211> 1041
<212> PRT
<213> Homo sapiens

<400> 52

Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu		
1	5	10
		15
Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg		
20	25	30
Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu		
35	40	45
Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr		
50	55	60
Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn		
65	70	75
		80
Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His		
85	90	95
Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn		
100	105	110
Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg		
115	120	125
Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu		
130	135	140
Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn		
145	150	155
		160

Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr
165 170 175

Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile
180 185 190

Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu
195 200 205

Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu
210 215 220

Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu
225 230 235 240

Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn
245 250 255

Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly
260 265 270

Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln
275 280 285

Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala
290 295 300

Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe
305 310 315 320

Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu
325 330 335

Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser
340 345 350

Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser
355 360 365

Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu
370 375 380

Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn
385 390 395 400

Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn
405 410 415

Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro
420 425 430

Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Phe Gln
435 440 445

Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His
450 455 460

Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala
465 470 475 480

Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile

	485	490	495
Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu			
500	505	510	
Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe Ser Ala			
515	520	525	
Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe			
530	535	540	
Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp			
545	550	555	560
Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His			
565	570	575	
Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser			
580	585	590	
His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys			
595	600	605	
Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp			
610	615	620	
Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn			
625	630	635	640
Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn			
645	650	655	
Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn			
660	665	670	
Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro			
675	680	685	
Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr			
690	695	700	
Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser			
705	710	715	720
His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser			
725	730	735	
Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr Ile Asn			
740	745	750	
Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met Leu Glu			
755	760	765	
Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp Phe Arg			
770	775	780	
Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu Val Asp			
785	790	795	800
Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser			
805	810	815	
Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe			

820 825 830
 Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala
 835 840 845

 His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu
 850 855 860

 Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr
 865 870 875 880

 Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp
 885 890 895

 Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn
 900 905 910

 Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile
 915 920 925

 Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe
 930 935 940

 Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe
 945 950 955 960

 Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile
 965 970 975

 Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu
 980 985 990

 Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro
 995 1000 1005

 Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu
 1010 1015 1020

 Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile
 1025 1030 1035

 Lys Gln Tyr
 1040

 <210> 53
 <211> 1041
 <212> PRT
 <213> Homo sapiens

 <400> 53

 Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu
 1 5 10 15

 Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg
 20 25 30

 Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu
 35 40 45

 Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr
 50 55 60

Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn
65 70 75 80

Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His
85 90 95

Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn
100 105 110

Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg
115 120 125

Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu
130 135 140

Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn
145 150 155 160

Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr
165 170 175

Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile
180 185 190

Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu
195 200 205

Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu
210 215 220

Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu
225 230 235 240

Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn
245 250 255

Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly
260 265 270

Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln
275 280 285

Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala
290 295 300

Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe
305 310 315 320

Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu
325 330 335

Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser
340 345 350

Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser
355 360 365

Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu
370 375 380

Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn

385	390	395	400
Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn			
405	410	415	
 Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro			
420	425	430	
 Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Phe Gln			
435	440	445	
 Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His			
450	455	460	
 Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala			
465	470	475	480
 Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile			
485	490	495	
 Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu			
500	505	510	
 Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe Ser Ala			
515	520	525	
 Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe			
530	535	540	
 Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp			
545	550	555	560
 Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His			
565	570	575	
 Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser			
580	585	590	
 His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys			
595	600	605	
 Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp			
610	615	620	
 Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn			
625	630	635	640
 Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn			
645	650	655	
 Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn			
660	665	670	
 Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro			
675	680	685	
 Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr			
690	695	700	
 Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser			
705	710	715	720
 His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser			

<210> 54
<211> 1059
<212> PRT
<213> Homo sapiens

<400> 54

Met Lys Glu Ser Ser Leu Gln Asn Ser Ser Cys Ser Leu Gly Lys Glu
1 5 10 15

Thr Lys Lys Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile
20 25 30

Phe Leu Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe
35 40 45

Ser Arg Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile
50 55 60

Ala Glu Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly
65 70 75 80

Lys Tyr Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile
85 90 95

Thr Asn Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu
100 105 110

Asn His Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln
115 120 125

Ser Asn Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn
130 135 140

Leu Arg Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser
145 150 155 160

Gly Leu Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile
165 170 175

Tyr Asn Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn
180 185 190

Leu Tyr Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr
195 200 205

Asn Ile Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu
210 215 220

Ser Leu Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser
225 230 235 240

Ser Leu Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser
245 250 255

Glu Glu Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser
260 265 270

Gly Asn Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys
275 280 285

Asp Gly Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu
290 295 300

Thr Gln Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile
305 310 315 320

Asn Ala Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu
325 330 335

Glu Phe Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr
340 345 350

Met Leu Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys
355 360 365

Gly Ser Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu
370 375 380

Leu Ser Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu
385 390 395 400

Arg Glu Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr
405 410 415

Ile Asn Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe
420 425 430

Gln Asn Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile
435 440 445

Ser Pro Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser
450 455 460

Phe Gln Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp
465 470 475 480

Pro His Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln
485 490 495

Cys Ala Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe
500 505 510

Phe Ile Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu
515 520 525

Asn Leu Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe
530 535 540

Ser Ala Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu
545 550 555 560

Asp Phe Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val
565 570 575

Leu Asp Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr
580 585 590

His His Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn
595 600 605

Leu Ser His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu

610	615	620
Ser Lys Ser Leu Val Glu	Leu Val Phe Ser Gly	Asn Arg Leu Asp Ile
625	630	635
640		
Leu Trp Asn Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu		
645	650	655
Lys Asn Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile		
660	665	670
Pro Asn Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His		
675	680	685
Ile Asn Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln		
690	695	700
Phe Pro Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe		
705	710	720
Leu Thr Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu		
725	730	735
Leu Ser His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu		
740	745	750
Val Ser Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr		
755	760	765
Ile Asn Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met		
770	775	780
Leu Glu Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp		
785	790	800
Phe Arg Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu		
805	810	815
Val Asp Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile		
820	825	830
Val Ser Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile		
835	840	845
Leu Phe Phe Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala		
850	855	860
Leu Ala His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val		
865	870	880
Cys Leu Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr		
885	890	895
Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr		
900	905	910
Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp		
915	920	925
Lys Asn Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu		
930	935	940
Ala Ile Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr		

945	950	955	960
Val Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr			
965	970		975
Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val			
980	985		990
Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu			
995	1000		1005
Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro			
1010	1015		1020
Asp Asn Pro Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn			
1025	1030		1035
Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val			
1040	1045		1050
Asp Ser Ile Lys Gln Tyr			
1055			

<210> 55
<211> 3220
<212> DNA
<213> murine

<400> 55		
attcagagtt ggatgttaag agagaaaacaa acgttttacc ttccctttgtc tatagaacat	60	
ggaaaaacatg ccccctcagt catggattct gacgtgcctt tgtctgctgt cctctggaac	120	
cagtgccatc ttccataaaag cgaactattc cagaagctat ccttgtgacg agataaggca	180	
caactccctt gtgattgcag aatgcaacca tcgtcaactg catgaagttc cccaaactat	240	
aggcaagtat gtgacaaaaca tagacttgc agacaatgcc attacacata taacgaaaga	300	
gtcctttcaa aagctgcaaa acctcactaa aatcgatctg aaccacaatg ccaaacaaca	360	
gcacccaaat gaaaataaaa atggtatgaa tattacagaa ggggcacttc tcagcctaag	420	
aatctaaaca gtttactgc tggaagacaa ccagttatat actatacctg ctgggttgcc	480	
tgagtctttg aaagaactta gcctaattca aaacaatata tttcaggtaa ctaaaaacaa	540	
cactttggg cttaggaact tgaaaagact ctatgggc tggaactgct attttaatg	600	
taatcaaacc tttaggttag aagatgggc attaaaaat cttatacact tgaaggtact	660	
ctcattatct ttcaataacc tttctatgt gcccccaaa ctaccaagtt ctctaaggaa	720	
acttttctg agtaatgcca aaatcatgaa catcaactcag gaagacttca aaggactgga	780	
aaatttaaca ttactagatc tgagtggaaa ctgtccaagg tgttacaatg ctccatttcc	840	
ttgcacacacct tgcaaggaaa actcatccat ccacatacat cctctggctt ttcaaagtct	900	
cacccaaacctt ctctatctaa acctttccag cactccctc aggacgattc ttctcacctg	960	
gtttgaaaat ctgtcaaattc tgaaggaact ccatttgaa ttcaactatt tagttcaaga	1020	

aattgcctcg gggcatttt taacaaaact acccagttt caaatccttg atttgtcctt 1080
caactttcaa tataaggaat atttacaatt tattaatatt tcctcaaatt tctctaagct 1140
tcgttctctc aagaagttgc acttaagagg ctatgtttc cgagaactta aaaagaagca 1200
tttcgagcat ctccagagtc ttccaaactt ggcaaccatc aacttggca ttaactttat 1260
tgagaaaatt gatttcaaag ctttccagaa ttttccaaa ctcgacgtt a tctatttatac 1320
aggaaatcgc atagcatctg tattagatgg tacagattat tcctcttggc gaaatcgtct 1380
tcggaaacct ctctcaacag acgatgatga gtttgcattt cacgtgaatt tttaccatag 1440
caccaaacct ttaataaaagc cacagtgtac tgcttatggc aaggccttgg atttaaatgg 1500
gaacaatatt ttcattattt ggaaaagcca atttgaaggt tttcaggata tcgcctgctt 1560
aaatctgtcc ttcaatgcc aatactcaagt gtttaatggc acagaattct cctccatgcc 1620
ccacattaaa tatttggatt taaccaacaa cagactagac tttgatgata acaatgcttt 1680
cagtgatctt cacgatctag aagtgcgttgc cctgagccac aatgcacact atttcagtat 1740
agcaggggta acgcaccgtc taggatttt ccagaactt aataaacctca ggggtttaaa 1800
cctgagccac aatggcattt acaccctcac agaggaaagt gagctgaaaa gcatctcact 1860
gaaagaattt gttttcagtg gaaatcgtct tgaccattt tggatgcaaa atgatggcaaa 1920
atactggtcc atttttaaaa gtctccagaa tttgatacgc ctggacttt catacaataa 1980
ccttcaacaa atccccaaatg gacatttcctt caatttgcctt cagagcctcc aagagttact 2040
tatcagtggt aacaaattac gtttctttaa ttggacatta ctccagtatt ttcctcacct 2100
tcacttgctg gatttacgaa gaaatgagct gtatttcta cccaaatgcc tatctaagtt 2160
tgcacattcc ctggagacac tgctactgag ccataatcat ttctctcacc taccctctgg 2220
cttcctctcc gaagccagga atctggtgca cctggatcta agtttcaaca caataaagat 2280
gatcaataaa tcctccctgc aaaccaagat gaaaacgaac ttgtctattc tggagctaca 2340
tgggaactat ttgactgca cgtgtgacat aagtgtttt cgaagctggc tagatgaaaa 2400
tctgaatatc acaatttcata aattggtaaa tggatgttgc tccaaatcctg gggatcaaaa 2460
atcaaagagt atcatgagcc tagatctcac gacttgcgtt tcggatacca ctgcagctgt 2520
cctgttttc ctcacattcc ttaccaccc catggttatg ttggctgctc tggttcacca 2580
cctgttttac tggatgtttt ggtttatcta tcacatgtgc tctgctaagt taaaaggcta 2640
caggacttca tccacatccc aaactttcta tggatgttgc tctgctaagt taaaaggcta 2700
tgcacatgtt actgactggg taatcaatga actgcgttac cacccatgttcaag agagtgaaga 2760
caaaagtgtc ctcccttgcgtt tagaggagag ggattggat ccaggattac ccatcattga 2820
taacccatg cagagcataa accagagcaa gaaaacaatc tttgttttaa ccaagaaata 2880

tgccaagagc tggaacttta aaacagctt ctacttggcc ttgcagaggc taatggatga	2940
gaacatggat gtgattattt tcatcctcct ggaaccagtg ttacagtact cacagtacct	3000
gaggcttcgg cagaggatct gtaagagctc catcctccag tggcccaaca atccaaagc	3060
agaaaacttg ttttggcaaa gtctgaaaaa tgtggtcttg actgaaaatg attcacggta	3120
tgacgatttg tacattgatt ccattaggca atactagtga tgggaagtca cgactctgcc	3180
atcataaaaa cacacagtt ctccttacaa tgaaccgaat	3220

<210> 56
<211> 3220
<212> DNA
<213> murine

<400> 56	
attcagagtt ggatgttaag agagaaaacaa acgttttacc ttcccttgc tatagaacat	60
ggaaaaacatg cccccctcagt catggattct gacgtgtttt tgtctgtgt cctctggAAC	120
cagtgccatc ttccataaaag cgaactattc cagaagctat ctttgtgacg agataaggca	180
caactcccctt gtgattgcag aatgcaacca tcgtcaactg catgaaggTC cccaaactat	240
aggcaagtat gtgacaaaaca tagacttgc agacaatgcc attacacata taacgaaaga	300
gtcctttcaa aagctgcaaa acctcaactaa aatcgatctg aaccacaatg ccaaacaaca	360
gcacccaaat gaaaataaaaa atggtatgaa tattacagaa ggggcacttc tcagcctaag	420
aaatctaaca gtttactgc tggaagacaa ccagttatat actatacctg ctgggttgcc	480
ttagtctttg aaagaactta gcctaattca aaacaatata tttcaggtaa ctaaaaacaa	540
cactttggg cttaggaact tggaaagact ctatTTGGC tggaaactgct attttaaatg	600
taatcaaacc tttaaggtag aagatgggc attaaaaat cttatacact tgaaggtact	660
ctcattatct ttcaataacc tttctatgt gccccccaaa ctaccaagtt ctctaaggaa	720
acttttctg agtaatgcca aaatcatgaa catcaactcag gaagacttca aaggactgga	780
aaatttaaca ttactagatc ttagtgaaa ctgtccaagg tggataatg ctccatttcc	840
ttgcacaccc tgcaggaaa actcatccat ccacatacat cctctggctt ttcaaggct	900
cacccaaactt ctctatctaa acctttccag cactccctc aggacgattc cttctacctg	960
gtttgaaaat ctgtcaaattc tgaaggaact ccattttgaa ttcaactatt tagttcaaga	1020
aattgcctcg ggggcatttt taacaaaact acccagttt caaatcctt atttgcctt	1080
caactttcaa tataaggaat atttacaatt tattaatatt tcctcaaatt tctctaagct	1140
tcgttctctc aagaagttgc acttaagagg ctatgtgttc cgagaactta aaaagaagca	1200
tttcgagcat ctccagagtc ttccaaactt ggcaaccatc aacttggca ttaactttat	1260

atcataaaaa cacacagctt ctccttacaa tgaaccgaat

3220

<210> 57
<211> 1032
<212> PRT
<213> murine

<400> 57

Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu
1 5 10 15

Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg
20 25 30

Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu
35 40 45

Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr
50 55 60

Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys
65 70 75 80

Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His
85 90 95

Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile
100 105 110

Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu
115 120 125

Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu
130 135 140

Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn
145 150 155 160

Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn
165 170 175

Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe
180 185 190

Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu
195 200 205

Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu
210 215 220

Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu
225 230 235 240

Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr
245 250 255

Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His
260 265 270

Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn
275 280 285

Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn
290 295 300

Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln
305 310 315 320

Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile
325 330 335

Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile
340 345 350

Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His
355 360 365

Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His
370 375 380

Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe
385 390 395 400

Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp
405 410 415

Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr
420 425 430

Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp
435 440 445

Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro
450 455 460

Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser
465 470 475 480

Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln
485 490 495

Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe
500 505 510

Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu
515 520 525

Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu
530 535 540

His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser
545 550 555 560

Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn
565 570 575

Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu
580 585 590

Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly

595	600	605
Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser		
610	615	620
Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn		
625	630	640
Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser		
645	650	655
Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp		
660	665	670
Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg		
675	680	685
Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser		
690	695	700
Leu Glu Thr Leu Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser		
705	710	720
Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe		
725	730	735
Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys		
740	745	750
Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr		
755	760	765
Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile		
770	775	780
Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln		
785	790	795
800		
Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp		
805	810	815
Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met		
820	825	830
Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp		
835	840	845
Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser		
850	855	860
Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys		
865	870	875
880		
Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu		
885	890	895
Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp		
900	905	910
Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn		
915	920	925
Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser		

930	935	940
Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp		
945	950	955
		960
Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln		
	965	970
		975
Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile		
	980	985
		990
Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser		
	995	1000
		1005
Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp		
	1010	1015
		1020
Leu Tyr Ile Asp Ser Ile Arg Gln Tyr		
	1025	1030
<210> 58		
<211> 1032		
<212> PRT		
<213> murine		
<400> 58		
Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu		
1	5	10
		15
Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg		
	20	25
		30
Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu		
	35	40
		45
Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr		
	50	55
		60
Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys		
65	70	75
		80
Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His		
	85	90
		95
Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile		
	100	105
		110
Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu		
	115	120
		125
Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu		
	130	135
		140
Lys Glu Leu Ser Leu Ile Gln Asn Ile Phe Gln Val Thr Lys Asn		
145	150	155
		160
Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn		
	165	170
		175
Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe		
	180	185
		190

Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu
195 200 205

Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu
210 215 220

Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu
225 230 235 240

Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr
245 250 255

Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His
260 265 270

Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn
275 280 285

Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn
290 295 300

Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln
305 310 315 320

Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile
325 330 335

Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile
340 345 350

Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His
355 360 365

Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His
370 375 380

Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe
385 390 395 400

Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp
405 410 415

Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr
420 425 430

Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp
435 440 445

Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro
450 455 460

Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser
465 470 475 480

Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln
485 490 495

Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe
500 505 510

Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu

515	520	525
Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu		
530	535	540
His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser		
545	550	555
Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn		
565	570	575
Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu		
580	585	590
Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly		
595	600	605
Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser		
610	615	620
Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn		
625	630	635
Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser		
645	650	655
Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp		
660	665	670
Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg		
675	680	685
Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser		
690	695	700
Leu Glu Thr Leu Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser		
705	710	715
Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe		
725	730	735
Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys		
740	745	750
Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr		
755	760	765
Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile		
770	775	780
Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln		
785	790	795
Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp		
805	810	815
Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met		
820	825	830
Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp		
835	840	845
Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser		

850	855	860
Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys		
865	870	875
Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu		
885	890	895
Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp		
900	905	910
Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn		
915	920	925
Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser		
930	935	940
Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp		
945	950	955
Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln		
965	970	975
Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile		
980	985	990
Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser		
995	1000	1005
Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp		
1010	1015	1020
Leu Tyr Ile Asp Ser Ile Arg Gln Tyr		
1025	1030	
<210> 59		
<211> 1032		
<212> PRT		
<213> murine		
<400> 59		
Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu		
1	5	10
15		
Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg		
20	25	30
Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu		
35	40	45
Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr		
50	55	60
Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys		
65	70	75
80		
Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His		
85	90	95
Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile		
100	105	110

Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu
115 120 125

Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu
130 135 140

Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn
145 150 155 160

Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn
165 170 175

Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe
180 185 190

Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu
195 200 205

Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu
210 215 220

Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu
225 230 235 240

Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr
245 250 255

Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His
260 265 270

Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn
275 280 285

Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn
290 295 300

Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln
305 310 315 320

Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile
325 330 335

Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile
340 345 350

Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His
355 360 365

Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His
370 375 380

Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe
385 390 395 400

Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp
405 410 415

Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr
420 425 430

Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp

435	440	445
Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro		
450	455	460
Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser		
465	470	480
Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln		
485	490	495
Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe		
500	505	510
Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu		
515	520	525
Thr Asn Asn Arg Leu Asp Phe Asp Asn Asn Ala Phe Ser Asp Leu		
530	535	540
His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser		
545	550	560
Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn		
565	570	575
Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu		
580	585	590
Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly		
595	600	605
Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser		
610	615	620
Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn		
625	630	640
Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser		
645	650	655
Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp		
660	665	670
Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg		
675	680	685
Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser		
690	695	700
Leu Glu Thr Leu Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser		
705	710	720
Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe		
725	730	735
Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys		
740	745	750
Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr		
755	760	765
Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile		

770	775	780
Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln		
785	790	795
Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp		
805	810	815
Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met		
820	825	830
Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp		
835	840	845
Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser		
850	855	860
Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys		
865	870	875
Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu		
885	890	895
Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp		
900	905	910
Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn		
915	920	925
Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser		
930	935	940
Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp		
945	950	955
Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln		
965	970	975
Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile		
980	985	990
Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser		
995	1000	1005
Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp		
1010	1015	1020
Leu Tyr Ile Asp Ser Ile Arg Gln Tyr		
1025	1030	

<210> 60
<211> 3352
<212> DNA
<213> Homo sapiens

<400> 60	
aggctggtat aaaaatctta cttcctctat tctctgagcc gctgctgccct ctgtggaaag	60
ggacctcgag tgtgaagcat cttccctgt agctgctgtc cagtctgccct gccagaccct	120
ctggagaagc ccctgcccc cagcatgggt ttctgcccga gcgccctgca cccgctgtct	180

ctcctggtgc aggccatcat gctggccatg accctggccc tgggtacctt gcctgccttc	240
ctaccctgtg agctccagcc ccacggcctg gtgaactgca actggctgtt cctgaagtct	300
gtgccccact tctccatggc agcacccctgt ggcaatgtca ccagccttcc cttgtcctcc	360
aaccgcatcc accacctcca tgattctgac tttgccacc tgcccagctt gcgccatctc	420
aacctcaagt ggaactgccc gccgggttggc ctcagccca tgcacttccc ctgcacatg	480
accatcgagc ccagcacctt cttggctgtg cccaccctgg aagagctaaa cctgagctac	540
aacaacatca tgactgtgcc tgcgctgccc aaatccctca tatccctgtc ctcagccat	600
accaacatcc ttagtgcata ctctgccagc ctgcggggcc tgcatgcctt gcgccctta	660
ttagatggacg gcaactgtta ttacaagaac ccctgcaggc aggcaactgga ggtggccccc	720
ggtgccctcc ttggcctggg caacctcacc cacctgtcac tcaagtacaa caacctcact	780
gtggtgccccc gcaacactgccc ttccagcctg gagtatctgc tggatgtccta caaccgcac	840
gtcaaactgg cgccctgagga cctggccaat ctgaccgccc tgcgtgtgct cgatgtggc	900
ggaaattgcc gccgctgcga ccacgctccc aaccctgca tggagtgccc tcgtcacttc	960
ccccagctac atcccgatac cttagccac ctgagccgtc ttgaaggcct ggtgttgaag	1020
gacagtttctc ttcctggct gaatgccagt tgggtccgtg ggctggaaaa cctccgagtg	1080
ctggacctga gtgagaactt cctctacaaa tgcataacta aaaccaaggc ctccaggc	1140
ctaacacagc tgcgcagact taacctgtcc ttcaattacc aaaagaggggt gtcctttgcc	1200
cacctgtctc tggcccttc cttagggagc ctggcgccc tgaaggagct ggacatgcac	1260
ggcatcttc tccgctact cgatgagacc acgctccggc cactggcccg cctgcccatt	1320
ctccagactc tgcgtctgca gatgaacttc atcaaccagg cccagctcgg catttcagg	1380
gccttcctg gcctgcgcta cgtggacctg tcggacaacc gcatcagcgg agcttcggag	1440
ctgacagcca ccatggggga ggcagatgga gggagaagg tctggctgca gcctggggac	1500
cttgcctccgg ccccagtgga cactcccagc tctgaagact tcaggccaa ctgcagcacc	1560
ctcaacttca cttggatct gtcacggAAC aacctggta ccgtgcagcc ggagatgttt	1620
gcccagctct cgacactgca gtgcctgcgc ctgagccaca actgcacatc gcaggcagtc	1680
aatggctccc agttcctgcc gctgaccggc ctgcaggtgc tagacctgtc ccgcaataag	1740
ctggacctct accacgagca ctcattcacg gagctaccgc gactggaggc cctggacctc	1800
agctacaaca gccagccctt tggcatgcag ggcgtggcc acaacttcag cttcgtggct	1860
cacctgcgca ccctgcgcca ctcagcctg gcccacaaca acatccacag ccaagtgtcc	1920
cagcagctct gcagttacgtc gctgcggggcc ctggacttca gcgcaatgc actggccat	1980
atgtggcccg agggagacct ctatctgcac ttcttccaag gcctgagcgg tttgtatctgg	2040
ctggacttgt cccagaaccg ctcgcacacc ctcctggccc aaaccctgca caaccctcccc	2100

aagaggctac aggtgctgcg tctccgtgac aattacctgg ctttctttaa gtggtgaggc	2160
ctccacttcc tgcccaaact ggaagtccctc gacctggcag gaaaccggct gaaggccctg	2220
accaatggca gcctgcctgc tggcacccgg ctccggaggc tggatgtcag ctgcaacagc	2280
atcagcttcg tggccccccgg cttttttcc aaggccaagg agctgcgaga gctcaacctt	2340
agcgccaacg ccctcaagac agtggaccac tcctggtttgc ggccctggc gagtgccctg	2400
caaatactag atgtaagcgc caaccctctg cactgcgcct gtggggcggc ctttatggac	2460
ttcctgctgg aggtgcaggc tgccgtgccc ggtctgccc gccgggtgaa gtgtggcagt	2520
ccggggccagc tccagggcct cagcatctt gcacaggacc tgccgcctctg cctggatgag	2580
gccctctcct gggactgttt cgccctctcg ctgctggctg tggctctggg cctgggtgtg	2640
cccatgctgc atcacctctg tggctggac ctctggtaact gttccacact gtgcctggcc	2700
tggctccct ggcggggcg gcaaagtggg cgagatgagg atgcctgcc ctacgatgcc	2760
ttcgtggct tcgacaaaac gcagagcgcgtt gttccacact gttccacact gtgcctggcc	2820
ggcagctgg aggagtgccg tggcgttgc gcactccgccc tggctctggg ggaacgcgac	2880
tggctgcctg gcaaaaccct ctttggaaac ctgtggcctt cggctatgg cagccgcaag	2940
acgctgtttt tgctggccca cacggaccgg gtcagtggtc tcttgcgcgc cagttcctg	3000
ctggcccagc agcgccctgct ggaggaccgc aaggacgtcg tggctgttgt gatcctgagc	3060
cctgacggcc gccgctcccg ctacgtgcgg ctgcgcgcgc gctctggcc ccagagtgtc	3120
ctcctctggc cccaccagcc cagtggtcag cgcagttctt gggcccgact gggcatggcc	3180
ctgaccaggg acaaccacca cttctataac cgaaacttctt gcaaggacc cacggccgaa	3240
tagccgttag ccgaaatcct gcacggtgcc acctccacac tcacctcacc tctgcctgcc	3300
tggtctgacc ctccccctgct cgcctccctc accccacacc tgacacagag ca	3352

<210> 61
<211> 3257
<212> DNA
<213> Homo sapiens

<400> 61	
ccgctgctgc ccctgtggga agggacctcg agtgtgaagc atccttcctt gtagctgt	60
tccagtctgc cgcgcagacc ctctggagaa gcccctgccc cccagcatgg gtttctgccc	120
cagcgcctgt caccgcgtgt ctctctgtgt gcaggccatc atgctggcca tgaccctggc	180
cctgggtacc ttgcctgcct tcctaccctg tgagctccag cccccacggcc tggtaactg	240
caactggctg ttccctgaagt ctgtgcggcc cttctccatg gcagcaccccc gtggcaatgt	300
caccagcctt tccttgcctt ccaaccgcatt ccaccaccc tcatgattctg actttgcctt	360

cctgcccagc ctgcggcata tcaaccaa gtgaaactgc cccgcgggttgc gcctcagcccc	420
catgcaacttc ccctgccaca tgaccatcgac gcccagcacc ttcttggtcg tgcccaccc	480
ggaagagcta aacctgagct acaacaacat catgactgtgc cctgcgcgtgc ccaaattccct	540
catatccctg tccctcagcc ataccaacat cctgatgcta gactctgcca gcctcgccgg	600
cctgcattgcc ctgcgcgttcc tattcatgga cggcaactgttattacaaga accccctgcag	660
gcaggcactg gaggtggccc cgggtgccttgc ggcaacctca cccacctgtc	720
actcaagtac aacaacctca ctgtggtgcc cgcacacccctgc cttccagcc tggagtatct	780
gctgttgtcc tacaaccgca tcgtcaaact ggcgcctgag gacctggcca atctgaccgc	840
cctgcgtgtgc ctcgatgtgg gcggaaatttgc gaccacgctc ccaacccctg	900
catggagtgc cctcgtcaact tccccagct acatcccgat accttcagcc acctgagccg	960
tcttgaaggc ctgggtgttga aggacagttc tcttcctgg ctgaatgcca gttgggtccg	1020
tgggctggga aacctccgag tgctggaccc gagtgagaac ttcccttata aatgcatacac	1080
taaaaaccaag gccttccagg gcctaacaca gctgcgcaag cttaacctgt cttcaatta	1140
ccaaaagagg gtgtccttttgc cccacctgtc tctggccctt tccttcggga gcctggtcgc	1200
cctgaaggag ctggacatgc acggcatctt cttccgctca ctcgatgaga ccacgctccg	1260
gccactggcc cgccctgccc tgctccagac tctgcgtctg cagatgaact tcatcaacca	1320
ggcccagctc ggcacatttca gggccttccc tggcctgcgc tacgtggacc tgtcggacaa	1380
ccgcatcagc ggagcttcgg agctgacagc caccatgggg gaggcagatg gaggggagaa	1440
ggtctggctg cagcctgggg accttgcgtcc ggccccagtg gacactccca gctctgaaga	1500
cttcaggccc aactgcagca ccctcaactt caccttggat ctgtcacgga acaacctgg	1560
gaccgtgcag cggagatgt ttgcccagct ctcgcacccgt cagtcgcgtgc gcctgagcc	1620
caactgcata tcgcaggcag tcaatggctc ccagttctg cccgtgacccg gtctgcaggt	1680
gctagacctg tcccacaata agctggaccc ctaccacgag cactcattca cggagctacc	1740
acgactggag gccctggacc ttagtacaa cagccagccc tttggcatgc agggcgtgg	1800
ccacaacttc agcttcgtgg ctcacccgtcg cacccgtcgcc cacctcagcc tggcccacaa	1860
caacatccac agccaagtgt cccagcagct ctgcagtgacg tcgctgcggg ccctggactt	1920
cagcggcaat gcactggccc atatgtggc cgagggagac ctctatctgc acttcttcca	1980
aggcctgagc ggtttgatct ggctggactt gtcccagaac cgcctgcaca ccctcctgcc	2040
ccaaacccctg cgcaacccctcc ccaagagccct acaggtgtcg cgtctccgtg acaattaccc	2100
ggccttctt aagtgggtgga gcctccactt cctgccccaaa ctggaaagtcc tcgacccgtgc	2160
aggaaaccag ctgaaggccc tgaccaatgg cagccctgcct gctggcaccggcgc	2220
gctggatgtc agctgcacaca gcatcagctt cgtggccccc ggcttctttt ccaaggccaa	2280

ggagctgcga gagctcaacc ttagcgccaa cgccctcaag acagtggacc actcctggtt	2340
tggggccctg gcgagtgccc tgcaaatact agatgttaagc gccaaccctc tgcaactgcgc	2400
ctgtggggcg gccttatgg acttcctgct ggaggtgcag gctgccgtgc ccggctcgcc	2460
cagccgggtg aagtgtggca gtccgggcca gtcaggagggc cttagcatct ttgcacagga	2520
cctgcgcctc tgcctggatg aggccctctc ctgggactgt ttcgcctct cgctgtggc	2580
tgtggctctg ggcctgggtg tgcccatgct gcatcacctc tgtggctggg acctctggta	2640
ctgcttccac ctgtgcctgg cctggcttcc ctgggggggg cggcaaagtg ggcgagatga	2700
ggatgccctg ccctacgatg cttcgtggt cttcgacaaa acgcagagcg cagtggcaga	2760
ctgggtgtac aacgagcttc gggggcagct ggaggagtgc cgtggcgct gggcaetccg	2820
cctgtgcctg gaggaacgcg actggctgcc tggcaaaacc ctcttgaga acctgtggc	2880
ctcggtctat ggcagccgca agacgctgtt tgtgtggcc cacacggacc gggtcagtgg	2940
tctcttgcgc gccagcttcc tgctggccca gcagcgctg ctggaggacc gcaaggacgt	3000
cgtggtgctg gtgatcctga gcccgtacgg cggccgctcc cgctacgtgc ggctgcgcca	3060
gcccctctgc cggcagagtg tcctcctctg gccccaccag cccagtggtc agcgacgctt	3120
ctgggcccag ctgggcatgg ccctgaccag ggacaaccac cacttctata accggaaactt	3180
ctgccaggga cccacggccg aatagccgtg agccggaatc ctgcacggtg ccacacctccac	3240
actcacctca cctctqc	3257

<210> 62
<211> 1032
<212> PRT
<213> *Homo sapiens*

<400> 62

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn
50 55 60

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp
65 70 75 80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp
85 . 90 95

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met

100 105 110
Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser
130 135 140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser
145 150 160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu
225 230 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe
260 265 270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe
290 295 300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 320

Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala
340 345 350

His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu
370 375 380

Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met
385 390 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu
420 425 430

Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu

435	440	445
Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu		
450	455	460
Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser		
465	470	475
Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser		
485	490	495
His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val		
500	505	510
Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu		
515	520	525
Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu		
530	535	540
Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly		
545	550	560
Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr		
565	570	575
Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser		
580	585	590
Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn		
595	600	605
Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe		
610	615	620
Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu		
625	630	640
His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln		
645	650	655
Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser		
660	665	670
Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg		
675	680	685
Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg		
690	695	700
Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe		
705	710	720
Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala		
725	730	735
Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu		
740	745	750
Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala		
755	760	765
Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu		

770	775	780
Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser		
785	790	795
800		
Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp		
805	810	815
820		
Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val		
825	830	835
Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His		
835	840	845
Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp		
850	855	860
Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln		
865	870	875
880		
Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu		
885	890	895
Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp		
900	905	910
Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr		
915	920	925
Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser		
930	935	940
Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu		
945	950	955
960		
Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg		
965	970	975
Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val		
980	985	990
Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln		
995	1000	1005
Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg		
1010	1015	1020
Asn Phe Cys Gln Gly Pro Thr Ala Glu		
1025	1030	
<210> 63		
<211> 1032		
<212> PRT		
<213> Homo sapiens		
<400> 63		
Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln		
1	5	10
15		
Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe		
20	25	30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu
 35 40 45
 Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn
 50 55 60
 Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp
 65 70 75 80
 Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp
 85 90 95
 Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met
 100 105 110
 Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
 115 120 125
 Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser
 130 135 140
 Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser
 145 150 155 160
 Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly
 165 170 175
 Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro
 180 185 190
 Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
 195 200 205
 Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr
 210 215 220
 Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu
 225 230 235 240
 Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
 245 250 255
 Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe
 260 265 270
 Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly
 275 280 285
 Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe
 290 295 300
 Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu
 305 310 315 320
 Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu
 325 330 335
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala
 340 345 350
 His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu

355 360 365
Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu
370 375 380

Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu
420 425 430

Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu
435 440 445

Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu
450 455 460

Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser
465 470 475 480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser
485 490 495

His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val
500 505 510

Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu
515 520 525

Ser His Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu
530 535 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly
545 550 555 560

Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr
565 570 575

Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser
580 585 590

Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn
595 600 605

Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe
610 615 620

Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu
625 630 635 640

His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln
645 650 655

Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser
660 665 670

Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Gln
675 680 685

Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg

690	695	700
Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe		
705	710	715
Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala		
725	730	735
Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu		
740	745	750
Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala		
755	760	765
Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu		
770	775	780
Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser		
785	790	795
Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp		
805	810	815
Asp Cys Phe Ala Leu Ser Leu Ieu Ala Val Ala Leu Gly Leu Gly Val		
820	825	830
Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His		
835	840	845
Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp		
850	855	860
Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln		
865	870	875
Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu		
885	890	895
Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp		
900	905	910
Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr		
915	920	925
Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser		
930	935	940
Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu		
945	950	955
Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg		
965	970	975
Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val		
980	985	990
Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln		
995	1000	1005
Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg		
1010	1015	1020
Asn Phe Cys Gln Gly Pro Thr Ala Glu		

1025 1030
<210> 64
<211> 333
<212> PRT
<213> Homo sapiens

<400> 64

Met Pro Met Lys Trp Ser Gly Trp Arg Trp Ser Trp Gly Pro Ala Thr
1 5 10 15

His Thr Ala Leu Pro Pro Pro Gln Gly Phe Cys Arg Ser Ala Leu His
20 25 30

Pro Leu Ser Leu Leu Val Gln Ala Ile Met Leu Ala Met Thr Leu Ala
35 40 45

Leu Gly Thr Leu Pro Ala Phe Leu Pro Cys Glu Leu Gln Pro His Gly
50 55 60

Leu Val Asn Cys Asn Trp Leu Phe Leu Lys Ser Val Pro His Phe Ser
65 70 75 80

Met Ala Ala Pro Arg Gly Asn Val Thr Ser Leu Ser Leu Ser Ser Asn
85 90 95

Arg Ile His His Leu His Asp Ser Asp Phe Ala His Leu Pro Ser Leu
100 105 110

Arg His Leu Asn Leu Lys Trp Asn Cys Pro Pro Val Gly Leu Ser Pro
115 120 125

Met His Phe Pro Cys His Met Thr Ile Glu Pro Ser Thr Phe Leu Ala
130 135 140

Val Pro Thr Leu Glu Glu Leu Asn Leu Ser Tyr Asn Asn Ile Met Thr
145 150 155 160

Val Pro Ala Leu Pro Lys Ser Leu Ile Ser Leu Ser Leu Ser His Thr
165 170 175

Asn Ile Leu Met Leu Asp Ser Ala Ser Leu Ala Gly Leu His Ala Leu
180 185 190

Arg Phe Leu Phe Met Asp Gly Asn Cys Tyr Tyr Lys Asn Pro Cys Arg
195 200 205

Gln Ala Leu Glu Val Ala Pro Gly Ala Leu Leu Gly Leu Gly Asn Leu
210 215 220

Thr His Leu Ser Leu Lys Tyr Asn Asn Leu Thr Val Val Pro Arg Asn
225 230 235 240

Leu Pro Ser Ser Leu Glu Tyr Leu Leu Leu Ser Tyr Asn Arg Ile Val
245 250 255

Lys Leu Ala Pro Glu Asp Leu Ala Asn Leu Thr Ala Leu Arg Val Leu
260 265 270

Asp Val Gly Gly Asn Cys Arg Arg Cys Asp His Ala Pro Asn Pro Cys
275 280 285

Met Glu Cys Pro Arg His Phe Pro Gln Leu His Pro Asp Thr Phe Ser
290 295 300

His Leu Ser Arg Leu Glu Gly Leu Val Leu Lys Asp Ser Ser Leu Ser
305 310 315 320

Trp Leu Asn Ala Ser Trp Phe Arg Gly Leu Gly Asn Leu
325 330

<210> 65
<211> 216
<212> PRT
<213> Homo sapiens

<400> 65

Met Leu Tyr Ser Ser Cys Lys Ser Arg Leu Leu Asp Ser Val Glu Gln
1 5 10 15

Asp Phe His Leu Glu Ile Ala Lys Lys Gly Phe Cys Arg Ser Ala Leu
20 25 30

His Pro Leu Ser Leu Leu Val Gln Ala Ile Met Leu Ala Met Thr Leu
35 40 45

Ala Leu Gly Thr Leu Pro Ala Phe Leu Pro Cys Glu Leu Gln Pro His
50 55 60

Gly Leu Val Asn Cys Asn Trp Leu Phe Leu Lys Ser Val Pro His Phe
65 70 75 80

Ser Met Ala Ala Pro Arg Gly Asn Val Thr Ser Leu Ser Leu Ser Ser
85 90 95

Asn Arg Ile His His Leu His Asp Ser Asp Phe Ala His Leu Pro Ser
100 105 110

Leu Arg His Leu Asn Leu Lys Trp Asn Cys Pro Pro Val Gly Leu Ser
115 120 125

Pro Met His Phe Pro Cys His Met Thr Ile Glu Pro Ser Thr Phe Leu
130 135 140

Ala Val Pro Thr Leu Glu Glu Leu Asn Leu Ser Tyr Asn Asn Ile Met
145 150 155 160

Thr Val Pro Ala Leu Pro Lys Ser Leu Ile Ser Leu Ser Leu Ser His
165 170 175

Thr Asn Ile Leu Met Leu Asp Ser Ala Ser Leu Ala Gly Leu His Ala
180 185 190

Leu Arg Phe Leu Phe Met Asp Gly Asn Cys Tyr Tyr Lys Asn Pro Cys
195 200 205

Arg Gln Ala Leu Glu Val Ala Pro
210 215

<210> 66

<211> 117
<212> PRT
<213> Homo sapiens

<400> 66

Met Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala
1 5 10 15
Phe Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp
20 25 30
Leu Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly
35 40 45
Asn Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His
50 55 60
Asp Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys
65 70 75 80
Trp Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His
85 90 95
Met Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu
100 105 110
Leu Asn Leu Ser Tyr
115

<210> 67
<211> 1032
<212> PRT
<213> Homo sapiens

<400> 67

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15
Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
20 25 30
Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu
35 40 45
Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn
50 55 60
Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp
65 70 75 80
Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp
85 90 95
Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met
100 105 110
Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser
130 135 140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser
145 150 155 160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe
260 265 270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe
290 295 300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala
340 345 350

His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu
370 375 380

Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu
420 425 430

Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu
435 440 445

Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu

450	455	460
Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser		
465	470	475
Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser		
485	490	495
His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val		
500	505	510
Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu		
515	520	525
Ser His Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu		
530	535	540
Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly		
545	550	555
Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr		
565	570	575
Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser		
580	585	590
Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn		
595	600	605
Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe		
610	615	620
Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu		
625	630	635
His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln		
645	650	655
Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser		
660	665	670
Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Gln		
675	680	685
Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg		
690	695	700
Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe		
705	710	715
720		
Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala		
725	730	735
Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu		
740	745	750
Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala		
755	760	765
Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu		
770	775	780
Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser		

785	790	795	800
Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp			
805	810	815	
Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val			
820	825	830	
Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His			
835	840	845	
Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp			
850	855	860	
Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln			
865	870	875	880
Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu			
885	890	895	
Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp			
900	905	910	
Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr			
915	920	925	
Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser			
930	935	940	
Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu			
945	950	955	960
Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg			
965	970	975	
Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val			
980	985	990	
Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln			
995	1000	1005	
Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg			
1010	1015	1020	
Asn Phe Cys Gln Gly Pro Thr Ala Glu			
1025	1030		
<210> 68			
<211> 3200			
<212> DNA			
<213> murine			
<400> 68			
tgtcagaggg agcctcgaaa gaatcctcca tctcccaaca tggttctccg tcgaaggact			60
ctgcacccct tgtccctcct ggtacaggct gcagtgcgtt ctgagactct ggccctgggt			120
accctgcctg ctttcctacc ctgtgagctg aagcctcatg gcctgggttga ctgcaattgg			180
ctgttcctga agtctgtacc ccgtttctct gcggcagcat cctgctccaa catcacccgc			240
ctctccttga tctccaaaccg tatccaccac ctgcacaact ccgacttcgt ccacctgtcc			300

aacctgcggc agctgaacct caagtggAAC tgccaccca ctggccttag ccccctgcac	360
ttctcttgcC acatgaccat tgagcccaga accttcctgg ctatgcgtac actggaggag	420
ctgaacctga gctataatgg tatcaccact gtgccccgac tgcccagctc cctggtaat	480
ctgagcctga gccacaccaa catcctggtt ctagatgcta acagcctcgc cggcctatac	540
agcctgcgcg ttctttcat ggacggAAC tgctactaca agaaccctg cacaggagcg	600
gtgaaggta ccccaggcgc cctcctggc ctgagcaatc tcacccatct gtctctgaag	660
tataacaacc tcacaaaggta gccccccaa ctgccccca gcctggagta cctcctggtg	720
tcctataacc tcattgtcaa gctggggcct gaagacctgg ccaatctgac ctcccttcga	780
gtactttagt tggtggaa ttgcgtcgc tgcgaccatg ccccaatcc ctgtatagaa	840
tgtggccaaa agtccctcca cctgcacccct gagaccttcc atcacctgag ccacatggaa	900
ggcctggtgc tgaaggacag ctctctccat acactgaact cttcctggtt ccaaggcttg	960
gtcaacctct cggtgctggc cctaagcgcg aactttctct atgaaagcat caaccacacc	1020
aatgccttcc agaacctaac ccgcctgcgc aagctcaacc tgtccttcaa ttaccgcaag	1080
aaggtatcct ttgcccccct ccacctggca agttccttca agaacctgggt gtcactgcag	1140
gagctgaaca tgaacggcat cttctccgc tcgctcaaca agtacacgct cagatggctg	1200
gccgatctgc ccaaactcca cactctgcat cttcaatga acttcatcaa ccaggcacag	1260
ctcagcatct ttggtagccctt ccgagccctt cgctttgtgg acttgcaga caatgcatac	1320
agtggccctt caacgctgtc agaagccacc cctgaagagg cagatgtgc agagcaggag	1380
gagctgttgt ctgcggatcc tcacccagct ccactgagca cccctgcttc taagaacttc	1440
atggacaggt gtaagaactt caagttcacc atggacctgt ctcggAACAA cctggtgact	1500
atcaagccag agatgttgtt caatctctca cgccctccagt gtcttagcct gagccacaac	1560
tccattgcac aggctgtcaa tggctctcag ttccgtccgc tgactaatct gcaggtgctg	1620
gacctgtccc ataacaaact ggacttgtac cactggaaat cgttcagtga gctaccacag	1680
ttgcaggccc tggacctgag ctacaacagc cagcccttta gcatgaaggg tataggccac	1740
aatttcagtt ttgtggccca tctgtccatg ctacacagcc ttgcctggc acacaatgac	1800
attcataccc gtgtgtcctc acatctcaac agcaactcag tgaggttct tgacttcagc	1860
ggcaacggta tggccgcata gttggatgag gggggccctt atctccattt cttccaaggc	1920
ctgagtgccc tgctgaagct ggacctgtct caaaataacc tgcatatcct cggccccag	1980
aacctgaca acctccccaa gagcctgaag ctgctgagcc tccgagacaa ctacatatct	2040
ttctttaact ggaccagtct gtccttcctg cccaaacctgg aagtccctaga cctggcaggc	2100
aaccagctaa aggccctgac caatggcacc ctgcctaattg gcaccctcct ccagaaactg	2160

gatgtcagca gcaacagtat cgtctctgtg gtcccagcct tttcgctct ggccgtcgag	2220
ctgaaagagg tcaaccttag ccacaacatt ctcaagacgg tggatcgctc ctgggttggg	2280
cccattgtga tgaacctgac agttctagac gtgagaagca accctctgca ctgtgcctgt	2340
ggggcagcct tcgttagactt actgttggag gtgcagacca aggtgcctgg cctggctaatt	2400
gtgtgaagt gtggcagccc cggccagctg cagggccgta gcatttcgc acaggacctg	2460
cggctgtgcc tggatgaggt cctcttttg gactgcttg gccttcact cttggctgtg	2520
gccgtggca tgggtgtgcc tatactgcac catctctgctg gctggacgt ctggtactgt	2580
tttcatctgt gcctggcatg gctacctttg ctggccgca gccgacgcag cgcccaagct	2640
ctccccatg atgccttcgt ggtgttcgt aaggcacaga gcgcagttgc ggactgggtg	2700
tataacgagc tgccgggtgcg gctggaggag cggcgccgcg gccgagccct acgcttgtgt	2760
ctggaggacc gagattggct gcctggccag acgctttcg agaacctctg ggctccatc	2820
tatggagcc gcaagactct atttgtgtcg gcccacacgg accgcgtcag tggcctcctg	2880
cgcaccagct tcctgctggc tcagcagegc ctgttggaaag accgcaagga cgtgggtgt	2940
ttgggtatcc tgcgtccgga tgcccacccgc tcccgctatg tgcgactgcg ccagcgtctc	3000
tgccgcccaga gtgtgtctt ctggcccccag cagcccaacg ggcagggggg cttctggcc	3060
cagctgagta cagccctgac tagggacaac cgccacttct ataaccagaa cttctgcccgg	3120
ggacctacag cagaatagct cagagcaaca gctggaaaca gctgcattt catgcctggt	3180
tcccgagttg ctctgcctgc	3200

<210> 69
<211> 3471
<212> DNA
<213> murine

<400> 69	
tgaaagtgtc acttcctcaa ttctctgaga gaccctggtg tggAACATCA ttctctgccg	60
cccagttgt cagagggaga ctggggagaa tcctccatct cccaacatgg ttctccgtcg	120
aaggactctg cacccttgcg ccctcctggt acaggctgca gtgctggctg agactctggc	180
cctgggtacc ctgcctgcct tcctaccctg tgagctgaag cctcatggcc tgggtggactg	240
caattggctg ttctgtatct ctgtaccccg tttctctgctg gcagcatact gctccaaat	300
cacccgcctc tcctgtatct ccaaccgtat ccaccacctg cacaactccg acttcgtcca	360
cctgtccaaac ctgcggcagc tgaacctcaa gtggaaactgt ccacccactg gccttagccc	420
cctgcacttc tcttggccaca tgaccattga gcccagaacc ttctggctt tgcgtacact	480
ggaggagctg aacctgagct ataatggtat caccactgtg ccccgactgc ccagctccct	540

ggtaatctg agcctgagcc acaccaacat cctggttcta gatgctaaca gcctcgccgg	600
cctatacagc ctgcgcgttc tcttcatgga cggaaactgc tactacaaga accctgcac	660
aggagcggtg aaggtgaccc caggcgccct cctgggcctg agcaatctca cccatctgtc	720
tctgaagtat aacaacctca caaagggtgcc cggccaactg cccccagcc tggagtacct	780
cctgggtgtcc tataacctca ttgtcaagct ggggcctgaa gacctggcca atctgacctc	840
ccttcagta cttgatgtgg gtgggaattt ccgtcgctgc gaccatgccc ccaatccctg	900
tatagaatgt ggccaaaagt ccctccaccc gcaccctgag accttccatc acctgagcca	960
tctgaaaggc ctggtgctga aggacagctc tctccatata ctgaactctt cctggttcca	1020
aggctggtc aacctctcg tgcgtggaccc aagcgagaac tttctctatg aaagcatcaa	1080
ccacaccaat gcctttcaga acctaaccgg cctgcgcag ctcaacctgt ccttcaatta	1140
ccgcaagaag gtatcctttg cccgcctcca cctggcaagt tccttcaaga acctgggtgc	1200
actgcaggag ctgaacatga acggcatctt cttccgctcg ctcaacaatg acacgctcag	1260
atggctggcc gatctgccc aactccacac tctgcacatcc caaatgaact tcatcaacca	1320
ggcacagctc agcatctttg gtaccttccg agcccttgc tttgtggact tgtcagacaa	1380
tcgcacatcgt gggccttcaa cgctgtcaga agccacccct gaagaggcag atgatgcaga	1440
gcaggaggag ctgttgtctg cggatcctca cccagctcca ctgagcaccc ctgcttctaa	1500
gaacttcatg gacaggtgtt agaacttcaa gttcaccatg gacctgtctc ggaacaacct	1560
ggtgactatc aagccagaga tgtttgc tctctcacgc ctccagtgtc tttagcctgag	1620
ccacaactcc attgcacagg ctgtcaatgg ctctcagttc ctgcccgtga ctaatctgca	1680
ggtgcggac ctgtcccata acaaactgga cttgtaccac tggaaatcgt tcagtgagct	1740
accacagttt caggccctgg acctgagcta caacagccag cccttttagca tgaagggtat	1800
aggccacaat ttcatccatct tgaccatct gtccatgcta cagagcctta gcctggcaca	1860
caatgacatt catacccggtg tgtcctcaca tctcaacagc aactcagtgt ggtttcttga	1920
cttcagcggc aacggtatgg gccgcgtgt ggttggggg ggcctttatc tccatttctt	1980
ccaaggcctg agtggcctgc tgaagctgga cctgtctcaa aataacctgc atatcctccg	2040
gccccagaac ctgacaacc tccccaaagag cctgaagctg ctgagcctcc gagacaacta	2100
cctatcttc tttaactgga ccagtctgtc ctccatcccc aacctggaaag tcctagaccc	2160
ggcaggcaac cagctaaagg ccctgaccaa tggcaccctg cctaatggca ccctccctca	2220
gaaactcgtatgtc acagtatcgt ctctgtggc ccagccttct tcgcgttggc	2280
ggtcgagctg aaagaggtca acctcagcca caacattctc aagacggtgg atcgcctctg	2340
gtttggccccc attgtatgtt acctgacagt tctagacgtg agaagcaacc ctctgcactg	2400
tgccctgtggg gcagccttcg tagacttact gttggaggtg cagaccaagg tgcctggcc	2460

ggctaatggt gtgaagtgtg gcagccccgg ccagctgcag ggccgttagca tcttcgcga	2520
ggacctgcgg ctgtgcctgg atgaggctct ctcttggac tgctttggcc tttcactctt	2580
ggctgtggcc gtgggcattgg tggtgccatat actgcaccat ctctgcggct gggacgtctg	2640
gtactgtttt catctgtgcc tggcatggct acctttgctg gcccgccagcc gacgcagcgc	2700
ccaaactctc ccttatgatg ctttcgtggt gttcgataag gcacagagcg cagttgccga	2760
ctgggtgtat aacgagctgc ggggtgcggct ggaggagcgg cgccgtcgcc gagccctacg	2820
cttgtgtctg gaggaccgag attggctgcc tggccagacg ctcttcgaga acctctggc	2880
ttccatctat gggagccgca agactctatt tgtgtggcc cacacggacc gcgtcagtgg	2940
cctcctgcgc accagcttcc tgctggctca gcagcgcctg ttggaagacc gcaaggacgt	3000
ggtgtgttg gtatccctgc gtccggatgc ccaccgcctcc cgctatgtgc gactgcgc	3060
gcgtctctgc cgccagagtg tgctcttctg gcccagcag cccaaacgggc aggggggctt	3120
ctggggccag ctgagtagacgg ccctgactag ggacaaccgc cacttctata accagaactt	3180
ctgccccggaa cctacagcag aatagcttag agcaacagct ggaaacagct gcatcttcat	3240
gcctggttcc cgagttgctc tgccctgcctt gctctgtctt actacaccgc tatttggcaa	3300
gtgcgcata tatgctacca agccaccagg cccacggagc aaagggttggc agtaaagggt	3360
attttcttc ccatgcatct ttcaggagag tgaagataga caccagaccc acacagaaca	3420
ggactggagt tcattctctg cccctccacc ccactttgcc tgcgtctgtat	3471

<210> 70
<211> 3340
<212> DNA
<213> murine

<400> 70	
tctctgagag accctgggt ggaacatcat tctctgcgc ccagttgtc agagggagcc	60
tccggagaat cctccatctc ccaacatggt tccctgcga aggactctgc accccttgc	120
cctccctggta caggctgcag tgctggctga gactctggcc ctgggtaccc tgccctgc	180
cctaccctgt gagctgaagc ctcatggct ggtggactgc aattggctgt tcctgaagtc	240
tgtacccgt ttctctgcgg cagcatctg ctccaacatc acccgccctc cttgtatctc	300
caaccgtatc caccacctgc acaactccga cttcgccac ctgtccaaacc tgccggcagct	360
gaacctcaag tggaaactgtc cacccactgg ctttagcccc ctgcacttct cttgccacat	420
gaccattgag cccagaacct tcctggctat gcgtacactg gaggagctga acctgagcta	480
taatggtatac accactgtgc cccgactgcc cagctccctg gtgaatctga gcctgagcca	540
caccaacatc ctgggtcttag atgctaacag cttcgccggc ctatacagcc tgccgcgttct	600

cttcatggac gggaaactgct actacaagaa cccctgcaca ggagcggtga aggtgacc	660
aggcgccctc ctgggcctga gcaatctcac ccatactgtct ctgaagtata acaacacctac	720
aaaggtgccc cgccaactgc cccccagcct ggagtacctc ctggtgtcct ataacacctat	780
tgtcaagctg gggcctgaag acctggccaa tctgacctcc cttcgagttac ttgatgtggg	840
tggaaattgc cgtcgctgcg accatgcccc caatccctgt atagaatgtg gccaaaagtc	900
cctccacctg caccctgaga cttccatca cctgagccat ctggaaggcc tgggtgtgaa	960
ggacagctct ctccatacac tgaactcttc ctggttccaa ggtctggtca acctctcggt	1020
gctggaccta agcgagaact ttctctatga aagcatcaac cacaccaatg ctttcagaa	1080
cctaaccgcg ctgcgcaagc tcaacctgtc cttcaattac cgcaagaagg tatcctttgc	1140
ccgcctccac ctggcaagtt cttcaagaa cctgggtgtca ctgcaggagc tgaacatgaa	1200
cggcatcttc ttccgctcgc tcaacaagta cacgctcaga tggctggccg atctgccc	1260
actccacact ctgcatacttc aaatgaactt catcaaccag gcacagctca gcatctttgg	1320
taccttccga gcccttcgct ttgtggactt gtcagacaat cgcatcagtg ggccttcaac	1380
gctgtcagaa gccacccctg aagaggcaga tgatgcagag caggaggagc tgggtctgc	1440
ggatcctcac ccagctccac tgagcacccc tgcttctaag aacttcatgg acaggtgtaa	1500
gaacttcaag ttccatatgg acctgtctcg gaacaacctg gtgactatca agccagagat	1560
gtttgtcaat ctctcacgccc tccagtgtct tagcctgagc cacaactcca ttgcacaggc	1620
tgtcaatggc tctcagttcc tgccgctgac taatctgcag gtgctggacc tgtcccataa	1680
caaactggac ttgtaccact ggaaatcggtt cagttagctt ccacagttgc aggccctgga	1740
cctggctac aacagccagc ctttagcat aaagggtata ggccacaatt tcagtttg	1800
ggcccatctg tccatgctac acagccttag cctggcacac aatgacattc ataccgtgt	1860
gtcctcacat ctcaacagca actcagtgag gtttcttgac ttcagcggca acggatggg	1920
ccgcatgtgg gatgaggggg gccttatct ccatttcttc caaggcctga gtggcctgt	1980
gaagctggac ctgtctaaa ataacctgca tattccctgg ccccagaacc ttgacaac	2040
ccccaaagac ctgaagctgc tgagcctccg agacaactac ctatcttct ttaactggac	2100
cagtctgtcc ttccatggccaa acctggaaatg cctagacccgt gcaggcaacc agctaaaggc	2160
cctgaccaat ggccatctgc ctaatggcac cttccatccag aaactggatg tcagcagcaa	2220
cagtatcgatc tctgtggccat cagccttctt cgctctggcg gtcgagctga aagaggtcaa	2280
cctcagccac aacattctca agacggtgga tgcgtccctgg tttggccca ttgtatgaa	2340
cctgacagtt cttagacgtga gaagcaaccc tctgcactgt gcctgtgggg cagccttcgt	2400
agacttactg ttggaggtgc agaccaaggt gcctggcctg gctaattggg tgaagtgtgg	2460
cagccccggc cagctgcagg ggcgttagcat cttcgacag gacctgcggc tggccctgga	2520

tgaggccctc tcttggact gctttggct ttcaactcttg gctgtggccg tgggcattgt	2580
ggtcctata ctgcaccatc tctgcggctg ggacgtctgg tactgtttc atctgtgcct	2640
ggcatggcta cctttgctgg cccgcagccg acgcagcgcc caagctctcc cctatgatgc	2700
cttcgtggtg ttcgataagg cacagagcgc agttgcggac tgggtgtata acgagctgcg	2760
ggtgcggctg gaggggcggc gcggtcgccg agccctacgc ttgtgtctgg aggaccgaga	2820
ttggctgcct gcccagacgc tcttcgagaa cctctggct tccatctatg ggagccgcaa	2880
gactctattt gtgtggccc acacggaccg cgtcagtggc ctccctgcga ccagcttct	2940
gctggctcag cagcgcctgt tggaagaccc caaggacgtg gtgggtttgg tgatctgcg	3000
tccggatgcc caccgcctcc gctatgtgcg actgcgccag cgtctctgcc gccagagtgt	3060
gctctttgg ccccagcagc ccaacggca ggggggcttc tgggcccagc tgagtacagc	3120
cctgactagg gacaaccgccc acttctataa ccagaacttc tgccggggac ctacagcaga	3180
atagctcaga gcaacagctg gaaacagctg catttcatg cctggttccc gagttgtct	3240
gcctgccttg ctctgtctta ctacaccgct atttggcaag tgcgcaatat atgctaccaa	3300
gccaccgggc ccacggagca aagggtggct gtaaaagggtta	3340

<210> 71
<211> 3471
<212> DNA
<213> murine

<400> 71 tgaaagtgtc acttcctcaa ttctctgaga gaccctggtg tggaacatca ttctctgccg	60
cccagttgt cagagggago ctggggagaa tcctccatct cccaacatgg ttctccgtcg	120
aaggactctg cacccttgcgtt ccctccgtgt acaggctgca gtgctggctg agactctggc	180
cctgggtacc ctgcctgcct tcctaccctg tgagctgaag cctcatggcc tggggactg	240
caattggctg ttcttgaagt ctgtaccccg tttctctgcg gcagcatcct gctccaacat	300
cacccgcctc tccttgcatttc ccaaccgtat ccaccacctg cacaactccg acttcgtcca	360
cctgtccaac ctgcggcagc tgaacctcaa gtggaaactgtt ccacccactg gccttagccc	420
cctgcacttc tcttgcacaca tgaccattga gcccagaacc ttctggctt tgcgtacact	480
ggaggagctg aacctgagct ataatggtat caccactgtg ccccgactgc ccagctccct	540
ggtaatctg agcctgagcc acaccaacat cctgggttcta gatgctaaca gcctcgccgg	600
cctatacagc ctgcgcgttc tcttcattggaa cggaaactgc tactacaaga acccctgcac	660
aggagcggtg aaggtgaccc caggcgcctt cctgggcctg agcaatctca cccatctgtc	720
tctgaagtat aacaacctca caaaggtgcc ccgcacactg cccccagcc tggagtacct	780

cctggtgtcc tataacctca ttgtcaagct gggcctgaa gacctggcca atctgaccc	840
ccttcgagta cttgtatgtgg gtgggaatttgc ccgtcgctgc gaccatcccc ccaatccctg	900
tatagaatgt ggccaaaaagt ccctccaccc gcaccctgag accttccatc acctgagcca	960
tctggaaaggc ctggtgctga aggacagctc tctccataca ctgaactctt cctggttcca	1020
aggtctggtc aacctctcg tgctggacct aaggcagaac tttctctatg aaagcatcaa	1080
ccacaccaat gccttcaga acctaaccgg cctgcgcaag ctcaacctgt ccttcaatta	1140
ccgcaagaag gtatcctttg cccgcctcca cctggcaagt tccttcaaga acctgggtc	1200
actgcaggag ctgaacatga acggcatctt ctcccgtcg ctcaacaagt acacgctcag	1260
atggctggcc gatctgccc aactccacac tctgcacatctt caaatgaact tcatcaacca	1320
ggcacagctc agcatcttgc gtaccttcgg agcccttcgc tttgtggact tgtcagacaa	1380
tcgcacatcgt gggcattcaa cgctgtcaga agccacccct gaagaggcag atgatgcaga	1440
gcaggaggag ctgttgcgtcg cggatccca cccagctcca ctgagcaccc ctgcttctaa	1500
gaacttcatg gacaggtgtaa agaacttcaa gttcaccatg gacctgtctc ggaacaacct	1560
ggtgactatac aagccagaga tgtttgcata tcttcacgc ctccagtgtc ttagcctgag	1620
ccacaactcc attgcacagg ctgtcaatgg ctctcagttc ctggcgctga ctaatctgca	1680
ggtgctggac ctgtccata acaaactgga cttgtaccac tggaaatcgt tcagtgagct	1740
accacagttg caggccctgg acctgagcta caacagccag cccttagca tgaagggtat	1800
aggccacaat ttcaatgggg tgacccatct gtccatgcta cagagcctta gcctggcaca	1860
caatgacatt catacccgta tgcttcaca tctcaacagc aactcagtga ggtttcttgc	1920
cttcagcggc aacggtatgg gcccgtgtg ggatgagggg ggcctttatc tccatttctt	1980
ccaaggcctg agtggcctgc tgaagctgga cctgtctcaa aataacctgc atatcctccg	2040
gccccagaac ctgacaacc tccccaaagag cctgaagctg ctgagcctcc gagacaacta	2100
cctatcttc tttaactgga ccagtctgtc ctccatcccc aacctggaaag tcctagaccc	2160
ggcaggcaac cagctaaagg ccctgaccaa tggcaccctg cctaatggca ccctccctca	2220
gaaaactcgat gtcagtagca acagtatcgt ctctgtggc ccagccttct tcgcctggc	2280
ggtcgagctg aaagaggtca acctcagcca caacattctc aagacgggtgg atcgcctctg	2340
gtttggggccc attgtatgtaa acctgacagtttcttgc tctagacgtg agaagcaacc ctctgcactg	2400
tgcctgtggg gcagccttcg tagacttact gttggaggtg cagaccaagg tgcctggcct	2460
ggctaatgggt gtgaagttgtg gcagccccgg ccagctgcag ggcctgtgc tcttcgcgc	2520
ggacctgcgg ctgtgcctgg atgaggcttgc ctcttggac tgctttggcc tttcactctt	2580
ggctgtggcc gtggcatgg tggcctat actgcacccat ctctgcggct gggacgtctg	2640
gtactgtttt catctgtgcc tggcatggct acctttgtcg gcccgcagcc gacgcagcgc	2700

ccaaactctc ccttatgatg cttcggtggt gttcgataag gcacagagcg cagttgccga 2760
 ctgggtgtat aacgagctgc gggtgccgct ggaggagcgg cgccgtcgcc gagccctacg 2820
 cttgtgtctg gaggaccgag attggctgcc tggccagacg ctcttcgaga acctctggc 2880
 ttccatctat gggagccgca agactctatt tgtgctggcc cacacggacc gcgtcagtgg 2940
 ctcctgcgc accagcttcc tgctggctca gcagcgcctg ttggaagacc gcaaggacgt 3000
 ggtggtgttg gtgatcctgc gtccggatgc ccaccgctcc cgctatgtgc gactgcgcca 3060
 gctgtctctgc cgccagagtg tgctttctg gccccagcag cccaacgggc aggggggctt 3120
 ctggggccag ctgagtagcag ccctgactag ggacaaccgc cacttctata accagaactt 3180
 ctgccccggga cctacagcag aatagcttag agcaacagct ggaaacagct gcatcttcat 3240
 gcctggttcc cgagttgctc tgctgcctt gctctgtctt actacaccgc tatttggcaa 3300
 gtgcgcaata tatgctacca agccaccagg cccacggagc aaaggttggc agtaaagggt 3360
 agtttttttc ccatgcatct ttcaggagag tgaagataga caccagaccc acacagaaca 3420
 ggactggagt tcattctctg cccctccacc ccactttgcc tgtctctgta t 3471

<210> 72
 <211> 1032
 <212> PRT
 <213> murine

<400> 72

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
 1 5 10 15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
 20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu
 35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn
 50 55 60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn
 65 70 75 80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp
 85 90 95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met
 100 105 110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu
 115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser
 130 135 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala
145 150 155 160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro
180 185 190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser
260 265 270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe
290 295 300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala
340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu
355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu
370 375 380

Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala
405 410 415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr
420 425 430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu
435 440 445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser
450 455 460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu

465	470	475	480
Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu			
485	490	495	
Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala			
500	505	510	
Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp			
515	520	525	
Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu			
530	535	540	
Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe			
545	550	555	560
Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser			
565	570	575	
Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val			
580	585	590	
Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly			
595	600	605	
Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe			
610	615	620	
Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn			
625	630	635	640
Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu			
645	650	655	
Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr			
660	665	670	
Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn			
675	680	685	
Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu			
690	695	700	
Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala			
705	710	715	720
Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn			
725	730	735	
Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn			
740	745	750	
Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly			
755	760	765	
Ala Ala Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly			
770	775	780	
Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg			
785	790	795	800
Ser Ile Phe Ala Gln Asn Leu Arg Leu Cys Leu Asp Glu Val Leu Ser			

385	390	395	400
Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala			
405		410	415
Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr			
420		425	430
Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu			
435		440	445
Leu Ile Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser			
450		455	460
Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu			
465		470	475
Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu			
485		490	495
Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala			
500		505	510
Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp			
515		520	525
Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu			
530		535	540
Leu Pro Gln Leu Gln Ala Leu Asp Leu Gly Tyr Asn Ser Gln Pro Phe			
545		550	560
Ser Ile Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser			
565		570	575
Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val			
580		585	590
Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly			
595		600	605
Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe			
610		615	620
Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn			
625		630	635
Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu			
645		650	655
Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr			
660		665	670
Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn			
675		680	685
Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu			
690		695	700
Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala			
705		710	715
Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn			

725	730	735
Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn		
740	745	750
Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly		
755	760	765
Ala Ala Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly		
770	775	780
Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg		
785	790	795
Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser		
805	810	815
Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val		
820	825	830
Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe		
835	840	845
His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser		
850	855	860
Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln		
865	870	875
Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu		
885	890	895
Gly Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp		
900	905	910
Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr		
915	920	925
Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser		
930	935	940
Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu		
945	950	955
Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His		
965	970	975
Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val		
980	985	990
Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln		
995	1000	1005
Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln		
1010	1015	1020
Asn Phe Cys Arg Gly Pro Thr Ala Glu		
1025	1030	

<210> 74
<211> 1032
<212> PRT

<213> murine
<400> 74

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ser Cys Ser Asn
50 55 60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn
65 70 75 80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met
100 105 110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser
130 135 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala
145 150 155 160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro
180 185 190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser
260 265 270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe
290 295 300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala
340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu
355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu
370 375 380

Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala
405 410 415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr
420 425 430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu
435 440 445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser
450 455 460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu
465 470 475 480

Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu
485 490 495

Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala
500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp
515 520 525

Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu
530 535 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe
545 550 555 560

Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Thr His Leu Ser
565 570 575

Met Leu Gln Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val
580 585 590

Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly
595 600 605

Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe
610 615 620

Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn
625 630 635 640

Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu

	645	650	655												
Lys	Leu	Leu	Ser	Leu	Arg	Asp	Asn	Tyr	Leu	Ser	Phe	Phe	Asn	Trp	Thr
	660	665	670												
Ser	Leu	Ser	Phe	Leu	Pro	Asn	Leu	Glu	Val	Leu	Asp	Leu	Ala	Gly	Asn
	675	680	685												
Gln	Leu	Lys	Ala	Leu	Thr	Asn	Gly	Thr	Leu	Pro	Asn	Gly	Thr	Leu	Leu
	690	695	700												
Gln	Lys	Leu	Asp	Val	Ser	Ser	Asn	Ser	Ile	Val	Ser	Val	Val	Pro	Ala
	705	710	715												
Phe	Phe	Ala	Leu	Ala	Val	Glu	Leu	Lys	Glu	Val	Asn	Leu	Ser	His	Asn
	725	730	735												
Ile	Leu	Lys	Thr	Val	Asp	Arg	Ser	Trp	Phe	Gly	Pro	Ile	Val	Met	Asn
	740	745	750												
Leu	Thr	Val	Leu	Asp	Val	Arg	Ser	Asn	Pro	Leu	His	Cys	Ala	Cys	Gly
	755	760	765												
Ala	Ala	Phe	Val	Asp	Leu	Leu	Glu	Val	Gln	Thr	Lys	Val	Pro	Gly	
	770	775	780												
Leu	Ala	Asn	Gly	Val	Lys	Cys	Gly	Ser	Pro	Gly	Gln	Leu	Gln	Gly	Arg
	785	790	795												
Ser	Ile	Phe	Ala	Gln	Asp	Leu	Arg	Leu	Cys	Leu	Asp	Glu	Val	Leu	Ser
	805	810	815												
Trp	Asp	Cys	Phe	Gly	Leu	Ser	Leu	Leu	Ala	Val	Ala	Val	Gly	Met	Val
	820	825	830												
Val	Pro	Ile	Leu	His	His	Leu	Cys	Gly	Trp	Asp	Val	Trp	Tyr	Cys	Phe
	835	840	845												
His	Leu	Cys	Leu	Ala	Trp	Leu	Pro	Leu	Leu	Ala	Arg	Ser	Arg	Arg	Ser
	850	855	860												
Ala	Gln	Thr	Leu	Pro	Tyr	Asp	Ala	Phe	Val	Val	Phe	Asp	Lys	Ala	Gln
	865	870	875												
Ser	Ala	Val	Ala	Asp	Trp	Val	Tyr	Asn	Glu	Leu	Arg	Val	Arg	Leu	Glu
	885	890	895												
Glu	Arg	Arg	Gly	Arg	Arg	Ala	Leu	Arg	Leu	Cys	Leu	Glu	Asp	Arg	Asp
	900	905	910												
Trp	Leu	Pro	Gly	Gln	Thr	Leu	Phe	Glu	Asn	Leu	Trp	Ala	Ser	Ile	Tyr
	915	920	925												
Gly	Ser	Arg	Lys	Thr	Leu	Phe	Val	Leu	Ala	His	Thr	Asp	Arg	Val	Ser
	930	935	940												
Gly	Leu	Leu	Arg	Thr	Ser	Phe	Leu	Leu	Ala	Gln	Gln	Arg	Leu	Leu	Glu
	945	950	955												
Asp	Arg	Lys	Asp	Val	Val	Val	Leu	Val	Ile	Leu	Arg	Pro	Asp	Ala	His
	965	970	975												
Arg	Ser	Arg	Tyr	Val	Arg	Leu	Arg	Gln	Arg	Leu	Cys	Arg	Gln	Ser	Val

980	985	990
Leu Phe Trp Pro Gln Gln Pro Asn	Gly Gln Gly Gly	Phe Trp Ala Gln
995	1000	1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln		
1010	1015	1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu		
1025	1030	

<210> 75
<211> 1032
<212> PRT
<213> murine

<400> 75

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln			
1	5	10	15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe		
20	25	30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu		
35	40	45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn		
50	55	60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His His Leu His Asn			
65	70	75	80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp		
85	90	95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met		
100	105	110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu		
115	120	125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser		
130	135	140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala			
145	150	155	160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly		
165	170	175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro		
180	185	190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr		
195	200	205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr		
210	215	220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu			
225	230	235	240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser
260 265 270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe
290 295 300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala
340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu
355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu
370 375 380

Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala
405 410 415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr
420 425 430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu
435 440 445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser
450 455 460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu
465 470 475 480

Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu
485 490 495

Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala
500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp
515 520 525

Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu
530 535 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe
545 550 555 560

Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Thr His Leu Ser

	565	570	575
Met Leu Gln Ser	Leu Ser Leu Ala His	Asn Asp Ile His	Thr Arg Val
580	585	590	
Ser Ser His Leu Asn Ser Asn Ser Val	Arg Phe Leu Asp Phe Ser Gly		
595	600	605	
Asn Gly Met Gly Arg Met Trp Asp Glu Gly	Gly Leu Tyr Leu His Phe		
610	615	620	
Phe Gln Gly Leu Ser Gly	Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn		
625	630	635	640
Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu			
645	650	655	
Lys Leu Leu Ser Leu Arg Asp Asn Tyr	Leu Ser Phe Phe Asn Trp Thr		
660	665	670	
Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn			
675	680	685	
Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu			
690	695	700	
Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala			
705	710	715	720
Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn			
725	730	735	
Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn			
740	745	750	
Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly			
755	760	765	
Ala Ala Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly			
770	775	780	
Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg			
785	790	795	800
Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser			
805	810	815	
Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val			
820	825	830	
Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe			
835	840	845	
His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser			
850	855	860	
Ala Gln Thr Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln			
865	870	875	880
Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu			
885	890	895	
Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp			

900	905	910
Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr		
915	920	925
Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser		
930	935	940
Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu		
945	950	955
Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His		
965	970	975
Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val		
980	985	990
Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln		
995	1000	1005
Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln		
1010	1015	1020
Asn Phe Cys Arg Gly Pro Thr Ala Glu		
1025	1030	

<210> 76
<211> 3002
<212> DNA
<213> Homo sapiens

<400> 76		
gtggcttggc attcaactggc aggtttcaga catttagatc tttcttttaa tgactaacac	60	
catgcctatac tgtggagaag ctggcaacat gtcacacctg gaaattgttt ttcaacatta	120	
atactattat ttggcagtaa tccagattgc tttgccacc aacctgaaga catatagagg	180	
cagaaggaca ggaataattc tatttgttc ctgtttgaa acttccatct gtaaggctat	240	
caaaaggaga tgtgagagag ggtatttgagt ctggcctgac aatgcagttc ttaaaccaaa	300	
ggtcattat gcttctcctc tctgagaatc ctgacttacc tcaacaacgg agacatggca	360	
cagtagccag cttggagact tctcagccaa tgctctgaga tcaagtcgaa gaccatat	420	
acagggtttt gagctcatct tcattcattca tatgaggaaa taagtggtaa aatccttgg	480	
aatacaatga gactcatcag aaacatttac atatttgtt gatattgtt gacagcagag	540	
ggtgtatgtc cagagctgcc agaagaaaagg gaactgtatca ccaactgtct caacatgtct	600	
ctaagaaaagg ttccccgcaga cttgacccca gccacaacga cactggattt atccataac	660	
ctcccttttc aactccagag ttcatgtttt cattctgtct ccaaactgag agtttgattt	720	
ctatgccata acagaattca acagctggat ctcaaaacct ttgaattcaa caaggagtt	780	
agatattttat atttgtctaa taacagactg aagagtgtaa cttggatattt actggcaggt	840	
ctcaggattt tagatcttcc tttaatgac ttgacacca tgcctatctg tgaggaagct	900	

ggcaacatgt cacacctgga aatcctaggt ttgagtgggg caaaaataca aaaatcagat	960
ttccagaaaa ttgctcatct gcatctaaat actgtcttct taggattcag aactcttcct	1020
cattatgaag aaggtagcct gcccatctta aacacaacaa aactgcacat tgtttacca	1080
atggacacaa atttctgggt tctttgcgt gatggaatca agacttcaa aatattagaa	1140
atgacaata tagatggcaa aagccaattt gtaagttatg aaatgcaacg aaatcttagt	1200
ttagaaaatg ctaagacatc gggtcttattg cttaataaaag ttgatttact ctgggacgac	1260
cttttcctta tcttacaatt tgtttggcat acatcagtgg aacacttca gatccgaaat	1320
gtgacttttgcgttggtaaggc ttatcttgac cacaattcat ttgactactc aaatactgta	1380
atgagaacta taaaattgga gcatgtacat ttcagagtgt tttacattca acaggataaa	1440
atctatttgc ttttgaccaa aatggacata gaaaacctga caatatcaa tgcacaaatg	1500
ccacacatgc ttttcccgaa ttatcctacg aaattccaat atttaaattt tgccaataat	1560
atcttaacag acgagttgtt taaaagaact atccaactgc ctcacttgaa aactctcatt	1620
ttgaatggca ataaactgga gacactttct ttagtaagtt gctttgctaa caacacaccc	1680
ttggaacact tggatctgag tcaaaatcta ttacaacata aaaatgatga aaattgctca	1740
tggccagaaa ctgtggtcaa tatgaatctg tcatacaata aattgtctga ttctgtcttc	1800
aggtgcttgc caaaaagtat tcaaatactt gacctaaata ataaccaaata ccaaactgta	1860
cctaaagaga ctattcatct gatggcctta cgagaactaa atattgcatt taattttcta	1920
actgatctcc ctggatgcag tcatttcagt agactttcag ttctgaacat tgaaatgaac	1980
ttcattctca gcccattctct ggattttgtt cagagctgcc aggaagttaa aactctaaat	2040
gcgggaagaa atccattccg gtgtacctgt gaattaaaaa atttcattca gcttgaacaca	2100
tattcagagg tcatgatggc tggatggtca gattcataca cctgtgaata ccctttaaac	2160
ctaaggggaa ttagttaaa agacgttcat ctccacgaat tatcttgcaa cacagctctg	2220
ttgattgtca ccattgtggc tattatgcta gttctggggc tggctgtggc cttctgtgt	2280
ctccactttg atctgccctg gatatctcagg atgcttaggtc aatgcacaca aacatggcac	2340
agggttagga aaacaaccca agaacaactc aagagaaatg tccgattcca cgcatttatt	2400
tcatacagtg aacatgattc tctgtgggtg aagaatgaat tgatccccaa tctagagaag	2460
gaagatgggtt ctatcttgcattttt gaaagctact ttgaccctgg caaaaggatt	2520
agtgaaaata ttgtaagctt cattgagaaa agctataagt ccattttgtt tttgtctccc	2580
aactttgtcc agaatgagtg gtgccattat gaattttact ttgcccacca caatcttc	2640
catgaaaatt ctgatcatat aattcttatac ttactggAAC ccattccatt ctattgcatt	2700
cccaccaggt atcataaaact gaaagctctc ctggaaaaaaa aagcataactt ggaatggccc	2760
aaggataggc gtaaatgtgg gctttctgg gcaaaccttc gagctgctat taatgttaat	2820

gtattagcca ccagagaaaat gtagactg cagacattca cagagtaaa tgaagagtct 2880
cgaggttcta caatctctct gatgagaaca gattgtctat aaaatcccac agtccttggg 2940
aagttgggga ccacatacac tacattgata caacctttat gatggcaatt 3000
tg 3002

<210> 77
<211> 811
<212> PRT
<213> Homo sapiens

<400> 77

Met Arg Leu Ile Arg Asn Ile Tyr Ile Phe Cys Ser Ile Val Met Thr
1 5 10 15

Ala Glu Gly Asp Ala Pro Glu Leu Pro Glu Glu Arg Glu Leu Met Thr
20 25 30

Asn Cys Ser Asn Met Ser Leu Arg Lys Val Pro Ala Asp Leu Thr Pro
35 40 45

Ala Thr Thr Thr Leu Asp Leu Ser Tyr Asn Leu Leu Phe Gln Leu Gln
50 55 60

Ser Ser Asp Phe His Ser Val Ser Lys Leu Arg Val Leu Ile Leu Cys
65 70 75 80

His Asn Arg Ile Gln Gln Leu Asp Leu Lys Thr Phe Glu Phe Asn Lys
85 90 95

Glu Leu Arg Tyr Leu Asp Leu Ser Asn Asn Arg Leu Lys Ser Val Thr
100 105 110

Trp Tyr Leu Leu Ala Gly Leu Arg Tyr Leu Asp Leu Ser Phe Asn Asp
115 120 125

Phe Asp Thr Met Pro Ile Cys Glu Glu Ala Gly Asn Met Ser His Leu
130 135 140

Glu Ile Leu Gly Leu Ser Gly Ala Lys Ile Gln Lys Ser Asp Phe Gln
145 150 155 160

Lys Ile Ala His Leu His Leu Asn Thr Val Phe Leu Gly Phe Arg Thr
165 170 175

Leu Pro His Tyr Glu Glu Gly Ser Leu Pro Ile Leu Asn Thr Thr Lys
180 185 190

Leu His Ile Val Leu Pro Met Asp Thr Asn Phe Trp Val Leu Leu Arg
195 200 205

Asp Gly Ile Lys Thr Ser Lys Ile Leu Glu Met Thr Asn Ile Asp Gly
210 215 220

Lys Ser Gln Phe Val Ser Tyr Glu Met Gln Arg Asn Leu Ser Leu Glu
225 230 235 240

Asn Ala Lys Thr Ser Val Leu Leu Leu Asn Lys Val Asp Leu Leu Trp
245 250 255

Asp Asp Leu Phe Leu Ile Leu Gln Phe Val Trp His Thr Ser Val Glu
260 265 270

His Phe Gln Ile Arg Asn Val Thr Phe Gly Gly Lys Ala Tyr Leu Asp
275 280 285

His Asn Ser Phe Asp Tyr Ser Asn Thr Val Met Arg Thr Ile Lys Leu
290 295 300

Glu His Val His Phe Arg Val Phe Tyr Ile Gln Gln Asp Lys Ile Tyr
305 310 315 320

Leu Leu Leu Thr Lys Met Asp Ile Glu Asn Leu Thr Ile Ser Asn Ala
325 330 335

Gln Met Pro His Met Leu Phe Pro Asn Tyr Pro Thr Lys Phe Gln Tyr
340 345 350

Leu Asn Phe Ala Asn Asn Ile Leu Thr Asp Glu Leu Phe Lys Arg Thr
355 360 365

Ile Gln Leu Pro His Leu Lys Thr Leu Ile Leu Asn Gly Asn Lys Leu
370 375 380

Glu Thr Leu Ser Leu Val Ser Cys Phe Ala Asn Asn Thr Pro Leu Glu
385 390 395 400

His Leu Asp Leu Ser Gln Asn Leu Leu Gln His Lys Asn Asp Glu Asn
405 410 415

Cys Ser Trp Pro Glu Thr Val Val Asn Met Asn Leu Ser Tyr Asn Lys
420 425 430

Leu Ser Asp Ser Val Phe Arg Cys Leu Pro Lys Ser Ile Gln Ile Leu
435 440 445

Asp Leu Asn Asn Asn Gln Ile Gln Thr Val Pro Lys Glu Thr Ile His
450 455 460

Leu Met Ala Leu Arg Glu Leu Asn Ile Ala Phe Asn Phe Leu Thr Asp
465 470 475 480

Leu Pro Gly Cys Ser His Phe Ser Arg Leu Ser Val Leu Asn Ile Glu
485 490 495

Met Asn Phe Ile Leu Ser Pro Ser Leu Asp Phe Val Gln Ser Cys Gln
500 505 510

Glu Val Lys Thr Leu Asn Ala Gly Arg Asn Pro Phe Arg Cys Thr Cys
515 520 525

Glu Leu Lys Asn Phe Ile Gln Leu Glu Thr Tyr Ser Glu Val Met Met
530 535 540

Val Gly Trp Ser Asp Ser Tyr Thr Cys Glu Tyr Pro Leu Asn Leu Arg
545 550 555 560

Gly Ile Arg Leu Lys Asp Val His Leu His Glu Leu Ser Cys Asn Thr

	565	570	575
Ala Leu Leu Ile Val Thr Ile Val Val Ile Met Leu Val Leu Gly Leu			
	580	585	590
Ala Val Ala Phe Cys Cys Leu His Phe Asp Leu Pro Trp Tyr Leu Arg			
	595	600	605
Met Leu Gly Gln Cys Thr Gln Thr Trp His Arg Val Arg Lys Thr Thr			
	610	615	620
Gln Glu Gln Leu Lys Arg Asn Val Arg Phe His Ala Phe Ile Ser Tyr			
	625	630	635
Ser Glu His Asp Ser Leu Trp Val Lys Asn Glu Leu Ile Pro Asn Leu			
	645	650	655
Glu Lys Glu Asp Gly Ser Ile Leu Ile Cys Leu Tyr Glu Ser Tyr Phe			
	660	665	670
Asp Pro Gly Lys Ser Ile Ser Glu Asn Ile Val Ser Phe Ile Glu Lys			
	675	680	685
Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Asn Glu			
	690	695	700
Trp Cys His Tyr Glu Phe Tyr Phe Ala His His Asn Leu Phe His Glu			
	705	710	715
Asn Ser Asp His Ile Ile Leu Ile Leu Glu Pro Ile Pro Phe Tyr			
	725	730	735
Cys Ile Pro Thr Arg Tyr His Lys Leu Lys Ala Leu Leu Glu Lys Lys			
	740	745	750
Ala Tyr Leu Glu Trp Pro Lys Asp Arg Arg Lys Cys Gly Leu Phe Trp			
	755	760	765
Ala Asn Leu Arg Ala Ala Ile Asn Val Asn Val Leu Ala Thr Arg Glu			
	770	775	780
Met Tyr Glu Leu Gln Thr Phe Thr Glu Leu Asn Glu Glu Ser Arg Gly			
	785	790	795
Ser Thr Ile Ser Leu Met Arg Thr Asp Cys Leu			
	805	810	

<210> 78
<211> 2760
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (2529)..(2529)
<223> n is a, c, g, or t

<400> 78
aagaatttgg actcatatca agatgctctg aagaagaaca accctttagg atagccactg 60
caacatcatg accaaagaca aagaacctat tgtaaaagc ttccatTTG tttgccttat 120

gatcataata gttggAACCA gaatccAGTT ctccGACGGA aatgaATTG cagtagACAA	180
gtcaaaaAGA ggtcttATTC atgttccAAA agacctaCCG ctgaaaACCA aagtctTAGA	240
tatgtctcAG aactacATCG ctgagCTTCA ggtctctgAC atgagCTTC tatcAGAGTT	300
gacagTTTG agacttCCC ataacAGAA ccagCTACTT gattTAAGTG ttttcaAGTT	360
caaccaggAT ttAGAATATT tggatttATC tcATAATCAG ttgcaAAAGA tatcCTGCCA	420
tcctattGTG agtttcAGGC atttagATCT ctcattCAAT gatttCAAGG ccctGCCAT	480
ctgtaaggAA tttggCAACT tatcacaACT gaatttCTTG ggatttgAGTG ctatGAAGCT	540
gcAAAAATTa gatttGCTGC caattGCTCA cttGcatCTA agtttatATCC ttctGGATT	600
aagaAAATTat tatataAAAG aaaatgAGAC agaaAGtCTA caaattCTGA atgcAAAAAC	660
ccttcacCTT gttttcACC caactAGTTT attcgCTATC caagtGAACA tatcAGTTA	720
tactttAGGG tgcttACAC tgactAAAT taaattGAAT gatgacaACT gtcaAGTTT	780
cattAAATTt ttatcAGAAC tcaccAGGG tccaACCTTA ctgaATTtTA ccctCAACCA	840
catagAAACG acttggAAAT gcctggTCAG agtCTTCAA tttcttGGC ccaaACCTGT	900
ggaatatCTC aatatttACa atttaACAA aattgAAAGC attcgtGAAG aagattttAC	960
ttattctAAA acgacATTGA aagcATTGAC aatAGAACAT atcacGAACC aagttttCT	1020
gttttCACAG acagCTTGT acaccGTGTT ttctGAGATG aacattATGA tgttaACCAT	1080
ttcagatACA cctttataAC acatGCTGTG tcctCATGCA ccaAGCACAT tcaAGTTT	1140
gaactttACC cagaACGTT tcacAGATAG tattttGAA aaatgttCCA cgtagttaA	1200
attggagACA ctatCTTAC aaaAGAATGG attAAAGAC ctTTTCAAAG tagtCTCAT	1260
gacgaaggAT atgcTTCTT tggAAataCT ggatgttagC tggAAattCTT tggAAatCTGG	1320
tagacataAA gaaaACTGCA cttgggtGA gagtagtAGtG gtgttaAATT tgtCTTCAA	1380
tatgCTTACT gactCTGTtT tcAGATGTTT acctcccAGG atcaAGGTAC ttGATCTCA	1440
cagcaataAA ataaAGAGCG ttccTAAACA agtCGtaAAA ctggAAAGCT tgcaAGAACT	1500
caatGTTGCT ttcaATTCTT taactGACCT tcctGGATGT ggcAGCTTA gcAGCCTTC	1560
tgtattGATC attGATCACA attcAGTTtC ccacCCATG gctGATTtC tccAGAGCTG	1620
ccagaAGATG aggtCAATAA aagcAGGGGA caatCCATC caatGTACtC gtGAGCTAAG	1680
agaatttGTC aaaaATATAG accaAGTATC aagtGAAGTG ttagAGGGCT ggcotGATT	1740
ttataAGTGT gactACCCAG aaagtTATAG aggaAGCCCA ctAAAGGACT ttcaCATGTC	1800
tgaatttACc tgcaACATAA ctctGCTGAT cgtcAccATC ggtGCCACCA tgctGGTGT	1860
ggctGTGACT gtGACCTCCC tctGcatCTA cttGGATGT ccctGGTATC tcaggatGGT	1920
gtGCCAGTGG acccAGACTC ggcgcAGGGC cagGAACATA cccttagAAAG aactCCAAAG	1980
aaacCTCCAG ttcatGCTT ttatttCATA tagtGAACAT gattctGCCT gggtGAAAAG	2040

tgaattggta ccttacctag	aaaaagaaga tatacagatt	tgtcttcatg agaggaactt	2100
tgtccctggc aagagcattg	tggaaaatat catcaactgc	attgagaaga gttacaagtc	2160
catcttggtt ttgtctcca	actttgtcca gagtgagtgg	tgccattacg aactctattt	2220
tgc当地atcac aatctcttc	atgaaggatc taataactta	atcctcatct tactggaacc	2280
cattccacag aacagcattc	ccaacaagta ccacaagctg	aaggctctca tgacgcagcg	2340
gacttatttg cagtggccca	aggagaaaaag caaacgtggg	ctctttggg ctaacattag	2400
agccgc当地ttt aatatgaaat	taacactagt cactgaaaac	aatgatgtga aatctaaaaa	2460
aaatttagga aattcaactt	aagaaaccat tatttacttg	gatgatggg aatagtacag	2520
tcgtaagtna ctgtctggag	gtgc当地ccat tattcctcatg	ccttcaggaa agacttaaca	2580
aaaacaatgt ttcatctggg	gaactgagct aggccgtgag	gttagcctgc cagttagaga	2640
cagcccagtc tcttctgggtt	taatcattat gtttcaaatt	gaaacagtct cttttgagta	2700
aatgctcagt tttcagctc	ctctccactc tgctttccca	aatggattct gttgggtgaag	2760

<210> 79
<211> 2753
<212> DNA
<213> Homo sapiens

<400> 79			
agaatttggta ctc当地atcaa	gatgctctga agaagaacaa	ccctttagga tagccactgc	60
aacatcatga ccaaagacaa	agaacctatt	gttaaaagct tccattttgt ttgc当地tatg	120
atcataatag ttggaaccag	aatccagttc	tccgacggaa atgaatttgc	180
tcaaaaagag gtcttattca	tgttccaaaaa	gacctaccgc tgaaaaccaa	240
atgtctcaga actacatcgc	tgagcttcag	gtctctgaca tgagcttct atcagagttg	300
acagtttga gactttccca	taacagaatc	cagctacttg atttaagtgt tttcaagttc	360
aaccaggatt tagaatat	tttggatct	cataatcagt tgcaaaaagat atcctgccat	420
cctattgtga gttttaggca	tttagatctc	tcattcaatg atttcaaggc cctgccc当地	480
tgtaaggaat ttggcaactt	atcacaactg	aatttcttgg gattgagtgc tatgaagctg	540
caaaaattag atttgc当地cc	aattgctcac	ttgcatctaa gttatatcct tctggattta	600
agaaaattatt atataaaaga	aatgagaca	gaaagtctac aaattctgaa tgcaaaaacc	660
cttc当地cttg ttttccaccc	aactagttt	ttcgctatcc aagtgaacat atcagttat	720
actttagggt gcttacaact	gactaatatt	aaattgaatg atgacaactg tcaagtttgc	780
ataaaatttt tatcagaact	caccagaggt	tcaaccttac tgaattttac cctcaaccac	840
atagaaaacga ctggaaatg	cctggc当地a	gtctttcaat ttcttggcc caaacctgtg	900

gaatatctca atatttacaa tttaacaata attgaaagca ttcgtgaaga agattttact	960
tattctaaaa cgacattgaa agcattgaca atagaacata tcacgaacca agttttctg	1020
ttttcacaga cagcttgta caccgtgtt tctgagatga acattatgat gttaaccatt	1080
tcagatacac cttttataca catgctgtgt cctcatgcac caagcacatt caagttttg	1140
aactttaccc agaacgttt cacagatagt attttgaaa aatgttccac gttagttaaa	1200
ttggagacac ttatcttaca aaaaaatgga taaaagacc tttcaaagt aggtctcatg	1260
acgaaggata tgccttctt ggaaatactg gatgttagct ggaattctt ggaatctgg	1320
agacataaag aaaactgcac ttgggtttag agtatagtgg tgttaaattt gtcttcaaatt	1380
atgcttactg actctgtttt cagatgtta cctcccagga tcaaggtact tgatctcac	1440
agcaataaaa taaagagcgt tcctaaacaa gtcgtaaaac tggaaagctt gcaagaactc	1500
aatgttgctt tcaattcttt aactgacett cctggatgtg gcagctttag cagccttct	1560
gtattgatca ttgatcacaa ttcagttcc caccatcg ctgatttctt ccagagctgc	1620
cagaagatga ggtcaataaa agcaggggac aatccattcc aatgtacotg tgagctaaga	1680
gaatttgtca aaaatataga ccaagtatca agtgaagtgt tagagggctg gcctgattct	1740
tataagtgtg actacccaga aagttataga ggaagcccac taaaggactt tcacatgtct	1800
gaattatcct gcaacataac tctgctgatc gtcaccatcg gtgccaccat gctgggttg	1860
gctgtactg tgacctccct ctgcatactac ttggatctgc cctggtatct caggatgg	1920
tgccagtgga cccagactcg ggcgcagggcc aggaacatac cttagaaga actccaaaga	1980
aacctccagt ttcatgcttt tatttcata agtgaacatg attctgcctg ggtaaaaagt	2040
gaatttgtac cttaacctaga aaaagaagat atacagattt gtcttcatga gaggaacttt	2100
gtccctggca agagcattgt gaaaaatatac atcaactgca ttgagaagag ttacaagtcc	2160
atctttgttt tgtctccaa ctttgtccag agtgagtggt gccattacga actctat	2220
gccccatcaca atctcttca tgaaggatct aataacttaa tcctcatctt actggAACCC	2280
attccacaga acagcattcc caacaagtac cacaagctga aggctctcat gacgcagcgg	2340
acttatttgc agtggccaa ggagaaaaagc aaacgtggc tctttggc taacattaga	2400
gccgctttta atatgaaatt aacactagtc actgaaaaca atgatgtgaa atctaaaaaa	2460
aatttaggaa attcaactta agaaaccatt atttacttgg atgatggta atagtagact	2520
cgtaagtaac tgtctggagg tgcctccatt atcctcatgc cttcaggaaa gacttaacaa	2580
aaacaatgtt tcatctgggg aactgagcta ggccgtgagg ttagcctgcc agttagagac	2640
agcccagtct cttctggttt aatcattatg tttcaaattt aaacagtctc tttttagttaa	2700
atgctcagtt ttcagctcc tctccactct gctttccaa atggattctg ttg	2753

<210> 80
<211> 796
<212> PRT
<213> Homo sapiens

<400> 80

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys
1 5 10 15

Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn
20 25 30

Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys
35 40 45

Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile
50 55 60

Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val
65 70 75 80

Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe
85 90 95

Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu
100 105 110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu
115 120 125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn
130 135 140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys
145 150 155 160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu
165 170 175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln
180 185 190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu
195 200 205

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln
210 215 220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys
225 230 235 240

Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Phe Thr Leu
245 250 255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe
260 265 270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile
275 280 285

Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu
290 295 300

Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser
305 310 315 320

Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu
325 330 335

Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro
340 345 350

Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser
355 360 365

Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu
370 375 380

Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys
385 390 395 400

Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu
405 410 415

Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val
420 425 430

Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu
435 440 445

Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser
450 455 460

Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val
465 470 475 480

Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser
485 490 495

Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala
500 505 510

Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp
515 520 525

Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile
530 535 540

Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys
545 550 555 560

Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His
565 570 575

Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly
580 585 590

Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr
595 600 605

Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr

610	615	620
Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu		
625	630	635
Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val		
645	650	655
Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys		
660	665	670
Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile		
675	680	685
Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro		
690	695	700
Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His		
705	710	715
His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu		
725	730	735
Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys		
740	745	750
Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser		
755	760	765
Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys		
770	775	780
Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser		
785	790	795

<210> 81

<211> 796

<212> PRT

<213> Homo sapiens

<400> 81

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys		
1	5	10
		15

Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn		
20	25	30

Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys		
35	40	45

Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile		
50	55	60

Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val		
65	70	75
		80

Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe		
85	90	95

Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu		
100	105	110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu
115 120 125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn
130 135 140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys
145 150 155 160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu
165 170 175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln
180 185 190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu
195 200 205

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln
210 215 220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys
225 230 235 240

Phe Leu Ser Glu Leu Thr Arg Gly Ser Thr Leu Leu Asn Phe Thr Leu
245 250 255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe
260 265 270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile
275 280 285

Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu
290 295 300

Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser
305 310 315 320

Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu
325 330 335

Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro
340 345 350

Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser
355 360 365

Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu
370 375 380

Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys
385 390 395 400

Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu
405 410 415

Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val
420 425 430

Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu

435 440 445
Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser
450 455 460

Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val
465 470 480

Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser
485 490 495

Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala
500 505 510

Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp
515 520 525

Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile
530 535 540

Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys
545 550 560

Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His
565 570 575

Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly
580 585 590

Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr
595 600 605

Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr
610 615 620

Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu
625 630 640

Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val
645 650 655

Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys
660 665 670

Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile
675 680 685

Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro
690 695 700

Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His
705 710 720

His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu
725 730 735

Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys
740 745 750

Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser
755 760 765

Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys

770	775	780
Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser		
785	790	795

<210> 82
<211> 796
<212> PRT
<213> Homo sapiens

<400> 82

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys		
1	5	10
		15

Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn		
20	25	30

Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys		
35	40	45

Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile		
50	55	60

Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val		
65	70	75
		80

Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe		
85	90	95

Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu		
100	105	110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu		
115	120	125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn		
130	135	140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys		
145	150	155
		160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu		
165	170	175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln		
180	185	190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu		
195	200	205

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln		
210	215	220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys		
225	230	235
		240

Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Phe Thr Leu		
245	250	255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe		
260	265	270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile
275 280 285

Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu
290 295 300

Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser
305 310 315 320

Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu
325 330 335

Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro
340 345 350

Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser
355 360 365

Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu
370 375 380

Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys
385 390 395 400

Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu
405 410 415

Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val
420 425 430

Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu
435 440 445

Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser
450 455 460

Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val
465 470 475 480

Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser
485 490 495

Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala
500 505 510

Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp
515 520 525

Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile
530 535 540

Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys
545 550 555 560

Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His
565 570 575

Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly
580 585 590

Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr

595	600	605
Leu Asp Leu Pro Trp Tyr	Leu Arg Met Val Cys Gln Trp Thr Gln Thr	
610	615	620
Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu		
625	630	635
Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val		
645	650	655
Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys		
660	665	670
Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile		
675	680	685
Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro		
690	695	700
Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His		
705	710	715
His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu		
725	730	735
Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys		
740	745	750
Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser		
755	760	765
Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys		
770	775	780
Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser		
785	790	795

<210> 83
 <211> 2604
 <212> DNA
 <213> murine

<400> 83	
aagtaaaaat gctgtgaaga atggtaaagt ccctctggga tagcctctgc aacatgagcc	60
aagacagaaa acccatcgta gggagtttcc actttgtttg cgcctggcc ttaatagtcg	120
gaagcatgac cccgttctct aatgaacttg agtctatggt agactattca aacaggaacc	180
ttactcatgt ccccaaagac ctgccaccaa gaacaaaagc cctgagtctg tctaaaaact	240
ctatatctga gcttcggatg cctgatatca gctttctgtc agagctgaga gttctgagac	300
tctcccacaa caggatacgg agccttgatt tccatgtatt cttgttcaat caggacttag	360
aataacctgga tgtctcacac aatcggttgc aaaacatctc ttgctgcacct atggcgagcc	420
tgaggcatct agacctctca ttcaatgact ttgatgtact gcctgtgtgt aaggaatttg	480
gcaacctgac gaagctgact ttccctggat taagtgtgc caagttccga caactggatc	540

tgctcccaact tgctcacttg catctaagct gcattttct ggacttagtg agtcata
taaaaggcg ggaaacagaa agtcttcaaga ttcccaatac caccgttctc cattggct
ttcatccaaa tagcttggc tctgttcaag tgaacatgtc tgtaaacgct ttaggacatt
tacaactgag taatattaaa ttgaatgtatg aaaactgtca aaggtaatg acattttat
cagaactcac cagaggtcca accttattga atgtgaccct ccagcacata gaaacaacct
ggaagtgc ggttaaactt ttccaaattct tttggccccg accgggtggag tacctcaata
tttacaactt aacgataact gagagaatcg acagggaga atttacttac tcggagacag
cactgaagtc actgatgata gaggcacgtca aaaaccaagt gttcccttta tcaaaggagg
cgctatactc ggtgtttgct gagatgaaca tcaagatgct ctctatctca gacaccctt
tcatccacat ggtgtgccccg ccatccccaa gtcatttac atttctgaac tttacccaga
atgttttac tgacagtgtt tttcaaggtt gttccacctt aaagagattg cagacactta
tcttacaaag gaatggtttg aagaactttt ttaaagtagc tctcatgact aagaatatgt
cctctctgga aactttggat gttagtttga attcttgaa ctctcatgca tatgacagga
catgcgcctg ggctgagagc atattgggt tgaatttgc ttcgaatatg cttacaggct
ctgtcttcag atgcttaccc cccaaagggtca aggtcccttga ctttcacaaac aacaggataa
tgagcatccc taaagatgtc acccacctgc aggctttgca ggaactcaat gtagcatcca
actcctaac tgaccttccct gggtgtgggg ccttcagcag ctttctgtg ctggtcatcg
accataactc agtttcccat ccctctgagg atttcttca gagctgtcag aatatttagat
ccctaacagc gggaaacaac ccattccaaat gcacatgtga gctgagggac tttgtcaaga
acataggctg ggttagcaaga gaagtgggtt agggctggcc tgactttac aggtgtgact
acccagaaag ctctaaggga actgcactga gggacttcca catgtctcca ctgtcctgt
atactgttct gctgactgtc accatcgccccg ccactatgtt ggtgctggct gtcactgggg
ctttccctcg tctctacttt gacctgcctt ggtatgtgag gatgctgtgt cagtgac
agaccaggca cagggccagg cacatccccct tagaggaact ccagagaaac ctccagttcc
atgctttgt ctcatcactg gagcatgatt ctgcctgggt gaagaacgaa ttactaccca
acctagagaa agatgacatc cgggtttgcc tccatgagag gaactttgtc cctggcaaga
gcattgtggaa gaacatcatc aatttcatttga agaagagttt caaggccatc tttgtgt
ctccccactt catccagagt gagtggtgcc attatgttactt ctatggcc catcataatc
tcttccatga aggctctgtat aacttaatcc tcatcttgc ggaacccatt ctacagaaca
acattccccag tagataaccac aagctgcggg ctctcatggc acagcggact tacttggat
ggcctactga gaagggcaaa cgtgggtgt tttggccaa ctttagagct tcatttatta
tgaagtttagc cttagtcaat gaggatgtatg tgaaaacttg aaacttgggt ttctaaactta

ataaaactgtc aacctggct ctcatgaaca ctgtggttt cagttcctac ctggaggtac 2520
ttctgttgtg gtgtcttagt ttgctctgtg cttatgataa ataacatgtt tagaagttagt 2580
ttatgaaggt gctaagttca ttaa 2604

<210> 84
<211> 2604
<212> DNA
<213> murine

<400> 84
aagtaaaaat gctgtgaaga atggtaaagt ccctctggga tagcctctgc aacatgagcc 60
aagacagaaa acccatcggt gggagttcc actttgtttg cgccctggcc ttaatagtcg 120
gaagcatgac cccgttctct aatgaacttg agtctatggt agactattca aacaggaacc 180
ttactcatgt ccccaaagac ctgccaccaa gaacaaaagc cctgagtctg tctcaaaact 240
ctatatctga gcttcggatg cctgatatac gcttctgtc agagctgaga gttctgagac 300
tctcccacaa caggatacgg agccttgatt tccatgtatt cttgttcaat caggacttag 360
aataacctgga tgtctcacac aatcggttgc aaaacatctc ttgctgcct atggcgagcc 420
tgaggcatct agacctctca ttcaatgact ttgatgtact gcctgtgtt aaggaatttg 480
gcaacctgac gaagctgact ttccctggat taagtgtgc caagttccga caactggatc 540
tgctccagt tgctcaacttgc catctaagct gcattcttct ggacttagtg agtcatcata 600
taaaaggcgg ggaaacagaa agtcttcaga ttcccaatac caccgttctc catttggct 660
ttcatccaaa tagttgttc tctgttcaag tgaacatgtc tgtaaacgct ttaggacatt 720
tacaactgag taatattaaa ttgaatgtatg aaaactgtca aaggtaatg acattttat 780
cagaactcac cagaggtcca accttattga atgtgaccct ccagcacata gaaacaacct 840
ggaagtgttc ggttaaactt ttccaaattct tttggccccg accgggtggag tacctcaata 900
tttacaactt aacgataact gagagaatcg acagggaga aatttacttac tcggagacag 960
cactgaagtc actgtatgata gacgttgc aaaaaccaagt gttcctctt tcaaaggagg 1020
cgctataactc ggtgtttgtc gagatgaaca tcaagatgtc ctctatctca gacacccctt 1080
tcatccacat ggtgtccccg ccatccccaa gtcatttac atttctgaac tttacccaga 1140
atgtttttac tgacagtgtt tttcaaggct gttccacctt aaagagattg cagacactta 1200
tcttacaaag gaatggttt aagaactttt ttaaagtgc tctcatgact aagaatatgt 1260
cctctctgga aactttggat gtttagttga attcttgc ctctcatgca tatgacagga 1320
catgcgcctg ggctgagagc atattgggt tgaatttgc ttcgaatatg cttacaggct 1380
ctgtcttcag atgcttaccc cccaaagggtca aggtccttga ctttcacaac aacaggataa 1440

tgagcatccc taaagatgtc acccacctgc aggctttgca ggaactcaat gtagcatcca	1500
actcctaac tgaccccttctt gggtgtgggg ccttcagcag cctttctgtg ctggcatcg	1560
accataactc agtttccccat ccctctgagg atttcttcca gagctgtcag aatatttagat	1620
ccctaacaac gggaaacaac ccattccaat gcacatgtga gctgagggac tttgtcaaga	1680
acataggctg ggttagcaaga gaagtggtgg agggctggcc tgactcttac aggtgtgact	1740
acccagaaag ctctaaggga actgcactga gggacttcca catgtctcca ctgtcctgtg	1800
atactgttct gctgactgtc accatcgggg ccactatgtc ggtgctggct gtcactgggg	1860
ctttccctcg tctctacttt gacctgcctt ggtatgtgag gatgctgtgt cagtggacac	1920
agaccaggca cagggccagg cacatcccct tagaggaact ccagagaaac ctccagttcc	1980
atgctttgt ctcatacagt gagcatgatt ctgcctgggt gaagaacgaa ttactaccca	2040
accttagagaa agatgacatc cgggtttgcc tccatgagag gaactttgtc cctggcaaga	2100
gcattgtgga gaacatcatc aatttcattt agaagagtta caaggccatc tttgtgtgt	2160
ctccccactt catccagagt gagtggtgcc attatgaact ctatttgcc catcataatc	2220
tcttccatga aggctctgat aacttaatcc tcatacttgct ggaaccattt ctacagaaca	2280
acattcccag tagataccac aagctgcggg ctctcatggc acagcggact tacttggaa	2340
ggcctactga gaaggcaaa cgtggctgt tttggccaa ccttagagct tcatttatta	2400
tgaagttagc ctttgtcaat gaggatgatg tgaaaacttg aaacttgggt ttcttaactta	2460
ataaaactgtc aacctggct ctcataaca ctgtggttt cagttcctac ctggaggta	2520
ttctgttgtg gtgtcttagt ttgctctgtg cttatgataa ataacatgtt tagaagtgt	2580
ttatgaaggt gctaagttca ttaa	2604

<210> 85
<211> 2421
<212> DNA
<213> murine

<400> 85 atggtaaaagt ccctctggga tagcctctgc aacatgagcc aagacagaaaa acccatcg	60
gggagttcc actttgtttt cgcctggcc ttaatagtcg gaagcatgac cccgttctct	120
aatgaacttg agtctatggt agactattca aacaggaacc ttactcatgt ccccaaagac	180
ctgccaccaa gaacaaaagc cctgagtctg tctaaaact ctatatctga gttcggatg	240
cctgatatac gctttctgtc agagctgaga gttctgagac tctcccacaa caggatacgg	300
agccttgatt tccatgtatt cttgttcaat caggacttag aataacctgga tgtctcacac	360
aatcggttgc aaaacatctc ttgctgcct atggcgagcc tgaggcatct agacactctca	420
ttcaatgact ttgatgtact gcctgtgtgt aaggaatttg gcaacctgac gaagctgact	480

ttcctggat taagtgtgc aaagttccga caactggatc tgctcccagt tgctcaacttg	540
catctaagct gcatttcttct ggacttagtg agttatcata taaaaggcgaa ggaaacagaa	600
agtcttcaga ttcccaatac caccgttctc catttggtct ttcatccaaa tagcttgttc	660
tctgttcaag tgaacatgtc tgtaaacgct ttaggacatt tacaactgag taatattaaa	720
ttgaatgatg aaaactgtca aaggtaatg acattttat cagaactcac cagaggtcca	780
accttattga atgtgaccct ccagcacata gaaacaacct ggaagtgctc ggttaaactt	840
ttcciaattct tttggccccg accgggtggag tacotcaata tttacaactt aacgataact	900
gagagaatcg acagggaaaga atttacttac tcggagacag cactgaagt actgatgata	960
gagcacgtca aaaaccaagt gttcctctt tcaaaggagg cgctatactc ggtgtttgct	1020
gagatgaaca tcaagatgct ctctatctca gacacccctt tcatccacat ggtgtgcccg	1080
ccatccccaa gctcatttac atttctgaac tttacccaga atgttttac tgacagtgtt	1140
tttcaaggct gttccacett aaagagattt cagacactta tcttacaaag gaatggttt	1200
aagaactttt ttaaagtagc tctcatgact aagaatatgt cctctctgga aactttggat	1260
gttagtttga atttcttcaa ctctcatgca tatgacagga catgcgcctg ggctgagagc	1320
atattggtgt tgaatttgc ttcgaatatg cttacaggct ctgtcttcag atgcttacct	1380
cccaagggtca aggtccttga ctttcacaac aacaggataa tgagcatccc taaagatgct	1440
acccacctgc aggctttgca ggaactcaat gtagcatcca actccttaac tgaccttcct	1500
gggtgtgggg ctttcagcag ctttctgtg ctggtcatcg accataactc agtttcccat	1560
ccctctgagg atttcttcca gagctgtcag aatatttagat ccctaacagc gggaaacaac	1620
ccattccaat gcacatgtga gctgaggac tttgtcaaga acataggctg gtagcaaga	1680
gaagtggtgg agggctggcc tgactcttac aggtgtgact acccagaaaag ctctaaggga	1740
actgcactga gggacttcca catgtctcca ctgtcctgtg atactgttct gctgactgtc	1800
accatcgggg ccactatgct ggtgctggct gtcaactgggg ctttcctctg tctctacttt	1860
gacctgcctt ggtatgtgag gatgctgtgt cagtgacac agaccaggca cagggccagg	1920
cacatccccct tagaggaact ccagagaaaac ctccagttcc atgctttgt ctcatacagt	1980
gagcatgatt ctgcctgggt gaagaacgaa ttactaccca acctagagaa agatgacatc	2040
cgggttgcc tccatgagag gaactttgct cctggcaaga gcattgtgga gaacatcatc	2100
atttcattt agaagagttt caaggccatc tttgtgtgt ctccccactt catccagagt	2160
gagtgggtgcc attatgaact ctatttgcc catcataatc tcttccatga aggctctgat	2220
aacttaatcc tcacatgtctt ggaaccattt ctacagaaca acattccag tagataccac	2280
aagctgcggg ctctcatggc acagcggact tacttggaaat ggcctactga gaagggcaaa	2340
cgtggctgt tttggccaa ctttagagct tcatttatta tgaagttagc cttagtcaat	2400

gaggatgtatg tgaaaacttg a

2421

<210> 86
<211> 806
<212> PRT
<213> murine

<400> 86

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg
1 5 10 15

Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile
20 25 30

Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp
35 40 45

Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg
50 55 60

Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met
65 70 75 80

Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His
85 90 95

Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp
100 105 110

Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys
115 120 125

Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe
130 135 140

Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr
145 150 155 160

Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro
165 170 175

Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser His
180 185 190

His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr
195 200 205

Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val
210 215 220

Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys
225 230 235 240

Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu
245 250 255

Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr
260 265 270

Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro
275 280 285

Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp
290 295 300

Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile
305 310 315 320

Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr
325 330 335

Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr
340 345 350

Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe
355 360 365

Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys
370 375 380

Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu
385 390 395 400

Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu
405 410 415

Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn Ser His Ala Tyr Asp
420 425 430

Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser
435 440 445

Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys
450 455 460

Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Pro Lys Asp Val
465 470 475 480

Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu
485 490 495

Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val
500 505 510

Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser
515 520 525

Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys
530 535 540

Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg
545 550 555 560

Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg Cys Asp Tyr Pro Glu
565 570 575

Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His Met Ser Pro Leu Ser
580 585 590

Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly Ala Thr Met Leu Val

595	600	605
Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp		
610	615	620
Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg		
625	630	635
His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe		
645	650	655
Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu		
660	665	670
Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn		
675	680	685
Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu		
690	695	700
Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser		
705	710	715
Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His		
725	730	735
Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Glu Pro Ile Leu Gln		
740	745	750
Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln		
755	760	765
Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe		
770	775	780
Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn		
785	790	795
Glu Asp Asp Val Lys Thr		
805		

<210> 87
<211> 806
<212> PRT
<213> murine

<400> 87

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg		
1	5	10
		15
Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile		
20	25	30
Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp		
35	40	45
Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg		
50	55	60
Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met		
65	70	75
		80

Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His
85 90 95

Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp
100 105 110

Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys
115 120 125

Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe
130 135 140

Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr
145 150 155 160

Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro
165 170 175

Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser Tyr
180 185 190

His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr
195 200 205

Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val
210 215 220

Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys
225 230 235 240

Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu
245 250 255

Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr
260 265 270

Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro
275 280 285

Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp
290 295 300

Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile
305 310 315 320

Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr
325 330 335

Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr
340 345 350

Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe
355 360 365

Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys
370 375 380

Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu
385 390 395 400

Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu

	405	410	415
Glu Thr Leu Asp Val Ser Leu Asn Ser	Leu Asn Ser His Ala Tyr Asp		
420	425	430	
Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser			
435	440	445	
Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys			
450	455	460	
Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Lys Asp Val			
465	470	475	480
Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu			
485	490	495	
Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val			
500	505	510	
Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser			
515	520	525	
Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys			
530	535	540	
Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg			
545	550	555	560
Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg Cys Asp Tyr Pro Glu			
565	570	575	
Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His Met Ser Pro Leu Ser			
580	585	590	
Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly Ala Thr Met Leu Val			
595	600	605	
Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp			
610	615	620	
Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg			
625	630	635	640
His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe			
645	650	655	
Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu			
660	665	670	
Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn			
675	680	685	
Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu			
690	695	700	
Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser			
705	710	715	720
Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His			
725	730	735	
Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Glu Pro Ile Leu Gln			

740	745	750
Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln		
755	760	765
Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe		
770	775	780
Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn		
785	790	795
Glu Asp Asp Val Lys Thr		
805		

<210> 88
<211> 806
<212> PRT
<213> murine

<400> 88

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg		
1	5	10
		15
Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile		
20	25	30
Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp		
35	40	45
Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg		
50	55	60
Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met		
65	70	75
		80
Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His		
85	90	95
Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Asn Gln Asp		
100	105	110
Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys		
115	120	125
Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe		
130	135	140
Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr		
145	150	155
		160
Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro		
165	170	175
Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser His		
180	185	190
His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr		
195	200	205
Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val		
210	215	220

Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys
225 230 235 240

Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu
245 250 255

Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr
260 265 270

Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro
275 280 285

Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp
290 295 300

Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile
305 310 315 320

Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr
325 330 335

Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr
340 345 350

Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe
355 360 365

Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys
370 375 380

Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu
385 390 395 400

Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu
405 410 415

Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn Ser His Ala Tyr Asp
420 425 430

Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser
435 440 445

Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys
450 455 460

Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Lys Asp Val
465 470 475 480

Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu
485 490 495

Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val
500 505 510

Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser
515 520 525

Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys
530 535 540

Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg

545	550	555	560
Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg Cys Asp Tyr Pro Glu			
565		570	575
Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His Met Ser Pro Leu Ser			
580	585	590	
Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly Ala Thr Met Leu Val			
595	600	605	
Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp			
610	615	620	
Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg			
625	630	635	640
His Ile Pro Leu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe			
645	650	655	
Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu			
660	665	670	
Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn			
675	680	685	
Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu			
690	695	700	
Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser			
705	710	715	720
Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His			
725	730	735	
Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Glu Pro Ile Leu Gln			
740	745	750	
Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln			
755	760	765	
Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe			
770	775	780	
Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn			
785	790	795	800
Glu Asp Asp Val Lys Thr			
805			

<210> 89
<211> 795
<212> PRT
<213> murine

<400> 89

Met Ser Gln Asp Arg Lys Pro Ile Val Gly Ser Phe His Phe Val Cys			
1	5	10	15
Ala Leu Ala Leu Ile Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu			
20		25	30

Glu Ser Met Val Asp Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys
 35 40 45
 Asp Leu Pro Pro Arg Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile
 50 55 60
 Ser Glu Leu Arg Met Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val
 65 70 75 80
 Leu Arg Leu Ser His Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe
 85 90 95
 Leu Phe Asn Gln Asp Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu
 100 105 110
 Gln Asn Ile Ser Cys Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu
 115 120 125
 Ser Phe Asn Asp Phe Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn
 130 135 140
 Leu Thr Lys Leu Thr Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln
 145 150 155 160
 Leu Asp Leu Leu Pro Val Ala His Leu His Leu Ser Cys Ile Leu Leu
 165 170 175
 Asp Leu Val Ser Tyr His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln
 180 185 190
 Ile Pro Asn Thr Thr Val Leu His Leu Val Phe His Pro Asn Ser Leu
 195 200 205
 Phe Ser Val Gln Val Asn Met Ser Val Asn Ala Leu Gly His Leu Gln
 210 215 220
 Leu Ser Asn Ile Lys Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr
 225 230 235 240
 Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu
 245 250 255
 Gln His Ile Glu Thr Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe
 260 265 270
 Phe Trp Pro Arg Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile
 275 280 285
 Thr Glu Arg Ile Asp Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu
 290 295 300
 Lys Ser Leu Met Ile Glu His Val Lys Asn Gln Val Phe Leu Phe Ser
 305 310 315 320
 Lys Glu Ala Leu Tyr Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu
 325 330 335
 Ser Ile Ser Asp Thr Pro Phe Ile His Met Val Cys Pro Pro Ser Pro
 340 345 350
 Ser Ser Phe Thr Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser

355	360	365
Val Phe Gln Gly Cys Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu		
370	375	380
Gln Arg Asn Gly Leu Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys		
385	390	395
Asn Met Ser Ser Leu Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn		
405	410	415
Ser His Ala Tyr Asp Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val		
420	425	430
Leu Asn Leu Ser Ser Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu		
435	440	445
Pro Pro Lys Val Lys Val Leu Asp Leu His Asn Asn Arg Ile Met Ser		
450	455	460
Ile Pro Lys Asp Val Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val		
465	470	475
Ala Ser Asn Ser Leu Thr Asp Ieu Pro Gly Cys Gly Ala Phe Ser Ser		
485	490	495
Leu Ser Val Leu Val Ile Asp His Asn Ser Val Ser His Pro Ser Glu		
500	505	510
Asp Phe Phe Gln Ser Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn		
515	520	525
Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile		
530	535	540
Gly Trp Val Ala Arg Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg		
545	550	555
Cys Asp Tyr Pro Glu Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His		
565	570	575
Met Ser Pro Leu Ser Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly		
580	585	590
Ala Thr Met Leu Val Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr		
595	600	605
Phe Asp Leu Pro Trp Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr		
610	615	620
Arg His Arg Ala Arg His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu		
625	630	635
Gln Phe His Ala Phe Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val		
645	650	655
Lys Asn Glu Leu Leu Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys		
660	665	670
Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile		
675	680	685
Ile Asn Phe Ile Glu Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro		

690 695 700
His Phe Ile Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His
705 710 715 720

His Asn Leu Phe His Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Leu
725 730 735

Glu Pro Ile Leu Gln Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg
740 745 750

Ala Leu Met Ala Gln Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly
755 760 765

Lys Arg Gly Leu Phe Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys
770 775 780

Leu Ala Leu Val Asn Glu Asp Asp Val Lys Thr
785 790 795

<210> 90
<211> 10
<212> DNA
<213> artificial sequence

<220>

<223> consensus p50 subunit

<220>
<221> misc_feature
<222> (7)..(7)
<223> N = c or t

<400> 90

ggggatnccc

10

<210> 91
<211> 10
<212> DNA
<213> artificial sequence

<220>

<223> consensus p65 subunit

<220>
<221> misc_feature
<222> (4)..(4)
<223> N = a or g

<220>
<221> misc_feature
<222> (5)..(5)
<223> N = a, c, g, or t

<400> 91

gggnnttcc

10

<210> 92

<211> 22
<212> DNA
<213> artificial sequence

<220>

<223> consensus subunit

<400> 92

agttgagggg actttccca agc

22

<210> 93
<211> 27
<212> DNA
<213> artificial sequence

<220>

<223> CREB binding site

<400> 93

agagattgcc tgacgtcaga gagctag

27

<210> 94
<211> 21
<212> DNA
<213> artificial sequence

<220>

<223> AP-1 binding site

<400> 94

cgcttgatga gtcagccgga a

21

<210> 95
<211> 15
<212> DNA
<213> artificial sequence

<220>

<223> AP-1 binding site

<400> 95

cgcatgagtc agaca

15

<210> 96
<211> 19
<212> DNA
<213> artificial sequence

<220>

<223> ISRE

<400> 96

tgcagaagtg aaactgagg 19
<210> 97
<211> 11
<212> DNA
<213> artificial sequence

<220>

<223> ISRE

<400> 97
agaacgaaac a 11

<210> 98
<211> 15
<212> DNA
<213> artificial sequence

<220>

<223> ISRE

<400> 98
gagaagtgaa agtgg 15

<210> 99
<211> 18
<212> DNA
<213> artificial sequence

<220>

<223> ISRE

<400> 99
taagaacatg aaactgaa 18

<210> 100
<211> 15
<212> DNA
<213> artificial sequence

<220>

<223> ISRE

<400> 100
atgaaactga aagta 15

<210> 101
<211> 16
<212> DNA
<213> artificial sequence

<220>

<223> ISRE

<400> 101
tgaaaaaccga aagcgc

16

<210> 102
<211> 13
<212> DNA
<213> artificial sequence

<220>

<223> ISRE

<400> 102
agaaaatggaa agt

13

<210> 103
<211> 9
<212> DNA
<213> artificial sequence

<220>

<223> SRE

<400> 103
tcaccccac

9

<210> 104
<211> 10
<212> DNA
<213> artificial sequence

<220>

<223> SRE

<400> 104
ctcaccccac

10

<210> 105
<211> 10
<212> DNA
<213> artificial sequence

<220>

<223> SRE

<400> 105
gccaccctac

10

<210> 106
<211> 17
<212> DNA
<213> artificial sequence

<220>
<223> NFAT

<400> 106
tatgaaacag ttttcc

17

<210> 107
<211> 9
<212> DNA
<213> artificial sequence

<220>

<223> NFAT

<400> 107
aggaaaactc

9

<210> 108
<211> 10
<212> DNA
<213> artificial sequence

<220>

<223> NFAT

<220>
<221> misc_feature
<222> (2)..(2)
<223> N = a or g

<220>
<221> misc_feature
<222> (5)..(5)
<223> N = a or g

<400> 108
anganattcc

10

<210> 109
<211> 16
<212> DNA
<213> artificial sequence

<220>

<223> NFAT

<400> 109
ccagttgagc cagaga

16

<210> 110
<211> 30
<212> DNA
<213> artificial sequence

<220>

<223> GAS

<400> 110
ctttcagttt catattactc taaatccatt

30

<210> 111
<211> 10
<212> DNA
<213> artificial sequence

<220>

<223> p53 consensus site

<220>
<221> misc_feature
<222> (1)..(3)
<223> N = a or g

<220>
<221> misc_feature
<222> (5)..(6)
<223> N = a or t

<220>
<221> misc_feature
<222> (8)..(10)
<223> N = c or t

<400> 111
nnncnngnnn

10

<210> 112
<211> 10
<212> DNA
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 112
aggcatgcct

10

<210> 113
<211> 10
<212> DNA
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 113
gggcttgccc

10

<210> 114

<211> 10
<212> DNA
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 114
gggcttgctt 10

<210> 115
<211> 13
<212> DNA
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 115
gcctggactt gcc 13

<210> 116
<211> 20
<212> DNA
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 116
ggacatgccc gggcatgtcc 20

<210> 117
<211> 23
<212> DNA
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 117
gttagcattag cccagacatg tcc 23

<210> 118
<211> 36
<212> DNA
<213> artificial sequence

<220>

<223> TARE

<400> 118
gaggtatgca gacaagagtc agagttcccc ctggaa 36

<210> 119
<211> 10
<212> DNA
<213> artificial sequence

<220>

<223> SRF

<220>
<221> misc_feature
<222> (3)..(8)
<223> N = a or t

<400> 119
ccnnnnnnngg 10

<210> 120
<211> 11
<212> DNA
<213> artificial sequence

<220>

<223> SRF

<400> 120
ccaaataagg c 11

<210> 121
<211> 670
<212> DNA
<213> Homo sapiens

<400> 121
agaaaaattt taaaaaattt ttcattcata ttttaggag tttaatgtatgt 60
aattatattt atattattaa tgttatctt tatagatttt tattttcat atgtacttt
atacaaaatt tacatgaaca aattacacta aaagttattt cacaaatata cttatcaa 120
taagttaaat gtcaatagct tttaaactt aatttttagtt taactttctt gtcattttt 180
actttgaata aaaagagcaa actttgttagt ttttatctgt gaagtagagg tatacgtaat 240
atacataaaat agatatgcc aatctgtgtt attaaaattt catgaagatt tcaatttagaa 300
aaaaatacca taaaaggctt tgagtgcagg tgaaaaatag gcaatgatga aaaaaatgt 360
aaaactttt aaacacatgt agagagtgcg taaagaaagc aaaaacagag atagaaagta 420
caactaggaa atttagaaaa tggaaattag tatgttcaact attaaagacc tatgcacaga 480
gcaaagtctt cagaaaaacctt agaggccgaa gttcaagggtt atccatctca agtagccttag 540
caatatttgc aacatcccaa tggccctgtc ctttttttta ctgatggccg tgctggtgct 600
cagctacaaa 660
670

<210> 122
<211> 207
<212> DNA
<213> Homo sapiens

<400> 122
aggttctctg aaggccttgc ttccctgcaga tgccttaaat agggAACATA ctgatttcca 60
ctttcttaat gcttctggac catttccatt tctgtttttg ctttccttct taactctta 120
catgagtttA gagccgtgtt tctcaatga tgggcttagca cgcgtaaAGAG ctccgttACCT 180
atcgatAGAG aaatgttctg gcacACTG 207

<210> 123
<211> 161
<212> DNA
<213> Homo sapiens

<400> 123
aggttctctg aaggcTTTgc ttccctgcaga tgccttaaat agggAACATA ctgatttcca 60
ctttcttaat gcttctggac cactttccat ttctgttttt gctttccttc ttGAactctt 120
tacatgagtt tagagccgtg tttctcaACC attttgtttt t 161

<210> 124
<211> 300
<212> DNA
<213> Homo sapiens

<400> 124
ttctcaggTC gtttgcttTC ctttgcttTC tcccaAGTCT tgTTTACAa tttgctttag 60
tcattcaCTG aaACTTTAAA aaACATTAGA aaACCTCACA gtttgtaAT ctTTTCCCT 120
attatatata tcataAGATA ggagCTTAAA taaAGAGTT tagAAACTAC taaaATgtAA 180
atgACATAGG AAAACTgAAA gggAGAGTG aaAGTgggAA attcctCTGA atAGAGAG 240
gaccatCTCA tataAAATAGG ccataAcccAc ggAGAAAGGA cattctaACT gcaACCTTc 300

<210> 125
<211> 401
<212> DNA
<213> Homo sapiens

<400> 125
gatctgtAAAT gaataAGCAG gaACTTTGAA gACTCAGTGA cTCAGTgAGT aataAAAGACT 60
cAGTgACTTC tgatCCTGTC ctaACTGCCA cTCCTGTG tcccaAGAAA gCGGCTTCCT 120
gCTCTGAG gaggACCCCT tccCTGGAA gTAAAGACTAA ggATGTCAGC AGAGAAATT 180
ttccACCATT ggtgCTTGGT caaAGAGGAA ACTGATGAGC tcACTCTAGA tgAGAGAG 240
gtgAGGGAGA gACAGAGACT CGAATTCCG gagCTATTc agTTTCTTT tccgTTTGT 300

gcaatttcac ttatgatacc ggccaatgct tggtgctat tttggaaact ccccttaggg	360
gatccccctc aactggccct ataaaagggcc agcctgagct g	401

<210> 126
<211> 781
<212> DNA
<213> Homo sapiens

<400> 126	
ggttgcgtatgt atgcctccct gagggtatTTT cactttctgc tcccattccgc ccctatgagc	60
gagtacctat gagcacagga tgtgcacata tttgagtctt attagtggta cacgcagttt	120
tatcatctcc ccaggtctgt gtctgtatga aatgtgcatt ggtgtgtgt tgacacgcgtg	180
tgttcccaact cggggaaatgt ggggagaggt gcatggagcc aagatgggtg gtAAATAGTA	240
tgtttctgaa attaaaggac taatgtggag gaaggcgccc cagatgtact aaaccctttg	300
ccttcatctc atcctctctg acttgggaag aaccaggatt ttgttttaa gcccttggc	360
atacagttgt tccatccccga catgaactca gcctcccgtc tgaccgcccc ttggccttcc	420
ttcttcctcg atctgtggaa cccaggaaat ctgccttagtg ctgtctccaa gcaccttggc	480
catgatgtaa acccagagaa attagcatct ccatttcctt ccttattccc cacccaaaag	540
tcatttcctc ttagttcatt acctgggatt ttgatgtcta tggccctcc tcgttattga	600
tacacacaca gagagagaca aacaaaaaag gaacttcttg aaattcccc agaaggTTT	660
gagagttgtt ttcaatgttg caacaagtca gtttctagtt taagttcca tcagaaagga	720
gtagagtata taagttccag taccagcaac agcagcagaa gaaacaacat ctgttcagg	780
g	781

<210> 127
<211> 277
<212> DNA
<213> Homo sapiens

<400> 127	
gcatctccat ctcccttcctt attccccacc caaaagtcat ttcccttttag ttcattacct	60
gggattttga tgtctatgtt ccctcctcggt tattgatACA cacacagaga gagacAAACA	120
aaaaaggaac ttcttgaaat tccccccagaa ggttttgaga gttttttca atgttgcaac	180
aagtcagttt ctatTTAAG tttccatcag aaaggagtag agtatataag ttccagtacc	240
agcaacacagca gcagaagaaa caacatctgt ttccaggg	277

<210> 128
<211> 305
<212> DNA
<213> Homo sapiens

<400> 128

caagacatgc caagtgctga gtcactaata aagaaaaaaag aagtaaagga agagtggttc	60
tgcttcttag cgctagccctc aatgacgacc taagctgcac tttccccct agttgtgtct	120
tgcgatgcta aaggacgtca ttgcacaatc ttaataaggt ttccaatcag ccccacccgc	180
tctggcccca ccctcaccct ccaacaaaga tttatcaaattt gtgggatttt cccatgagtc	240
tcaatattag agtctcaacc cccaataaaat ataggactgg agatgtctct gaggctcatt	300
ctgcc	305

<210> 129
<211> 1181
<212> DNA
<213> Homo sapiens

<400> 129	
cctgcaagag acaccatcct gaggggaaga gggcttctga accagcttga cccaaataaga	60
aattcttggg tgccgacggg gacagcagat tcagagccta gagccgtgcc tgctccgtat	120
gtttccttct agttttttt tgatttcaaa tcaagactta cagggagagg gagcgataaa	180
cacaaactct gcaagatgcc acaaggctt ccttgacat cccaaacaaa gaagggtgagt	240
agtaatctcc cccttctgc cctgaaccaa gtggcttcag taagttcag ggctccagga	300
gacctggca tgccaggatgcc gatgaaacag tggtaagag actcagtggc agtggcagtgc	360
gggagagcac tcgcagcaca ggcaaacctc tggcacaaga gcaaagtctt cactggagga	420
ttcccaaggg tcaacttgggagggcaggc agcagccaaac ctccctctaag tgggctgaag	480
caggtaaga aatggcagaa gacgcgggtgg tggcaaaaag ggtcacacaca ctccacctgg	540
agacgccttg aagtaactgc acgaaatttg agggtggcca ggcagttcta caacagccgc	600
ctcacaggaa gagccagaac acagcaagaa ctcaagatgac tggtagtatt accttctca	660
taatcccagg ctggggggc tgctgatggag tcagaggaaa ctcaagttcag aacatcttt	720
gtttttacaa tacaaattaa ctggAACGCT aaattcttagc ctgttaatct ggtcaactgaa	780
aaaaaaaaaaaa ttttttttttt ttcaaaaaac atagcttttag cttatTTTT ttttctttt	840
gtaaaaacttc gtgcattact tcagctttac tcttgtcaag acatgccaag tgctgagtca	900
ctaataaaaga aaaaagaagt aaaggaagag tggttctgct tcttagcgct agcctcaatg	960
acgacctaag ctgcactttt cccccctagtt gtgtcttgcg atgctaaagg acgtcattgc	1020
acaatcttaa taaggttcc aatcagcccc acccgctctg gccccacccct caccctccaa	1080
caaagattta tcaaatgtgg gatTTCCCA tgagtctcaa tattagagtc tcaaccccca	1140
ataaaatata gactggagat gtctctgagg ctcattctgc c	1181

<210> 130
<211> 778
<212> DNA

<213> Homo sapiens

<400> 130

ctaccacttg tctattctgc	tatatagtca gtccttacat	tgctttcttc ttctgataga	60
ccaaactctt taaggacaag	tacctagtct tatctatttc	tagatcccc acattactca	120
gaaagttact ccataaatgt	ttgtggaact gattctatg	tgaagacatg tgccccttca	180
ctctgttaac tagcattaga	aaaacaatc ttttggaaag	ttgttagtatg cccctaagag	240
cagtaacagt tcctagaaac	tctctaaaat gcttagaaaa	agatttattt taaattacct	300
ccccaaataaa atgattggct	ggcttatctt caccatcatg	atagcatctg taattaactg	360
aaaaaaaaata attatgccat	taaaagaaaa tcatccatga	tcttggttcta acacctgcca	420
ctctagtaact atatctgtca	catggcttat gataaagtta	tctagaaata aaaaagcata	480
caattgataa ttccaccaaat	tgtggagctt cagtattttt	aatgttatatt aaaattaaat	540
tatTTTaaag atcaaagaaa	actttcgatca tactccgtat	ttgataagga acaaataagga	600
agtgtatga ctcagggttt	ccctgaggggg atggccatc	agttgcaaattt cgtggaaattt	660
cctctgacat aatgaaaaga	tgagggtgca taagttctct	agtagggtga tgatataaaaa	720
agccaccgga gcactccata	aggcacaaaac tttcagagac	agcagagcac acaagctt	778

<210> 131

<211> 207

<212> DNA

<213> Homo sapiens

<400> 131

actccgtatt tgataaggaa	caaataaggaa gtgtgatgac	tcagggttgc cctgagggga	60
tgggccccatca gttgcaaattc	gtggaatttc ctctgacata	atgaaaagat gagggtgcatt	120
aagttctcta gtagggtgat	gatataaaaa gccaccggag	cactccataa ggcacaaaact	180
ttcagagaca gcagagcacaca	caagctt		207

<210> 132

<211> 645

<212> DNA

<213> Homo sapiens

<400> 132

gggggtgatt tcactccccg	gggctgtccc aggcttgtcc	ctgctacccg caccagcct	60
ttcctgaggc ctcagaacctg	ccaccaagcc cccagctcct	tctccccgca gggcccaaacc	120
acaggcctca ggactcaaca	cagttttcc ctccaacccc	gttttctctc cctcaacggaa	180
ctcagtttc tgaagccccct	cccagttctta gttctatctt	tttcctgcatt cctgtctggaa	240
agtttagaagg aaacagacca	cagacctggc cccaaaaga	aatggaggca ataggttttgg	300
aggggcatgg ggacggggtt	cagcctccag ggtcctacac	acaaatcagt cagtggccca	360

gaagaccccc ctcggaatcg gagcaggag gatggggagt gtgaggggta tccttgatgc	420
tttgtgtcc ccaacttcc aaatccccgc cccgcgatg gagaagaaac cgagacagaa	480
ggtgcagggc ccactaccgc ttccctccaga tgagctcatg ggtttctcca ccaaggaagt	540
tttccgctgg ttgaatgatt ctcccgc ctcctctcg ccccagggac atataaaggc	600
agttgttggc acacccagcc agcagacgct ccctcagcaa ggaca	645

<210> 133
<211> 457
<212> DNA
<213> Homo sapiens

<400> 133	
gcctgtactc agccaagggt gcagagatgt tatatatgt tgctcttcag ggaaccgggc	60
ctccagctca caccggcagct gctcaaccac ctccctctcg aattgactgt cccttctttg	120
gaactctagg cctgacccca ctccctggcc ctcccagccc acgattcccc tgacccgact	180
ccctttccca gaactcagtc gcctgaaccc ccagcctgtg gttctctcct aggccctcagc	240
ctttcctgcc tttgactgaa acagcagtat cttctaagcc ctgggggctt cccggggccc	300
cagccccgac cttagaacccg cccgctgcct gccacgctgc cactgccgt tcctctataa	360
agggacctga gcgtccgggc ccaggggctc cgacacagcag gtgaggctct cctgccccat	420
ctccttgggc tgccccgtct tcgtgctttg gactacc	457

<210> 134
<211> 973
<212> DNA
<213> Homo sapiens

<400> 134	
gcagcaaatac agaatggcag tttgattcat ggtgctgaga ctggaggttc ctctgctgtta	60
ggctcagaat atgtctaagc aattgaggaa tgtctcagaa aacgtggggc tagtgtgcca	120
tatttatctg caaagccatt ttccctccct aattctgatt ggataagggc attacagttt	180
acttagcaaa acctgctggc tggctctggg gaagtcccat gttgcagact cgaaggtatt	240
atttatttta gcttccaagt tacggaattt ccctctgctc ctctttttt ggtatagtg	300
aatttaggttt cactttccaa aacatgaact gttcttgaa aaaaagaact tcattgcata	360
tagaaaaaaaaa caaagggtgc aatccattct aactataatg cttttctca acacttaaac	420
ttttacagtt actttcagag gttatttttc aaaatatccc cagtaataga aattttcat	480
cctttatagg taaacctaatttttggtaa cagcaagttt tgccctgatta ttggaaacagt	540
gatttacctg gacagtccctc cttgatcaaa tactataaag taataggact ggcctgcttt	600
gacagggtca aagatctgga actggcaagt tttaaataat tcaataaaatg ctttgatcat	660
tcataaacacc attagattaa gtaaatagcc tccaaacataa ctatTTTgag ggaaaacatt	720

gctcattgg gtagtctgatt tgtggtgtgt taaaacaagt ttcacgtctt atagcagtcc 780
 ctgaatgaaa acatcataag atggtatcta gaatggtgtg agaaaaggat tcatacgat 840
 cctagggtta ttgtaaaaaaaaaa caaagggtgc ttttgagga aatgaattta aaagcggggg 900
 ggcacgcata gagacagacc ttggaaagt agttgagac agaaggaaaa cagttgatt 960
 tacgatgggg ttc 973

<210> 135
 <211> 333
 <212> DNA
 <213> Homo sapiens

<400> 135
 gctaccttaa gaaggctggt taccatctgg gttttcacag tgcttcaca ttcttatacac 60
 tttcaacact actgcaaata ggaaggaca gtaacattta gaagagaaca aaacagaaac 120
 tcttggaaagc aggaaagggtg catgactcaa agagggaaat tcctgtgcca taaaaggatt 180
 gctggtgtat aaaatgctct atatatgcca attatcaatt tccttcatg ttcagcattt 240
 ctactccttc caagaagagc agcaaagctg aagtttagcag cagcagcacc agcagcaaca 300
 gcaaaaaaca aacatgagtg tgaagggcat ggc 333

<210> 136
 <211> 1048
 <212> DNA
 <213> Homo sapiens

<400> 136
 ggtgaccaag aatgtgagca agcccaggca cagccactgt gggcgccctga ccaaacagca 60
 ctaaatttgt gtgggacatg atcccagagg tgtgtggctt cacccctcaa cgagtggcgt 120
 ggcatggagt tactgaatct ccaaggtcaa acaggccctc aaattcatca agaaaagggt 180
 agggacaaac atctgtacca agagaaggca ggaggagctg agcaacgtcc tgctgccatg 240
 aggaaagcag ctgccaagaa ggactgagcc cctgccccatct gcctataatg aaagcttgc 300
 aaaataaaaat aaatataaaa taaagtaata aaattaaatt aaatttaaaa ataaaaataaa 360
 gcaaaacaaa ataaaatata taaagtaaaa attgttaaaa tgcaaaaacaa tatggacata 420
 aatacagaaa cacagggaaa cttctttagg cactcattta caggtaaaaa tatgaaattg 480
 aataaaaggctc atctgggtgtc aaataatata ggccttatct attataagag tttggactga 540
 aaagcaaaaag tgagataaca aaaaaaaagct tttcagaata ttatTTGta tagatATGt 600
 aaggatgaag ggtgggtgaa aggacaaaaa acagaaacac agtcttcctg aatgaatgac 660
 aatcagaatt ccgctgccc aagtagtccg acaattaaat ggatttctag gaaaagctac 720
 cttaagaagg ctggttacca tctgggtttt cacagtgctt tcacatttctt atcactttca 780

acactactgc aaataggaag ggacagtaac atttagaaga gaacaaaaca gaaactcttg 840
 gaagcagggaa aggtgcatga ctc当地atagg gaaattcctg tgccataaaa ggattgctgg 900
 tgtataaaaat gctcttatata tgccaattat caatttcctt tcatgttcag catttctact 960
 ccttccaaga agagcagcaa agctgaagtt agcagcagca gcaccagcag caacagcaaa 1020
 aaacaaaacat gagtgtgaag ggc当地tggc 1048

<210> 137
<211> 504
<212> DNA
<213> Homo sapiens

<400> 137
 agggggcccc gcagcagccc cttggcttcc cttctccctt geetcccccc cggggctccg 60
 gttcagaggc actctggcg cctgctacag cttccaaact gcgccgcttc cttcttcggc 120
 agaaaaggac tttcagatgc ggccggccgcg gcccggcga ctcaggacag cgccccctcc 180
 cctaacggcc gcctctccct ctccccctcg cccgccccgg ctccccccacc tctgggaagg 240
 cgctgggggt gtggccaggg accggtataa agtccgggggg agccggtccc gggcagccgc 300
 tcagccccct gcccctcgcc gcccggccgc tgc当地tggcc gggccgagga tgc当地ggcag 360
 cgc当地tggcg gcaaggcttg ctccctccgg cacgc当地tgc aacttccccct gctacgtccc 420
 cgttc当地cccg ccggggccgc ccgtctcccc gccc当地tccg ggtc当地ggtcc tccaggagcg 480
 ccaggc当地tgc cc当地cgctgtg ccct 504

<210> 138
<211> 1042
<212> DNA
<213> Homo sapiens

<400> 138
 gatcacaaca gctctacaaa tacacaatga ttacaaggaa tggc当地ccca ctggagttgt 60
 tcaacgc当地aa acttgc当地at tgcaagtggc aatctccag gc当地tgc当地cc ctccacgc当地t 120
 gggc当地tgaat gggc当地tggaga ggcaaaacatc caagaaggag gaagaggctc ggc当地ggcacct 180
 ccctccccgg gagttctgct gattccatct tggc当地aagca gggc当地ggacca gggcc当地aaat 240
 ggc当地ctggg gagattgc当地gg gggc当地gggaga ggtc当地aagg ggcaagtc当地gg aagagc当地tgc当地t 300
 taacgtctta gggc当地tccag gc当地ttctgt gccc当地tagct gtgc当地tgc当地tac gcttacccc 360
 acctcaggag gcttggctc cagc当地gggtga ggctggaaagc accgggggtgc ggtggaaagg 420
 gctctgtcca ggaagaccgg atccgc当地agag cc当地ggaggcc gggc当地taggaa gtccctttct 480
 cggc当地gggaga ctgaggccgc cttggc当地gggg cggc当地ggc当地gaga ctccctccgag gtc当地ggaaag 540
 gggc当地cccgcc agc当地ggccct tggc当地tccct tctcccttgc ctccctccg gggc当地tcccggt 600

tcagaggcac tctggcgcc tgctacagct tccaaactgc gcccgttccct tcttcggcag 660
aaaaggactt tcagatgcgg cggcgccggc ggccggcact caggacagcg cccccctcccc 720
taacggccgc ctctccctct cccccctcgcc cgccccggct ccccccacctc tgggaaggcg 780
ctgggggtgt ggccaggac cggataaaag tccgggggag ccggtcccgg gcagccgctc 840
agccccctgc ccctcgccgc cggccgcctg cctggggccgg gccgaggatg cggcgcagcg 900
cctcggccgc caggcttgct ccctccggca cgcctgctaa cttcccccgc tacgtccccg 960
ttcggccgc gggccgcccc gtctccccgc gcccctccgg tccggtcctc caggagcgcc 1020
aggcgctgcc gccgtgtgcc ct 1042

<210> 139
<211> 24
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 139
tcgtcgaaaa gacgttttgtt cgtt

24

<210> 140
<211> 24
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 140
tcgtcgaaaa gtcgtttttt tcga

24

<210> 141
<211> 24
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 141
tcgtcgaaaa gtcgtttcgtt cgtt

24

<210> 142
<211> 24
<212> DNA
<213> artificial sequence

<220>
<223> Immunostimulatory nucleic acid

<400> 142
tcgtcgttc gtcgtttgt cgtt

24

<210> 143
<211> 21
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 143
tcgtcgttt tcggtcgtt t

21

<210> 144
<211> 22
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 144
tcgtcgttt tcgtgcgtt tt

22

<210> 145
<211> 22
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 145
tcgtcgttt cggcgccgc cg

22

<210> 146
<211> 24
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 146
tcgtcgttt acggcgccgt gccg

24

<210> 147
<211> 24
<212> DNA

```
<213> artificial sequence
<220>

<223> Immunostimulatory nucleic acid

<220>
<221> misc_feature
<222> (2)..(2)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (5)..(5)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (21)..(21)
<223> N = 5-methylcytosine

<400> 147
tngtngttt gtngtttgt ngtt
```

24

```
<210> 148
<211> 27
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<220>
<221> misc_feature
<222> (2)..(2)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (5)..(5)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (11)..(11)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(14)
<223> N = 5-methylcytosine
```

<220>
<221> misc_feature
<222> (16)..(16)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (19)..(19)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (22)..(22)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (26)..(27)
<223> N = 5-methylcytosine

<400> 148
tngtngtgt ntngntttnt tnttgnn

27

<210> 149
<211> 21
<212> DNA
<213> artificial sequence

<220>
<223> Immunostimulatory nucleic acid

<220>
<221> misc_feature
<222> (2)..(2)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (8)..(8)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (20)..(20)

<223> N = 5-methylcytosine
<400> 149
gngtttgntr ttnttnttggn g

21

<210> 150
<211> 20
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<220>
<221> misc_feature
<222> (2)..(4)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (8)..(8)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (15)..(16)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (19)..(19)
<223> N = 5-methylcytosine

<400> 150
gnnnaagntg gnatnnngtna

20

<210> 151
<211> 15
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 151
tcctggcgaaat

15

<210> 152
<211> 42
<212> DNA
<213> artificial sequence

<220>

<400> 152
gaaactcgag ccaccatgag acagacttg ccttgtatct ac

42

<210> 153
<211> 37
<212> DNA
<213> artificial sequence

<220>

<223> Oligonucleotide

<400> 153
gaaagaattc ttaatgtaca gagttttgg atccaag

37

<210> 154
<211> 24
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 154
tgctgctttt gtgctttgt gctt

24

<210> 155
<211> 20
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 155
tccatgacgt tcctgatgct

20

<210> 156
<211> 20
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 156
tccatgagct tcctgatgct

20

<210> 157
<211> 20
<212> DNA
<213> artificial sequence

WO 2004/094671

PCT/US2004/012788

<223> Immunostimulatory nucleic acid
<220>
<221> misc_feature
<222> (8)..(8)
<223> N = 5-methylcytosine

<400> 157
tccatgangt tcctgatgct

20

<210> 158
<211> 22
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 158
tcgtcgaaaa cggcgccgcg cg

22

<210> 159
<211> 21
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 159
ggggacgacg tgctgggggg g

21

<210> 160
<211> 22
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 160
tgctgctttt cggcgccgcg cg

22

<210> 161
<211> 21
<212> DNA
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 161
ggggagcagc tgctgggggg g

21